

**Cytoplasmic dynein heavy chain1 genes, expression products,
non-human animal model: uses in human neurological diseases**

FIELD OF THE INVENTION

5 The present invention *inter alia* relates to a non-human animal model for movement hyperactivity, hyperexcitability disorders (*e.g.* myoclonic cramping, epilepsy), excitotoxicity disorders, and neurodegeneration. This animal model bears a mutation in the cytoplasmic dynein heavy chain1 gene. The invention also relates to modified peptides and the corresponding nucleic acid sequences of the modified
10 mouse and human cytoplasmic cytoplasmic dynein heavy chain1. Furthermore, the invention relates to the use of these peptides and nucleic acids for manufacturing therapeutics suitable for the treatment of diseases, such as Alzheimer's disease, Huntington's disease, Parkinson's disease and amyotrophic lateral sclerosis (ALS), as well as other diseases associated with overexpression, over-activity, or undesirable
15 activity of cytoplasmic dynein heavy chain1.

BACKGROUND OF THE INVENTION

Eukaryotic cells are characterized by biochemical and physiological processes which under normal conditions are exquisitely balanced to achieve the preservation and propagation of the cells. When such cells are components of multicellular
20 organisms such as vertebrates, or more particularly organisms such as mammals, the regulation of the biochemical and physiological processes involves intricate signaling pathways. Frequently, such signaling pathways consist of extracellular signaling proteins, cellular receptors that bind the signaling proteins and signal transducing components located within the cells.

25 Signaling processes may elicit a variety of effects on cells and tissues, including by way of nonlimiting example induction of cell or tissue proliferation, suppression of growth or proliferation and induction or suppression of differentiation or maturation of a cell or tissue.

Many pathological conditions involve dysregulation of expression of important effector proteins. In certain classes of pathologies the dysregulation is manifested as a diminished or suppressed level of synthesis and secretion of protein effectors. In a clinical setting a subject may be suspected of suffering from a condition brought on by diminished or suppressed levels of a protein effector of interest. Therefore, there is a need to assay for the level of the protein effector of interest in a biological sample from such a subject and to compare the level with that characteristic of a nonpathological condition. There is a further need to provide the protein effector as a product of manufacture. Administration of the effector to a subject in need thereof is useful in treatment of the pathological condition. Accordingly, there is a need for a method of treatment of a pathological condition brought on by a diminished, suppressed, or in some cases elevated, level of the protein effector of interest.

Motor neuron degenerative diseases are severely debilitating and largely fatal in humans as well as other mammalian species. Several hypotheses have been proposed to explain the pathogenesis of the diseases, but none addressed the underlying cause for the specificity of disease in motor neurons, the late onset of the disease, and the cumulative progressive nature of the disease.

Degenerative disorders of motor neurons include a range of progressive diseases such as amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA), the most common genetic cause of death of children (Nicole, S. et al., J. Muscle Nerve 26, 4-13, 2002).

In ALS, commonly known as Lou Gehrig's Disease in the US, the motor neurons (nerve cells in the brain, brain stem, and spinal cord that control movement of the skeletal muscles) gradually degenerate, resulting in progressive weakness and functional loss of involved muscles. Diseases that cause selective progressive death of motor neurons are surprisingly common -- ALS is the third most frequent neurodegenerative cause of adult death, after Alzheimer disease and Parkinson disease, and is significantly more common than multiple sclerosis (Motor Neurone Disease Association Information Sheet Number 9, Motor Neurone Disease Association, 1998). Targeted at adults in their prime years of life, the average age of onset is the mid-fifties, although adults of all ages can be affected. Men get the disease

slightly more often than women. Worldwide, the incidences of ALS is 0.5 to 2.4 cases per 100,000, with a prevalence of 2.5 to 7 cases per 100,000 population (Cleveland, D.W. and Rothstein, J.D. *Nat. Rev. Neurosci* 2, 806-819, 2001). The prevalence of ALS in the United States will probably increase dramatically as the baby boomer generation ages. In ALS the majority of patients die within 2 – 5 years of clinical onset (Motor Neurone Disease Association Information Sheet Number 9, Motor Neurone Disease Association (1998). ALS and related motor neuron disorders are not contagious but in some cases known to be hereditarily transmitted. Up to 10% of ALS is familial (FALS) and causative mutations have been found in the SOD1 gene that account for up to 20% of these FALS cases (Julien, J.P., *Cell* 104, 581-591, 2001). SOD1 encodes the ubiquitously expressed enzyme superoxide dismutase 1 which takes on an unknown dominant gain of function in ALS that results in the selective death of motor neurons. Mutations have also been found in alsin, probably a GTPase regulatory protein, in rare juvenile recessive forms of motor neuron disease (Hadano, S. et al. *Nat. Genet.* 29, 166-173, 2001; Yang, Y. et al. *Nat. Genet.* 29, 160-165, 2001). In a few sporadic ALS patients and one FALS case mutations have been identified in the NFH (neurofilament heavy chain) gene (Robberecht, W. J. *Neurol* 247, 2-6, 2000). Approximately, 90% of all ALS is without history and is referred to as sporadic ALS, although the clinical course and the neuropathological alterations are often indistinguishable from the proven cases of genetic disease. If a genetic cause would be responsible also for a subgroup of so called sporadic ALS, the mutation would likely be germline or very early embryonic, as mosaic type pathological alterations expected in later acquired mutations are not reported nor expectable in ALS.

25

Currently, diagnosing ALS is a combination of medical history and physical and neurological examinations performed by a clinical neurologist (Brooks, Benjamin R., *El Escorial J Neurol Sci* 124 (Suppl.), pages 96-107, 1994; Karitzky J, Ludolph AC. *J Neurol Sci*, Oct 15;191(1-2):35-41, 2001; Ludolph AC, and Knirsch U, *J Neurol Sci*, Jun;165 Suppl 1:S14-20, 1999). An electromyogram is a diagnostic test which is done to determine abnormal nerve and muscle activity. The clinical examination and tests also rule out other conditions that might mimic motor neuron disease. The certainty of the diagnosis is determined by the clinical evidence of upper and lower motor neuron signs, according to the criteria established by the World

30

Federation of Neurology. Therefore, a definitive diagnosis of ALS is performed when clearly detectable classical clinical signs such as muscular fibrillation of distal muscle groups or tongue, difficulty to swallow, and predominantly distal muscular atrophy with the typical histological picture of grouped angular shaped atrophic muscle fibres
5 indicative of muscle denervation are present which means that the disease course is already proceeded.

Some persons are diagnosed to have other clinical variant forms of motor neuron disease which may later evolve into classical ALS over time. These clinical
10 subtypes of motor neuron disease include: Progressive bulbar palsy (PBP) which affects the brain stem (referred to as bulbar involvement), causes weakness of the speech and swallowing muscles. Progressive muscular atrophy (PMA) which affects the lower motor neurons causes skeletal muscle wasting. Primary lateral sclerosis (PLS) which affects the upper motor neurons causes muscle spasticity and may be
15 slowly progressive over many years (Brooks, BR.: El Escorial J Neurol Sci 124 (Suppl.), 1994, pages 96-107).

The most common form of spinal muscular atrophy (SMA) affects up to 1 in 6,000 newborns and is the leading hereditary cause of infant mortality worldwide,
20 causing death before the age of 2 years. Defects in the widely expressed SMN1 (survival motor neuron 1) gene are responsible for most SMA (Hofmann, Y. and Wirth, B. Hum. Mol. Genet. 11, 2037-2049, 2002; Lefebvre, S. et al.. Cell 80, 155-165, 1995).

25 Another inherited motor neuron degeneration of early adulthood is the spinobulbar muscular atrophy (SBMA), which in some families is linked to a X-chromosomal trait and CAG triplet repeat expansion within the androgen receptor (Sparfeld AD et al., Arch. Neurol. 59:1921-1926, 2002). SBMA x-linked is also termed Kennedy disease. However, there are also SBMA like syndromes following
30 autosomal inheritance, the underlying mutations are not yet identified.

Current hypothesis to the pathogenesis of motor neuron degeneration address a variety of cellular insults that may intersect, leading individually or in concert to motor neuron degeneration, motor neuron death and finally ALS (Julien, J.P. Cell 104,

581-591, 2001). A faulty gene and excess glutamate may lead to damaging free radicals, which can harm the nerve cell's DNA (Munch, C et al., J Neurochem, Aug. 82(3):594-603, 2002; Ludolph AC, and Meyer T, Riepe MW J Neurol 2000 Mar;247 Suppl 1:17-16; Meyer T et al. J Neurol Neurosurg Psychiatry, Dec;65(6):954, 1998; 5 Meyer T. et al., J Neurol Neurosurg Psychiatry, Oct;65(4):594-6, 1998). Glutamate also may lead to the production of detrimental calcium, which can churn out its own supply of DNA-harming free radicals. The free radicals also may injure neurofilaments, proteins that serve as the skeleton of the cell. In addition, the immune system (Hofmann, Y. and Wirth, B. Hum. Mol. Genet. 11, 2037-2049, 2002) may be 10 involved in harming neurons. Abnormalities can lead to an accumulation of the toxic calcium.

Glutamate-induced excitotoxicity is a potential contributor to ALS pathogenesis. Depolarization of the neuronal membrane after activation of neuronal 15 glutamate receptors activates voltage-dependent Ca^{2+} channels, allowing Ca^{2+} entry into the cell. Thus, excess activation of neuronal glutamate receptors can cause cell death via alterations in cytosolic free Ca^{2+} homeostasis. For spinal motor neurons, rapid recovery of synaptic glutamate is accomplished by the glutamate transporter EAAT2 present in astrocytes. Loss of EAAT2 transporter could lead to increased 20 extracellular concentrations of glutamate and excitotoxic degeneration of motor neurons (Julien, Review; Cell. 2001 Feb 23;104(4):581-91).

ALS researchers at the John Hopkins University have recently enabled mouse 25 ALS models to make an excess of glutamate transport proteins in both brains and spinal cords. Preliminary studies of these mice show huge increases in their survival time, which led to the development of an "EAAT2 replacement therapy" for ALS patients at the John Hopkins University (The Robert Packard Center for ALS Research at John Hopkins, www.alscenter.org, 2002).

30 The excitotoxicity hypothesis is supported by the observation that the majority of sporadic ALS cases (~ 65%) have a reduction in the astroglial glutamate transporter EAAT2 in motor cortex and spinal cord (Rothstein et al., Ann Neurol. 1995 Jul;38(1):73-84). Germline mutations in the EAAT2 gene are very rare. Only one sporadic ALS case was identified with an EAAT2 gene variant that affects N-linked

glycosylation and glutamate clearance capacity (Aoki et al., *Ann Neurol.* 1998 May;43(5):645-53; Trotti et al., *J Biol Chem.* 2001 Jan 5;276(1):576-82.).

One major support for the excitotoxicity hypothesis comes from the first drug
5 therapy for ALS which is Riluzole (Rilutek, (Rhone-Poulenc Rorer Pharmaceuticals
Inc., College-ville, PA) approved by the FDA in 1995), an ant glutamate compound.
Riluzole retards nerve cells' release of glutamate. Although the effects of Riluzole are
clearly modest, it has been the only drug that reliably shows clinical efficacy
compared to the dozens of drugs studied by clinicians around the world in thousands of
10 ALS patients (Nervous Breakdown, A detailed analysis of the neurology market, UBS
Warburg, June 2001). Riluzole was reported to extend survival of ALS diagnosed
patients for a few months. However, all therapeutic approaches tested so far are prone
to fail when applied in later stages of the disease (Al-Chalabi A, and Leigh PN. *Curr
Opin Neurol*, Aug;13(4):397-405, 2000; Munch C, and Ludolph AC. *Neurol*
15 *Neurochir Pol*, ;35(1 Suppl):41-50, 2001; Ludolph AC. *J Neurol*, Dec;247:13-18,
2000). Therefore, an early or even subclinical diagnostic marker might also have
implications for therapeutic effectiveness.

It has been postulated that defects in axonal transport may be an underlying
20 common pathway that leads to the degeneration of motor neurons in ALS patients and
in relevant spontaneous and transgenic mouse models such as wobbler, nmd or SOD1
(Yang, Y. et al., *Nat. Genet.* 29, 160-165, 2001; Cleveland DW. *Neuron*,
Nov;24(3):515-20, 1999; Jonsson PA et al. *Neurobiol Dis.*, Aug;10(3):327-33, 2002;
Winter SM et al. *J Neurol.*, Oct;247(10):783-6, 2000) For example, SOD mice with a
25 mutation in the SOD-1 gene display a motor neuron degenerative phenotype with a
decreased rate of slow axonal transport (Collard et al., *Nature* 375:61-64, 1995;
Zhang et al., *J. Cell Biol.* 139:1307-1315, 1997; Williamson and Cleveland, *Nat.
Neurosci.* 2:50-56, 1999.

30 Motor neurons of the brain and spinal cord are characterized by the length of
their axons, which can reach a meter in length in an adult human. The significant
length of these neuronal projections makes active axonal transport essential for normal
cellular function. The axonal transport is microtubule dependant and includes both, an
anterograde transport of organelles to the axonal synapse and the retrograde transport

of multivesicular bodies and trophic factors back to the neuron cell body. The retrograde transport is mediated by the dynein-dynactin complex.

The dynein-dynactin complex

5 Dyneins are cytoskeletal motor proteins. These can be defined as molecules that convert chemical energy, originating from nucleotide hydrolysis, into the mechanical force necessary for them to move along cytoskeletal polymers (*cf* Vallee and Howard (1990) *Annu. Rev. Biochem* 59: 909-932). Dyneins and kinesins constitute the superfamily of microtubule-dependent motor proteins, (Hirokawa
10 (1998) *Science* 279, 519-526). Although the superfamily of dyneins is probably less diverse than that of kinesins, the family, which contributes to the structure and function of flagellar and ciliary axonemes (axonemal dyneins), comprises more than a dozen dynein heavy chain isoforms (Milisav (1998) *Cell Motil Cytoskeleton* 39, 261-272). Only four dynein heavy chain isoforms, contributing to different forms of the
15 protein complex, called cytoplasmic dynein, are known in mammals.

The most abundant form of cytoplasmic dynein, whose identity is defined by the cytoplasmic dynein heavy chain1, is involved in a wide range of cellular functions. In mouse and human, the homologous proteins are referred to as cytoplasmic dynein
20 heavy chain1. These proteins correspond, respectively, to the translation product of the transcript of the mouse gene *Dnchc1* (Genbank Accession No. AY004877) and the translation product of the full-length cDNA of the human gene *DNCH1*. The full-length human cytoplasmic dynein heavy chain1 cDNA is disclosed herein (SEQ ID NO:17). Several lines of evidence (*e.g.* immunodepletion of cytoplasmic dynein
25 heavy chain1 in *in vitro* motility studies and antibody injection) revealed that it functions as a molecular motor in prometaphase chromosome movement, mitotic spindle pole organization, Golgi organization, spindle orientation, nuclear migration, microtubule organization and reorganization and intracellular trafficking, including retrograde axonal transport, of membraneous organelles, (*e.g.* lysosomes and
30 endosomes) (for review see Milisav (1998) *Cell Motil Cytoskeleton* 39, 261-272). Another isoform has been reported to be involved in intraflagellar protein transport (Pazour *et al.* (1999) *J Cell Biol* 144, 473-481). Cytoplasmic dynein was initially identified in nervous tissue (Paschal *et al.* (1987) *J Cell Biol* 105, 1273-1282) although it is expressed in several tissues (Mikami *et al.* (1993) *Neuron* 10, 787-796).

Harada *et al.* ((1998) J Cell Biol 141, 51-59) generated mice lacking cytoplasmic dynein heavy chain 1 by targeted disruption of the *cDHC* (= *Dnchc1*) gene. Whereas *cDHC*^{-/-} preimplantation embryos were microscopically indistinguishable from *cDHC*^{+/-} and *cDHC*^{+/+} littermates, by 8.5 days p.c., no *cDHC*^{-/-} embryo were found. This observation demonstrates that cytoplasmic dynein is essential for embryonic development. In conjunction with the functional data mentioned above, Harada *et al.* found that cells from *cDHC*^{-/-} blastocysts, in contrast to those from *cDHC*^{+/+} blastocysts, were incapable of dividing in culture. Additionally, the Golgi complex was highly vesiculated and distributed in these cells as were the endosomes and lysosomes.

The cytoplasmic dynein complex consists of at least four classes of subunits: heavy, intermediate, light intermediate and light dynein chains. The dynein intermediate chain, dynein light intermediate chain, and dynein light chain specify the intracellular location of the dynein complex and regulate its motor activity, whereas the dynein heavy chains contain the machinery which imparts the motor activity.

The architecture of the complex is dominated by two heavy chains of 530 kDa each, which form a stem by the interaction of a large portion (amino acids 300 – 1140) of their N-termini. This stem also binds the dynein chains of lower molecular weight, *e.g.* two 74 kDa intermediate chains (between amino acids 446 and 701 of the heavy chains) and four 53-59 kDa light intermediate chains (between amino acids 649 and 800 of the heavy chains) (Tynan *et al.* (2000) J Biol Chem. 275, 32769-32774). Several 8-22 kDa light chains bind to the complex via interaction with the intermediate or light intermediate chains (*cf* Makoka *et al.* (2002) Biochemistry 41, 4302-4311). The intermediate chains probably impart the tethering of the dynein complex to the cargos (review: Asai and Koonce (2001) Trends Cell Biol 11, 196-202). Intracellular transport processes mediated by cytoplasmic dynein additionally involve a variety of accessory proteins that are thought to target the cytoplasmic dynein complex to the intracellular cargos. Another large complex formed by several of these accessory proteins is named dynactin. Dynactin binds to dynein by the interaction of a subunit called p150Glued with the dynein intermediate chains (Vaughan and Vallee(1995) J Cell Biol 131, 1507-1516). This interaction implicates

dynactin as a receptor or adaptor that mediates the association of cytoplasmic dynein with cargo. Subsequent studies have demonstrated the essential nature of the dynein-dynactin interaction for most examples of dynein-mediated transport (Holleran et al., Int. Rev. Cytol. 182:69-109, 1998)

5

The binding of dynactin to dynein is essential for dynein-dependent intracellular movements (Gill *et al.* (1991) J Cell Biol 115, 1639-1650; Schroer and Sheetz (1991) J Cell Biol 115, 1309-1318) including those required for neuronal function. It has been shown that antibodies which specifically disrupt the binding of
10 dynactin to dynein block vesicle motility along microtubules in extruded squid axoplasm (Waterman-Storer *et al.* (1997) Proc Natl Acad Sci USA 94, 12180-12185). Additionally, an overexpression of the dynamitin subunit of dynactin, which results in the dissociation of the dynactin complex, (Eckley *et al.* (1999) J Cell Biol 147, 307-320) causes an inhibition of dynein-mediated processes in the cell (Burkhardt *et al.*
15 (1997) J Cell Biol 139, 469-484).

Dynein-mediated intracellular movements are directed along microtubules towards their proximal (-) ends. This process is accomplished by ATP hydrolysis, which is predominantly catalysed by the first of four (counted from the one nearest to
20 the N-terminus) P-loop motifs of each of two C-terminal globular heads which are formed by approximately 3000 amino acids of each of the two dynein heavy chains. Both globular heads also contain a microtubule binding domain, which is thought to be located at the tip of a stalk (Asai and Koonce (2001) Trends Cell Biol 11, 196-202).

25

The dynein-dynactin complex and neurodegeneration

Recently, disruption of the dynein-dynactin complex in postnatal motor neurons of transgenic mice that overexpress dynamitin has been shown to result in reduction of microtubule based axonal transport and degeneration of the motor
30 neurons and muscle atrophy over a time-course of many months (LaMonte *et al.* (2002) Neuron 34, 715-727) The pathology described therein is the result of a highly artificial transgenic approach for regional and time dependent disruption of the dynein-dynactin complex selectively in adult motor neurons. This situation is not comparable with any clinical situation with an underlying genetic cause, but would

only address motor neuron specific stress factors for the dynein-dynactin system. The model described by LaMonte et al. is thus quite different from the model described in the present invention.

5 No effective therapy exists for the neurodegenerative disorders described herein. The selective nature of the degeneration is unexplained, but may relate to the highly specialized form and function of the motor neuron. There are known gene mutations in some familial cases of ALS and in almost all SMA, but the underlying defect in the majority of familial and sporadic ALS and a small proportion of SMA
10 remains unknown. As mentioned before, in ALS the pathogenetic link between causal mutations in *SOD1* (superoxide dismutase) and the death of motor neurons is not clear, although a variety of mechanisms have been proposed, including pathways disrupting neurofilament secondary structure (Miller (2002) Cell Mol Life Sci 59, 323-330) that result in slowing of axonal transport. Only in 2 % of ALS cases a
15 preclinical genetic diagnosis by detection of SOD1 mutations responsible for 20% of familial ALS is possible. No preclinical or subclinical diagnostic tool for the broad majority of ALS cases is available, therefore treatment can so far only start late in the course of the disease when already a large number of motor neurons have died. Therapy might not be suitable to stop the ongoing disease process. Therefore, new
20 diagnostic tools such as a genetic test for disease relevant genes are urgently needed.

 The present invention provides an animal model for correlating mutations or defects in the cytoplasmic dynein heavy chain1 gene with human disorders, including movement hyperactivity, hyperexcitability disorders (e.g. myoclonic cramping,
25 epilepsy), excitotoxicity disorders, and neurodegeneration, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, and specifically motor neuron degeneration, such as ALS (Amyotrophic Lateral Sclerosis), SMA (Spinal Muscular Atrophy), SBMA (Bulbo-Spinal Muscular Atrophy), PBP (progressive Bulbar Palpsy), PMA (Progressive Muscular Atrophy), and PLS (Primary Lateral Sclerosis),
30 resulting in whole or in part from these mutations or defects in the cytoplasmic dynein heavy chain1 gene or the protein it encodes. The Cra1 (cramping 1) mutation in cytoplasmic dynein itself results in progressive motor neuron degeneration in heterozygous mice. Specifically, this invention provides an animal model that demonstrates the role of cytoplasmic dynein heavy chain1 in movement hyperactivity,

hyperexcitability disorders (e.g. myoclonic cramping, epilepsy), excitotoxicity disorders and neurodegeneration, specifically α -motor neuron degeneration, resulting from a mutation or defect in cytoplasmic dynein heavy chain1. The Cra1 animal model described herein demonstrates a germline missense mutation that causes subtle changes in the cytoplasmic dynein heavy chain 1, and is sufficient to specifically induce age dependent motor neuron degeneration without grossly affecting the housekeeping function of the dynein-dynactin complex in other cell types. The Cra1 mutation in cytoplasmic dynein heavy chain 1 allows normal development and normal function of the organism in early adulthood. The animal model provided herein meets the currently unfulfilled need for a validated model to study the causes and precise physiological effects of such diseases associated with aberrant cytoplasmic dynein heavy chain1 function. Similarly, this invention provides a means for identifying antagonists and inhibitors for cytoplasmic dynein heavy chain1 in such disorders.

The present invention also provides significant data useful in neurobiology and clinical research, as it describes in an animal model a new pathway involved in neurodegeneration, and also suggests a possible genetic cause for ALS/Lou Gehrig's disease.

Furthermore, the present invention provides diagnostic tests for latent or progressive diseases, or a propensity to develop a disease or passing on a contributing or causatory recessive genetic mutation to progeny, wherein the disease is selected from, but not limited to, the group of human disorders, including movement hyperactivity, hyperexcitability disorders (e.g. myoclonic cramping, epilepsy), excitotoxicity disorders, and neurodegeneration, in particular Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, spinal muscular atrophy, and fiber type grouping in Musculus tibialis anterior. More specifically the present invention provides diagnostic tests for latent or progressive diseases, or a propensity to develop a disease or passing on a contributing or causatory recessive genetic mutation to progeny, wherein the disease is selected from, but not limited to, the group of human motor neuron degeneration disorders, including ALS (Amyotrophic Lateral Sclerosis), SMA (Spinal Muscular Atrophy), SBMA (Bulbo-Spinal Muscular Atrophy), PBP (progressive Bulbar Palsy), PMA (Progressive Muscular Atrophy), and PLS (Primary Lateral Sclerosis).

SUMMARY OF THE INVENTION

This invention provides *inter alia* a non-human animal useful as a model of dynein heavy chain disorders in humans, particularly cytoplasmic dynein heavy chain1 disorders.

In one embodiment, the invention provides an animal model which carries a mutated cytoplasmic dynein heavy chain1 gene encoding a cytoplasmic dynein heavy chain1 protein with a modified amino acid sequence compared to the wild type sequence. The invention also provides cell lines derived from the animal model of the present invention.

The present invention also relates to the use of the animal model of the invention for the study of disorders associated with deficiencies or malfunctions in cytoplasmic dynein heavy chain1. In one embodiment, the invention provides methods of diagnosis for deficiencies or malfunction in cytoplasmic dynein heavy chain1 or the gene encoding it. In another embodiment, the invention provides a method for screening of preventive or therapeutic agents of disorders and symptoms associated with movement hyperactivity, hyperexcitability disorders (e.g. myoclonic cramping, epilepsy), excitotoxicity disorders and neurodegenerative diseases; overactivity or undesirable activity of endogenous cytoplasmic dynein heavy chain1; overexpression, over-production or under-production of endogenous cytoplasmic dynein heavy chain1; an excessive or undesirable condition shown to be modulated by endogenous cytoplasmic dynein heavy chain1.

25

Furthermore, the present invention provides mutated cytoplasmic dynein heavy chain1 nucleic acids and amino acids having modified sequences compared to the wild type sequence, as well as vectors and cell lines for expressing the muteins recombinantly. These mutated nucleic acids and amino acids may also be used in the diagnostic and therapeutic methods contemplated herein. In a specific embodiment, the cytoplasmic dynein heavy chain1 mutein has an amino acid substitution at a position that corresponds to a conserved amino acid of mouse or human cytoplasmic

30

dynein heavy chain 1 as described in an individualized manner in connection with the preferred muteins of the invention below. In a specific embodiment, the cytoplasmic dynein heavy chain1 mutein has an amino acid substitution, e.g., at position 1055 resulting from a point mutation at nucleotide +3169 of the coding sequence, corresponding to position 3328 of SEQ ID NO:1 (Genbank Acc. No. AY004877; murine Dnchc1 mRNA). Also provided are recombinantly generated cytoplasmic dynein heavy chain1 muteins of the invention (both the murine and human orthologs), as well as antibodies binding to these muteins, and chimeric protein derivatives of these cytoplasmic dynein heavy chain1 muteins.

10

Uses of these muteins as modulators (e.g. agonists or antagonists) of endogenous cytoplasmic dynein heavy chain1 activity are also contemplated. Consequently, pharmaceutical compositions comprising the cytoplasmic dynein heavy chain1 muteins of this invention with or without a pharmaceutically acceptable carrier are also contemplated. Specifically, the invention includes the use of the cytoplasmic dynein heavy chain1 muteins of the present invention, the polynucleotides encoding them, and vectors bearing said polynucleotides, for the prevention, treatment or amelioration of a medical condition in a mammalian subject, particularly a human subject. In particular, the invention provides the use of these muteins for the manufacture of a medicament for prevention, treatment or amelioration of any medical conditions characterized by movement hyperactivity, hyperexcitability disorders (e.g. myoclonic cramping, epilepsy), excitotoxicity disorders and neurodegeneration.

15

The invention also includes a method of gene delivery and expression in a target cell of a mammal, comprising the step of introducing a viral vector into the target cell, wherein the viral vector is derived from a virus that has a low replicative efficiency in the target cell and has at least one insertion site containing a wild type or mutant cytoplasmic dynein heavy chain1 nucleic acid, wherein the nucleic acid is operably linked to a promoter capable of expression in the host. In a preferred embodiment, the viral vector is a non-lytic viral vector.

25

30

The invention also provides a method of gene delivery and expression in a target cell of a mammal comprising the steps of: (a) providing an isolated nucleic acid

fragment of wild type or mutant cytoplasmic dynein heavy chain1 of the invention; (b) selecting a viral vector derived from a virus that has a low replicative efficiency in the target cell, wherein the vector has at least one insertion site for insertion of said isolated nucleic acid fragment operably linked to a promoter capable of expression in the target cells; (c) inserting the isolated nucleic acid fragment into the insertion site, and (d) introducing the vector into said target cell wherein said gene is expressed at detectable levels. In a preferred embodiment, the virus is selected from the group consisting of retrovirus, adenovirus, and pox virus. In another embodiment, the virus is a strain that has been genetically modified or selected to be non-virulent in a host. In another embodiment, the pox virus is vaccinia. In one embodiment, the virus is selected from the group consisting of retrovirus, adenovirus, iridoviruses, coronaviruses, togaviruses, caliciviruses and picornaviruses.

In the context of the present invention it has been recognized that all members (or subunits) of the dynein-dynactin complex should be considered as suitable targets for screening for a predisposition in hereditary and sporadic forms of motor neuron degenerative diseases like ALS (Amyotrophic Lateral Sclerosis), SMA (Spinal Muscular Atrophy), SBMA (Bulbo-Spinal Muscular Atrophy), PBP (progressive Bulbar Palpsy), PMA (Progressive Muscular Atrophy), and PLS (Primary Lateral Sclerosis). It is also contemplated that not only diseases such as ALS but also other neurodegenerative disorders will be connected to mutations or alterations within the dynein-dynactin complex. This applies, e.g., to disorders which are connected to axonal transport dysfunction such as Huntington's disease (dynein-dynactin binds Huntington associated binding protein 1 (Hap1)), Parkinson's disease (demonstration of inclusion body formation similar to ALS indicated intracellular transport errors) or Alzheimer's disease (disturbance of glutamate homeostasis similar to ALS could be a result of altered retrograde axonal transport kinetics). Thus, such neurodegenerative diseases are likewise disease targets contemplated e.g. in connection with the methods of screening for a predisposition for a neurodegenerative disease according to the present invention.

Accordingly, the present invention provides in a further embodiment a method of identifying a protein or nucleic acid marker indicative of an increased risk of a mammalian subject, particularly a human subject, or a mouse, a rat, a rabbit, a cow or

a hamster, preferably a mouse or a rat, of developing a neurodegenerative disease, said method comprising the step of analyzing a test sample derived from said subject for the presence of a difference compared to a similar test sample if derived from a subject of the same species unaffected by or known not to be at risk of developing
5 said disease, wherein said difference is indicative of the presence of a mutation in an allele of a gene coding for a protein, which is a subunit of the dynactin/dynein complex.

In a further aspect, the present invention provides a method of identifying a
10 protein or nucleic acid marker indicative of an association of a neurodegenerative disease in a mammalian subject, particularly a human subject, or a mouse, a rat, a rabbit, a cow or a hamster, preferably a mouse or a rat, with a mutation in an allele of a gene coding for a protein, which is a subunit of the dynactin/dynein complex.

15 In yet a further aspect of the present invention, a method is provided for identifying a predisposition of a mammalian subject, particularly a human subject, or a mouse, a rat, a rabbit, a cow or a hamster, preferably a mouse or a rat, for developing a neurodegenerative disease, said method comprising the step of determining whether a test sample derived from said subject indicates the presence of
20 a mutation in an allele of a gene coding for a protein, which is a subunit of the dynactin/dynein complex, indicative of an increased risk of said subject of developing said neurodegenerative disease.

Also provided is a method for determining whether a neurodegenerative
25 disease in a mammalian subject, particularly a human subject, or a mouse, a rat, a rabbit, a cow or a hamster, preferably a mouse or a rat, is associated with a mutation in an allele of a gene coding for a protein, which is a subunit of the dynactin/dynein complex, said method comprising the step of determining whether a test sample derived from said subject indicates the presence of a mutation in an allele of a gene
30 coding for said protein.

In yet another aspect of the present invention, oligonucleotides suitable for identifying the above-mentioned mutations, kits containing such oligonucleotides, and

solid supports, such as DNA chips, to which said oligonucleotides are bound, are provided.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In addition, the examples are illustrative only and are not intended to be limiting.

Features and advantages of the invention in addition to those explained above will be apparent from the following detailed description and claims.

15

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 presents a heterozygous *Cra1* animal (right) compared to a wildtype mouse (left) demonstrating cramping of the hindlimbs and forelimbs of the mutant animal.

20

Figure 2 is a chart diagram, indicating movement as ambulatory activity expressed as beam breaks (average counts per hour) detected by a Cage Rack Photobeam Activity Cage System (San Diego Instruments, Inc., San Diego, CA, USA) of heterozygous *Cra1* (*Cra1*+/+) animals and wildtype individuals during four 6-hour periods of an artificial 24 hour diurnal cycle, in which darkness lasted from 6pm to 6am, and the period from 6 am to 6 pm was light.

25

Figure 3 is a listing of the latency to fall values (seconds) of heterozygous *Cra1* mice (*Cra1*+/+) and control individuals (+/+) in a semi-quantitative hanging wire assay. Muscle endurance of adult heterozygous *Cra1* individuals (*Cra1*+/+) was measured in comparison to wildtype individuals by measuring the mouse's latency to fall from an inverted wire grid, as described in Example 3.

30

Figure 4 depicts photomicrographs of hematoxylin and eosin (H&E) stained histological sections of a *Cra1*^{+/+} and a wildtype mouse hippocampus. Neurons characterized by reversible excitatory neuronal damage can be identified by the dark staining ("dark neurons"; indicated by arrows). (See Example 5)

5

Figure 5 depicts photomicrographs of cross sections of the lumbar area of spinal cords from a wild type (left panel) and a homozygous *Cra1*/*Cra1* individual (right panel). The top row photomicrographs depicts a drastic reduction of the number of neurons in the anterior horn area of the *Cra1*/*Cra1* individual (right), as compared to the wildtype (left). In the middle row, TUNEL stains of anterior horn are shown (see arrow), demonstrating significantly enhanced levels of apoptosis in the anterior horns of the *Cra1*/*Cra1* individuals (right). In the upper row of photomicrographs a reduction is seen in the number of spinal ganglia neurons of *Cra1*/*Cra1* individuals (right).

15

Figure 5.2 shows that progressive impairment of muscle function and motor coordination is associated with decreasing numbers of α -motor neurons and altered composition of muscle fibre types. Motor neuron degeneration in 16 month old *Cra1*^{+/+} heterozygotes (b, d, f) mice in comparison to wildtype (+/+) littermates (a, c, e) (a-d: immunohistochemistry using NeuN primary antibody; e, f: H&E histochemical staining). Loss of spinal α -motor neurons in 16 months old *Cra1*^{+/+} (h) mice is accompanied by altered composition of muscle fibre types, with a predominance of large type 1 fibres in Periodic acid-Schiff (PAS) staining, compared to +/+ littermates (g).

25

Figure 6 represents a list of selected genes expressed in fetal brain of individual *Cra1*/*Cra1* mice, shown to be transcriptionally deregulated by comparison of transcript levels to those detected in wildtype individuals. The direction of deregulation (up or down) and the biological significance of those genes is indicated.

30

Figure 7 schematically depicts an exon structure comparison of the human cytoplasmic dynein heavy chain1 (HsDNCH1) and the mouse cytoplasmic dynein heavy chain1 (MmDnchc1) genes. Exonic sequences were aligned with sequencer software (version 4.0.5, GeneCodes Corp., Ann Arbor Mi, USA). Assembly of the

human exons and the mouse exons, respectively, results in a full-length cDNA of human DNCH1 and a full-length cDNA of mouse Dnchc1 (representing the protein coding sequence within the mRNA, defined under GenBank Accession No. AY004877) as indicated by the arrows at the top of the figure. Equivalent exons are paired, with the human exon positioned above the corresponding mouse exon.

Figure 8 is a comparative listing of all exons of the mouse (MmDnchc1) and human (Hs DNCH1) dynein heavy chain1 genes. The size of each exon is indicated by its length in basepairs (bp). The human gene consists of 78 exons, and the mouse gene consists of 77 exons. The difference in exon number between these two species is caused by an additional RNA splice event in human, separating exon 67 (61 bp) and exon 68 (124 bp); mouse exon 67 having 185 bp.

Figure 9 depicts the amino acid sequence alignment between the human (Hs DNCH1) and the mouse (Mm Dnchc1) cytoplasmic dynein heavy chain1 proteins. Black boxes indicate amino acid identity, and grey boxes indicate conserved amino acid substitutions. The degree of identity is 97%.

Figure 10 depicts the amino acid sequence alignment between the human (Hs DNCH1), the mouse (Mm Dnchc1), and the rat cytoplasmic dynein heavy chain1 proteins, indicating highly conserved amino acid residues between species. Black boxes indicate amino acid identity, and grey boxes indicate conserved amino acid substitutions. The degree of identity is 96%.

Figure 11 depicts the amino acid sequence alignment between the human and the mouse cytoplasmic dynein intermediate chain 1 proteins. Black boxes indicate amino acid identity, and grey boxes indicate conserved amino acid substitutions. The degree of identity is 88%.

Figure 12 depicts the amino acid sequence alignment between the human, the mouse, and the rat cytoplasmic dynein intermediate chain 1 proteins, indicating highly conserved amino acid residues between species. Black boxes indicate amino acid identity, and grey boxes indicate conserved amino acid substitutions. The degree of identity is 87%.

Figure 13 depicts the amino acid sequence alignment between the human and the mouse cytoplasmic dynein intermediate chain 2 proteins. Black boxes indicate amino acid identity, and grey boxes indicate conserved amino acid substitutions. The degree of identity is 94%.

Figure 14 depicts the amino acid sequence alignment between the human, the mouse, and the rat cytoplasmic dynein intermediate chain 2 proteins, indicating highly conserved amino acid residues between species. Black boxes indicate amino acid identity, and grey boxes indicate conserved amino acid substitutions. The degree of identity is 93.5%.

Figure 15 depicts the amino acid sequence alignment between the human and the mouse DCTN1 proteins. Black boxes indicate amino acid identity, and grey boxes indicate conserved amino acid substitutions. The degree of identity is 97%.

Figure 16 depicts the amino acid sequence alignment between the human, the mouse, and the rat DCTN 1 proteins, indicating highly conserved amino acid residues between species. Black boxes indicate amino acid identity, and grey boxes indicate conserved amino acid substitutions. The degree of identity is 95%.

DETAILED DESCRIPTION OF THE INVENTION

This invention provides a non-human animal useful as a model of dynein heavy chain disorders in humans, particularly cytoplasmic dynein heavy chain1 disorders. The *Cral* mutation, disclosed herein, was generated in offspring of male C3HeB/FeJ mice (*Cral*, Institute of Mammalian Genetics at the GSF – National Research Center for Environment and Health) mutagenized with *N*-ethyl-*N*-nitrosourea (ENU). The mutation was detected by *Cral* mice displaying an unusual twisting of the body and clenching of the hindlimbs when suspended by the tail. Subsequent breeding and phenotype analysis showed *Cral* as an autosomal dominant trait that gives rise to progressive loss of muscle tone and locomotor ability in heterozygous mice, although life-span appears normal. Furthermore, *Cral*

heterozygotes were impaired in motor coordination tests and in muscle function tests. Homozygous *Cral* mice die shortly after birth, and exhibit increased neuronal apoptosis. It is predicted that these homozygous mice also have neuronal inclusion bodies that are positive for both neurofilaments and SOD1 protein. This result
5 implicates modulation of dynein gene function in mechanisms of human motor neuron degeneration, and cell death in general. It also shows an unexpected link between the dynein complex and SOD1 function that may shed further light on why SOD1 mutations cause motor neuron degeneration and ALS.

10 Dyneins are implicated in a number of different diseases and disorders. Abnormalities in axonal transport are described in the human disease ALS (Sasaki and Iwata (1996) *Neurology* 47, 535-540). Such abnormalities are also observed in several mouse models with motor neuron degeneration, *e.g.* the wobbler mouse (Mitsumoto *et al.* (1986) *Ann Neurol* 19, 36-43) and transgenic mice overexpressing the heavy chain
15 of neurofilament protein (Collard *et al.* (1995) *Nature* 375, 61-64), SOD-1 (Zhang *et al.* (1997) *J Cell Biol* 139, 1307-1315) and dynamin (LaMonte *et al.* (2002) *Neuron* 34, 715-727). Studies in *Drosophila* have shown that mutations in the cytoplasmic dynein heavy chain (cDhc64c) lead to a disruption of axonal organelle transport in both directions and as a consequence to axonal swelling and posterior paralysis
20 (Martin *et al.* (1999) *Mol Biol Cell* 10, 3717-3728).

In contrast to the dynactin-overexpressing transgenic mouse described by LaMonte *et al.* ((2002) *Neuron* 34, 715-727) which is characterized by an indirect mechanism of inhibition of dynein function in only the neurons, the mouse mutant of
25 the present invention is suitable to investigate the role of cytoplasmic dynein heavy chain1 not only in transport processes in neurons but in all cell types expressing cytoplasmic dynein heavy chain1. Additionally, the mouse mutant of the present invention enables the analysis of cytoplasmic dynein malfunction during development whereas the transgenic mouse described by LaMonte *et al.* ((2002) *Neuron* 34, 715-
30 727) does not express the transgene before birth and, therefore, it is characterized by a late onset of symptoms. It has been shown that dynein can associate with its cargo also through interactions with proteins other than dynactin (for review: Karcher *et al.* (2002) *Trends in Cell Biology* 12, 21-27). Since the mutation found in the cytoplasmic dynein heavy chain 1 gene of the mouse mutant of the present invention

is located outside the binding site for the dynein intermediate chains which impart the binding of dynactin, the mouse mutant of the present invention will prove useful for studying dynactin-independent dynein functions.

5 Apart from diseases characterized by motoneuron degeneration other types of neurodegenerative diseases and age-related neurodegenerative processes may be related to disturbances of axonal transport. One example is the atrophy of basal forebrain cholinergic neurons in the rat which have been shown to be accompanied by an impairment of uptake or retrograde transport of tracer molecules (De Lacalle et al,
10 (1996) *Neuroscience* 75, 19-27). It is predicted that dynein function may play a role in the development of such neurodegenerative diseases and age-related neurodegenerative processes, and embodiments of the invention include correlative diagnostic methods, therapeutic medicaments and treatments, as described in greater detail below.

15

Another example is Huntington's disease. HAP1, a neuronal cytoplasmic protein, is associated with huntingtin, the protein which carries a polyglutamine repeat that is expanded in Huntington's disease (>36 units). It has been shown that the affinity of HAP1 for huntingtin is increased if the latter bears an expanded
20 polyglutamine repeat (cf Li et al. (2002) *J Biol Chem*, in press). HAP1 has been found on synaptic vesicles (Gutekunst et al. (1998) *J Neurosci* 18, 7674-7686) and it binds to P150 (Li et al. (1998) *J Biol Chem* 273, 19220-19227), the largest subunit of the dynactin complex, which in turn, is required for cytoplasmic dynein mediated intracellular movement including retrograde axonal transport. Functional results
25 obtained by Block-Galarza ((1997) *Neuroreport* 8, 2247-2251) are in agreement with this potential link between huntingtin and dynein-mediated axonal transport processes. Additionally, Li et al. ((2002) *J Biol Chem*, in press) provided evidence that HAP1 is involved in the regulation of vesicular trafficking from early endosomes to the late endocytotic compartment as does dynein (Apodaca (2001) *Traffic* 2, 149-159).
30 Recent work by Kamal et al. (2000, *Neuron* 28, 449-459) suggests that the amyloid precursor protein (APP), which plays a major role in the development of Alzheimer's disease might function as a membrane bound cargo receptor for kinesin which is responsible for the anterograde transport of vesicles in neurons. Gunawardena and Goldstein ((2001) *Neuron* 32, 389-401) again found that the axonal transport

phenotypes of certain Appl (the Drosophila homolog of APP) mutants are suppressed by a reduction of dynein expression. This result for the first time suggests a functional link between dynein and APP.

5 The mouse mutant of the present invention provides a means to analyze whether three proteins (huntingtin, HAP1 and APP) involved in the pathogenesis of the neurodegenerative diseases, Huntington's disease and Alzheimer's dementia are linked by the same intracellular transport pathways. This connection will help reveal the pathogenetic mechanisms of both diseases.

10

Lissencephaly syndromes are a family of diseases which involve incomplete development of the human brain (Dobyns et al. (1993) JAMA 270, 2838-2842) characterized by extensive disorganization of cortical neurons. This defect is thought to be due to a failure of the capability of neuronal cell body migration during the early stage of brain development. As a consequence of this, the convolutions characteristic of the normal brain surface are reduced in extent and number leading to a smooth appearance of wide portions of the brain.

20 Syndromes involving lissencephaly include Norman-Roberts Syndrome, Fukuyama Syndrome, Walker-Warberg Syndrome and Miller-Dieker Syndrome. Some cases of isolated lissencephaly have been shown to arise from mutations in the LIS-1 gene (e.g. Lo Nigro et al. (1997) Hum Mol Genet 6, 157-164).

25 Recent work has implicated the human LIS-1 gene in the regulation of function of cytoplasmic dyneins (for review see Vallee et al. (2000) Biochim Biophys Acta 1496, 89-98). Neurons in genetic mosaics of Drosophila which contain a mutated cytoplasmic dynein heavy chain (Dhc64C) display phenotypes similar to Lis 1 mutants (Liu et al. (2000) Nat Cell Biol 2, 776-783). We predict that deregulation of cytoplasmic dynein might be of causative relevance for the development of lissencephalic symptoms.

30

Homozygous null mice for the Lis1 gene die early in embryogenesis whereas mice bearing mutations which cause different degrees of reduction of the function of Lis1 exhibit corresponding degrees of brain disorganization as well as cerebellar

defects (Hirotsume et al. (1998) Nature Genetics 19, 333-339). The mouse mutant of the present invention provides a mean to comparatively analyze the overlap and the differences of cytoplasmic dynein and Lis 1 function in a mammalian model organism.

5

The homozygous knockout of the gene encoding cytoplasmic dynein heavy chain1 in the mouse results in embryonic lethality before 8.5 days post coitus. Heterozygous individuals have no obvious phenotype (Harada et al. (1998) J Cell Biol 141, 51-59). The transgenic dynamitin-overexpressing mouse described by LaMonte et al. ((2002) Neuron 34, 715-727) is characterized by a motoneuron specific inhibition of the functions of cytoplasmic dynein, which is mediated by the accessory protein complex dynactin. Due to the developmental regulation of the transgene by the Thy2 promotor of the transgene construct, inhibition is restricted to postnatal stages.

15

There is no animal model available which reflects the consequences of malfunction of cytoplasmic dynein heavy chain1 in vivo in all types of cells and during embryonic and fetal development. The mutation leading to cytoplasmic dynein heavy chain1 dysfunction in the mouse model of the present invention is located within a region of cytoplasmic dynein heavy chain1 dimerization (Tynan et al. (2000) J Biol Chem 275, 32769-32774) which does not overlap with intermediate chain binding. Intermediate chain binding is required for dynactin binding although Vaughan and Vallee ((1995) J Cell Biol 131, 1507-1516) and Tynan et al. ((2000) J Biol Chem 275, 32769-32774) have provided evidence for the existence of non-dynactin based cargo binding mechanisms.

25

The characterization of such an animal model (*i.e.* one that reflects the consequences of malfunction of cytoplasmic dynein heavy chain1 *in vivo* in all types of cells and during embryonic and fetal development) would provide a model for determining the consequences of cytoplasmic dynein malfunction in humans. This in turn would help to evaluate the role of dynein malfunction in various disease processes such as those described above.

30

The present invention provides a non-human animal model which expresses a modified cytoplasmic dynein heavy chain1 protein compared to the amino acid sequence of the wild type protein. The expressed cytoplasmic dynein heavy chain1 may have similarity in sequence and secondary structure to a vertebrate cytoplasmic
5 dynein heavy chain1. In a preferred embodiment, the vertebrate is preferably from a genus selected from the group consisting of *Homo sapiens*, *Mus musculus* (e.g. mice), *Rattus* (e.g. rats), *Oryctolagus* (e.g. rabbits) and *Mesocricetus* (e.g. hamsters).

Animals carrying a mutated cytoplasmic dynein heavy chain1 allele expressing
10 the modified cytoplasmic dynein heavy chain1, exhibit a variety of phenotypical features including: myoclonic cramps (which are especially pronounced in the hindlimbs), movement hyperactivity, reduced muscle endurance, excitatory neuronal damage ("dark neurons") in the hippocampus (gyrus dentatus, CA4, CA3) as well as in the upper layer of the cortex and in the Purkinje cell layer of the cerebellum. These
15 animals also exhibit decreasing numbers of α -motor neurons and altered composition of musculus vastus fibre types.

Compared with heterozygous animals, homozygous individuals exhibit an elevated incidence of perinatal lethality (100% in homozygous animals, *versus*
20 approximately 20% amongst heterozygous animals), accelerated neurondegeneration in the anterior horns of the spinal cord, and accelerated neurodegeneration in the dorsal root ganglia. Neurodegeneration in heterozygous animals is apparent at a much later stage, *i.e.* late adulthood.

25 The observed neurological phenotype of myoclonic cramping and epilepsy in combination with the morphological correlate of reversible excitatory neuronal cell stress within the hippocampal layers CA4 and CA3 are indications for a hyperexcitability status in Cra1 animals. This in turn is consistent with an ambulatory locomotor hyperactivity of Cra1 animals. Hyperexcitation, if occurring repeatedly or
30 continuously over longer periods of time, could result in excitotoxicity by mechanisms such as enhanced generation of reactive oxygen species (ROS) (see Haberny *et al.* (2002) Toxicol Sci, 68, 9-17; Bondy and LeBel, (1993) Free Radic Biol Med 14, 633-642; Tapia *et al.* (1993) Neurochem Int 34, 23-31; Niebroj-Dobosz *et al.* (2002) Acta Neurol Scand 106, 39-43; Shaw and Bains (2002) Cell Mol Biol

(Noisy-le-grand) 48, 127-136). ROS are suggested to be involved in the development of several neurodegenerative disorders, *e.g.* ALS, Parkinson's disease and Alzheimer's disease as well as aging. Therefore there is a possible link between the hyperexcitation status in Cral animals and the development of neurodegeneration at a later age.

The term "modified" according to the present invention refers to an alteration compared to the wild type. The term "phenotype" according to the invention refers to a collection of morphological, physiological, behavioral and biochemical traits possessed by a cell or organism that results from the interaction of the genotype and the environment. As mentioned above, the animal model of the present invention displays readily observable abnormalities. In a preferred embodiment the animal of the invention shows at least 2, preferably at least 4, more preferably 6 and most preferably all of the above listed phenotypical features.

15

Nucleic Acids

The present invention provides nucleic acid sequences encoding wild type and mutated murine and human cytoplasmic dynein heavy chain1 proteins, *i.e.*, muteins as described in an individualized manner in connection with the preferred muteins of the invention below. Specifically, this invention provides mutated nucleic acid sequences for wild type murine cytoplasmic dynein heavy chain1 mRNA (GenBank Accession Number AY004877.1, SEQ ID NO:1). For example, a mutated version of SEQ ID NO:1, containing a point mutation at position 3328 (which is position +3164 of the polypeptide coding sequence) is shown in SEQ ID NO:3. In addition, this invention provides a mutated coding nucleic acid sequence for human cytoplasmic dynein heavy chain1 containing the open reading frame for the human ortholog nucleic acid sequence, with a point mutation at the corresponding position (position +3170) in the sequence, as shown in SEQ ID NO:5. In addition, this invention provides the wild type coding nucleic acid sequence for human cytoplasmic dynein heavy chain1, as shown in SEQ ID NO:17.

30

Table 1. GenBank Accession Number AY004877.1 (SEQ ID NO:1)

gi|9717244|gb|AY004877.1| Mus musculus cytoplasmic dynein heavy chain1 mRNA, complete cds

35

GCCGCGTTCGACAGCCGGCTCCGCTGTCCGCAGTCGGCCGCGGGTT
AGCGGGCAGAGCGTCTCCTGTCGCCGGTTCCCCTCGCTTACTGCT
CTCTCGTGCCGGAGGCCGCTCCTCTCGGCTCTCGCTCTCTCTT
5 TCTATCTCTCTCCCTTCCGCGGATCCGCCATGTCGGAGCCGGGCG
GCGGCGAGGACGGCTCGGCAGGCCTGGAGGTGTCGGCGGTGCAGA
ATGTGGCGGACGTGGCGGTGCTGCAGAAGCACCTGCGTAAGCTGG
TGCCGCTGCTGCTGGAGGACGGCGGCGACGCGCCGGCTGCGCTGG
AGCGGGCGCTGGAGGAGAAGAGCGCCCTGGAGCAGATGCGCAAGT
10 TCCTGTCAGACCCGACAGGTCCACACGGTCTTGGTGGAGCGCTCCA
CCCTCAAAGAGGACGTTGGTGATGAAGGAGAAGAGGAGAAAGAAT
TCATTTCTTATAACATCAACATAGACATTATTACGGGGTAAAGT
CCAACAGCTTGGCGTTCATCAAGCGAGCTCCTGTGATTGATGCAG
ACAAGCCAGTGTCGTCCCAGCTCCGAGTCCTCACTCTGAGTGAAG
15 ACTCGCCGTATGAGACACTGCACTCTTTCATCAGCAATGCAGTGG
CTCCTTTCTTTAAGTCTACATCAGAGAGTCTGGCAAAGCAGACA
GGGATGGTGATAAGATGGCTCCTTCAGTTGAAAAAAGATTGCAG
AGCTTGAAATGGGACTCCTCCACCTGCAGCAGAACATTGAGATCC
CAGAGATCAGCTTGCCAAATTCATCCCATCATCACGAACGTTGCGA
20 AGCAGTGCTATGAGCGCGGAGAAAAGCCCAAAGTTACAGATTTTG
GTGATAAGGTTGAAGACCCAACCTTCTTAAACCAATTACAGTCTG
GAGTTAATCGGTGGATCCGAGAAATTCAAAAGGTGACCAAGCTTG
ACCGGGATCCAGCATCAGGAAGTGCCTTGCAGGAAATCAGCTTTT
GGCTAAACTTGGAACGTGCGTTGTACCGCATCCAAGAGAAGCGGG
25 AGAGCCCCGAGGTGCTCCTGACTCTGGACATCCTGAAGCATGGCA
AACGTTTCCATGCCACTGTGAGTTTTGACACTGACACAGGTCTGA
AGCAGGCGTTGGAAACGGTGAATGACTACAACCTCTGATGAAAG
ACTTCCCTCTGAATGACTTGCTGTCTGCCACGGAGCTGGACAAGA
TAAGGCAGGCCCTTGTTGCAATTTTTCACACATCTGAGAAAGATCC
30 GCAACACGAAGTACCCGATTACGCGGGCCCTGCGTCTCGTGGAGG
CCATCTCCAGAGACCTGAGTTCTCAGCTGCTCAAGGTCTTGGGCA
CTCGGAAGTTGATGCATGTAGCCTATGAAGAGTTTGAAAAGGTCA
TGCTGGCTTGCTTCGAAGTCTTCCAGACGTGGGACGACGAGTACG
AGAAGCTCCAGGTGCTGCTGCGAGACATCGTCAAGAGGAAGCGGG
35 AGGAGAACCTGAAGATGGTGTGGCGCATCAACCCCGCTCACAGGA
AGCTTCAGGCCCGCCTCGACCAGATGAGGAAGTTCCGCCGCCAGC
ACGAGCAGCTGAGGGCTGTCATTGTGAGGGTCCTGAGGCCACAGG
TCACAGCAGTCGCACAACAGAACCAAGGAGAAGCACCTGAACCCC
AAGACATGAAAGTGGCCGAGGTGCTCTTTGATGCTGCCGACGCCA
40 ACACCATTGAGGAGGTGAACCTGGCCTACGAGAATGTCAAGGAAG
TCGATGGTCTGGATGTTTCCAAAGAAGGGACGGAGGCCTGGGAGG
CCGCGATGAAGAGATACGATGAGAGGATCGACCGTGTGGAGACCC
GCATCACCGCCCCGCTCCGAGATCAGCTCGGCACGGCCAAGAATG
CCAATGAGATGTTTCAGGATTTTCTCCAGGTTCAATGCACTGTTTCG
45 TCCGCCCCACACATCCGAGGGGCCATTTCGTGAATACCAGACCCAGC
TGATCCAACGTGTGAAAGATGACATCGAATCTCTGCACGACAAGT
TCAAGGTCCAGTACCCGCAAAGCCAAGCTTGTAATAAGATCATG
TCCGTGACCTGCCCCCGTGTGAGGGTCTATCATCTGGGCTAAAC
AGATCGACAGACAGCTCACTGCCTACATGAAGCGAGTGGAGGATG
50 TCCTGGGCAAAGGCTGGGAGAACCACGTGGAAGGGCAGAAGCTGA
AGCAGGATGGAGACAGCTTCCGAATGAAGCTCAACACCCAGGAGA
TCTTCGATGACTGGGCGAGGAAGGTTTCAGCAGCGCAACCTTGGTG
TCTCCGGGCGCATCTTCACCATGAGAGCGCTCGCGTGCGGGGCC
GCACCTGGGAATGTCCTCAAGCTAAAGGTGAACTTCCTTCCAGAGA
55 TCATAACACTCTCCAAAGAAGTCCGGAACCTCAAGTGGCTTGGCT
TCCGAGTGCCACTTGCAATTGTGAACAAGGCTCACCAAGCCAACC

AGCTCTACCCATTTGCCATCTCGCTGATTGAAAGCGTCCGGACTT
ACGAGCGCACCTGTGAGAAGGTGGAGGAGCGCAATACCATTTCCC
TGCTAGTGGCCGGCCTAAAGAAGGAGGTGCAGGCCTTAATCGCAG
AAGGCATCGCGTTGGTGTGGGAGTCCTACAAGCTCGACCCCTACG
5 TGCAGCGCCTGGCAGAGACGGTTTTTCAACTTCCAGGAGAAGGTGG
ACGACCTACTGATTATTGAGGAAAAGATAGACCTGGAGGTCCGCT
CCTTGGAACCTGCATGTATGACCACAAGACATTCTCAGAGATCT
TGAACAGAGTGCAGAAAGCAGTGGACGACCTAAACCTGCACTCCT
ATTCCAATCTGCCCATCTGGGTCAACAAGCTGGACATGGAGATTG
10 AAAGGATACTGGGCGTCCGCCTGCAAGCTGGCCTTCGAGCTTGA
CCCAGGTTCTTCTTGGACAAGCTGAGGATAAAGCAGAAGTCGACA
TGGATACAGATGCTCCACAAGTCAGTCACAAGCCTGGTGGAGAGC
CCAAGATCAAAAACGTGGTTCACGAGCTGAGGATAACAAATCAGG
TCATCTATCTGAACCCACCCATTGAGGAGTGCAGGTACAAGCTGT
15 ACCAGGAGATGTTTCGCGTGGAAAGATGGTGTGTGCTGTCCCTGCCCA
GGATCCAGAGCCAGAGGTACCAGGTGGGAGTGCATTACGAGTTGA
CGGAGGAAGAGAAGTTCTATCGGAATGCACTGACAAGGATGCCCG
ACGGCCCTGTTCGCCCTGGAAGAGTCCCTACTCTGCGGTTCATGGGCA
TAGTGAAGTTGAGCAGTATGTTAAGGTTTGGCTTCAGTACC
20 AGTGTGTTGTGGGATATGCAGGCAGAAAACATTTACAACAGGCTAG
GGGAAGATCTCAACAAGTGGCAAGCTCTCCTGGTCCAGATAAGGA
AAGCCAGAGGAACCTTTGACAATGCGGAAACCAAGAAAGAGTTTG
GTCCGGTGGTGATAGATTACGGCAAGGTCCAGTCCAAGGTGAACT
TGAAGTATGACTCCTGGCATAAGGAGGTTCTCAGCAAGTTTGGGC
25 AGATGCTGGGCTCAAACATGACAGAATTCCTACTCCCAGATCTCAA
AGTCTCGCCAAGAGCTGGAGCAGCACTCCGTTGACACAGCCAGTA
CCTCTGACGCGGTGACCTTCATCACCTATGTGCAGTCTCTGAAAC
GGAAGATCAAACAGTTTGAGAAGCAAGTTGAACTCTACCGCAATG
GTCAGCGTCTGCTGGAAAAACAAAGGTTCCAGTTCCCGCCTTCTT
30 GGCTTTACATTGACAACATCGAGGGTGAGTGGGGGGCCTTCAATG
ACATCATGCGGCGGAAGGACTCTGCCATTACAGCAACAGGTGGCAA
ACCTGCAAATGAAGATCGTACAGGAGGACAGAGCTGTGGAAAGCC
GGACCACGGATCTGTTGACAGACTGGGAGAAGACCAACCTGTCA
CAGGCAATCTGCGTCTGAGGAGGCTCTTCAGGCCCTCACCATAT
35 ATGAAGGGAAGTTTCGGCCGGCTGAAGGACGACAGAGAGAAATGTG
CAAAGGCTAAGGAAGCGTTGGAACCTCACAGACACAGGCCTCCTCA
GTGGCAGTGAAGAGCGTGTACAGGTGGCCTTGGAGGAGTTACAAG
ACCTCAAAGGTGTGTGGTCAGAGCTTTCTAAGGTCTGGGAACAAA
TTGATCAAATGAAGGAGCAGCCGTGGGTCTCCGTTACGCCTCGGA
40 AGCTTCGACAAAACCTAGACGGCCTCTTGAACCAGCTGAAGAACT
TCCCTGCGAGGCTTCGGCAGTATGCTTCCTATGAGTTTGTTCAGA
GGCTGCTGAAAGGCTACATGAAGATAAACATGTTGGTAATTGAAC
TGAAATCAGAAGCACTCAAAGACCGGCACTGGAAACAGCTGATGA
AGAGGCTTCATGTAACTGGGTGGTTTCTGAGCTGACGCTGGGCC
45 AGATCTGGGACGTGGACCTTCAGAAGAACGAAGCTGTCGTCAAGG
ATGTGCTGCTGGTGGCACAAGGCGAGATGGCCTTGGAGAATTTT
TGAAGCAGATACGAGAAGTGTGGAACACATACGAACTAGACTTGG
TCAACTATCAGAACAAATGCCGCCTCATCCGAGGCTGGGATGACC
TCTTCAACAAGGTCAAGGAGCATATCAACAGCGTCTCTGCCATGA
50 AACTCTCTCCCTATTACAAGGTTTTTGAAGAAGATGCCCTGAGCT
GGGAGGACAAGCTGAACCGAATCATGGCTCTCTTTGACGTGTGGA
TTGACGTGCAGAGGCGCTGGGTCTACTTGAAGGCATCTTCACAG
GCAGTGCAGGACATCAAACATCTGCTGCCTGTGGAAACCCAGCGCT
TCCAGAGTATCAGCACGGAGTTTTTGGCTCTGATGAAAAAGTCT
55 CCAAGTCTCCACTTGTGATGGATGTTCTGAACATACAGGGAGTCC
AGAGGTCTCTGGAAGGTTGGCAGACCTGCTGGGGAAGATCCAGA

AAGCATTGGGGGAGTACCTGGAACGGGAGCGCTCGTCTTTCCCCA
GGTTCTACTTTGTGGGTGATGAGGATTTGCTTGAGATCATTGGGA
ATAGCAAGAACGTGGCTAAGTTGCAGAAGCACTTCAAGAAAATGT
TGGCCGGCGTTTCCAGCATCATCTTAAATGAGGATAACTCTGTGG
5 TCCTCGGCATCTCATCCCAGAAAGGGGAGGAGGTTATGTTTAAAA
CTCCAGTGTCCATCACTGAACACCCCAAAATCAATGAGTGGCTCA
CTCTGGTGGAAAAGGAGATGAGAGTCACCTTGGCTAAACTTCTGG
CAGAGTCTGTTACAGAAGTGGAGATTTTTGGAAAAGCAACTTCTA
TTGACCCAAATACCTACATTACTTGGATTGATAAATACCAGGCCC
10 AGCTAGTGGTATTGTGAGCCAGATAGCCTGGTCCGAGAACGTGG
AGAATGCGCTGAGCAACGTTGGGGGAGGTGGTGATGTGGGGCCCT
TGCAGTCTGTGCTGAGCAATGTGGAGGTCACTCAACGTCTTAG
CGGACTCTGTCCTCATGGAGCAGCCTCCTCTCCGGAGACGGAAGC
TGGAGCACTTGATCACAGAGCTGGTTCACCAAAGAGACGTTACCA
15 GGTCCTTGATCAAAAGCAAGATCGACAACGCCAAATCTTTCGAAT
GGCTCAGCCAGATGCGATTTTACTTTGACCCTAAGCAAACGGACG
TGTTACAGCAGCTGTCCATTGAGATGGCCAATGCCAAGTTTAACT
ACGGCTTTGAGTACCTGGGTGTTCAAGACAAGCTGGTTCAGACGC
CCCTCACTGACCGTTGCTATTTGACAATGACACAAGCTTTGGAGG
20 CCAGGCTTGGGGGCTCCCCATTGGACCTGCTGGAACCGGAAAGA
CGGAGTCCGTCAAAGCCCTCGGCCATCAGCTGGGGCGGTTCTGCT
TAGTTTTCAACTGTGACGAAACCTTTGATTTCCAGGCGATGGGAC
GTATCTTTGTGGGGCTTTGCCAAGTGGGCGCGTGGGGCTGCTTTG
ATGAGTTTAACCGCCTGGAGGAGCGGATGCTCTCAGCTGTATCCC
25 AGCAGGTGCAGTGCATACAAGAGGCACTGCGGGAGCATTCCAACC
CCAATAAGACAGACCTCAGCCCCATTACTTGTGAGCTGCTGA
ACAAACAAGTCAAGGTTAGCCCAGACATGGCTATCTTCATCACC
TGAACCCAGGCTATGCAGGTCGCTCAAACCTCCCGACACCTCA
AGAAGCTCTTCCGGAGCTTGGCGATGACCAAGCCTGACCGGCAGC
30 TGATCGCCCAGGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG
AGGTCCTTGCCAACAAGATCGTCCCCTTCTTCAAACCTGTGTGATG
AGCAACTGTCTTCTCAAAGCCATTATGACTTTGGGCTTCGGGCTT
TGAAGAGTGTGCTTGTAAGTGCAGGCAATGTGAAGAGGGAGAGGA
TCCAGAAGATAAAGAGGGAGAAAGAAGACGGGGGGAAGCAGTTG
35 ATGAAGGAGAGATCGCTGAGAACCTACCTGAGCAGGAGATTCTGA
TCCAGAGTGTCTGCGAGACAATGGTGCCCCAAGCTGGTGGCAGAAG
ATATCCCGCTGCTCTTCAGCCTCCTGTCTGACGTGTTCCCTGGAG
TCCAGTACCACCGTGGGGAGATGACAGCCCTTCGAGAAGAGCTGA
AGAAAGTGTGTCAGGAGATGTACTTGACATATGGCGACGGAGAAG
40 AAGTTGGCGGGATGTGGGTTGAAAAGGTTCTCCAGCTCTATCAGA
TCACGCAGATTAACCACGGCCTGATGATGGTTGGGCCTTCAGGAA
GTGGGAAGAGCATGGCCTGGCGAGTGTGCTGAAGGCTCTAGAGA
GGCTTGAGGGTGTGGAGGGCGTGGCCACATAATTGACCCCAAGG
CCATCAGCAAAGACCACCTCTACGGAACCTTGGATCCCAACACCA
45 GGGAGTGGACAGACGGACTCTTCACACACGTGCTGAGAAAGATCA
TAGACAATGTGAGAGGTGAGCTGCAGAAACGCCAGTGGATTGTCT
TTGATGGCGATGTGGACCCCGAGTGGGTGGAGAACCTGAACTCCG
TGCTGGATGACAACAAGCTCCTGACGCTGCCTAATGGAGAGCGCC
TTAGCCTGCCTCCCAATGTGCGGATAATGTTTGAAGTGCAGGACT
50 TGAAATACGCGACGCTGGCCACGGTGTCTCGCTGTGGCATGGTGT
GGTTCAGTGAGGACGTCTGAGCACAGACATGATCTTAAATAACT
TCCTGGCCAGGCTGCGCAGCATTCCTTGGATGAAGGGGAGGACG
AGGCACAGCGTAGGCGAAAAGGCAAAGAAGACGAGGGCGAAGAGG
CGGCTTCTCCAATGCTACAGATTCAAAGAGATGCAGCAACGATCA
55 TGCAGCCGTACTTCACGTCCAACGGCCTGGTCACCAAGGCGCTGG
AGCACGCCTTCAAGCTGGAGCACATCATGGACCTGACGCGCCTGC

GCTGCCTGGGCTCGCTCTTCTCCATGCTGCACCAGGCCTGCCGCA
ACGTGGCGCAGTACAATGCCAACCATCCTGATTTCCCATGCAGA
TTGAGCAGCTGGAGCGCTACATTAGCGCTATCTGGTTTACGCCA
TCCTCTGGTCCTTATCTGGAGACAGCCGGCTGAAGATGAGAGCAG
5 AGCTGGGCGAGTACATCCGGAGGATCACCCTGTGCCGCTGCCCCA
CTGCGCCCAACGTCCCCATCATTGACTATGAGGTGTCCATCAGTG
GAGAGTGGTCGCCGTGGCAGGCCAAGGTGCCTCAGATTGAAGTGG
AGACACACAAGGTGGCAGCCCCAGATGTCGTCGTGCCAACCTTAG
ATACAGTCCGCCATGAAGCTCTCCTGTACACTTGGCTGGCTGAAC
10 ACAAACCCCTGGTCTTATGTGGCCCTCCTGGGTCTGGCAAGACCA
TGACACTCTTCAGTGCTCTCCGGGCCTTGCTGACATGGAGGTTG
TGGGCCTAAACTTCTCAAGTGCCACTACACCAGAGCTGTTGCTGA
AGACGTTTGACCACTACTGCGAATACAGGCGCACACCTAACGGTG
TTGTCTTGGCTCCTGTTTCAAGCTTGGAAAGTGGCTGGTCTTGTCT
15 GTGATGAAATCAACTTGCCCGATATGGATAAATACGGCACACAGA
GAGTCATCTCCTTCATCAGACAGATGGTGGAGCATGGAGCCTTCT
ATCGTACCTCAGACCAACGTGGGTAAAGCTAGAGAGAATCCAGT
TTGTTGGGGCTTGCAATCCACCCACTGACCCTGGGAGAAAGCCCC
TCTCACACAGGTTCTTGCGCCACGTGCCTGTTGTATATGTGGATT
20 ACCCAGGACCAGCCTCCCTGACGCAAATCTATGGCACCTTCAACC
GCGCCATGCTGAGGCTCATTCCCTCTCTCCGTACCTATGCAGAAC
CCCTCACTGCCGCCATGGTGGAGTTCTATACCATGTCCACAGGAGC
GGTTTACTCAGGACACACAGCCACACTATATCTACTCGCCCCGTG
AGATGACTCGGTGGGTAAAGGAATCTTTGAAGCACTGAGACCCC
25 TGGAGACATTGCCTGTTGAAGGTCTCATTCTGATTTGGGCACATG
AAGCCCTCCGTCTCTTCCAAGACAGGCTTGTGGAGGATGAGGAGC
GGCGCTGGACTGACGAAAACATTGACATGGTTGCCTTGAAGCACT
TCCCTAACATAGACAAAGAGAAAGCCATGAGCCGGCCTATCCTGT
ACAGCAACTGGCTGTCAAAGGATTATATCCCAGTTGACCAAGAAG
30 AGCTAAGGGATTATGTCAAGGCTAGGCTGAAGGTCTTCTATGAAG
AAGAACTTGATGTTCCCTTGGTCTTGTTCATGAAGTTCTGGACC
ATGTGCTGAGGATAGACAGAATATCCGACAACCTCAAGGCCATC
TGCTTCTGATTGGTGTTAGTGGAGCTGGAAAAACCACTGTCTC
GCTTTGTGCGCTGGATGAATGGCTTGAGTGTATACCAGATTAAAG
35 TCCACAGGAAGTACACTGGGGAAGACTTCGATGAAGATCTTAGGA
CAGTGCTGAGACGGTCTGGCTGTAAAAATGAAAAGATAGCATTCA
TAATGGATGAGTCCAACGTCTTAGATTCCGGATTCTTGGAACGAA
TGAATACCTTCTGGCTAATGGCGAGGTTCTTGGCTCTTTGAAG
GGGATGAGTACGCCACGCTGATGACACAGTGCAAAGAGGGGGCCC
40 AGAAGGAGGGGCTCATGCTGGACTCCACGAGGAGCTCTACAAGT
GGTTCACCAGCCAGGTGATCCGCAACCTGCACGTGGTCTTCACCA
TGAACCCGTCCTCAGAGGGGCTCAAGGACAGGGCGGCCACCTCAC
CAGCCCTTTTCAACAGGTGTGTGCTGAACTGGTTTGGTGACTGGT
CCACTGAAGCACTGTATCAAGTCCGCAAGAATTCACCAGTAAGA
45 TGGACCTGGAGAAGCCGAACCTATATAGTGCCTGACTACATGCCAG
TTGTGTATGATAAACTGCCGCAGCCCCAACACACCGGGAAGCCA
TTGTGAACAGCTGTGTGTTTGTCCATCAGACTCTTCACCAGGCTA
ATGCGCGCCTGGCGAAGCGAGGTGGCAGAACGATGGCCATCACAC
CTCGGCACTACCTGGACTTCATCAACCACTACGCCAACCTCTTCC
50 ATGAGAAGCGCAGCGAGTTGGAGGAGCAGCAGATGCACCTGAATG
TTGGGCTCCGAAAAATCAAAGAGACCGTGGACCAGGTGGAAGAAC
TGCGCCGTGACCTGAGGATCAAGAGCCAAGAGCTGGAGGTCAAGA
ACGCAGCGGCCAATGACAAGCTGAAGAAAATGGTGAAAGACCAGC
AAGAGGCTGAGAAGAAGAAGGTGATGAGCCAAGAAATCCAGGAGC
55 AGCTACACAAACAGCAGGAAGTGATCGCAGACAAGCAGATGAGTG
TCAAGGAGGACCTGGATAAAGTGGAGCCTGCTGTATCGAGGCCC

AGAACGCTGTGAAGTCCATCAAGAAGCAGCACCTGGTGGAGGTGA
GGTCCATGGCCAACCCTCCTGCAGCTGTGAAGCTGGCTCTGGAGT
CCATCTGCCTGCTGCTTGGTGAGAGCACCACGGACTGGAAGCAGA
TCCGCTCCATCATCATGAGAGAGAAC TTCATCCCCACCATCGTCA
5 ACTTCTCGGCTGAGGAGATCAGTGATGCCATACGAGAGAAGATGA
AGAAAACTACATGTCCAACCCAGTTACAACATATGAGATCGTCA
ACCGGGCTTCCCTGGCTTGTGGTCCTATGGTGAAGTGGGCGATTG
CACAGCTCAATTATGCAGACATGTTAAAGCGAGTGGAGCCCCTGA
GGAATGAGCTGCAGAAGCTGGAAGATGACGCCAAGGACAACCAGC
10 AGAAAGCCAATGAGGTGGAGCAGATGATCAGGGACCTGGAAGCCA
GCATTGCCCGCTACAAGGAGGAGTACGCTGTCTCATCTCTGAGG
CCCAGGCCATCAAGGCAGACCTGGCAGCTGTGGAAGCAAAGGTAA
ACCGGAGCACTGCATTCTAAAGAGTTTATCTGCCGAAAGGGAAC
GTTGGGAAAAGACGAGTGAACTTTCAAAAACCAGATGTCTACCA
15 TTGCTGGGGACTGCCTCCTGTGCGCGGCCCTTCATTGCTTACGCTG
GCTACTTTGACCAGCAAATGCGCCAGAACTTGTTTACCACCTGGT
CTCATCACTTACAGCAAGCCAACATCCAGTTCCGCACAGACATTG
CAAGGACGGAGTACCTCTCCAATGCTGACGAACGCCTCCGCTGGC
AGGCCAGCTCTCTGCCTGCCGACGACCTGTGCACAGAGAATGCCA
20 TCATGCTAAAACGATTCAATAGGTACCGCTGATCATCGACCCCT
CCGGACAGGCCACAGAATTTCATCATGAATGAATATAAGGACCCGA
AGATCACAAAGGACCAGCTTCTTAGATGATGCCTTCCGGAAGAATT
TGGAGAGTGCTCTGAGATTTGGCAATCCCCTTCTTGTCCAGGATG
TGGAAAGCTACGATCCAGTTTGAATCCAGTACTGAACCGTGAAG
25 TTCGGCGAACAGGAGGGAGGGTGCTGATTACCCTCGGTGACCAAG
ACATAGACCTGTCACCATCCTTTGTCTCTTTCTGTCTACCCGAG
ACCCAACGTGGAGTTCCACACGACCTCTGCTCCCGGGTGACCT
TTGTGAACCTTACCGTCAACCGCAGCAGTTTACAGAGCCAGTGTC
TCAATGAAGTGCTTAAAGCAGAAAGGCCAGACGTGGACGAGAAGC
30 GCTCCGACCTCCTGAACTGCAAGGGGAGTTCCAACCTCCGTTTAC
GGCAGCTTGAAAAGTCTCTGCTCCAAGCTCTGAATGAGGTAAAAG
GCCGCATTCTGGTTGACGACACCATCATTACAACCCCTGGAGAATC
TGAAGCGGGAAGCTGCCGAGGTTACCAGAAAGGTGGAGGAGACAG
ATATTGTCTATGCAGGAGGTGGAGACCGTGTCACGACGTACCTGC
35 CGCTGTCCACTGCCTGCAGCAGCATCTACTTCACTATGGAGTCCT
TGAAGCAGGTTCACTTCTGTACCAGTACTCTCTGCAGTTCTTCC
TGGACATCTACCACAACGTGCTGTATGAGAACCCCAACCTGAAGG
GTGCCACCGATCACACACAGCGCCTCTCCGTGATAACCAAGGACC
TCTTCCAGGTGGCCTTTAACCGAGTGGCTCGAGGCATGCTGCACC
40 AGGACCACATCACCTTCGCCATGCTGCTAGCGAGGATCAAGCTGA
AAGGCACCGTGGGGGAGCCCACCTATGATGCAGAGTTCCAGCACT
TCCTCAGAGGGAAGGAGATTGTGCTGAGTGCTGGCTCCACCCCCA
AAATCCAGGGCCTGACCGTAGAGCAGGCAGAAGCTGTCTGAGGT
TGAGCTGTCTGCCTGCATTTAAAGATCTGATTGCCAAGGTGCAGG
45 CAGATGAGCAGTTTGGCATTGCTGGCTGGATAGCAGTTTACCAGAGC
AGACCGTGCCATACCTCTGGAGCGAGGAAACGCCTACAACCTCCCA
TTGGGCAGGCCATCCACCGCCTGCTCCTGATTCAAGCCTTCCGAC
CCGACCGCCTGTTGGCCATGGCCACATGTTTGTTCACAAACC
TCGGAGAGTCTTTCATGTCCATCATGGAGCAGCCTCTCGACCTCA
50 CCCACATTGTGGGCACAGAGGTGAAGCCAAACACACCTGTCCTGA
TGTGCTCTGTGCCTGGGTATGATGCCAGCGGACATGTTGAGGACC
TCGCAGCAGAGCAGAACACGCAGATCACGTCTATTGCCATCGGCT
CAGCAGAAGGCTTTAACCAAGCAGATAAGGCCATCAACACCGCCG
TGAAGTCAGGCAGGTGGGTGATGTTGAAGAACGTGCACCTGGCCC
55 CGGGCTGGCTGATGCAGCTGGAGAAGAAGCTGCACTCCCTGCAGC
CCCACGCCTGCTTCCGACTTTTCTCACCATGGAGATCAACCCCA

AGGTGCCCCGTGAACCTGCTCCGTGCTGGTCCGGATCTTTGTGTTTG
 AGCCACCACCCGGAGTGAAAGCCAACATGCTGAGGACATTTAGCA
 GCATCCCTGTCTCTAGGATATGCAAGTCTCCAAATGAGCGCGCCC
 GCTTGTATTTCTGCTGGCTTGGTTCATGCCATCATCCAAGAGC
 5 GCCTGCGCTATGCTCCACTGGGGTGGTCAAAGAAGTACGAATTTG
 GAGAATCTGACCTTCGATCAGCTTGTGACACGGTGGACACGTGGC
 TGGACGACACAGCCAAGGGCCGGCAGAACATCTCACC GGATAAGA
 TCCCATGGTCTGCCCTGAAGACCCTGATGGCGCAGTCCATCTATG
 GTGGGCGGGTGGACAATGAGTTCGACCAGCGTCTGCTCAACACCT
 10 TCCTGGAGCGGCTGTTTACCACCCGACGCTTCGACAGTGAATTCA
 AGCTGGCGTGCAAGGTTGACGGGCACAAGGACATCCAGATGCCTG
 ATGGTATCAGGCGAGAGGAGTTTGTGACGTGGGTGGAGCTGCTGC
 CTGACGCCCAGACACCCTCATGGCTGGGCCTCCCCAACAATGCTG
 AAAGGGTCTGCTTACCACCCAAGGCGTGGACATGATCAGCAAGA
 15 TGCTGAAGATGCAGATGCTGGAGGACGAGGATGACCTGGCCTACG
 CAGAGACGGAGAAGAAGGCAAGGACGGACTCCACCTCCGATGGCC
 GTCCAGCCTGGATGAGGACACTGCACACCACGGCGTCCAACCTGGC
 TGCACCTCATCCACAGACACTGAGCCCCCTGAAGCGCACCGTGG
 AGAACATCAAGGATCCTTTGTTTAGGTTCTTTGAGAGAGAAGTAA
 20 AGATGGGGGCCAAGTTACTCCAAGATGTGCGCCAAGACCTTGCTG
 ACGTCGTTCAAGTGTGCGAGGGGAAAAAGAAGCAGACAACTACC
 TGCGCACGCTCATCAATGAGCTGGTGAAAGGGATCTTGCCTCGGA
 GCTGGTCCCATTTACACAGTGCCTGCAGGCATGACGGTGATCCAGT
 GGGTGTGAGATTTAGCGAGAGGATCAAACAGCTGCAGAACATCT
 25 CACAAGCAGCTGCATCTGGTGGTGCCAAGGAAGTGAAGAACATCC
 ACGTGTGCCTGGGTGGCCTGTTTGTACCTGAGGCCTACATCACTG
 CCACCAGACAGTATGTGGCACAAGCTAACAGCTGGTCCCTGGAGG
 AACTCTGCCTGGAAGTCAATGTCACCGCCTCACAGAGTGCCACCC
 TTGATGCCTGCAGCTTTGGAGTCACAGGTCTGAAGCTCCAAGGGG
 30 CCACGTGCAGCAACAACAAGCTATCACTCTCCAATGCCATCTCCA
 CAGTCCTCCCCCTCACACAGCTGCGCTGGGTGAAACAAACAAGCG
 CCGAGAAGAAGGCCAGCGTGGTGACCTTACCTGTCTACCTGAAC
 TCAACCGGGCAGACCTCATCTTACCGTGGACTTTGAAATTGCTA
 CAAAGGAAGATCCTCGCAGCTTCTATGAGCGTGGAGTTGCCGTTT
 35 TGTGCACTGAGTAAAGCTAGACTTTTCTCCAGTCCTCTTTCTGGA
 ATAGGAAACTCCCAATATTTAACCTTCATTCATCCTTAACGGTGT
 GGAAGGGTTGATGGACTGGAAAGCAAGTGGTTGGTTCGCGTTGGC
 GGGTGACAGGTGCTGCGGTTGGAGACGGTGGGATGGGAGAAGAGA
 AGAGTGCGCTGTCCGAGGGCTGACCGAATGGCTGGGTTTGTAGTAA
 40 TAAACACTAAGCATGACGGGCAAAAAAAAAAAAAAAAAAAAAA

Table 2. Mutated murine cytoplasmic dynein heavy chain1, mRNA (SEQ ID NO:3)

GCCGCGTCGACAGCCGGCTCCGCTGTCCGCAGTCGGCCGCGGGTTAGCGGGC
 45 AGAGCGTCTCCTGTGCGCGGTTCCCTCGCTTACTGCTCTCTCGTGCCGGAG
 GCCGCTCCTCTCGGCTCTCGCTCTCTCTTTCTATCTCTCTCCCTTCCGCG
 GATCCGCCATGTCGGAGCCGGGCGGCGGAGGACGGCTCGGCAGGCCTGGA
 GGTGTGCGCGGTGCAGAATGTGGCGGACGTGGCGGTGCTGCAGAAGCACCTG
 CGTAAGCTGGTGCCGCTGCTGCTGGAGGACGGCGGCGACGCGCCGGCTGCGC
 50 TGGAGGCGGCGCTGGAGGAGAAGAGCGCCCTGGAGCAGATGCGCAAGTTCCT
 GTCAGACCCGCGAGGTCCACACGGTCTGGTGGAGCGCTCCACCCTCAAAGAG
 GACGTTGGTGATGAAGGAGAAGAGGAGAAAGAATTCATTTCTATAACATCA
 ACATAGACATTCATTACGGGGTAAAGTCCAACAGCTTGGCGTTCATCAAGCG
 AGCTCCTGTGATTGATGCAGACAAGCCAGTGTCTCCAGCTCCGAGTCTCT

ACTCTGAGTGAAGACTCGCCGTATGAGACACTGCACTCTTTCATCAGCAATG
CAGTGGCTCCTTTCTTTAAGTCCTACATCAGAGAGTCTGGCAAAGCAGACAG
GGATGGTGATAAGATGGCTCCTTCAGTTGAAAAAAGATTGCAGAGCTTGAA
ATGGGACTCCTCCACCTGCAGCAGAACATTGAGATCCCAGAGATCAGCTTGC
5 CAATTCATCCCATCATCACGAACGTTGCGAAGCAGTGCTATGAGCGCGGAGA
AAAGCCCAAAGTTACAGATTTTGGTGATAAGGTTGAAGACCCAACTTTCCTT
AACCAATTACAGTCTGGAGTTAATCGGTGGATCCGAGAAATCAAAAGGTGA
CCAAGCTTGACCGGGATCCAGCATCAGGAAGTGCCTTGCAGGAAATCAGCTT
10 TTGGCTAAACTTGGAACGTGCGTTGTACCGCATCCAAGAGAAGCGGGAGAGC
CCCGAGGTGCTCCTGACTCTGGACATCCTGAAGCATGGCAAACGTTTCCATG
CCACTGTCTAGTTTGTGACACTGACACAGGTCTGAAGCAGGCGTTGGAACCGT
GAATGACTACAACCCTCTGATGAAAGACTTCCCTCTGAATGACTTGCTGTCT
GCCACGGAGCTGGACAAGATAAGGCAGGCCCTTGTGCAATTTTCACACATC
TGAGAAAGATCCGCAACACGAAGTACCCGATTACGCGGGCCCTGCGTCTCGT
15 GGAGGCCATCTCCAGAGACCTGAGTTCTCAGCTGCTCAAGGTCTTGGGCACT
CGGAAGTTGATGCATGTAGCCTATGAAGAGTTTGAAGAGGTCATGGTGGCTT
GCTTCGAAGTCTTCCAGACGTGGGACGACGAGTACGAGAAGCTCCAGGTGCT
GCTGCGAGACATCGTCAAGAGGAAGCGGGAGGAGAACCTGAAGATGGTGTGG
CGCATCAACCCCGCTCACAGGAAGCTTCAGGCCCGCCTCGACCAGATGAGGA
20 AGTTCGCGCCGAGCAGCAGCAGCTGAGGGCTGTCTATTGTGAGGTCCTGAG
GCCACAGGTACAGCAGTTCGCACAACAGAACCAAGGAGAAGCACCTGAACCC
CAAGACATGAAAGTGGCCGAGGTGCTCTTTGATGCTGCCGACGCCAACACCA
TTGAGGAGGTGAACCTGGCCTACGAGAATGTCAAGGAAGTCGATGGTCTGGA
TGTTTCCAAAGAAGGGACGGAGGCCCTGGGAGGCCGCGATGAAGAGATACGAT
25 GAGAGGATCGACCGTGTGGAGACCCGCATCACCGCCCGCCTCCGAGATCAGC
TCGGCACGGCCAAGAATGCCAATGAGATGTTCAGGATTTTCTCCAGGTTCAA
TGCACTGTTTCGTCCGCCCACACATCCGAGGGGCCATTTCGTGAATACCAGACC
CAGCTGATCCAACGTGTGAAAGATGACATCGAATCTCTGCACGACAAGTTCA
AGGTCCAGTACCCGCAAAGCCAAGCTTGTAAATGAGTCATGTCCGTGACCT
30 GCCCCCGTGTTCAGGGTCTATCATCTGGGCTAAACAGATCGACAGACAGCTC
ACTGCCATACATGAAGCGAGTGGAGGATGTCTGGGCAAAGGCTGGGAGAACC
ACGTGGAAGGGCAGAAGCTGAAGCAGGATGGAGACAGCTTCCGAATGAAGCT
CAACACCCAGGAGATCTTCGATGACTGGGCGAGGAAGGTTTCAGCAGCGCAAC
CTTGGTGTCTCCGGGCGCATCTTACCATTGAGAGCGCTCGCGTGGCGGGCC
35 GCACTGGGAATGTCTCCTCAAGCTAAAGGTGAACCTTCCTTCCAGAGATCATAAC
ACTCTCCAAAGAAGTCCGGAACCTCAAGTGGCTTGGCTTCCGAGTGCCACTT
GCAATTGTGAACAAGGCTCACCAAGCCAACCAGCTCTACCCATTTGCCATCT
CGCTGATTGAAAGCGTCCGGACTTACGAGCGCACCTGTGAGAAGGTGGAGGA
GCGCAATACCATTTCCCTGCTAGTGGCCGGCCTAAAGAAGGAGGTGCAGGCC
40 TTAATCGCAGAAGGCATCGCGTTGGTGTGGGAGTCTTACAAGCTCGACCCCT
ACGTGCAGCGCTGGCAGAGACGGTTTTCAACTTCCAGGAGAAGGTGGACGA
CCTACTGATTATTGAGGAAAAGATAGACCTGGAGGTCCGCTCCTTGGAACC
TGCATGTATGACCACAAGACATTCTCAGAGATCTTGAACAGAGTGCAGAAAG
CAGTGGACGACCTAAACCTGCACTCCTATTCCAATCTGCCATCTGGGTCAA
45 CAAGCTGGACATGGAGATTGAAAGGATACTGGGCGTCCGCCTGCAAGCTGGC
CTTCGAGCTTGGACCCAGGTTCTTCTTGGACAAGCTGAGGATAAAGCAGAAG
TCGACATGGATACAGATGCTCCACAAGTCAGTCACAAGCCTGGTGGAGAGCC
CAAGATCAAAAACGTGGTTACAGAGCTGAGGATAACAAATCAGGTCTATCTAT
CTGAACCCACCCATTGAGGAGTGCAGGTACAAGCTGTACCAGGAGATGTTTCG
50 CGTGGAAAGATGGTGTGCTGTCCCTGCCAGGATCCAGAGCCAGAGGTACCA
GGTGGGAGTGCAATTACGAGTTGACGGAGGAAGAGAAGTTCTATCGGAATGCA
CTGACAAGGATGCCGACGGCCCTGTGCGCCTGGAAGAGTCTTACTCTGCGG
TCATGGGCATAGTGACTGAAGTTGAGCAGTATGTTAAGGTTTGGCTTCAGTG
CAGTGTTTGTGGGATATGCAGGCAGAAAACATTTACAACAGGCTAGGGGAA
55 GATCTCAACAAGTGGAAGCTCTCCTGGTCCAGATAAGGAAAGCCAGAGGAA
CCTTTGACAAATGCGGAAACCAAGAAAGAGTTTGGTCCGCTGGTGATAGATTA

CGGCAAGGTCCAGTCCAAGGTGAACTTGAAGTATGACTCCTGGCATAAGGAG
GTTCTCAGCAAGTTTGGGCAGATGCTGGGCTCAAACATGACAGAATCCACT
CCCAGATCTCAAAGTCTCGCCAAGAGCTGGAGCAGCACTCCGTTGACACAGC
CAGTACCTCTGACGCGGTGACCTTCATCACCTATGTGCAGTCTCTGAAACGG
5 AAGATCAAACAGTTTGAGAAGCAAGTTGAACTCTACCGCAATGGTCAGCGTC
TGCTGGAAAAACAAAGGTTCCAGTTCCTCGCCTTCTTGGCTTTACATTGACAA
CATCGAGGGTGAGTGGGGGGCCTTCAATGACATCATGCGGCGGAAGGACTCT
GCCATTGAGCAACAGGTGGCAAACCTGCAAATGAAGATCGTACAGGAGGACA
GAGCTGTGGAAGCCGGACCAAGGATCTGTTGACAGACTGGGAGAAGACCAA
10 ACCTGTACAGGCAATCTGCGTCTGAGGAGGCTCTTCAGGCCCTCACCAT
TATGAAGGGAAGTTTCGGCCGGCTGAAGGACGACAGAGAGAAATGTGCAAAGG
CTAAGGAAGCGTTGGAACACAGACACAGGCCTCCTCAGTGGCAGTGAAGA
GCGTGTACAGGTGGCCTTGGAGGAGTTACAAGACCTCAAAGGTGTGTGGTCA
GAGCTTTCTAAGGTCTGGGAACAAATGATCAAATGAAGGAGCAGCCGTGGG
15 TCTCCGTTGAGCCTCGGAAGCTTCGACAAAACCTAGACGGCCTCTTGAACCA
GCTGAAGAACTTCCCTGCGAGGCTTCGGCAGTATGCTTCTATGAGTTTGT
CAGAGGCTGCTGAAAGGCTACATGAAGATAAACATGTTGGTAATTGAACTGA
AATCAGAAGCACTCAAAGACCGGCACTGGAAACAGCTGATGAAGAGGCTTCA
TGTTAACTGGGTGGTTTCTGAGCTGACGCTGGGCCAGATCTGGGACGTGGAC
20 CTTCAGAAGAACGAAGCTGTCGTCAAGGATGTGCTGCTGGTGGCACAAGGCG
AGATGGCCTTGAAGAATTTTGAAGCAGATACGAGAAGTGTGGAACACATA
CGAACTAGACTTGGTCAACTATCAGAACAAATGCCGCCTCATCCGAGGCTGG
GATGACCTCTTCAACAAGGTCAAGGAGCATATCAACAGCGTCTCTGCCATGA
AACTCTCTCCCTATTACAAGTTTTTGAAGAAGATGCCCTGAGCTGGGAGGA
25 CAAGCTGAACCGAATCATGGCTCTCTTTGACGTGTGGATTGACGTGCAGAGG
CGCTGGGTCTACTTGAAGGCATCTTCACAGGCAGTGGGACATCAAACATC
TGCTGCCTGTGGAACCCAGCGCTTCAGAGTATCAGCACGGAGTTTTTGGC
TCTGATGAAAAAGTCTCCAAGTCTCCACTTGTGATGGATGTTCTGAACATA
CAGGGAGTCCAGAGGTCTCTGGAAGGTTGGCAGACCTGCTGGGGAAGATCC
30 AGAAAGCATTGGGGGAGTACCTGGAACGGGAGCGCTCGTCTTTCCCAGGTT
CTACTTTGTGGGTGATGAGGATTTGCTTGAGATCATTGGGAATAGCAAGAAC
GTGGCTAAGTTGCAGAAGCACTTCAAGAAAATGTTCCGCCGGCGTTTCAGCA
TCATCTTAAATGAGGATAACTCTGTGGTCTCGGCATCTCATCCCGAGAAGG
GGAGGAGTTATGTTTAAACTCCAGTGTCCATCACTGAACACCCCAAAATC
35 AATGAGTGGCTCACTCTGGTGGAAAAGGAGATGAGAGTCACCTTGGCTAAAC
TTCTGGCAGAGTCTGTTACAGAAGTGGAGATTTTTGGAAAAGCAACTTCTAT
TGACCCAAATACCTACATTACTTGGATTGATAAATACCAGGCCAGCTAGTG
GTATTGTCAGCCAGATAGCCTGGTCCGAGAACGTGGAGAATGCGCTGAGCA
ACGTTGGGGGAGGTGGTGATGTGGGGCCCTTGCACTGTGCTGAGCAATGT
40 GGAGGTCACACTCAACGTCTTAGCGGACTCTGTCTCATGGAGCAGCCTCCT
CTCCGGAGACGGAAGCTGGAGCACTTGATCACAGAGCTGGTTACCAAAGAG
ACGTTACCAGGTCTTGATCAAAAGCAAGATCGACAACGCCAAATCTTTCGA
ATGGCTCAGCCAGATGCGATTTTACTTTGACCTAAGCAAACGGACGTGTTA
CAGCAGCTGTCCATTGAGATGGCCAATGCCAAGTTTAACTACGGCTTTGAGT
45 ACCTGGGTGTTCAAGACAAGCTTGGTTGAGACGCCCTCACTGACCGTTGCTA
TTTGACAATGACACAAGCTTTGGAGGCCAGGCTTGGGGGCTCCCCATTTGGA
CCTGCTGGAACCGGAAAGACGGAGTCCGTCAAAGCCCTCGGCCATCAGCTGG
GGCGGTTCTGTTAGTTTTCAACTGTGACGAAACCTTTGATTTCCAGGCGAT
GGGACGTATCTTTGTGGGGCTTTGCCAAGTGGGCGCGTGGGGCTGCTTTGAT
50 GAGTTTAACCGCTGGAGGAGCGGATGCTCTCAGCTGTATCCCAGCAGGTGC
AGTGCATACAAGAGGCACTGCGGGAGCATCCAACCCCACTACGACAAGAC
CTCAGCCCCATTAATTGTGAGCTGCTGAACAAACAGTCAAGGTTAGCCCA
GACATGGCTATCTTCATCACCATGAACCCAGGCTATGCAGGTGCGTCAAACC
55 TCCCCGACAACCTCAAGAAGCTCTTCCGGAGCTTGGCGATGACCAAGCCTGA
CCGGCAGCTGATCGCCAGGTGATGCTGTACTCGCAGGGCTTCCGACTGCT
GAGGTCCTTGCCAACAAGATCGTCCCGTTCTTCAAACCTGTGTGATGAGCAAC

TGCTCTCTCAAAGCCATTATGACTTTGGGCTTCGGGCTTTGAAGAGTGTGCT
TGTAAGTGCAGGCAATGTGAAGAGGGAGAGGATCCAGAAGATAAAGAGGGAG
AAAGAAGAACGGGGGAAGCAGTTGATGAAGGAGAGATCGCTGAGAACCTAC
CTGAGCAGGAGATTCTGATCCAGAGTGTCTGCGAGACAATGGTGCCCAAGCT
5 GGTGGCAGAAGATATCCCGCTGCTCTTCAGCCTCCTGTCTGACGTGTTCCCT
GGAGTCCAGTACCACCGTGGGGAGATGACAGCCCTTCGAGAAGAGCTGAAGA
AAGTGTGTCTCAGGAGATGTAATTGACATATGGCGACGGAGAAGAAGTTGGCGG
GATGTGGGTTGAAAAGGTTCTCCAGCTCTATCAGATCACGCAGATTAACCAC
GGCCTGATGATGGTTGGGCCTTCAGGAAGTGGGAAGAGCATGGCCTGGCGAG
10 TGCTGCTGAAGGCTCTAGAGAGGCTTGAGGGTGTGGAGGGCGTGGCCACAT
AATTGACCCCAAGGCCATCAGCAAAGACCACCTCTACGGAACCTTGGATCCC
AACACCAGGGAGTGGACAGACGGACTCTTCACACACGTGCTGAGAAAGATCA
TAGACAATGTGAGAGGTGAGCTGCAGAAACGCCAGTGGATTGTCTTTGATGG
CGATGTGGACCCCGAGTGGGTGGAGAACCTGAACTCCGTGCTGGATGACAAC
15 AAGCTCCTGACGCTGCCTAATGGAGAGCGCCTTAGCCTGCCTCCCAATGTGC
GGATAATGTTTGAAGTGCAGGACTTGAAATACGCGACGCTGGCCACGGTGTC
TCGCTGTGGCATGGTGTGGTTCAGTGAGGACGTCTTGAGCACAGACATGATC
TTAAATAACTTCCTGGCCAGGCTGCGCAGCATTCCCCTGGATGAAGGGGAGG
ACGAGGCACAGCGTAGGCGAAAAGGCAAAGAAGACGAGGGCGAAGAGGGCGG
20 TTCTCCAATGCTACAGATTCAAAGAGATGCAGCAACGATCATGCAGCCGTAC
TTCACGTCCAACGGCCTGGTCACCAAGGCGCTGGAGCACGCCCTCAAGCTGG
AGCACATCATGGACCTGACGCGCCTGCGCTGCCTGGGCTCGCTCTTCTCCAT
GCTGCACCAGGCCTGCCGCAACGTGGCGCAGTACAATGCCAACCATCCTGAT
TTCCCCATGCAGATTGAGCAGCTGGAGCGCTACATTACGCGCTATCTGGTTT
25 ACGCCATCCTCTGGTCTTATCTGGAGACAGCCGGCTGAAGATGAGAGCAGA
GCTGGGCGAGTACATCCGGAGGATCACCCTGTGCCGCTGCCCACTGCGCCC
AACGTCCCCATCATTGACTATGAGGTGTCCATCAGTGGAGAGTGGTCGCGGT
GGCAGGCCAAGGTGCCCTCAGATTGAAGTGGAGACACACAAGGTGGCAGCCCC
AGATGTCTGTCGTGCCAACCTTAGATACAGTCCGCCATGAAGCTCTCCTGTAC
30 ACTTGGCTGGCTGAACACAAACCCCTGGTCTTATGTGGCCCTCCTGGGTCTG
GCAAGACCATGACACTCTTCAGTGCTCTCCGGGCTTGCCCTGACATGGAGGT
TGTGGGCTAAACTTCTCAAGTGCCACTACACCAGAGCTGTTGCTGAAGACG
TTTGACCACTACTGCGAATACAGGCGCACACCTAACGGTGTTGTCTTGGCTC
CTGTTACGCTTGGAAGTGGCTGGTCTTGTCTGTGATGAAATCAACTGGC
35 CGATATGGATAAATACGGCACACAGAGAGTCATCTCCTTCATCAGACAGATG
GTGGAGCATGGAGCCTTCTATCGTACCTCAGACCAACGTGGGTAAAGCTAG
AGAGAATCCAGTTTGTGGGGCTTGCAATCCACCCACTGACCCTGGGAGAAA
GCCCCCTCACACAGGTTCTTGCGCCACGTGCCTGTTGTATATGTGGATTAC
CCAGGACCAGCCTCCCTGACGCAAATCTATGGCACCTTCAACCGGCCATGC
40 TGAGGCTCATTCCCTCTCTCCGTACCTATGCAGAACCCCTCACTGCCGCCAT
GGTGGAGTTCTATACCATGTACAGGAGCGGTTTACTCAGGACACACAGCCA
CACTATATCTACTCGCCCCGTGAGATGACTCGGTGGGTAAAGAGGAATCTTTG
AAGCACTGAGACCCCTGGAGACATTGCCTGTTGAAGGTCTCATTGATTTG
GGCACATGAAGCCCTCCGTCTCTTCCAAGACAGGCTTGTGGAGGATGAGGAG
45 CGGCGCTGGACTGACGAAAACATTGACATGGTTGCCTTGAAGCACTTCCCTA
ACATAGACAAAGAGAAAGCCATGAGCCGGCTATCCTGTACAGCAACTGGCT
GTCAAAGGATTATATCCCAGTTGACCAAGAAGAGCTAAGGGATTATGTCAAG
GCTAGGCTGAAGGTCTTCTATGAAGAAGAACTTGATGTTCCCTTGGTCTTGT
TCAATGAAGTTCTGGACCATGTGCTGAGGATAGACAGAATATTCGACAACC
50 TCAAGGCCATCTGCTTCTGATTGGTGTAGTGGAGCTGGAAAAACACCCTG
TCTCGCTTGTGCGCTGGATGAATGGCTTGAGTGTATACCAGATTAAGGTCC
ACAGGAAGTACACTGGGGAAGACTTCGATGAAGATCTTAGGACAGTGCTGAG
ACGGTCTGGCTGTAAAAATGAAAAGATAGCATTCAATGGATGAGTCCAAC
GTCTTAGATTCCGGATTCTTGAACGAATGAATACCCTTCTGGCTAATGGCG
55 AGGTTCTTGGGCTCTTTGAAGGGGATGAGTACGCCACGCTGATGACACAGTG
CAAAGAGGGGGCCCAAGAGGGGGCTCATGCTGGACTCCCACGAGGAGCTC

TACAAGTGGTTCACCAGCCAGGTGATCCGCAACCTGCACGTGGTCTTCACCA
TGAACCCGTCCTCAGAGGGGCTCAAGGACAGGGCGGCCACCTCACCAGCCCT
TTTCAACAGGTGTGTGCTGAACTGGTTTGGTGACTGGTCCACTGAAGCACTG
TATCAAGTCGGCAAAGAATTACCAGTAAGATGGACCTGGAGAAGCCGAACT
5 ATATAGTGCCTGACTACATGCCAGTTGTGTATGATAAACTGCCGCAGCCCCC
AACACACCCGGAAGCCATTGTGAACAGCTGTGTGTTTGTCCATCAGACTCTT
CACCAGGCTAATGCGCGCCTGGCGAAGCGAGGTGGCAGAACGATGGCCATCA
CACCTCGGCACTACCTGGACTTCATCAACCACTACGCCAACCTCTTCCATGA
GAAGCGCAGCGAGTTGGAGGAGCAGCAGATGCACCTGAATGTTGGGCTCCGA
10 AAAATCAAAGAGACCGTGGACCAGGTGGAAGAAGTGCGCCGTGACCTGAGGA
TCAAGAGCCAAGAGCTGGAGGTCAAGAACGCAGCGGCCAATGACAAGCTGAA
GAAAATGGTGAAAGACCAGCAAGAGGCTGAGAAGAAGAAGGTCATGAGCCAA
GAAATCCAGGAGCAGCTACACAAACAGCAGGAAGTGATCGCAGACAAGCAGA
TGAGTGTCAAGGAGGACCTGGATAAAGTGGAGCCTGCTGTCATCGAGGCCCA
15 GAACGCTGTGAAGTCCATCAAGAAGCAGCACCTGGTGGAGGTGAGGTCCATG
GCCAACCTCCTGCAGCTGTGAAGCTGGCTCTGGAGTCCATCTGCCTGCTGC
TTGGTGAGAGCACCACGGACTGGAAGCAGATCCGCTCCATCATCATGAGAGA
GAACTTCATCCCCACCATCGTCAACTTCTCGGCTGAGGAGATCAGTGATGCC
ATACGAGAGAAGATGAAGAAAACTACATGTCCAACCCCAAGTTACAACATG
20 AGATCGTCAACCGGGCTTCCCTGGCTTGTGGTCTATGGTGAAGTGGGCGAT
TGCACAGCTCAATTATGCAGACATGTTAAAGCGAGTGGAGCCCCTGAGGAAT
GAGCTGCAGAAGCTGGAAGATGACGCCAAGGACAACCAGCAGAAAGCCATG
AGGTGGAGCAGATGATCAGGGACCTGGAAGCCAGCATTGCCCGCTACAAGGA
GGAGTACGCTGTCTCATCTCTGAGGCCAGGCCATCAAGGCAGACCTGGCA
25 GCTGTGGAAGCAAAGGTAAACCGGAGCACTGCACCTCTAAAGAGTTTATCTG
CCGAAAGGAACGTTGGGAAAAGACGAGTGAACTTTCAAAAACAGATGTC
TACCATTGCTGGGGACTGCCTCCTGTCGGCGGCCTTCATTGCTTACGCTGGC
TACTTTGACCAGCAAATGCGCCAGAACTTGTTTACCACCTGGTCTCATCACT
TACAGCAAGCCAACATCCAGTTCGCGCACAGACATTGCAAGGACGGAGTACCT
30 CTCCAATGCTGACGAACGCCTCCGCTGGCAGGCCAGCTCTCTGCCTGCCGAC
GACCTGTGCACAGAGAATGCCATCATGCTAAAACGATTCAATAGGTACCCGC
TGATCATCGACCCCTCCGGACAGGCCACAGAATTATCATGAATGAATATAA
GGACCGGAAGATCACAAGGACCAGCTTCTTAGATGATGCCTTCCGGAAGAAT
TTGGAGAGTGCTCTGAGATTTGGCAATCCCTTCTTGTCAGGATGTGGAAA
35 GCTACGATCCAGTTTTGAATCCAGTACTGAACCGTGAAGTTCGGCGAACAGG
AGGGAGGGTGCTGATTACCCTCGGTGACCAAGACATAGACCTGTCACCATCC
TTTGTCTATCTTTCTGTCTACCCGAGACCCAACTGTGGAGTTCACACAGACC
TCTGCTCCCGGTGACCTTTGTGAACCTCACCGTCACCCGCAGCAGTTTACA
GAGCCAGTGTCTCAATGAAGTGCTTAAAGCAGAAAGGCCAGACGTGGACGAG
40 AAGCGCTCCGACCTCCTGAACTGCAAGGGGAGTTCCAACCTCCGTTTACGGC
AGCTTGAAAAGTCTCTGCTCCAAGCTCTGAATGAGGTAAAAGGCCGCATTCT
GGTTGACGACACCATCATTACAACCTGGAGAATCTGAAGCGGGAAGCTGCC
GAGGTTACCAGAAAGGTGGAGGAGACAGATATTGTCATGCAGGAGGTGGAGA
CCGTGTCCAGCAGTACCTGCCGCTGTCCACTGCCTGCAGCAGCATCTACTT
45 CACTATGGAGTCCCTTGAAGCAGGTTCACTTCCTGTACCAGTACTCTCTGCAG
TTCTTCCCTGGACATCTACCACAACGTGCTGTATGAGAACCCCAACCTGAAGG
GTGCCACCGATCACACACAGCGCCTCTCCGTCATAACCAAGGACCTCTTCCA
GGTGGCCTTTAACCGAGTGGCTCGAGGCATGCTGCACCAGGACCACATCACC
TTCGCCATGCTGCTAGCGAGGATCAAGCTGAAAGGCACCGTGGGGGAGCCCA
50 CCTATGATGCAGAGTTCAGCACTTCCTCAGAGGGAAGGAGATTGTGCTGAG
TGCTGGCTCCACCCCCAAATCCAGGGCCTGACCGTAGAGCAGGCAGAAGCT
GTCGTGAGGTTGAGCTGTCTGCCTGCATTTAAAGATCTGATTGCCAAGGTGC
AGGCAGATGAGCAGTTTGGCATTGCTGGTGGATAGCAGTTACCAGAGCAGAC
CGTGCCATACCTCTGGAGCGAGGAAACGCCTACAACCTCCATTGGGCAGGCC
55 ATCCACCGCCTGCTCCTGATTCAAGCCTTCCGACCCGACCGCCTGTTGGCCA
TGGCCACATGTTTGTTCACAAACCTCGGAGAGTCCTTCATGTCCATCAT

GGAGCAGCCTCTCGACCTCACCCACATTGTGGGCACAGAGGTGAAGCCAAAC
 ACACCTGTCTGATGTGCTCTGTGCCTGGGTATGATGCCAGCGGACATGTTG
 AGGACCTCGCAGCAGAGCAGAACACGCAGATCACGTCTATTGCCATCGGCTC
 AGCAGAAGGCTTTAACCAAGCAGATAAGGCCATCAACACCGCCGTGAAGTCA
 5 GGCAGGTGGGTGATGTTGAAGAACGTGCACCTGGCCCCGGGTGGCTGATGC
 AGCTGGAGAAGAAGCTGCACTCCCTGCAGCCCCACGCCTGCTTCCGACTTTT
 CCTCACCATGGAGATCAACCCCAAGGTGCCCCGTGAACCTGCTCCGTGCTGGT
 CGGATCTTTGTGTTTGAGCCACCACCCGGAGTGAAAGCCAACATGCTGAGGA
 CATTAGCAGCATCCCTGTCTCTAGGATATGCAAGTCTCCAAATGAGCGCGC
 10 CCGCTTGATTTCTGCTGGCTTGGTTCCATGCCATCATCCAAGAGCGCCTG
 CGCTATGCTCCACTGGGGTGGTCAAAGAAGTACGAATTTGGAGAATCTGACC
 TTCGATCAGCTTGTGACACGGTGGACACGTGGCTGGACGACACAGCCAAGGG
 CCGGCAGAACATCTCACCAGATAAGATCCCATGGTCTGCCCTGAAGACCTG
 ATGGCGCAGTCCATCTATGGTGGGCGGGTGGACAATGAGTTCGACCAGCGTC
 15 TGCTCAACACCTTCCTGGAGCGGCTGTTACACCACCCGCAGCTTCGACAGTGA
 ATTCAAGCTGGCGTGCAAGGTTGACGGGCACAAGGACATCCAGATGCCTGAT
 GGTATCAGGCGAGAGGAGTTTGTGCACTGGGTGGAGCTGCTGCCTGACGCCC
 AGACACCTCATGGCTGGGCCCTCCCCAACAATGCTGAAAGGGTCTGCTTAC
 CACCAAGGCGTGGACATGATCAGCAAGATGCTGAAGATGCAGATGCTGGAG
 20 GACGAGGATGACCTGGCCTACGCAGAGACGGAGAAGAAGGCAAGGACGACT
 CCACCTCCGATGGCCGTCCAGCCTGGATGAGGACACTGCACACCACGGCGTC
 CAACTGGCTGCACCTCATCCACAGACACTGAGCCCCCTGAAGCGCACCGTG
 GAGAACATCAAGGATCCTTTGTTAGGTTCTTTGAGAGAGAAGTAAAGATGG
 GGGCCAAGTTACTCCAAGATGTGCGCCAAGACCTTGCTGACGTCGTTCAAGT
 25 GTGCGAGGGGAAAAAGAAGCAGACAACTACCTGCGCACGCTCATCAATGAG
 CTGGTGAAAGGGATCTTGCTCGGAGCTGGTCCCATTACACAGTGCCTGCAG
 GCATGACGGTGATCCAGTGGGTGTCAGATTTAGCGAGAGGATCAAACAGCT
 GCAGAACATCTCACAAGCAGCTGCATCTGGTGGTGCCAAGGAAGTGAAGAAC
 ATCCACGTGTGCCTGGGTGGCCTGTTTGTACCTGAGGCCTACATCACTGCCA
 30 CCAGACAGTATGTGGCACAAGCTAACAGCTGGTCCCTGGAGGAACTCTGCCT
 GGAAGTCAATGTCACCGCCTCACAGAGTGCCACCCTTGATGCCTGCAGCTT
 GGAGTCACAGGTCTGAAGCTCAAGGGGCCACGTGCAGCAACAACAAGCTAT
 CACTCTCCAATGCCATCTCCACAGTCTCTCCCCCTCACACAGCTGCGCTGGGT
 GAAACAAACAAGCGCCGAGAAGAAGGCCAGCGTGGTGACCTTACCTGTCTAC
 35 CTGAACTTCAACCGGGCAGACCTCATCTTACCGTGGACTTTGAAATTGCTA
 CAAAGGAAGATCCTCGCAGCTTCTATGAGCGTGGAGTTGCCGTTCTGTGCAC
 TGAGTAAAGCTAGACTTTTCTCCAGTCTCTTCTGGAATAGGAACTCCCA
 ATATTTAACCTTCATTATCCTTAACGGTGTGGAAGGGTTGATGGACTGGAA
 AGCAAAGTGGTTGGTTTCGCGTTGGCGGGTGACAGGTGCTGCGGTTGGAGACGG
 40 TGGGATGGGAGAAGAGAAGAGTGCCTGTCCGAGGGCTGACCGAATGGCTGG
 GTTTAGTAAATAAAACACTAAGCATGACGGGCAAAAAAAAAAAAAAAAAA

Table 3. Mutated human cytoplasmic dynein heavy chain 1, cDNA (SEQ ID NO:5)

45 ATGTCGGAGCCCCGGGGCGGGCGGGCGGCGAGGACGGCTCGGCCGGA
 TTGGAAGTGTCGGCCGTGCAGAATGTGGCGGACGTGTCGGTGCTG
 CAGAAGCACCTGCGCAAGCTGGTGCCGCTGCTGCTGGAGGACGGC
 GCGGAGGCGCCGGCCGCGCTGGAGGCGGCGCTGGAGGAGAAGAGC
 50 GCCCTGGAGCAGATGCGCAAGTTCTTTTCGGACCCGCAGGTCCAC
 ACGGTGCTGGTGGAGCGCTCCACGCTCAAAGAGGACGTGGTGAT
 GAAGGAGAAGAAGAAAAAGAATTCAATTCCTATAACATCAACATA
 GACATTCATTATGGGGTTAAATCCAATAGCTTGGCATTCTATAAA

CGTACTCCCGTGATTGATGCAGATAAACCCGTGTCTTCTCAGCTC
CGGGTCCTTACACTCAGTGAAGACTCGCCCTACGAACTTTGCAT
TCTTTCATTAGCAATGCAGTGGCTCCTTTTTTTAAGTCCTACATT
AGAGAGTCTGGCAAGGCAGACAGGGATGGTGATAAAATGGCTCCT
5 TCAGTTGAAAAGAAGATTGCAGAACTCGAAATGGGACTCCTTCAC
TTGCAGCAAAATATTGAAATTCGGGAGATCAGCCTGCCGATTTCAT
CCAATGATCACAAATGTTGCAAAACAGTGTTATGAGCGTGGAGAA
AAGCCAAAAGTTACAGACTTTGGTGATAAGGTTGAAGACCCAACA
TTTCTTAATCAGTTACAATCTGGAGTTAACCCTGGATCCGAGAA
10 ATTCAAAAAGTGACCAAACTGGATCGAGATCCTGCATCAGGAAC
GCCTTACAGGAAATTAGTTTTTGGCTAAACTTGGAACGTGCGTTA
TACCGCATCCAGGAGAAACGGGAGAGCCCGGAAGTTCTCCTGACT
CTGGATATCTTGAAACATGGCAAGCGCTTCCATGCCACCGTCAGT
TTTGACACTGACACAGGTCTAAAACAGGCTTTGGAACTGTGAAT
15 GACTACAATCCTCTGATGAAAGATTTCCCTCTGAATGATTTGCTG
TCTGCCACGGAGCTGGACAAAATAAGACAGGCGCTTGTGCCATT
TTCACACATTTGAGAAAGATCCGAAACACAAAATATCCTATTTCAG
AGGGCACTGCGTTTTGGTGGAGGCAATTTCAAGAGACTTGAGTTCT
CAATTACTCAAAGTATTGGGCACTAGGAAATTGATGCATGTTGCT
20 TATGAAGAATTTGAAAAAGTTATGGTAGCATGCTTTGAAGTTTTT
CAGACTTGGGATGATGAGTATGAGAACTTCAGGTATTGTTGAGA
GACATCGTCAAAAGAAAAAGGGAAGAAAATCTGAAGATGGTGTGG
CGTATCAACCCTGCCCACAGGAAGCTGCAGGCCCGCCTTGACCAG
ATGAGAAAAATTTAGACGCCAGCATGAACAGCTAAGAGCTGTTATC
25 GTCAGGGTCCTGAGGCCACAGGTACCGGCAGTTGCACAACAGAAT
CAAGGAGAGGTCCCTGAACCCCAAGATATGAAAGTGGCTGAGGTT
CTCTTTGATGCTGCAGATGCAAATGCCATTGAGGAAGTAAACCTT
GCTTATGAGAACGTCAAGGAAGTGGATGGACTGGATGTTTCCAAA
GAGGGCACGGAAGCCTGGGAGGCTGCTATGAAGAGGTACGATGAG
30 AGGATCGACAGAGTGGAGACCCGGATCACCGCTCGCCTTCGGGAT
CAGCTTGGCACAGCCAAGAATGCCAACGAGATGTTTAGGATTTTC
TCCAGGTTTAATGCACTGTTTGTGAGGCCTCACATCCGTGGGGCC
ATTCGCGAATACCAGACCCAGCTGATCCAGCGCGTGAAAGATGAC
ATTGAGTCTCTTCACGACAAGTTCAAGGTCCAGTACCCACAGAGT
35 CAGGCTTGTAAGATGAGTCACGTTTCGTGACTTGCCCCCTGTGTCA
GGGTCTATCATCTGGGCTAAACAGATCGACAGGCAGCTGACGGCC
TACATGAAGCGGGTGGAAAGATGTCCTTGGCAAGGGCTGGGAGAAT
CACGTGGAGGGGCAGAAGCTGAAGCAGGATGGAGACAGCTTCCGC
ATGAAGCTCAACACGCAGGAGATCTTTGATGACTGGGCAAGGAAG
40 GTGCAGCAGCGCAACCTCGGTGTCTCGGGGCGCATTTTCACCATC
GAAAGTACTCGGGTTTCGGGGCCGAACTGGAAATGTGCTTAAGCTG
AAAGTTAACTTTCTTCCTGAGATTATCACACTATCCAAAGAAGTC
CGGAACCTCAAATGGCTTGGTTTTCCGCGTCCCCTGGCGATTGTG
AACAAAGCCCATCAAGCAAACCAGCTTTACCCGTTTGCCATCTCA
45 CTGATCGAGAGCGTTTCGTACCTATGAACGGACCTGCGAGAAGGTG
GAGGAGCGGAACACCATTTCCCTTTTGGTGGCTGGCTTGAAAAAG
GAAGTGCAGGCCCTGATCGCAGAAGGCATTGCGTTGGTGTGGGAG
TCCTACAACTTGACCCATATGTACAGCGCTTAGCAGAGACTGTC
TTCAACTTCCAAGAAAAGGTGGATGATCTGCTGATCATTGAAGAA
50 AAAATAGACCTAGAAGTCCGTTCCCTTGGAACTTGTATGTATGAC
CATAAGACATTCTCGGAAATCTTGAACAGAGTCCAGAAAGCAGTG
GATGACTTAAATCTGCACTCCTATTCCAATTTGCCCATCTGGGTC
AACAAGCTTGACATGGAGATTGAAAGAATATTGGGCGTCCGTCTG
CAAGCTGGCCTGAGAGCTTGGACGCAGGTTCTTCTTGGACAAGCT
55 GAAGATAAAGCAGAAGTTGACATGGACACAGATGCTCCACAAGTT
AGTCACAAGCCTGGTGGAGAGCCAAAGATCAAAAATGTCGTTTCAT

GAGCTAAGAATAACCAATCAGGTAATCTACTTGAATCCACCAATT
GAAGAGTGCAGATACAAGCTGTATCAGGAAATGTTTGCCTGGAAG
ATGGTTGTACTGTCTCTCCCCAGGATCCAGAGTCAGAGGTACCAG
GTGGGTGTACATTACGAATTGACTGAGGAAGAGAAATTCTATCGG
5 AATGCTTTAACACGGATGCCTGATGGCCCTGTTGCCCTGGAAGAG
TCGTATTCTGCTGTCTATGGGCATTGTATCTGAAGTTGAACAGTAT
GTCAAGGTTTGGCTTCAGTCTCAGTGTATGAGGATATGCAAGCT
GAAAACATCTATAACAGACTTGGAGAAGATCTCAACAAATGGCAG
GCTCTCCTGGTCCAAATAAGGAAGGCCAGAGGAACCTTTGACAAT
10 GCAGAAACCAAGAAAGAGTTTGGACCAGTAGTTATAGATTATGGC
AAGGTACAATCTAAGGTGAACCTTGAAATATGACTCTTGGCATAAG
GAGGTTCTTAGCAAATTTGGGCAGATGCTAGGATCAAACATGACG
GAATTCCATTCCCAGATCTCAAAGTCCCGCCAAGAGTTGGAGCAG
CACTCAGTAGACACGGCCAGCACCTCCGATGCAGTGACCTTCATC
15 ACCTATGTGCAGTCTTTGAAACGGAAGATCAAGCAGTTTGAGAAG
CAAGTTGAGCTCTACCGCAATGGCCAGCGCTTACTGGAAAAGCAA
AGGTTCCAGTTCCCACCTTCCTGGCTTTATATTGACAACATCGAG
GGAGAGTGGGGAGCCTTCAATGACATCATGCGGCGAAAGGACTCT
GCCATTTCAGCAGCAGGTGGCAAACCTGCAAATGAAGATTGTCCAG
20 GAGGATCGGGCCGTGGAAAGCCGACACCGACCTGCTGACTGAC
TGGGAGAAGACCAAGCCTGTCACGGGCAACCTTCGCCCAGAAGAG
GCACCTTCAGGCTCTCACCATATATGAGGGGAAGTTTGGTAGGCTG
AAGGACGACAGAGAGAAGTGTGCAAAGGCCAAGGAGCGCTGGAA
TTGACAGATACTGGGCTTCTCAGTGGCAGTGAAGAGCGCGTGACG
25 GTGGCCTTAGAAGAATTACAGGACCTCAAAGGCGTTTGGTCAGAA
CTTTCTAAGGTTTGGGAGCAAATCGATCAGATGAAGGAGCAACCC
TGGGTTTTCAGTACAGCCTCGAAAGCTTCGACAAAATTTGGATGCC
CTCCTGAACCAGCTGAAAAGCTTCCTGCCCCGTTGCGACAGTAT
GCGTCCTATGAGTTTGTTCAGAGGCTTCTGAAAGGTTACATGAAG
30 ATAAATATGCTGGTGATTGAACTGAAATCCGAAGCACTTAAAGAC
CGCCATTGGAAACAGCTCATGAAAAGGCTTCACGTTAATTGGGTT
GTTTCTGAGCTAACCCTTGGCCAAATCTGGGATGTTGACTTGCAG
AAAAATGAAGCGATTGTCAAGGATGTACTGCTTGTGGCACAAGGG
GAGATGGCTTTGGAAGAATTTTGAAGCAGATAAGAGAAGTGTGG
35 AATACTTATGAACTAGACTTGGTTAATTATCAGAACAAGTGCCGC
TTGATCCGTGGCTGGGATGACCTCTTCAACAAGGTCAAAGAACAC
ATCAACAGCGTCTCGGCCATGAAGCTCTCTCCGTATTACAAGGTT
TTTGAAGAGGATGCTCTCAGCTGGGAAGATAAGCTGAACAGGATC
ATGGCTCTCTTTGATGTGTGGATTGATGTGCAGAGGCGGTGGGTC
40 TACCTGGAAGGTATCTTCACAGGCAGTGCAGATATCAAGCACCTG
CTGCCAGTGGAAACCCAGCGGTTTCAGAGCATCAGCACTGAGTTT
TTGGCTCTAATGAAAAAAGTGTCCAAGTCTCCCCCTTGTATGGAT
GTTCTGAACATCCAGGGAGTACAGAGGTCTCTGGAAAGATTGGCA
GACCTGCTAGGAAAGATCCAGAAAGCATTGGGAGAATATCTGGAA
45 AGAGAGCGGTCTCTTTCCCCAGGTTCTATTTTGTGGGTGATGAA
GATTTGCTTGAAATCATTGGAAACAGCAAGAATGTCGCTAAATTA
CAGAAACACTTCAAGAAGATGTTTGTCTGGAGTTTCGAGCATCATC
CTGAACGAGGATAACTCTGTTGTTTTGGGTATTTTCATCTCGGGAA
GGAGAGGAGGTTATGTTTAAAACTCCTGTGTCAATTACTGAACAT
50 CCCAAAATCAATGAGTGGCTCACATTGGTAGAAAAGGAGATGAGA
GTCACCCCTGGCCAAACTGCTTGTGAGTCTGTTACGGAAGTTGAG
ATTTTTGGTAAAGCAACTTCAATTGACCCAAATACCTACATCACT
TGGATTGATAAATACCAGGCCAGCTTGTGGTTTTTGTGAGCCAG
ATAGCCTGGTCTGAGAACGTGGAGACCGCACTGAGCAGCATGGGC
55 GGAGGTGGAGATGCCGCGCCCTTGCACTCTGTGCTGAGCAATGTG
GAGGTCACCCCTCAATGTGTTAGCAGACTCTGTCTCATGGAGCAG

CCCCACTCCGAAGGCGGAAGCTAGAACACTTGATTACAGAGTTG
GTTCAACCAGAGAGATGTTACAAGGTCCTTGATCAAAGCAAGATT
GACAACGCCAAATCTTTTGAATGGCTCAGCCAGATGCGATTTTAC
TTTGACCCTAAGCAAACCTGATGTGTTACAGCAGTTGTCAATTCAA
5 ATGGCAAATGCCAAATTTAACTATGGCTTTGAGTACCTGGGTGTT
CAGGACAAACTGGTCCAGACCCCCCTCACTGACCGCTGCTATTTG
ACAATGACACAAGCCTTGGAGGCCAGGCTGGGGGGTTCCCCATTT
GGACCTGCTGGAACCTGGGAAAACAGAGTCTGTCAAAGCTCTTGGC
CATCAGCTTGGACGGTTTGTTTTAGTTTTCAACTGTGATGAAACC
10 TTTGATTTCCAGGCAATGGGCCGGATCTTTGTGGGCCCTTTGCCAG
GTGGGTGCCTGGGGCTGCTTTGACGAGTTCAACCGCTGGAGGAG
CGGATGCTCTCGGCTGTGTCCCAGCAGGTGCAGTGCATACAGGAA
GCACTGCGTGAACATTCCAACCCCAACTACGACAAGACCTCTGCC
CCCATTACTTGTGAGCTGCTGAACAAACAAGTCAAGGTGAGCCCG
15 GACATGGCCATCTTCATCACCATGAACCTGGCTACGCGGGCCGG
TCTAACCTTCCTGACAACTTGAAGAAGCTGTTCCGGAGCTTGGCC
ATGACCAAGCCCGACCGGCAGTTAATCGCCAGGTTCATGCTGTAC
TCACAGGGTTTCCGCACTGCTGAAGTGCTTGCCAACAAAATCGTC
CCGTTTTTTTAACTATGCGATGAGCAGCTCTCTTCCCAAAGCCAT
20 TATGACTTCGGTCTTTCGGGCTTTGAAGAGTGCTGGTGAGTGCA
GGCAATGTGAAGAGAGAGAGAATCCAGAAGATAAAGAGGGAGAAA
GAGGAACGAGGGGAAGCAGTTGATGAAGGAGAAATTGCTGAAAAT
CTCCCTGAACAAGAGATTCTGATACAGAGCGTCTGTGAGACGATG
GTGCCAAAGCTGGTGGCAGAGGACATCCCGCTGCTCTTCAGCCTC
25 CTGTGCGACGTGTTCCCTGGAGTCCAGTATCACAGGGGTGAGATG
ACTGCCCTTCGAGAGGAGCTGAAGAAAGTGCTCAGGAGATGTAT
TTGACATATGGAGATGGAGAAGAAGTTGGTGGAATGTGGGTTGAA
AAGGTTCTCCAGCTCTATCAGATCACCCAGATCAATCATGGCCTG
ATGATGGTGGGGCCCTCGGGAAGTGGGAAGAGCATGGCCTGGCGT
30 GTCTGCTGAAGGCATTGGAGAGACTCGAGGGTGTGGAAGGTGTG
GCCCATATCATCGACCCCAAGGCCATCAGCAAAGACCACCTCTAC
GGAACCTTGACCCCAACACCAGGGAATGGACAGATGGGCTCTTC
ACACACGTGCTGAGAAAGATCATCGACAGCGTGAGAGGCGAGCTG
CAGAAGCGCCAGTGGATCGTCTTCGATGGCGATGTGGATCCAGAG
35 TGGGTTGAGAACTTGAACCTCAGTGCTGGATGACAATAAGCTCCTA
ACTTTGCCCAATGGAGAGCGCCTCAGTCTTCCACCCAATGTGAGA
ATAATGTTTGAGGTACAGGACTTGAAATACGCGACCTTGGCCACA
GTGTGCGCTGCGGCATGGTCTGGTTTCACTGAGGATGTGCTGAGC
ACCGACATGATCTTCAACAACCTTCTGGCCAGGCTGCGCAGCATC
40 CCGCTGGATGAAGGGGAGGATGAGGCACAGCGGCGGCGTAAGGGC
AAAGAGGATGAGGGGGAGGAGGCCGCTTCCCCCATGCTGCAGATC
CAAAGAGATGCAGCTACGATCATGCAACCGTACTTCACGTCCAAC
GGCCTGGTCACCAAGGCGCTAGAGCACGCCTTCCAGCTGGAGCAC
ATCATGGACCTAACACGCCTGCGCTGCCTGGGCTCGCTCTTCTCC
45 ATGCTGCACCAGGCTGCGCAACGTGGCGCAGTATAACGCCAAC
CATCCCGACTTCCCCATGCAGATCGAGCAGCTGGAGCGCTACATT
CAGCGATATCTGGTTTTATGCCATACTCTGGTCCCTGTCTGGAGAC
AGCCGGCTAAAAATGAGAGCAGAGCTGGGTGAATACATCAGAAGA
ATCACGACCGTGCCTCTGCCCCACTGCGCCCAACATAACCCATTATC
50 GATTATGAGGTGTCCATCAGCGGAGAATGGTCTCCGTGGCAGGCC
AAGGTGCCTCAGATTGAAGTGGAGACGCACAAGGTGGCAGCCCCCT
GATGTGTCGTGCAACGCTGGACACAGTCCGCCACGAAGCCCTC
TTGTACACTTGGCTGGCCGAACACAAGCCCCCTGGTCTTGTGTGGC
CCTCCTGGGTCTGGCAAGACCATGACACTCTTCAGCGCCCTCCGG
55 GCCTTGCTGACATGGAGGTGGTGGGTCTCAACTTCTCCAGTGCT
ACTACTCCAGAGCTGCTTCTGAAGACTTTTGATCACTACTGCGAG

TACAGGCGCACACCTAATGGGGTGGTTTTGGCTCCTGTTCAACTT
GGAAAGTGGCTGGTGTGTTCTGTGATGAAATCAACTTGCCAGAT
ATGGATAAAATATGGGACCCAGAGGGTCATATCCTTCATCAGACAG
ATGGTGGAGCACGGAGGCTTTTACCGTACCTCAGATCAAACATGG
5 GTGAAGCTGGAGAGAATCCAGTTTGTGGGGCTTGTAATCCCCC
ACAGACCCTGGAAGAAAGCCCCTCTCACACAGGTTTCTGCGCCAC
GTGCCTGTCGTGTATGTGGATTACCCGGGCCCCGCTCCCTCACA
CAGATCTACGGCACCTTCAACCGCGCCATGCTGAGGCTCATTCCA
TCCCTGCGGACGTATGCAGAGCCGCTCACTGCTGCCATGGTGGAG
10 TTCTACACCATGTCTCAGGAGAGATTACCCAGGATACACAACCT
CACTATATCTATTACCCCGTGAAATGACTAGGTGGGTGAGAGGC
ATCTTTGAAGCGCTGAGACCTCTGGAGACCCTGCCTGTTGAAGGC
CTCATTTCGGATTTGGGCACATGAAGCTCTGCGTCTCTTCCAAGAT
AGACTCGTAGAGGATGAGGAGAGGCGTTGGACTGATGAGAACATC
15 GACACGGTTGCTCTGAAGCACTTCCCTAACATCGACAGAGAGAAG
GCAATGAGCCGACCCATCTTGTACAGCAACTGGCTGTCAAAGGAT
TACATCCAGTAGACCAAGAAGAGTTAAGAGATTATGTCAAAGCT
AGGCTGAAGGTCTTTTATGAAGAAGAAGCTTGATGTTCCGCTGGTG
CTGTTTAATGAAGTCCTAGACCACGTGCTGAGGATTGACAGAATA
20 TTCCGTCAACCTCAAGGCCACTTGCTTCTGATTGGTGTAGTGGA
GCAGGAAAACTACCCTGTCTCGTTTCGTCGCCTGGATGAACGGT
TTGAGTGTGTACCAGATTAAGGTCCATAGGAAGTACACAGGGGAA
GACTTTGATGAAGATCTACGGACAGTGTTGAGACGTTCTGGCTGT
AAAAATGAAAAGATAGCATTATAATGGATGAATCTAATGTGTTA
25 GATTCTGGATTCTGAGCGAATGAATACCCTTCTGGCCAATGGA
GAGGTGCCTGGTCTCTTTGAAGGAGACGAGTATGCCACCTTGATG
ACGCAGTGCAAAGAGGGGGCACAGAAGGAAGGCCTGATGCTGGAC
TCGCACGAGGAGCTCTACAAGTGGTTCCTAGCCAGGTTATCCGC
AACCTCCACGTCGTGTTTACCATGAACCCGTCCTCGGAGGGACTC
30 AAGGACCGGGCAGCTACATCACCAGCACTTTTCAACAGGTGTGTG
TTGAATTGGTTTGGAGACTGGTCCACCGAAGCACTGTATCAGGTT
GGCAAAGAATTACAAAGTAAGATGGATCTGGAGAAGCCAAATTAC
ATCGTGCCTGATTACATGCCAGTTGTGTATGATAAGCTGCCGCAG
CCACCATCCCATCGGGAAGCCATTGTGAACAGCTGTGTGTTTGT
35 CATCAGACTCTTACCAGGCGAATGCTCGGCTAGCAAAGCGAGGC
GGCAGAACGATGGCCATCACCCCTCGCCACTACCTGGACTTCATC
AATCACTATGCCAACCTGTTCCACGAGAAGCGGAGCGAGCTGGAG
GAGCAGCAGATGCACCTGAACGTGGGGCTCAGGAAGATCAAAGAG
ACAGTCGACCAGGTAGAAGAACTGCGTCGTGACTTGAGGATAAAG
40 AGCCAAGAGCTGGAGGTGAAGAATGCAGCAGCCAATGACAAGCTG
AAAAAGATGGTGAAAGACCAGCAGGAGGCTGAAAAGAAGAAGGTT
ATGAGCCAAGAAATCCAGGAACAGCTGCATAAGCAGCAGGAGGTA
ATTGCAGACAAACAGATGAGTGTCAAAGAAGATCTTGATAAGGTG
GAACCTGCCGTCATTGAGGCCAGAAATGCTGTGAAGTCGATCAAG
45 AAGCAGCACCTGGTGGAGGTGAGGTCCATGGCCAACCTCCTGCT
GCTGTGAAGCTGGCGCTGGAGTCCATCTGCCTGCTGCTGGGGGAA
AGACCCACAGACTGGAAGCAGATCCGCTCCATCATCATGCGGGAG
AACTTCATCCCCACCATCGTCAACTTCTCTGCAGAGGAGATCAGT
GACGCCATAAGGGAGAAGATGAAGAAAAATTACATGTCCAATCCA
50 AGTTACAATTATGAAATTGTGAATCGGGCTTCCCTGGCTTGCGGC
CCTATGGTGAAATGGGCAATTGCACAGCTTAACTATGCAGACATG
TAAAGAGAGTGGAGCCCCTACGCAATGAGCTGCAGAAGCTGGAA
GATGACGCCAAGGACAACCAGCAGAAGGCCAACGAGGTGGAGCAG
ATGATCCGAGACCTGGAAGCCAGCATCGCCCGCTACAAGGAGGAA
55 TACGCCGTCTGATCTCAGAGGCCCAGGCCATCAAGGCAGACCTG
GCAGCTGTCGAGGCAAAAGTAAACCGGAGCACTGCTCTTCTGAAG

AGCTTGTCTGCTGAACGTGAACGATGGGAAAAACAAGTGAAACT
TTCAAAAACCAGATGTCCACCATTGCTGGGGACTGTCTCTTGTCA
GCTGCGTTTCATTGCCTACGCGGGTTACTTTGACCAGCAGATGCGT
CAGAACTTGTTCACCTACCTGGTCCCATCACCTACAGCAAGCCAAC
5 ATCCAGTTCCGTACAGATATTGCCAGGACGGAATACCTTTCCAAT
GCTGATGAGCGTCTTCGCTGGCAGGCCAGCTCCTTGCCCTGCTGAT
GACCTTTGCACAGAAAATGCCATCATGCTGAAACGATTCAATAGG
TATCCGCTGATCATTGACCCCTCTGGACAGGCCACAGAATTCATT
10 ATGAATGAATATAAGGATCGTAAGATCACACGGACCAGCTTCCTG
GATGACGCCTTCAGAAAGAACTTAGAGAGTGCAGTGAAGATTCCGT
AACCCCTTCTGGTCCAGGATGTGGAAAGCTACGATCCAGTTTGG
AACCCGGTGCTGAACCGTGAAGTGCGGCGAACAGGGGGGAGAGTG
CTGATCACTCTCGGGGACCAGGACATAGACCTGTCGCCATCGTTT
GTCATCTTCTGTCACCCGGGATCCAAGTTCGAGTTCCACCA
15 GATCTCTGTTCCCGGGTACTTTTGTAAGTTCACAGTTACCCGT
AGCAGTTTACAAAGCCAGTGTCTAAATGAAGTACTTAAAGCAGAA
AGACCTGATGTGGACGAGAAACGATCTGATCTTCTTAAACTTCAA
GGGGAATTTACAGCTCCGTTTGCCTCAGCTGGAAAAATCTCTACTA
CAAGCTCTGAACGAGGTGAAAGGGCGCATTTTGGATGACGACACG
20 ATCATAACCACTCTGGAGAACCTGAAGAGAGAGGCTGCAGAGGTG
ACCAGGAAAGTTGAGGAGACGGACATTGTCTATGCAGGAGGTGGAG
ACCGTGTCCAGCAGTACCTCCCGCTCTCCACCGCCTGCAGCAGC
ATCTACTTCACCATGGAGTCCCTCAAGCAGATACACTTCTTGTAC
CAGTACTCCCTCCAGTTTTTCTGGACATTTATCACAACGTCTTA
25 TACGAGAACCCGAACCTGAAGGGTGTACCGACCACACACAGCGC
CTGTCCATTATAACAAAGGACCTCTTCCAGGTGGCGTTTAACCGA
GTGGCTCGAGGCATGCTGCATCAGGACCACATTACCTTTGCCATG
CTGCTGGCAAGAATCAAAGTGAAGGGCACCGTGGGGGAGCCACC
TACGATGCAGAAATCCAGCACTTCTTGAGAGGAAATGAGATTGTC
30 CTGAGTGCTGGCTCCACCCCCAGGATCCAGGGCCTGACTGTGGAG
CAGGCGGAGGCGGTGGTGAGGCTGAGCTGCCTTCCCGCGTTTAAAG
GACTTGATTGCAAAGGTTGAGGACAGCAGCAATTTGGCATCTGG
CTGGACAGCAGCTCCCCGGAGCAGACTGTGCCCTACCTCTGGAGT
GAAGAAACACCTGCAACACCCATTGGCCAGGCCATCCACCGCTG
35 CTCTGATCCAGGCTTCCGGGCCGATCGCCTGTTGGCCATGGCC
CACATGTTTGTTCACAAACCTTGGGGAGTCTTTTCATGTCCATC
ATGGAGCAGCCGCTCGACCTGACCCACATTGTGGGCACAGAGGTG
AAGCCCAACACTCCTGTCTTAATGTGCTCTGTGCCTGGTTATGAT
GCCAGTGGACATGTGAGGACCTTGACGCCGAGCAGAACACGCAG
40 ATCACTTCAATTGCAATCGGCTCTGCAGAAGGCTTTAACCAAGCA
GATAAGGCAATAAACACCGCTGTAAAGTCGGGCAGGTGGGTGATG
CTGAAGAATGTGCATCTGGCCCCAGGGTGGCTGATGCAGCTGGAG
AAGAAGTTGCATTCCCTGCAGCCGCATGCCTGCTTCCGACTCTTC
CTCACCATGGAGATCAACCCCAAGGTGCCTGTGAATCTGCTCCGT
45 GCGGGCCGCATCTTTGTGTTGAGCCACCGCCAGGGGTGAAGGCC
AACATGCTGAGGACGTTTACGAGCATTCCCGTCTCAGCGATATGC
AAGTCTCCCAACGAGCGTGCCGCTTGTACTTCTGCTGGCCTGG
TTTCATGCGATCATCCAAGAACGCTTACGATACGCACCACTGGGG
TGGTCAAAGAAGTATGAATTTGGAGAGTCTGACCTGCGGTGAGCT
50 TGCGATACGGTGGACACGTGGCTGGATGACACGGCCAAGGGCAGG
CAGAACATCTCACCGGATAAGATCCCGTGGTCTGCACTAAAGACC
TTAATGGCCCAGTCCATTTATGGCGGGCGCGTGGACAACGAGTTT
GACCAGCGTCTGCTCAACACCTTCTGGAGCGCCTGTTTACAACC
AGGAGTTTCGACAGTGAGTTTAAAGCTGGCATGCAAGGTGACGGA
55 CATAAAGACATTCAAATGCCAGATGGCATCAGGCGAGAGGAGTTT
GTGCAGTGGGTGGAGTTGCTCCCCGACACCCAGACGCCCTCTCTGG

CTGGGCCTGCCCAACAACGCCGAGAGAGTCCTCCTTACCACACAG
 GGTGTGGACATGATCAGTAAAATGCTGAAGATGCAGATGTTGGAG
 GATGAGGACGACCTGGCCTACGCAGAGACTGAGAAGAAGACGAGG
 ACAGACTCCACGTCCGACGGGCGCCCTGCCTGGATGCGGACACTG
 5 CACACCACCGCGTCCAACCTGGCTGCACCTCATCCCCAGACGCTG
 AGCCACCTCAAGCGCACCGTGGAGAATATCAAGGATCCTTTGTTC
 AGGTTCTTTGAGAGAGAAGTGAAGATGGGCGCAAAGCTGCTTCAG
 GACGTTGCCAGGACCTTGACAGATGTCGTCCAGGTGTGCGAAGGA
 AAGAAGAAGCAGACCAACTACTTGCGCACGCTGATCAACGAGCTA
 10 GTGAAAGGGATCTTGCCCTCGGAGCTGGTCCCACTACACGGTGCCT
 GCCGGCATGACCGTCATCCAGTGGGTGTCCGACTTCAGCGAGAGG
 ATCAAACAGCTGCAGAACATCTCACTGGCAGCTGCATCTGGTGGC
 GCCAAGGAGCTAAAGAACATCCACGTGTGCCTGGGTGGCTGTTC
 GTGCCTGAGGCGTACATCACTGCCACCAGGCAGTATGTGGCCCAG
 15 GCCAACAGCTGGTCCCTGGAGGAGCTCTGCCTGGAAGTCAACGTC
 ACCACCTCACAGGGCGCCACCCTTGACGCTTGACGCTTCGGAGTC
 ACGGGTTTGAAACTTCAAGGGGCCACGTGCAACAACAACAAGCTG
 TCACTGTCCAATGCCATCTCAACCGCCCTTCCCCTGACGCAGCTG
 CGCTGGGTCAAGCAGACAAACACCGAGAAGAAGGCCAGTGTGGTA
 20 ACCTTACCTGTCTACCTGAACTTCAACCGTGCAGACCTCATCTTC
 ACCGTGGACTTCGAAATTGCTACAAAGGAGGATCCTCGCAGCTTC
 TACGAGCGGGGTGTCGCAGTCTTGTGCACAGAGTAA

25 Table 4. Wild type human cytoplasmic dynein heavy chain 1, cDNA (SEQ ID
 NO:17)

ATGTCGGAGCCCGGGGGCGGCGGCGGCGAGGACGGCTCGGCCGGA
 TTGGAAGTGTCGGCCGTGCAGAATGTGGCGGACGTGTCGGTGCTG
 CAGAAGCACCTGCGCAAGCTGGTGCCGCTGCTGCTGGAGGACGGC
 30 GGCGAGGCGCCGGCCGCGCTGGAGGCGGCGCTGGAGGAGAAGAGC
 GCCCTGGAGCAGATGCGCAAGTTCCTTTTCGGACCCGCAGGTCCAC
 ACGGTGCTGGTGGAGCGCTCCACGCTCAAAGAGGACGTGGTGAT
 GAAGGAGAAGAAGAAAAAGAATTCATTTCTATAACATCAACATA
 GACATTCATTATGGGGTTAAATCCAATAGCTTGGCATTTCATTA
 35 CGTACTCCCGTGATTGATGCAGATAAACCCGTGTCTTCTCAGCTC
 CGGGTCCTTACACTCAGTGAAGACTCGCCCTACGAACTTTGCAT
 TCTTTTCATTAGCAATGCAGTGGCTCCTTTTTTTAAGTCCTACAT
 AGAGAGTCTGGCAAGGCAGACAGGGATGGTGATAAAATGGCTCCT
 TCAGTTGAAAAGAAGATTGCAGAACTCGAAATGGGACTCCTTCAC
 40 TTGCAGCAAAATATTGAAATCCGGAGATCAGCCTGCCGATTCAT
 CCAATGATCACAAATGTTGCAAAACAGTGTTATGAGCGTGGAGAA
 AAGCCAAAAGTTACAGACTTTGGTGATAAGGTTGAAGACCCAACA
 TTTCTTAATCAGTTACAATCTGGAGTTAACCGCTGGATCCGAGAA
 ATTCAAAAAGTGACCAACTGGATCGAGATCCTGCATCAGGAACT
 45 GCCTTACAGGAAATTAGTTTTTTGGCTAACTTGGAACGTGCGTTA
 TACCGCATCCAGGAGAAACGGGAGAGCCCGGAAGTTCTCCTGACT
 CTGGATATCTTGAAACATGGCAAGCGCTTCCATGCCACCGTCAGT
 TTTGACACTGACACAGGTCTAAACAGGCTTTGGAACTGTGAAT
 GACTACAATCCTCTGATGAAAGATTTCCCTCTGAATGATTTGCTG
 50 TCTGCCACGGAGCTGGACAAAATAAGACAGGCGCTTGTTGCCATT
 TTCACACATTTGAGAAAGATCCGAAACACAAAATATCCTATTCAG
 AGGGCACTGCGTTTTGGTGGAGGCAATTTCAAGAGACTTGAGTTCT
 CAATTACTCAAAGTATTGGGCACTAGGAAATTGATGCATGTTGCT

TATGAAGAATTTGAAAAAGTTATGGTAGCATGCTTTGAAGTTTTT
CAGACTTGGGATGATGAGTATGAGAACTTCAGGTATTGTTGAGA
GACATCGTCAAAAGAAAAAGGGAAGAAAATCTGAAGATGGTGTGG
CGTATCAACCCTGCCACAGGAAGCTGCAGGCCCGCCTTGACCAG
5 ATGAGAAAATTTAGACGCCAGCATGAACAGCTAAGAGCTGTTATC
GTCAGGGTCCTGAGGCCACAGGTCACGGCAGTTGCACAACAGAAT
CAAGGAGAGGTCCCTGAACCCCAAGATATGAAAGTGGCTGAGGTT
CTCTTTGATGCTGCAGATGCAAATGCCATTGAGGAAGTAAACCTT
GCTTATGAGAACGTCAAGGAAGTGGATGGACTGGATGTTTCCAAA
10 GAGGGCACGGAAGCCTGGGAGGCTGCTATGAAGAGGTACGATGAG
AGGATCGACAGAGTGGAGACCCGGATCACCGCTCGCCTTCGGGAT
CAGCTTGGCACAGCCAAGAATGCCAACGAGATGTTTAGGATTTTC
TCCAGGTTTAAATGCACTGTTTGTGAGGCCCTCACATCCGTGGGGCC
ATTCGCGAATAACCAGACCCAGCTGATCCAGCGCGTGAAAGATGAC
15 ATTGAGTCTCTTCACGACAAGTTCAGGTCCAGTACCCACAGAGT
CAGGCTTGTAAGATGAGTCACGTTTCGTGACTTGCCCCCTGTGTCA
GGGTCTATCATCTGGGCTAAACAGATCGACAGGCAGCTGACGGCC
TACATGAAGCGGGTGGAAAGATGTCCTTGGCAAGGGCTGGGAGAAT
CACGTGGAGGGGCAGAAGCTGAAGCAGGATGGAGACAGCTTCCGC
20 ATGAAGCTCAACACGCAGGAGATCTTTGATGACTGGGCAAGGAAG
GTGCAGCAGCGCAACCTCGGTGTCTCGGGGCGCATTTCACCATC
GAAAGTACTCGGGTTCGGGGCCGAACCTGGAATGTGCTTAAGCTG
AAAGTTAACTTTCTTCTGAGATTATCACACTATCCAAAGAAGTC
CGGAACCTCAAATGGCTTGGTTTCCGCGTCCCCTGGCGATTGTG
25 AACAAAGCCCATCAAGCAAACCAGCTTTACCCGTTTGCCATCTCA
CTGATCGAGAGCGTTTCGTACCTATGAACGGACCTGCGAGAAGGTG
GAGGAGCGGAACACCATTTCCTTTTGGTGGCTGGCTTGAAAAG
GAAGTGCAGGCCCTGATCGCAGAAGGCATTGCGTTGGTGTGGGAG
TCCTACAACTTGACCCATATGTACAGCGCTTAGCAGAGACTGTC
30 TTCAACTTCCAAGAAAAGGTGGATGATCTGCTGATCATTGAAGAA
AAAATAGACCTAGAAGTCCGTTTCTTGGAACTTGTATGTATGAC
CATAAGACATTCTCGGAAATCTTGAACAGAGTCCAGAAAGCAGTG
GATGACTTAAATCTGCACTCCTATTCCAATTTGCCATCTGGGTG
AACAAGCTTGACATGGAGATTGAAAGAATATTGGGCGTCCGTCTG
35 CAAGCTGGCCTGAGAGCTTGGACGCAGGTTCTTCTTGGACAAGCT
GAAGATAAAGCAGAAGTTGACATGGACACAGATGCTCCACAAGTT
AGTCACAAGCCTGGTGGAGAGCCAAAGATCAAAAATGTCGTTTCAT
GAGCTAAGAATAACCAATCAGGTAATCTACTTGAATCCACCAATT
GAAGAGTGCAGATACAAGCTGTATCAGGAAATGTTTGCCTGGAAG
40 ATGGTTGTACTGTCTCTCCCCAGGATCCAGAGTCAGAGGTACCAG
GTGGGTGTACATTACGAATTGACTGAGGAAGAGAAATCTATCGG
AATGCTTTAACACGGATGCCTGATGGCCCTGTTGCCCTGGAAGAG
TCGTATTCTGCTGTCTATGGGCATTGTATCTGAAGTTGAACAGTAT
GTCAAGGTTTGGCTTCAGTATCAGTGTTTATGGGATATGCAAGCT
45 GAAAACATCTATAACAGACTTGGAGAAGATCTCAACAAATGGCAG
GCTCTCCTGGTCCAAATAAGGAAGGCCAGAGGAACCTTTGACAAT
GCAGAAACCAAGAAAGAGTTTGGACCAGTAGTTATAGATTATGGC
AAGGTACAATCTAAGGTGAACTTGAAATATGACTCTTGGCATAAG
GAGGTTCTTAGCAAATTTGGGCAGATGCTAGGATCAAACATGACG
50 GAATTCCATTCCCAGATCTCAAAGTCCCGCCAAGAGTTGGAGCAG
CACTCAGTAGACACGGCCAGCACCTCCGATGCAGTGACCTTCATC
ACCTATGTGCAGTCTTTGAAACGGAAGATCAAGCAGTTTGAGAAG
CAAGTTGAGCTCTACCGCAATGGCCAGCGCTTACTGGAAAAGCAA
AGGTTCCAGTTCCCACCTTCTGGCTTTATATTGACAACATCGAG
55 GGAGAGTGGGGAGCCTTCAATGACATCATGCGGCGAAAGGACTCT
GCCATTGAGCAGCAGGTGGCAAACCTGCAAATGAAGATTGTCCAG

GAGGATCGGGCCGTGGAAAGCCGCACCACCGACCTGCTGACTGAC
TGGGAGAAGACCAAGCCTGTCACGGGCAACCTTCGCCCAGAAGAG
GCACTTCAGGCTCTCACCATATATGAGGGGAAGTTTGGTAGGCTG
AAGGACGACAGAGAGAAGTGTGCAAAGGCCAAGGAGGCGCTGGAA
5 TTGACAGATACTGGGCTTCTCAGTGGCAGTGAAGAGCGCGTGCAG
GTGGCCTTAGAAGAATTACAGGACCTCAAAGGCGTTTGGTCAGAA
CTTTCTAAGGTTTGGGAGCAAAATCGATCAGATGAAGGAGCAACCC
TGGGTTTTCAGTACAGCCTCGAAAGCTTCGACAAAATTTGGATGCC
CTCCTGAACCAGCTGAAAAGCTTCCCTGCCCCGGTTGCGACAGTAT
10 GCGTCCTATGAGTTTGTTCAGAGGCTTCTGAAAGGTTACATGAAG
ATAAATATGCTGGTGATTGAACTGAAATCCGAAGCACTTAAAGAC
CGCCATTGGAAACAGCTCATGAAAAGGCTTCACGTTAATTGGGTT
GTTTCTGAGCTAACCCTTGGCCAAATCTGGGATGTTGACTTGCAG
AAAAATGAAGCGATTGTCAAGGATGTACTGCTTGTGGCACAAGGG
15 GAGATGGCTTTGGAAGAATTTTGAAGCAGATAAGAGAAGTGTGG
AATACTTATGAACTAGACTTGGTTAATTATCAGAACAAGTCCCGC
TTGATCCGTGGCTGGGATGACCTCTTCAACAAGGTCAAAGAACAC
ATCAACAGCGTCTCGGCCATGAAGCTCTCTCCGTATTACAAGGTT
TTTGAAGAGGATGCTCTCAGCTGGGAAGATAAGCTGAACAGGATC
20 ATGGCTCTCTTTGATGTGTGGATTGATGTGCAGAGGCGGTGGGTC
TACCTGGAAGGTATCTTCACAGGCAGTGCAGATATCAAGCACCTG
CTGCCAGTGGAAACCCAGCGGTTTCAGAGCATCAGCACTGAGTTT
TTGGCTCTAATGAAAAAAGTGTCCAAGTCTCCCCTTGTTATGGAT
GTTCTGAACATCCAGGGAGTACAGAGGTCTCTGGAAAGATTGGCA
25 GACCTGCTAGGAAAGATCCAGAAAGCATTGGGAGAATATCTGGAA
AGAGAGCGGTCTATCTTTCCCAGGTTCTATTTTGTGGGTGATGAA
GATTTGCTTGAATCATTGGAAACAGCAAGAATGTCGCTAAATTA
CAGAAACACTTCAAGAAGATGTTTGCTGGAGTTTCGAGCATCATC
CTGAACGAGGATAACTCTGTTGTTTTGGGTATTTTCATCTCGGGAA
30 GGAGAGGAGGTTATGTTTTAAACTCCTGTGTCAATTACTGAACAT
CCCAAAATCAATGAGTGGCTCACATTGGTAGAAAAGGAGATGAGA
GTCACCTTGGCCAAACTGCTTGTGAGTCTGTTACGGAAGTTGAG
ATTTTTGGTAAAGCAACTTCAATTGACCCAAATACCTACATCACT
TGGATTGATAAATACCAGGCCAGCTTGTGGTTTTGTCAGCCAG
35 ATAGCCTGCTCTGAGAACGTGGAGACCGCACTGAGCAGCATGGGC
GGAGGTGGAGATGCCGCGCCCTTGCACTCTGTGCTGAGCAATGTG
GAGGTCACCTCAATGTGTTAGCAGACTCTGTCTCATGGAGCAG
CCCCACTCCGAAGGCGGAAGCTAGAACACTTGATTACAGAGTTG
GTTCAACAGAGAGATGTTACAAGGTCCTTGATCAAAAGCAAGATT
40 GACAACGCCAAATCTTTTGAATGGCTCAGCCAGATGCGATTTTAC
TTTGACCCTAAGCAAACCTGATGTGTTACAGCAGTTGTCAATTCAA
ATGGCAAATGCCAAATTTAACTATGGCTTTGAGTACCTGGGTGTT
CAGGACAACTGGTCCAGACCCCCCTCACTGACCGCTGCTATTTG
ACAATGACACAAGCCTTGGAGGCCAGGCTGGGGGGTTCCCCATTT
45 GGACCTGCTGGAACGGGAAAACAGAGTCTGTCAAAGCTCTTGGC
CATCAGCTTGGACGGTTTTGTTTTAGTTTTCAACTGTGATGAAACC
TTTGATTTCCAGGCAATGGGCCGGATCTTTGTGGGCCTTTGCCAG
GTGGGTGCCTGGGGCTGCTTTGACGAGTTCAACCGCCTGGAGGAG
CGGATGCTCTCGGCTGTGTCCAGCAGGTGCAGTGCATACAGGAA
50 GCACTGCGTGAACATTCCAACCCCAACTACGACAAGACCTCTGCC
CCCATTACTTGTGAGCTGCTGAACAAACAAGTCAAGGTGAGCCCG
GACATGGCCATCTTCATCACCATGAACCCTGGCTACGCGGGCCGG
TCTAACCTTCCTGACAACTTGAAGAAGCTGTTCCGGAGCTTGGCC
ATGACCAAGCCCGACCGGCAGTTAATCGCCCAGGTGATGCTGTAC
55 TCACAGGGTTTCCGCACTGCTGAAGTGCTTGCCAACAAAATCGTC
CCGTTTTTTAACTATGCGATGAGCAGCTCTCTTCCCAAAGCCAT

TATGACTTCGGTCTTCGGGCTTTGAAGAGTGTGCTGGTGAGTGCA
GGCAATGTGAAGAGAGAGAGAATCCAGAAGATAAAGAGGGAGAAA
GAGGAACGAGGGGAAGCAGTTGATGAAGGAGAAATTGCTGAAAAT
CTCCCTGAACAAGAGATTCTGATACAGAGCGTCTGTGAGACGATG
5 GTGCCAAAGCTGGTGGCAGAGGACATCCCGCTGCTCTTCAGCCTC
CTGTGCGACGTGTTCCCTGGAGTCCAGTATCACAGGGGTGAGATG
ACTGCCCTTCGAGAGGAGCTGAAGAAAGTGTGTCAGGAGATGTAT
TTGACATATGGAGATGGAGAAGAAGTTGGTGGAATGTGGGTTGAA
AAGGTTCTCCAGCTCTATCAGATCACCCAGATCAATCATGGCCTG
10 ATGATGGTGGGGCCCTCGGGAAGTGGGAAGAGCATGGCCTGGCGT
GTCCTGCTGAAGGCATTGGAGAGACTCGAGGGTGTGGAAGGTGTG
GCCCATATCATCGACCCCAAGGCCATCAGCAAAGACCACCTCTAC
GGAACCCTGGACCCCAACACCAGGGAATGGACAGATGGGCTCTTC
ACACACGTGCTGAGAAAGATCATCGACAGCGTGAGAGGCGAGCTG
15 CAGAAGCGCCAGTGGATCGTCTTCGATGGCGATGTGGATCCAGAG
TGGGTTGAGAACTTGAACCTCAGTGCTGGATGACAATAAGCTCCTA
ACTTTGCCCCAATGGAGAGCGCCTCAGTCTTCCACCCAATGTGAGA
ATAATGTTTGAGGTACAGGACTTGAAATACGCGACCTTGGCCACA
GTGTGCGCTGCGGCATGGTCTGGTTTCAGTGAGGATGTGCTGAGC
20 ACCGACATGATCTTCAACAACCTTCTGGCCAGGCTGCGCAGCATC
CCGCTGGATGAAGGGGAGGATGAGGCACAGCGGCGGCGTAAGGGC
AAAGAGGATGAGGGGGAGGAGGCGCCTTCCCCATGCTGCAGATC
CAAAGAGATGCAGCTACGATCATGCAACCGTACTTCACGTCCAAC
GGCCTGGTCACCAAGGCGCTAGAGCACGCCTTCCAGCTGGAGCAC
25 ATCATGGACCTAACACGCCTGCGCTGCCTGGGCTCGCTCTTCTCC
ATGCTGCACCAGGCCTGCCGCAACGTGGCGCAGTATAACGCCAAC
CATCCCGACTTCCCCATGCAGATCGAGCAGCTGGAGCGCTACATT
CAGCGATATCTGGTTTATGCCATACTCTGGTCCCTGTCTGGAGAC
AGCCGGCTAAAAATGAGAGCAGAGCTGGGTGAATACATCAGAAGA
30 ATCACGACCGTGCCTCTGCCACTGCGCCCAACATAACCCATTATC
GATTATGAGGTGTCCATCAGCGGAGAATGGTCTCCGTGGCAGGCC
AAGGTGCCTCAGATTGAAGTGGAGACGCACAAGGTGGCAGCCCCCT
GATGTCGTCGTGCCAACGCTGGACACAGTCCGCCACGAAGCCCTC
TTGTACACTTGGCTGGCCGAACACAAGCCCCCTGGTCTTGTGTGGC
35 CCTCCTGGGTCTGGCAAGACCATGACACTCTTCAGCGCCCTCCGG
GCCTTGCTGACATGGAGGTGGTGGGTCTCAACTTCTCCAGTGCT
ACTACTCCAGAGCTGCTTCTGAAGACTTTTGATCACTACTGCGAG
TACAGGCGCACACCTAATGGGGTGGTTTTGGCTCCTGTTCAACTT
GGAAAGTGGCTGGTGTGTTCTGTGATGAAATCAACTTGCCAGAT
40 ATGGATAAATATGGGACCCAGAGGGTCATATCCTTCATCAGACAG
ATGGTGGAGCACGGAGGCTTTTACCGTACCTCAGATCAAACATGG
GTGAAGCTGGAGAGAATCCAGTTTGTGTTGGGGCTTGTAATCCCCC
ACAGACCCTGGAAGAAAGCCCCCTCTCACACAGGTTCCTGCGCCAC
GTGCTGTCGTGTATGTGGATTACCCGGGGCCCCGCTCCCTCACA
45 CAGATCTACGGCACCTTCAACCGCGCCATGCTGAGGCTCATTCCA
TCCCTGCGGACGTATGCAGAGCCGCTCACTGCTGCCATGGTGGAG
TTCTACACCATGTCTCAGGAGAGATTACCCAGGATACACAACCT
CACTATATCTATTACCCCGTGAAATGACTAGGTGGGTGAGAGGC
ATCTTTGAAGCGCTGAGACCTCTGGAGACCCTGCCTGTTGAAGGC
50 CTCATTCCGATTTGGGCACATGAAGCTCTGCGTCTTCCAAGAT
AGACTCGTAGAGGATGAGGAGAGGCGTTGGACTGATGAGAACATC
GACACGGTTGCTCTGAAGCACTTCCCTAACATCGACAGAGAGAAG
GCAATGAGCCGACCCATCTTGTACAGCAACTGGCTGTCAAAGGAT
TACATCCCAGTAGACCAAGAAGAGTTAAGAGATTATGTCAAAGCT
55 AGGCTGAAGGTCTTTTATGAAGAAGAACTTGATGTTCCGCTGGTG
CTGTTTAATGAAGTCTAGACCACGTGCTGAGGATTGACAGAATA

TTCCGTCAACCTCAAGGCCACTTGCTTCTGATTGGTGTAGTGGA
GCAGGAAAACTACCCTGTCTCGTTTCGTGCGCTGGATGAACGGT
TTGAGTGTGTACCAGATTAAGGTCCATAGGAAGTACACAGGGGAA
GACTTTGATGAAGATCTACGGACAGTGTTGAGACGTTCTGGCTGT
5 AAAAATGAAAAGATAGCATTTATAATGGATGAATCTAATGTGTTA
GATTCTGGATTCTTGGAGCGAATGAATACCCCTTCTGGCCAATGGA
GAGGTGCCTGGTCTCTTTGAAGGAGACGAGTATGCCACCTTGATG
ACGCAGTGCAAAGAGGGGGCACAGAAGGAAGGCCTGATGCTGGAC
TCGCACGAGGAGCTCTACAAGTGGTTCCTAGCCAGGTTATCCGC
10 AACCTCCACGTCGTGTTTACCATGAACCCGTCCTCGGAGGGACTC
AAGGACCGGGCAGCTACATCACCAGCACTTTTCAACAGGTGTGTG
TTGAATTGGTTTGGAGACTGGTCCACCGAAGCACTGTATCAGGTT
GGCAAAGAATTCAACAAGTAAGATGGATCTGGAGAAGCCAAATTAC
ATCGTGCCTGATTACATGCCAGTTGTGTATGATAAGCTGCCGCAG
15 CCACCATCCCATCGGGAAGCCATTGTGAACAGCTGTGTGTTTGT
CATCAGACTCTTACCAGGCGAATGCTCGGCTAGCAAAGCGAGGC
GGCAGAACGATGGCCATCACCCCTCGCCACTACCTGGACTTCATC
AATCACTATGCCAACCTGTTCCACGAGAAGCGGAGCGAGCTGGAG
GAGCAGCAGATGCACTTGAACGTGGGGCTCAGGAAGATCAAAGAG
20 ACAGTCGACCAGGTAGAAGAACTGCGTCGTGACTTGAGGATAAAG
AGCCAAGAGCTGGAGGTGAAGAATGCAGCAGCCAATGACAAGCTG
AAAAAGATGGTGAAGACCAGCAGGAGGCTGAAAAGAAGAAGGTT
ATGAGCCAAGAAATCCAGGAACAGCTGCATAAGCAGCAGGAGGTA
ATTGCAGACAAACAGATGAGTGTCAAAGAAGATCTTGATAAGGTG
25 GAACCTGCCGTCATTGAGGCCCAGAATGCTGTGAAGTCGATCAAG
AAGCAGCACCTGGTGGAGGTGAGGTCCATGGCCAACCCCTCTGCT
GCTGTGAAGCTGGCGCTGGAGTCCATCTGCCTGCTGCTGGGGGAA
AGCACCACAGACTGGAAGCAGATCCGCTCCATCATCATGCGGGAG
AACTTCATCCCCACCATCGTCAACTTCTCTGCAGAGGAGATCAGT
30 GACGCCATAAGGGAGAAGATGAAGAAAAATTACATGTCCAATCCA
AGTTACAATTATGAAATTGTGAATCGGGCTTCCCTGGCTTGCGGC
CCTATGGTGAAATGGGCAATTGCACAGCTTAACTATGCAGACATG
TTAAAGAGAGTGGAGCCCCACGCAATGAGCTGCAGAAGCTGGAA
GATGACGCCAAGGACAACCAGCAGAAGGCCAACGAGGTGGAGCAG
35 ATGATCCGAGACCTGGAAGCCAGCATCGCCCGCTACAAGGAGGAA
TACGCCGTCCTGATCTCAGAGGCCCAGGCCATCAAGGCAGACCTG
GCAGCTGTCGAGGCAAAAAGTAAACCGGAGCACTGCTCTTCTGAAG
AGCTTGTCTGCTGAACGTGAACGATGGGAAAAACAAGTGAACT
TTCAAAAACCAGATGTCCACCATTGCTGGGGACTGTCTTTGTCA
40 GCTGCGTTCATTGCCTACGCGGGTTACTTTGACCAGCAGATGCGT
CAGAACTTGTTCACTACCTGGTCCCATCACCTACAGCAAGCCAAC
ATCCAGTTCGCTACAGATATTGCCAGGACGGAATACCTTTCCAAT
GCTGATGAGCGTCTTCGCTGGCAGGCCAGCTCCTTGCTGCTGAT
GACCTTTGCACAGAAAATGCCATCATGCTGAAACGATTCAATAGG
45 TATCCGCTGATCATTGACCCCTCTGGACAGGCCACAGAATTCATT
ATGAATGAATATAAGGATCGTAAGATCACACGGACCAGCTTCCTG
GATGACGCCTTCAGAAAGAACTTAGAGAGTGCACTGAGATTCGGT
AACCCCTTCTGGTCCAGGATGTGGAAAGCTACGATCCAGTTTTG
AACCCGGTGTGAACCGTGAAGTGCGGCGAACAGGGGGGAGAGTG
50 CTGATCACTCTCGGGGACCAGGACATAGACCTGTCGCCATCGTTT
GTCATCTTCTGTCCACCCGGGATCCAAGTGTGAGTTCCACCA
GATCTCTGTTCCCGGGTTACTTTTGTAAGTTTACAGTTACCCGT
AGCAGTTTACAAAGCCAGTGTCTAAATGAAGTACTTAAAGCAGAA
AGACCTGATGTGGACGAGAAACGATCTGATCTTCTTAAACTTCAA
55 GGGGAATTTAGCTCCGTTTTCGTGAGCTGGAAAAATCTCTACTA
CAAGCTCTGAACGAGGTGAAAGGGCGCATTTTGGATGACGACACG

ATCATAACCACTCTGGAGAACCTGAAGAGAGAGGCTGCAGAGGTC
ACCAGGAAAGTTGAGGAGACGGACATTGTCATGCAGGAGGTGGAG
ACCGTGTCAGCAGTACCTCCCGCTCTCCACCGCCTGCAGCAGC
ATCTACTTCACCATGGAGTCCCTCAAGCAGATACACTTCTTGATC
5 CAGTACTCCCTCCAGTTTTTCTGGACATTTATCACAAACGTCCTA
TACGAGAACCCGAACCTGAAGGGTGTACCGACCACACACAGCGC
CTGTCCATTATAACAAAGGACCTCTTCCAGGTGGCGTTTAACCGA
GTGGCTCGAGGCATGCTGCATCAGGACCACATTACCTTTGCCATG
CTGCTGGCAAGAATCAAACCTGAAGGGCACCGTGGGGGAGCCCACC
10 TACGATGCAGAATTCCAGCACTTCTTGAGAGGAAATGAGATTGTC
CTGAGTGTGCTCCACCCCAGGATCCAGGGCCTGACTGTGGAG
CAGGCGGAGGCGGTGGTGAGGCTGAGCTGCCTTCCCGCGTTTAAG
GACTTGATTGCAAAGGTTCAAGGCAGACGAGCAATTTGGCATCTGG
CTGGACAGCAGCTCCCCGGAGCAGACTGTGCCCTACCTCTGGAGT
15 GAAGAAACACCTGCAACACCCATTGGCCAGGCCATCCACCGCCTG
CTCCTGATCCAGGCTTTCCGGCCCCGATCGCCTGTTGGCCATGGCC
CACATGTTTGTTCACAAACCTTGGGGAGTCTTTCATGTCCATC
ATGGAGCAGCCGCTCGACCTGACCCACATTGTGGGCACAGAGGTG
AAGCCCAACACTCCTGTCTTAATGTGCTCTGTGCCTGGTTATGAT
20 GCCAGTGGACATGTGAGGACCTTGACGCCGAGCAGAACACGCAG
ATCACTTCAATTGCAATCGGCTCTGCAGAAGGCTTTAACCAAGCA
GATAAGGCAATAAACACCGCTGTAAAGTCGGGCAGGTGGGTGATG
CTGAAGAATGTGCATCTGGCCCCAGGGTGGCTGATGCAGCTGGAG
AAGAAGTTGCATTCCCTGCAGCCGCATGCCTGCTTCCGACTCTTC
25 CTCACCATGGAGATCAACCCCAAGGTGCCTGTGAATCTGCTCCGT
GCGGGCCGCATCTTTGTGTTGAGCCACCGCCAGGGGTGAAGGCC
AACATGCTGAGGACGTTCAAGCAGCATTCCCGTCTCACGGATATGC
AAGTCTCCCAACGAGCGTGCCCGCTTGTAATCTCTGCTGGCCTGG
TTTCATGCGATCATCCAAGAACGCTTACGATACGCACCACTGGGG
30 TGGTCAAAGAAGTATGAATTTGGAGAGTCTGACCTGCGGTGAGCT
TGCGATACGGTGGACACGTGGCTGGATGACACGGCCAAGGGCAGG
CAGAACATCTCACCGGATAAGATCCCGTGGTCTGCACTAAAGACC
TTAATGGCCAGTCCATTTATGGCGGGCGCGTGGACAACGAGTTT
GACCAGCGTCTGCTCAACACCTTCCCTGGAGCGCCTGTTCAACAAC
35 AGGAGTTTCGACAGTGAGTTTAAGCTGGCATGCAAGGTGACGGA
CATAAAGACATTCAAATGCCAGATGGCATCAGGCGAGAGGAGTTT
GTGCAGTGGGTGGAGTTGCTCCCCGACACCCAGACGCCCTCCTGG
CTGGGCCTGCCCAACAACGCCGAGAGAGTCTCCTTACCACACAG
GGTGTGGACATGATCAGTAAAATGCTGAAGATGCAGATGTTGGAG
40 GATGAGGACGACCTGGCCTACGCAGAGACTGAGAAGAAGACGAGG
ACAGACTCCACGTCCGACGGGCGCCCTGCCTGGATGCGGACACTG
CACACCACCGCGTCCAACCTGGCTGCACCTCATCCCCAGACGCTG
AGCCACCTCAAGCGCACCGTGGAGAATATCAAGGATCCTTTGTTC
AGGTTCTTTGAGAGAGAAGTGAAGATGGGCGCAAAGCTGCTTCAG
45 GACGTTCCGACGACCTTGACAGATGTCGTCCAGGTGTGCGAAGGA
AAGAAGAAGCAGACCACTACTTGCGCACGCTGATCAACGAGCTA
GTGAAAGGGATCTTGCCCTCGGAGCTGGTCCCACTACACGGTGCCT
GCCGGCATGACCGTCATCCAGTGGGTGTCCGACTTCAGCGAGAGG
ATCAAACAGCTGCAGAACATCTCACTGGCAGCTGCATCTGGTGGC
50 GCCAAGGAGCTAAAGAACATCCACGTGTGCCTGGGTGGCCTGTTT
GTGCCTGAGGCGTACATCACTGCCACCAGGCAGTATGTGGCCAG
GCCAACAGCTGGTCCCTGGAGGAGCTCTGCCTGGAAGTCAACGTC
ACCACCTCACAGGGCGCCACCCCTTGACGCTTGACGCTTCGGAGTC
ACGGGTTTGAAACTTCAAGGGGCCACGTGCAACAACAACAAGCTG
55 TCACTGTCCAATGCCATCTCAACCGCCCTTCCCCTGACGCAGCTG
CGCTGGGTCAAGCAGACAAACACCGAGAAGAAGGCCAGTGTGGTA

ACCTTACCTGTCTACCTGAACTTCACCCGTGCAGACCTCATCTTC
ACCGTGGACTTCGAAATTGCTACAAAGGAGGATCCTCGCAGCTTC
TACGAGCGGGGTGTCGCAGTCTTGTGCACAGAGTAA

5

Other nucleic acid sequences that are contemplated as within the scope of this invention include sequences that hybridize to the nucleic acid sequences encoding cytoplasmic dynein heavy chain1 shown in SEQ ID NOS:1, 3, 5, and 17, other than those known in the prior art (as described above), with at least 75%, preferably at least 80%, more preferably at least 90%, even more preferably 95% and most preferably at least 99% sequence homology to the sequence of SEQ ID NOS: 1, 3, 5, or 17. Additionally, nucleic acid sequences that are degenerate with respect to the foregoing sequences are contemplated.

15

The nucleic acid sequences encoding cytoplasmic dynein heavy chain1 or mutant cytoplasmic dynein heavy chain1 of the invention may exist alone or in combination with other nucleic acids as, for example, vector molecules, such as plasmids, including expression or cloning vectors.

20

The term "nucleic acid sequence" as used herein refers to any contiguous sequence series of nucleotide bases, *e.g.*, a polynucleotide, and may be ribonucleic acid (RNA) or deoxy-ribonucleic acid (DNA). Preferably the nucleic acid sequence is cDNA.

25

The term "isolated nucleic acid molecule", as utilized herein, refers to a nucleic acid molecule that is separated from other nucleic acid molecules ordinarily present in the natural source of the nucleic acid. Preferably, an "isolated" nucleic acid is free of sequences which naturally flank the nucleic acid (*e.g.*, sequences located at the 5'- and 3'-termini of the nucleic acid) in the genomic DNA of the organism that is the natural (wild type) source of the DNA.

30

Cytoplasmic dynein heavy chain1 molecules can be isolated using standard hybridization and cloning techniques, as described, for instance, in Sambrook *et al.* (eds.), *Molecular Cloning: A Laboratory Manual* (2nd Ed.) (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, USA, 1989); and Ausubel *et al.* (eds.),

35

Current Protocols in Molecular Biology (John Wiley & Sons, New York, NY, USA, 1993).

A nucleic acid of the invention can be amplified using cDNA, mRNA or, alternatively, genomic DNA, as a template and appropriate oligonucleotide primers according to standard PCR amplification techniques. The nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis. Furthermore, oligonucleotides corresponding to cytoplasmic dynein heavy chain1 nucleotide sequences can be prepared by standard synthetic techniques, *e.g.*, using an automated DNA synthesizer.

As used herein, the term "oligonucleotide" refers to a series of linked nucleotide residues, which oligonucleotide has a sufficient number of nucleotide bases to be used in a PCR reaction. A short oligonucleotide sequence may be based on, or designed from, a genomic or cDNA sequence and is used to amplify, confirm, or reveal the presence of an identical, similar or complementary DNA or RNA in a particular cell or tissue. Generally, the term "oligonucleotide" is used to refer to a series of contiguous nucleotides (a polynucleotide) of about 100 nucleotides (nt) or less, *e.g.*, portions of a nucleic acid sequence of about 100 nt, 50 nt, or 20 nt in length, preferably nucleotide sequences of about 15 nt to 30 nt in length.

As used herein, the term "complementary" refers to Watson-Crick or Hoogsteen base pairing between nucleotide units of a nucleic acid molecule, and the term "binding" means the physical or chemical interaction between two polypeptides or compounds or associated polypeptides or compounds or combinations thereof.

The terms "homologous nucleic acid sequence" or "homologous amino acid sequence," or variations thereof, refer to sequences characterized by a homology at the nucleotide level or amino acid level, respectively. Homologous nucleotide sequences encode those sequences coding for isoforms of cytoplasmic dynein heavy chain1 polypeptides. Isoforms can be expressed in different tissues of the same organism as a result of, for example, alternative splicing of RNA. Alternatively, isoforms can be encoded by different genes.

As used herein, the phrase "stringent hybridization conditions" refers to conditions under which a probe, primer or oligonucleotide will hybridize to its target sequence, but to no other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures than shorter sequences. Generally, stringent conditions are selected to be about 5°C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. The T_m is the temperature (under defined ionic strength, pH and nucleic acid concentration) at which 50% of the probes complementary to the target sequence hybridize to the target sequence at equilibrium. Since the target sequences are generally present at excess, at T_m, 50% of the probes are occupied at equilibrium. Typically, stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, typically about 0.01 to 1.0 M sodium ion (or other salts) at pH 7.0 to 8.3, and the temperature is at least about 30°C for short probes, primers or oligonucleotides (e.g., 10 nt to 50 nt) and at least about 60°C for longer probes, primers and oligonucleotides. Stringent conditions may also be achieved with the addition of destabilizing agents, such as formamide. Stringent conditions are known to those skilled in the art and can be found in Ausubel *et al.* (eds.), *Current Protocols in Molecular Biology* (John Wiley & Sons, New York, NY, USA, 1989) at 6.3.1-6.3.6. Preferably, the conditions are such that sequences at least about 65%, 70%, 75%, 85%, 90%, 95%, 98%, or 99% homologous to each other typically remain hybridized to each other. A non-limiting example of stringent hybridization conditions are hybridization in a high salt buffer comprising 6X SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 mg/ml denatured salmon sperm DNA at 65°C, followed by one or more washes in 0.2X SSC, 0.01% BSA at 50°C.

As used herein, the term "ortholog" denotes a polypeptide or protein obtained from one species that is the functional counterpart of a polypeptide or protein from a different species. Sequence differences among orthologs are the result of speciation.

Amino Acids

The present invention also provides murine and human cytoplasmic dynein heavy chain1 amino acid sequences (wild type polypeptides and muteins). As used herein, the term "mutein" applies to a protein arising as a result of a mutation. The

wild type murine cytoplasmic dynein heavy chain1 amino acid sequence is shown in SEQ ID NO:2. A mutated version wherein Tyr at position 1055 has been mutated to a Cys is shown in SEQ ID NO:4. A preferred embodiment is of a human mutein with the same amino acid change at the corresponding position (native Tyr residue to mutant Cys residue at position 1057) in the sequence is shown in SEQ ID NO:6. Another preferred embodiment is the wild type human dynein heavy chain 1 amino acid sequence, as shown in SEQ ID NO:18.

Table 5. Accession Number AAF91078 (SEQ ID NO:2)

```

10  MSEPGGGEDGSAGLEVS AVQNVADVA VLQKHRLKLVPLLLEDGGD
    APAALEAALEEKSALEQMRKFLSDPQVHTVLVERSTLKEDVGDEG
    EEEKEFISYNINIDIHYGVKSNLAFIKRAPVIDADKPVSSQLRV
    LTLSEDSPYETLHSFISNAVAPFFKSYIRESGKADRDGDKMAPSV
15  EKKIAELEMGLLHLQQNIEIPEISLPIHPITNVAKQCYERGEKP
    KVTDFGDKVEDPTFLNQLQSGVNRWIREIQVTKLDRDPASGTAL
    QEISFWLNLERALYRIQEKRESPEVLLTLDILKHGKRHFATVSFD
    TDTGLKQALETVNDYNPLMKDFPLNDLLSATEL DKIRQALVAIFT
    HLRKIRNTKYPIQRALRLVEAISRDLS SQLLKVLGTRKLMHVAYE
20  EFEKVMVACFEVFQTDDEYEKLQVLLRDIVKRKREENLKMVWRI
    NPAHRKLQARLDQMRKFRRQHEQLRAVIVRVLRPQVTAVAQQNQG
    EAPEPQDMKVAEVLFDAADANTIEEVNLAYENVKEVDGLDVSKEG
    TEAWEAAMKRYDERIDRVETRITARLRDQLGTAKNANEMFRIFSR
    FNALFVRPHIRGAIREYQTQLIQRVKDDIESLHDKFKVQYPQSQA
25  CKMSHVRDLPPVSGSIIWAKQIDRQLTAYMKRVEDVLGKGWENHV
    EGQKLKQDGDSFRMKLNTQEIFDDWARKVQQRNLGVSGRIFTIES
    ARVRGRTGNVLKLVNLFPEIITLSKEVRNLKWLGFVRPLAIVNK
    AHQANQLYPFAISLIESVRTYERTCEKVEERN TISLLVAGLKKEV
    QALIAEGIALVWESYKLDPYVQRLAETVFN FQEKVDDLLIIEEKI
30  DLEVRSLCTMYDHKTFSEILNRVQKAVDDLNLHSYSNLPWVVK
    LDMEIERILGVRLQAGLRAWTQVLLGQAEDKAEVDMDTDAPQVSH
    KPGGEPKIKNVVHEL RITNQVIYLNPPIEECRYKLYQEMFAWKMV
    VLSLPRIQSQRVQGVHYELTEEEKFYRNALTRMPDGPVALEESY
    SAVMGIVTEVEQYVKVWLQYQCLWDMQAENIYNRLGEDLNKWQAL
35  LVQIRKARGTFDNAETKKEFGPVVIDYGKVQSKVNLKYDSWHKEV
    LSKFGQMLGSGNMTEFHSQISKS RQELEQHSVD TASTSDAVTFITY
    VQSLKRRIKQFEKQVELYRNGQRLLEKQRFQFPFSWLYIDNIEGE
    WGFANDIMRRKDSAIQQQVANLQMKIVQEDRAVESRTTDLTLDWE
    KTKPVTGNLRPEEALQALTIYEGKFGRLKDDREKCAKAKEALELT
40  DTGLLSGSEERVQVLEELQDLKGVWSEL SKVWEQIDQMKEQPWV
    SVQPRKLRQNL DGLLNQLKNFPARLRQYASYEFVQRLLKG YMKIN
    MLVIELKSEALKDRHWKQLMKRLHVNWV VSELTGQIWDVDLQKN
    EAVVKDVLVLAQGEMALEEFLKQIREVWNTYELDLVNYQNKRLI
    RGWDDL FNKVKEHINSVSAMKLS PYYKVFEEDALSWEDKLN RIMA
45  LFDVWIDVQRRWVYLEGIFTGSADIKHLLPVETQRFQSISTEFLA
    LMKKVSKSPLVMDVLNIQGVQRSLE RLADLLGKIQKALGEYLERE
    RSSFPRFYFVGDEDLLEIIGNSKNVAKLQKHFKKMFAGVSSII LN
    EDNSVVLGISSREGEV MFKTPVSITEHPKINEWLT LVEKEMRVT
    LAKLLAESVTEVEIFGKATSIDPNTYITWIDKYQAQLVVL SAQIA
50  WSENVENALSNVGGG DVGPLQSVLSNVEVT LNVLADSVLMEQPP
  
```

LRRRKLEHLITELVHQRDVTRSLIKSKIDNAKSEWLSQMRFYFD
PKQTDVLOQLSIQMANAKFNYGFEYLGVDKLVQTPLTDRCYLTMT
TQALEARLGGSPFGPAGTGKTESVKALGHQLGRFVLVFNCDETFD
FQAMGRI FVGLCQVGAWGCFDEFNRLEERMLSAVSQQVQCIQEAL
5 REHSNPNYDKTSAPITCELLNKQVKVSPDMAIFITMNPYAGRSN
LPDNLKKLFRSLAMTKPDRQLIAQVMLYSQGFRTAEVLANKIVPF
FKLCDEQLSSQSHYDFGLRALKSVLVSAGNVKREIRIQKIKREEE
RGEAVDEGEIAENLPEQEILIQSVCEMVPKLVAEIPLLFSLS
DVFFPGVQYHRGEMTALREELKKVCQEMYLTYGDEEVGGMWVEKV
10 LQLYQITQINHGMLMMVGPSGSGKSMARVLLKALERLEGVEGVAH
IIDPKAISKDHLVGTLDPNLTREWTDGLFTHVLRKI IDNVRGELQK
RQWIVFDGDVDPEWVENLNSVLDNKLTLTPNGERLSLPPNVRIM
FEVQDLKYATLATVSRGMVWFSEDLSTDMILNNFLARLRSIPL
DEGEDEAQRRRKGKEDEGEEAASPMLQIQORDAATIMQPYFTSNGL
15 VTKALEHAFKLEHIMDLTRLRCLGSLFMSMLHQACRNVAQYNANHP
DFPMQIEQLERYIQRYLVYAILWSLSGDSRLKMRAELGEYIRIT
TVPLPTAPNVPIIDYEVSSISGEWSPWQAKVPQIEVETHKVAAPDV
VVPTLDTVRHEALLYTWLAEHKPLVLCGPPGSGKMTLFSALRAL
PDMEVVGLNFSSATTPELLLKTFDHYCEYRRTPNGVV LAPVQLGK
20 WLVLFCDEINLPMDKYGTRVISFIRQMVHGAFYRTSDQTWVK
LERIQFVGACNPPTDPGRKPLSHRFLRHVPVVYVDYPGPASLTQI
YGTFNRAMLRILPSLRTYAEPLTAAMVEFYTMSQERFTQDTPHY
IYSPREMTRWVRGIFEALRPLETLPVEGLIRIWAHEALRLFQDR
VEDEERRWTDENIDMVALKHFPNIDKEKAMSRPILYSNWLKDYI
25 PVDQEELRDYVKARLKVFYEEELDVPLVLFNEVL DHVLRIDRIFR
QPQGHLLIGVSGAGKTTLSRFVAMNGLSVYQIKVHRKYTGEDF
DEDLRTVLRSGCKNEKIAFIMDESNVLD SGFLERMNTLLANGEV
PGLFEGDEYATLMTQCKEGAQKEGLMLDSHEELYKWFTSQVIRNL
HVVFTMNPSSEGLKDRAATSPALFNRCVLNWFGDWSTEALYQVGK
30 EFTSKMDLEKPNYIVPDYMPVYDKLPQPPTHREAI VNSCVFVHQ
TLHQANARLAKRGGRTMAITPRHYLDFINHYANLFHEKRSELEEQ
QMHLNVGLRKIKETVDQVEELRRDLRIKSQELEVKNAAANDKLKK
MVKDQQEAEKKKVMSEIQEQLHKQEQEVIADKQMSVKEDLDKVEP
AVIEAQNAVKS IKKQHLVEVRSMANPPAAVKLALESICLLGEST
35 TDWKQIRSIIMRENFIPTIVNFSAEIISDAIREKMKNYMSNP
NYEIVNRASLACGPMVKWAIQNLNYADMLKRVEPLRNELOKLEDD
AKDNQQKANEVEQMIRDLEASIARYKEEYAVLISEAQAIKADLAA
VEAKVNRSTALLKSLSAERERWEKTSETFKNQ MSTIAGDCLLSAA
FIAYAGYFDQQMRQNLFTTWSHHLQQANIQFRTDIARTEYLSNAD
40 ERLRWQASSLPADDLC TENAIMLKRFNRYPLIIDPSGQATEFIMN
EYKDRKITRTSFLDDAFRKNLESALRFGNPLLVDVESYDPVLNP
VLNREVRRTGGRVLITLGDQDIDLSPSFVIFLSTRDPTVEFPDDL
CSRVT FVNFTVTRSSLQSQCLNEVLKAERPDVDEKRSDLLKLQGE
FQLRLRQLEKSLQALNEVKGRILVDDTIITLLENLKREAAEVTR
45 KVEETDIVMQEVETVSQQYLPSTACSSYFTMESLQVHFLYQY
SLQFFLDIYHNVL YENPNLKGATDHTQRLSVITKDLFQVAFNRVA
RGMLHQDHITFAMLLARIKLKGTVG EPTYDAEFQHF LRGKEIVLS
AGSTPKIQGLTVEQAEAVVRLSCLPAFKDLIAKVQADEQFGIWL
SSSPEQTPYLWSEETPTTPIGQAIHRLLLIQAFRPDRLLAMAHM
50 FVSTNLGESFMSIMEQPLDLTHIVGTEVKPNTPVL MCSVPGYDAS
GHVEDLAAEQNTQITSIAIGSAEGFNQADK AINTAVKSGRWMLK
NVHLAPGWLMOLEKKLHSLQPHACFRFLTMEINPKVPVNLLRAG
RIFVFEP PPPGVKANMLRTFSSI PVS RICKSPNERARLYFLLAWFH
AIIQERLRYAPLGWSKKYEFGESDLRSACDTVD TWLDDTAKGRQN
55 ISPDKIPWSALKTLMAQSIYGRVDNEFDQRLNLTFLERLFTTRS
FDSEFKLACKVDGHKDIQMPDGIRREEFVQWV ELLPDAQTPSWLG

LPNNAERVLLTTQGVDMISKMLKMQMLEDEDDLAYAETEEKKARTD
 STSDGRPAWMRTLHTTASNWLHLIPQTLSPKRTVENIKDPLFRF
 FEREVKMGAKLLQDVRQDLADVQVCEGKKKQNTYLRTLINELVK
 GILPRSWSHYTVPAGMTVIQWVSDFSERIKQLQNISQAAASGGAK
 5 ELKNIHVCLGGLFVPEAYITATRQYVAQANSWSLEELCLEVNVT
 SQSATLDACSFVGTGLKLGATCSNNKLSLSNAISTVPLPLTQLRW
 VKQTSAEKKASVVTLPVYLNFTRADLIFTVD FEIATKEDPRS FYE
 RGVAVLCTE

10 **Table 6.** Mutated murine cytoplasmic dynein heavy chain1 amino acid sequence
 (SEQ ID NO:4)

MSEPGGGEDGSAGLEVSAVQNVADVAVLQKHLRKLVPLLLEDGGD
 APAALEEALEEKSALEQMRKFLSDPQVHTVLVERSTLKEDVGDEG
 EEEKEFISYNINIDIHYGVKSNSLAFIKRAPVIDADKPVSSQLRV
 15 LTLSEDSPYETLHSFISNAVAPFFKSYIRESKGADRDGDKMAPSV
 EKKIAELEMGLLHLQONIEIPEISLPIHPIITNVAKQCYERGEKP
 KVTDFGDKVEDPTFLNQLQSGVNRWIREIQKVTKLDRDPASGTAL
 QEISFWNLNLERALYRIQEKRESPEVLLTLDILKHGKRHFATVSFD
 TDTGLKQALETVNDYNPLMKDFPLNDLLSATEL DKIRQALVAIFT
 20 HLRKIRNTKYP IQRALRLVEAISRDLSQLLKVLGTRKLMHVAYE
 EFEKVMVACFEVFQTDDEYEKQLQVLLRDIVKRKREENLKMVWRI
 NPAHRKLQARLDQMRKFRRQHEQLRAVIVRVLRPQVTAVAQQNQG
 EAPEPQDMKVAEVLFDAADANTIEEVNLAYENVKEVDGLDVSKEG
 TEAWEAAMKRYDERIDRVETRITARLRDQLGTAKNANEMFRIFSR
 25 FNALFVRPHIRGAIREYQTQLIQRVKDDIESLHDKFKVQYPQSQA
 CKMSHVRDLPPVSGSI IWAKQIDRQLTAYMKRVEDVLGKGWENHV
 EGQKLKQDGDSFRMKNLTQEIFDDWARKVQQRNLGVSGRIFTIES
 ARVRGRTGNVLKLKVNFLPEIITLSKEVRNLKWLGFVRVPLAIVNK
 AHQANQLYPFAISLIESVRTYERTCEKVEERNTISLLVAGLKKEV
 30 QALIAEGIALVWESYKLDPYVQRLAETVFNFQEKVDDLLIIEEKI
 DLEVRSLCTCMYDHKT FSEILNRVQKAVDDLNLHSYNSLPWVKN
 LDMEIERILGVRLQAGLRAWTQVLLGQAEDKAEVMDMDTAPQVSH
 KPGGEPKIKNVVHEL RITNQVIYLNPPIEECRYKLYQEMFAWKMV
 VLSLPRIQSQRVQGVHYELTEEEKFYRNALTRMPDGPVALEESY
 35 SAVMGIVTEVEQYVKVWLQEQCLWDMQAENIYNRLGEDLNKWQAL
 LVQIRKARGTFDNAETKKEFGPVVIDYGVQSKVNLKYDSWHKEV
 LSKFGQMLGSGNMTEFHSQISKSQRQELEQHSVDTASTSDAVTFITY
 VQSLKRKIKQFEKQVELYRNGQRLLEKQRFQFPSPSWLYIDNIEGE
 WGAFNDIMRRKDSAIQQQVANLQMKIVQEDRAVESRTDOLLTDWE
 40 KTKPVTGNLRPEEALQALTIYEGKFGRLKDDREKCAKAKEALELT
 DTGLLSGSEERVQVALEELQDLKGVWSELSKVWEQIDQMKEQPWV
 SVQPRKLRQNL DGLLNQLKNFPARLRQYASYEFVQRLLKGMYKIN
 MLVIELKSEALKDRHWKQLMKRLHVNWVSELTLGQIWDVDLQKN
 EAVVKDVLLVAQGEMALEEFLKQIREVWNTYELDLVNYQNKRLI
 45 RGWDDL FNKVKEHINSVSAMKLSPPYKVFEEADLSWEDKLN RIMA
 LFDVWIDVQRRWVYLEGIFTGSADIKHLLPVETQRFQSISTEFLA
 LMKKVSKSPLVMDVLNIQGVQRSRLERLADLLGKIQKALGEYLERE
 RSSFPRFYFVGDEDLLEIIGNSKNVAKLQKHFKKMFAGVSSIIIN
 EDNSVVLGISSREGEEVMFKTPV SITEHPKINEWLT LVEKEMRVT
 50 LAKLLAESVTEVEIFGKATSIDPNTYITWIDKYQAQLVVL SAQIA
 WSENVENALS NVGGGGDVGP LQSVLSNVEVT LNVLADSVLMEQPP
 LRRRKLEHLITELVHQRDVTRSLIKSKIDNAKSFEWLSQMRFYFD
 PKQTDVLQQLSIQMANAKFNYGFEYLGVDKLVQTPLTDRCYLTM
 TQALEARLGGSPFGPAGTGKTESVKALGHQLGRFVLVFNCDETFD

FQAMGRIFVGLCQVGAWGCFDEFNRLEERMLSAVSQQVQCIQEAL
REHSNPNYDKTSAPITCELLNKQVKVSPDMAIFITMNPYAGRSN
LPDNLKKLFRSLAMTKPDRQLIAQVMVLYSQGFRTAEVLANKIVPF
FKLCDEQLSSQSHYDFGLRALKSVLVSAGNVKRERIQKIKREKEE
5 RGEAVDEGEIAENLPEQEILIQSV CETMVPKLV AEDIPLLFSLLS
DVFPGVQYHRGEMTALREELKKVCQEMYLT YGDGEEVGGMWVEKV
LQLYQITQINHGMMVGPSPSGSKSMAWRVLLKALERLEGVEGVAH
IIDPKAISKDHL YGTLD PNTREWTDGLFTHVLRKIIDNVRGELQK
RQWIVFDGDVDPEWVENLNSVLD DNKLLTLPNGERLSLPPNVRIM
10 FEVQDLKYATLATVSRGMVWFSEDLSTDMILNNFLARLRSIPL
DEGEDEAQRRRKGEDEGE EEAAS PMLQIQORDAATIMQPYFTSNGL
VTKALEHAFKLEHIMDLTRLRCLGSLF SMLHQACRNVAQYNANHP
DFPMQIEQLERYIQRYLVYAILWSLSGDSRLKMRAELGEYIRIT
TVPLPTAPNVPIIDYEV SISGEWSPWQAKVPQIEVETHKVAAPDV
15 VVPTLDTVRHEALLYTWLAEHKPLVLCGPPGSGKTM TLFSA LRAL
PDMEVVG LNFSSATTPEL LLLKTFDHYCEYRRTPNGVVLAPVQLGK
WLVLFCDEINLPMDKYGTORVISFIRQMVEHGAFYRTSDQTWVK
LERIQFVGACNPPTDPGRKPLSHRFLRHVPV VYVDYPGPASLTQI
YGTFNRA MLRLIPSLRTYAEPLTAAMV EFTMSQERFTQDTQPHY
20 IYSPREMTRWVRGIFEALRPLETLPVEGLIRIWAHEALRLFQDRL
VEDEERRWTDENIDMVALKHFPNIDKEKAMSRPILYSNWLSKDYI
PVDQEELRDYVKARLKVFYEEELD VPLVLFNEVL DHVLRIDRIFR
QPQGHLLLLIGVSGAGKTTLSRFVAMNGLSVYQIKVHRKYTGEDF
DEDLRTVLR RSGCKNEKIAFIMDES NVLDSGF LERMNTLLANGEV
25 PGLFEGDEYATLMTQCKEGAQKEGLMLDSHEELYKWFTSQVIRNL
HVVFTMNPSS EGLKDRAATSPALFNRCVLNWFGDWSTEALYQVGK
EFTSKMDLEKPNYIVPDYMPV VYDKLPQPPTHREAI VNSCVFVHQ
TLHQANARLAKRGGRTMAITPRHYLDFINHYANLFHEKRSELEEQ
QMHLNVGLRKIKETVDQVEELRRDLRIKSQELEVKNAAANDK LKK
30 MVKDQQEAEKKVMSQEIQEQLHKQQEV IADKQMSVKEDLDKVEP
AVIEAQNAVKS IKKQHLVEVRSMANPPAAVKLALESICLLLGEST
TDWKQIRSIIMRENFIPTIVNFS AEIISDAIREKMKKNYMSNPSY
NYEIVNRASLACGPMVKWAI AQLNYADMLKRVEPLRNLQKLEDD
AKDNQQKANEVEQMIRDLEASIARYKEEYAVLISEAQAIKADLAA
35 VEAKVNRSTALLKSLSAERERWEKTSETFKNQ MSTIAGDCLLSAA
FIAYAGYFDQQMRQNLFTTWSHHLQQANIQFRTDIARTEYLSNAD
ERLRWQASSLPADDLCTENAIMLKRFNRYPLIIDPSGQATEFIMN
EYKDRKITRTSFLDDAFRKNLESALRFGNPLLVDVESYDPVLNP
VLNREVRRTGGRVLITLGDQDIDLSPSFVIFLSTRDPTVEFPDDL
40 CSRVTFTVNFTVTRSSLSQSC LNEVLKAERP DVDEKRSDLLKLQGE
FQLRLRQLEKSL LQALNEVKGRILVDDTIIT TLENL KREAAEVTR
KVEETDIVMQEVETVSQQYLPLSTACSS IYFTMESLKQVHFLYQY
SLQFFLDIYHNVLYENPNLKGATDHTQRLSVITKDLFQVAFNRVA
RGMHLHQDHITFAMLLARIKLGTVGEPTYDAEFQHFLRGKEIVLS
45 AGSTPKIQGLTVEQAEAVVRLSCLPAFKDLIAKVQADEQFGIWLD
SSSPEQTVPYLWSEETPTTPIGQAIHRLLLIQAFRPDRLLAMAHM
FVSTNLGESFMSIMEQPLDLTHIVGTEVKPNTPVL MCSVPGYDAS
GHVEDLAAEQNTQITSIAIGSAEGFNQADK AINTAVKSGRWMLK
NVHLAPGWL MQLEKKLHSLQPHACFRLFLTMEINPKVPVNLLRAG
50 RIFVFEP PPVGKANMLRTFSSIPVSRICKSPNERARLYFLLAWFH
AIIQERLRYAPLGWSKKYEFGESDLRSACDTVDTWLD DTA KGRQN
ISPDKIPWSALKTLMAQSIYGG RVDNEFDQRLNNTFLERLFTTRS
FDSEFKLACKVDGHKDIQMPDGIRREEFVQWV ELLPDAQTPSWLG
LPNNAERVLLTTQGVDMISKMLKMQL EDEDDLAYAET EKKARTD
55 STSDGRPAWMRTLHTTASNWLHLIPQTLSP LKRTVENIKDPLFRF
FEREVKMGAKLLQDV RQDLADV VQVCEGKKKQTN YLRTLINELVK

GILPRSWSHYTVPAGMTVIQWVSDFSERIKQLQNISQAAASGGAK
 ELKNIHVCLGGLFVPEAYITATRQYVAQANSWSLEELCLEVNVT
 5 SQSATLDACSEFGVTGLKLQGATCSNNKLSLSNAISTVLPLTQLRW
 VKQTSAEKKASVVTLPVYLNFTRADLIFTVD FEIATKEDPRS FYE
 RGVAVLCTE

Table 7. Mutated human cytoplasmic dynein heavy chain1 amino acid sequence
 (SEQ ID NO:6)

10 MSEPGGGGGEDGSAGLEVS AVQNVADVSVLQKHLRKLVP LLLLEDGGEAP
 AALEAALEEKSALEQMRKFLSDPQVHTVLVERSTLKEVDGDEGEEKEF
 ISYNINIDIHYGVKSNSLAFIKRTPVIDADKPVSSQLRVLTLSEDSPYE
 TLHSFISNAVAPFFKSYIRESGKADRDGDKMAPSVEKKIAELEMG LHL
 QQNIEIPEISLPIHPMITNVAKQCYERGEKPKVTD FGDKVEDPTFLNQL
 15 QSGVNRWIREIQVTKLDRDPASGTALQEISFWLNLERALYRIQEKRES
 PEVLLTLDILKHGKR FHATVSFDTDTGLKQALETVNDYNPLMKDFPLND
 LLSATELDKIRQALVAIFTHLRKIRNTKYPIQRALRLVEAISRLSSQL
 LKVLGTRKLMHVAYEEFEKVMVACFEVFQTDWDEYEKLQVLLRDIVKRK
 REENLKMVWRINPAHRKLQARLDQMRKFRRQHEQLRAVIVRVLRPQVTA
 VAQQNQGEVPEPQDMKVAEVLFDAADANAIEEVNLAYENVKEVDGLDVS
 20 KEGTEAWEAAMKRYDERIDRVETRITARLRDQLGTAKNANEMFRISRF
 NALFVRPHIRGAIREYQTQLIQRVKDDIESLHDKFKVQYPQSQACKMSH
 VRDLPPVSGSIIWAKQIDRQLTAYMKRVEDVLGKGWENHVEGQKLKQDG
 DSFRMKLNTQEIFDDWARKVQQRNLGVSGRIFTIESTRVRGRTGNVLKL
 KVNFLPEIITLSKEVRNLKWLGFVRVPLAIVNKAHQANQLYPPFAISLIES
 25 VRTYERTCEKVEERN TISLLVAGLKKEVQALIAEGIALVWESYKLDPYV
 QRLAETVFNFEKVDLLIIEEKIDLEVRSL ETCMYDHKTFSEILNRVQ
 KAVDDNLNHSYSNLP I WVNKL DMEIERILGVRLQAGLRAWTQVLLGQAE
 DKA EVDMDTDAPQVSHKPGGEPKIKNVVHEL RITNQVIYLNPPIEECRY
 KLYQEMFAWKMVVLSLPRIQSQR YQGVVHYELTEEEKFYRNALTRMPDG
 30 PVALEESYSAVMGIVSEVEQYV KVLQECQLWDMQAENIYNRLGEDLNK
 WQALLVQIRKARGTFD NAETKKEFGPVVIDY GKVQSKVNLKYDSWHKEV
 LSKFGQMLGSGNMTEFHSQISKS RQELEQHSVD TASTSDAVTFITYVQSL
 KRKIKQFEKQVELYRNGQR LLEKQRFQFP PSWLYIDNIEGEWGAFNDIM
 RRKDSAIQQQVANLQMKIVQEDRAVESRTTDL TDWEKTKPVTGNLRPE
 35 EALQALTIYEGKFGR LKDDREKCAKAKEALELTD TGLLSGSEERVQVAL
 EELQDLKG VWSSELSKVWEQIDQMKEQPWVS VQPRKLRQNL DALLNQLKS
 FPARLRQYASYEFVQRLLKGYMKINMLVIELKSEALKDRHWKQLMKRLH
 VNVVVS ELTLGQIWDV DLQKNEAIVKDVLLVAQ GEMALEEFLKQIREVW
 NTYELDLVNYQNKCR LIRGWDDL FNKVKEHINSVSAMKLS PYYKVFEED
 40 ALSWEDKLN RIMALFDVWIDVQRRWVYLEGIFTGSADIKHLLPVETQRF
 QSISTEFLALMKK VSKSP LVM DV LNIQGVQRS LERLADLLGKI QKALGE
 YLERERSSFP RYFVGD EDLLEIIGNSKNVAKLQKHFKKMFAGVSSIIL
 NEDNSVVLGISSREGE EVMFKTPVSITEHPKIN EWLT LVEKEMRVTLAK
 45 LLAESVTEVEIFG KATSIDPNTYITWIDKYQAQLV VLSAQIAWSEN VET
 ALSSMGGGGDAAPLHSVLSNVEVT LNLVADS VLM EQPPLRRRKLEHLIT
 ELVHQRDVTRSLIKSKIDNAKSF EWL SQMRFYFDPKQTDVLQQLSIQMA
 NAKFNYGFEYLG VQDKLVQTPLTDRCYLTMTQALEARLGGSFPGPAGTG
 KTESVKALGHQLGRFVLVFNCD ETD FQAMGRIFVGLCQVGAWGCFDEF
 NRLEERMLSAVSQQVQCIQEALREHSNP NYDKTSAPITCELLNKQVKVS
 50 PDMAIFITMNP GYAGRSNLPDNLKKLFRSLAMTKPDRQLIAQVMLYSQG
 FRTAEVLANKIVPFFKLCDEQLSSQSHYDFGLRALKSVLVSAGNVKRER
 IQKIKREKEERGEAVDEGEIAENLPEQEILIQSV CETMVPKLV AEDIPL
 LFSLLSDVFPGVQYHRGEMTALREELKKVCQEMYLT YGDGEEVGGMWVE
 KVLQLYQITQINHG LMMVGP SGSGKSMAWRVLLKALERLEGEVGAHII
 55 DPKAISKDHL YGTLDPNTREWT DGLFTHVLRKIIDSVRGELQKRQWIVF
 DGDVDPEWVENLNSVLD DNKLLTLPNGERLSLPPNVRIMFEVQDLKYAT
 LATVSRCGMVWFSE DVLSTDMIFNNFLARLSIPLDEGEDEAQR RRKKGK
 EDEGEEAASPMLQIQ RDAATIMQPYFTS NGLVTKALEHAFQLEHIMDLT

RLRLGSLFSLMLHQACRNVAQYNANHPDFPMQIEQLERYIQRYLVYAIL
 WSLSGDSRLKMRAELGEYIRRITTVPLPTAPNIPIDYEVSISGEWSPW
 QAKVPQIEVETHKVAAPDVVPTLDTVRHEALLYTWLAEHKPLVLCGPP
 GSGKTMTLFSALRALPDMEVVGLENFSSATTPELLLKTDFDHYCEYRRTPN
 5 GVVLAAPVQLGKWLVLFCDEINLPMDKYGTQRVISFIRQMVEHGGFYRT
 SDQTWVKLERIQFVGACNPPTDPGRKPLSHRFLRHVPVVVVDYFGPASL
 TQIYGTFNRAMLRLIPSLRTYAEPLTAAMVEFYTMSQERFTQDTQPHYI
 YSPREMTRWVRGIFEALRPLETLPVEGLIRIWAHEALRLFQDRLVEDEE
 RRWTDENIDTVALKHFNPIDREKAMSRPILYSNWSKDYIPVDQEELRD
 10 YVKARLKVFEELDVPLVLFNEVLDHVLRIDRIFRQPQGHLLIGVSG
 AGKTTLSRFVAMNGLSVYQIKVHRKYTGEDFDEDLRTVLRRSGCKNEK
 IAFIMDESNVLDSGFLERMNTLLANGEVPGLFEGDEYATLMTQCKEQAQ
 KEGMLDSHEELYKWFTSQVIRNLHVFTMNPSSSEGLKDRAATSPALFN
 RCVLNWFGDWSTEALYQVGKEFTSKMDLEKPNYIVPDYMPVVYDKLPQP
 15 PSHREAIVNSCVFVHQTTLHQANARLAKRGRTMAITPRHYLDFINHYAN
 LFHEKRSELEEQQMHLNVGLRKIKETVDQVEELRRDLRIKSQELEVKNA
 AANDKLKKMVKDQQEAEKKKVMSSQEIQEQLHKQOEVIADKQMSVKEDLD
 KVEPAVIEAQNNAVKSIIKQHLVEVRSMANPPAAVKLALESICLLLGEST
 TDWKQIRSIIMRENFIPTIVNFSAAEISDAIREKMKKNYMSNPSYNYEI
 20 VNRSALACGPMVKWAIQAQLNYADMLKRVEPLRNELOKLEDDAKDNQOKA
 NEVEQMIRDLEASIARYKEEYAVLISEAQAIKADLAHAVEAKVNRSTALL
 KSLSAERERWEKTSETFKNQMSTIAGDCLLSAAFIAYAGYFDQMQRQNL
 FTTWSHHLQQANIQFRTDIARTEYLSNADERLRWQASSLPADDLCTENA
 IMLKRFNRYPLIIDPSGQATEFIMNEYKDRKITRTSFLDDAFRKNLESA
 25 LRFGNPLLVDVESYDPVLNPVLNREVRRTGGRVLITLGDQDIDLSPSF
 VIFLSTRDPTVEFPDLCSTVFTVNFTVTRSSLQSQCLNEVLKAERP DV
 DEKRSDDLKLQGEFQLRLRQLEKSLQLALNEVKGRILDDDTIITLLENL
 KREAAEVTRKVEETDIVMQEVETVSQQYLPLSTACSSIFTMESLKQIH
 FLYQYSLQFFLDIYHNVLYENPNLKGVT DHTQRLSIITKDLFQVAFNRV
 30 ARGMLHQDHITFAMLLARIKLGTVGEPTYDAEFQHFRLRGNEIVLSAGS
 TPRIQGLTVEQAEAVVRLSCLPAFKDLIAKVQADEQFGIWL DSSSPEQT
 VPYLWSEETPATPIGQAIHRLLLIQA FRPDRLLAMAHMFVSTNLGESFM
 SIMEQPLDLTHIVGTEVKPNTPVLMCSVPGYDASGHVEDLAAEQNTQIT
 SIAIGSAEGFNQADKAINAVKSGRWMLKNVHLAPGWLMLQLEKKLHSL
 35 QPHACFRFLTMEINPKVPVNLRLRAGRIFVFEPPPGVKANMLRTFSSIP
 VSRICKSPNERARLYFLLAWFHAI IQERLRYAPLGWSKKYEFGESDLRS
 ACDTVDTWLDDTAKGRQNI SPDKIPWSALKTLMAQSIYGGGRVDNEFDQR
 LLNTFLERLFTTTRSFDFSEFKLACKVDG HKDIQMPDGI RREEFVQWVELL
 PDTQTPSWLGLPNNAERVLLTTQGVDMISKMLKMQMLEDEDDLAYAETE
 40 KKTRTDSTSDGRPAWMRTLHTTASNWLHLIPQTLSHLKRVTENIKDPLF
 RFFEREVKMGAKLLQDVRQDLADVQVCEGKKKQTNYLRTLINELVKG I
 LPRSWSHYTVPAGMTVIQWVSDFSERIKQLQNI SLAAASGGAKELKNIH
 VCLGGFLVPEAYITATRQYVAQANSWSLEELCLEVNVTT SQGATLDACS
 FGV TGLKLQGATC NNNKLSLSNAISTALPLTQLRWVKQT NTEKKASVVT
 45 LPVYLNFTRADLIFTVD FEIATKEDPRS FYERGVAVLCTE

Table 8. Wild type human cytoplasmic dynein heavy chain1 amino acid sequence
(SEQ ID NO:18)

50 MSEPGGGGGEDGSAGLEVSAVQNVADVSVLQKHLRKLVP LLLLEDG
 GEAPAALEAALEEKSALEQMRKFLSDPQVHTVLVERSTLKEDVGD
 EGEEKEFISYNINIDIHYGVKSNSLAFIKRTPVIDADKPVSSQL
 RVLTLSSEDSPTYETLHSPISNAVAPFFKSYIRESGKADR DGDKMAP
 SVEKKIAELEMGLLHLQQNIEIPEISLPIHPMITNVAKQCYERGE
 55 KPKVTDGDKVEDPTFLNQLQSGVNRWIREIQKVTKLDRDPASGT
 ALQEISFWNLRLALYRIQEKRESPEVLLTLDILKHGKR FHATVS
 FDTDTGLKQALETVNDYNPLMKDFPLNDLLSATEL DKIRQALVAI

FTHLRKIRNTKYPIQRALRLVEAISRDLSQLLKVLGTRKLMHVA
YEEFEKVMVACFEVFQTDDEYEKLVLLRDIVKRKREENLKMVW
RINPAHRKLQARLDQMRKFRRQHEQLRAVIVRVLRPQVTAVAQQN
QGEVPEPQDMKVAEVLFDAAADANAIEEVNLAYENVKEVDGLDVS
5 EGTEAWEAAMKRYDERIDRVETRITARLRDQLGTAKNANEMFRIF
SRFNALFVRPHIRGAIREYQQTQLIQRVKDDIESLHDKFKVQYPQS
QACKMSHVRDLPPVSGSIIWAKQIDRQLTAYMKRVEDVLGKGWEN
HVEGQKLKQDGDGDSFRMKNLTQEIFDDWARKVQQRNLGVSGRIFTI
ESTRVRGRTGNVLKLVNLFPEIITLSKEVRNLKWLGFVRPLAIV
10 NKAHQANQLYPFAISLIESVRTYERTCEKVEERNTISLLVAGLKK
EVQALIAEGIALVWESYKLDPYVQRLAETVFNFQEKVDDLLIIIEE
KIDLEVRSLCTCMYDHKTFSEILNRVQKAVDDNLHSSYNLPIWV
NKLDMEIERILGVRLQAGLRAWTQVLLGQAEDKAEVDMDTDAPQV
SHKPGGEPKIKNVVHELRTNQVIYLNPPIEECRYKLYQEMFAWK
15 MVVLSLPRIQSQRVQGVHYELTEEEKFYRNALTRMPDGPVALEE
SYSAVMGIVSEVEQYVKVWLQYQCLWDMQAENIYNRLGEDLNKWQ
ALLVQIRKARGTFDNAETKKEFGPVVIDYGKVQSKVNLKYDSWHK
EVLSKFGQMLGSMTEFHSQISKSQRQELEQHSVDTASTSDAVTFI
TYVQSLKRRIKQFEKQVELYRNGQRLLEKQRFQFPSPWLYIDNIE
20 GEWGAFNDIMRRKDSAIQQQVANLQMKIVQEDRAVESRTDLLTD
WEKTKPVTGNLRPEEALQALTIYEGKFGRKDDREKCAKAKEALE
LTDGTLLSGSEERVQVALEELQDLKGVWSELKSVWEQIDQMKEQP
WVSQPRKLRQNLDAALLNQLKSFARLRQYASIEFVQRLKGYMK
INMLVIELKSEALKDRHWKQLMKRLHVNWVSELTLGQIWDVDLQ
25 KNEAIVKDVLLVAQGEMALEEFLKQIREVWNTYELDLVNYQNKCR
LIRGWDDLFNKVKEHINSVSAMKLSPIYKVFEEADALSWEDKLNRI
MALFDVWIDVQRRWVYLEGIFTGSADIKHLLPVETQRFQSISTEF
LALMKKVS KSPVMDVLNIQGVQRSLERLADLLGKIQKALGEYLE
RERS SFPRFYFVGDEDLLEIIGNSKNVAKLQKHFKKMFAGVSSII
30 LNE DNSVVLGISSREGEV MFKTPVSITEHPKINEWLTLEKEMR
VTLAKLLAESVTEVEIFGKATSIDPNTYITWIDKYQAQLVLSAQ
IAWSENVETALSSMGGGGDAAPLHSVLSNVEVTNLNLADSVLMEQ
PPLRRRKLEHLITELVHQRDVTRSLIKSKIDNAKSFEWLSQMRFY
FDPKQTDVLQQLSIQMANAKFNYGFEYLVQDKLVQTPLTDRCYL
35 TMTQALEARLGGSPFGPAGTGKTESVKALGHQLGRFVLVFNCD
FDFQAMGRIFVGLCQVGAWGCFDEFNRLEERMLSAVSQQVQCIQE
ALREHSNPNDKTSAPITCELLNKQVKVSPDMAIFITMNPYAGR
SNLPDNLKKLFRSLAMTKPDRQLIAQVMLYSQGFRTAEVLANKIV
PFFKLCDEQLSSQSHYDFGLRALKSVLVSAGNVKRERIQKIKREK
40 EERGEAVDEGEIAENLPEQEILIQSV CETMVPKLVAEDIPLLFSL
LSDVFPQVQYHRGEMTALREELKKVCQEMYLT YGDGEEVGGMWVE
KVLQLYQITQINHGLMMVGPSGSGKSMARVLLKALERLEGVEGV
AHIIDPKAISKDHL YGTLD PNTREWT DGLFTHVLRKIIDSVRGEL
QKRQWIVFDGDVDP EWVENLNSVLDNKLTLTPNGERLSLPPNVR
45 IMFEVQDLKYATLATVSRGCMVWFSEDLVSTDMIFNNFLARLSI
PLDEGEDEAQRRRKGEDEGEAA SPMLQIQRDAATIMQPYFTSN
GLVTKALEHAFQLEHIMDLTRLRCLGSLF SMLHQACRNVAQYNAN
HPDFPMQIEQLERYIQRYLVYAILWSLSGDSRLKMRAELGEYIRR
ITTVPLPTAPNIPIIDYEV SISGEWSPWQAKVPQIEVETHKVAAP
50 DVVVPTLDTVRHEALLYTWLAEHKPLVLCGPPGSGKTM TLFSA LR
ALPDMEVVGLNFSSATTP ELLKTFDHYCEYRRTPNGVV LAPVQL
GKWLVLFCDEINLPDMDKYGTQRVISFIRQMVEHGGFYRTSDQTW
VKLERIQFVGACNPPTDPGRKPLSHRFLRHVPVVYVDYPGPASLT
QIYGT FNRA MLRLIPSLRTYAEPLTAAMVEFYTMSQERFTQDTQP
55 HYIYSPREMT RWVRGIF EALRPLETLPVEGLIRIWAHEALRLFQD
RLVEDEERRWTDENIDTVALKHFPNIDREKAMSRPILYSNWLSKD

-58-

YIPVDQEELRDYVKARLKVFYEEELDVPVLVLFNEVL DHVLRIDRI
 FRQPQGHLLIGVSGAGKTTLSRFVAMNGLSVYQIKVHRKYTGE
 DFDEDLRTVLRSSGCKNEKIAFIMDESNVLDSGFLERMNTLLANG
 EVPGLFEGDEYATLMTQCKEGAQKEGLMLDSHEELYKWFTSQVIR
 5 NLHVVFMTMNPSSSEGLKDRAATSPALFNRCVLNWFWDWSTEALYQV
 GKEFTSKMDLEKPNYIVPDYMPVVYDKLPQPPSHREAI VNSCVFV
 HQTLHQANARLAKRGGRTMAITPRHYLDFINHYANLFHEKRSELE
 EQQMHLNVGLRKKIKETVDQVEELRRDLRIKSQELEVKNAAANDKL
 KKMVKDQQEAEKKKVM SQEIQEQLHKQQEVIADKQMSVKEDLDKV
 10 EPAVIEAQNAVKSIIKKQHLVEVRSMANPPAAVKLALESICLLGE
 STTDWKQIRSIIMRENFIPTIVNFSAAEISDAIREKMKKNYMSNP
 SYNVEIVNRASLACGPMVKWAIAQLNYADMLKRVEPLRNELOKLE
 DDAKDNQQKANEVEQMIRDLEASIARYKEEYAVLISEAQAIKADL
 AAVEAKVNRSTALLKSLSAERERWEKTSETFKNQ MSTIAGDCLLS
 15 AAFIAYAGYFDQQMRQNLFTTWSHHLQQANI QFRTDIARTEYLSN
 ADERLRWQASSLPADDLCTENAIMLKRFNRYPLIIDPSGQATEFI
 MNEYKDRKITRTSFLDDAFRKNLESALRFGNPLLVDVESYDPVL
 NPVLNREVRRTGGRVLITLGDQDIDLSPSFVIFLSTRDPTVEFPP
 DLCSRVT FVNFTVTRSSLSQCLNEVLKAERP DVDEKRSDDLKLQ
 20 GEFQLRLRQLEKSL LQALNEVKGRILDDDTIITLENL KREAAEV
 TRKVEETDIVMQEVETVSQQYLP LSTACSSIYFTMESL KQIHFLY
 QYSLQFFLDIYHNVL YENPNLKGVT DHTQRLSIITKDLFQVAFNR
 VARGMLHQDHITFAMLLARIKLKGT VGEPTYDAEFQHFLRGNEIV
 LSAGSTPRIQGLTVEQAEAVVRLSCLPAFKDLIAKVQADEQFGIW
 25 LDSSSPEQTPYPLWSEETPATPIGQAIHRLLLIQA FRPDRL LAMA
 HMFVSTNLGESFMSIMEQPLDLTHIVGTEVKPNT PVL MCSVPGYD
 ASGHVEDLAAEQNTQITSIAIGSAEGFNQADKAINTAVKSGRWVM
 LKNVHLAPGWL MQLEKKLHSLQPHACFRLFLTMEINPKVPVNLLR
 AGRI FVFEP PPVGKANMLRTFSSI PVS RICKSPNERARLYFLLAW
 30 FHAI IQERLRYAPLGWSKKYEFGESDLRSACDTVDTWLD DDTAKGR
 QNISPDKIPWSALKTLMAQSIYGG RVDNEFDQRLNNTFLERLFTT
 RSFDSEFKLACKVDGHKDIQMPDGIRREEFVQWV ELLPDTQTPSW
 LGLPNNAERVLLTTQGVDMISKMLKMOMLEDEDD LAYAE TEKKTR
 TDSTSDGRPAWMRTLHTTASNWLHLIPQTL SHLKRTVENIKDPLF
 35 RFFEREVKMGAKLLQDVRQDLADVQVCEGKKKQTNYLRTLINEL
 VKGILPRSWSHYTV PAGMTVIQWVSDFSERIKQLQNI SLAAASGG
 AKELKNIHVCLGGLFVPEAYITATRQYVAQANSWSLEELCLEVNV
 TTSQGATLDACSFGVTGLKLQGATC NNNKLSLSNAISTALPLTQL
 RWVKQTNTEKKASVVTL PVYLNFTRADLIFTVD FEIATKEDPRSF
 40 YERGVAVLCTE

Preferably, the wild type residue of the modified human cytoplasmic dynein
 heavy chain1 protein is replaced by an amino acid with different size and/or polarity,
 45 *e.g.*, a non-conservative amino acid substitution.

Preferably, residue 1055 of murine cytoplasmic dynein heavy chain1 and
 residue 1057 of human cytoplasmic dynein heavy chain1 according to the present
 invention is replaced by an amino acid other than Trp or Phe and preferably is

replaced by an amino acid selected from Ala, Ser, Thr, Pro, Gly, Met, Leu, Ile, Val, or Cys, more preferably by Met, Leu, Ile, Val, or Cys, and most preferably by Cys.

In a most preferred embodiment the murine cytoplasmic dynein heavy chain1
5 mutein of the present invention has the amino acid sequence shown in SEQ ID NO:4. In another preferred embodiment the human cytoplasmic dynein heavy chain1 mutein of the present invention has the amino acid sequence shown in SEQ ID NO:6.

The present invention is not limited to muteins with a mutation of the residue
10 at, e.g., position 1055 of the amino acid sequence shown in SEQ ID NO: 4, and it is not limited to the mutation of the residue at, e.g., position 1057 of the amino acid sequence shown in SEQ ID NO: 6 or at a corresponding position in other dynein heavy chain proteins (especially cytoplasmic dynein heavy chain1 proteins from different species). Rather it encompasses additional muteins with modifications in the
15 amino acid sequence of the mouse or human cytoplasmic dynein heavy chain1 proteins as long as they impart a phenotype as described herein in connection with the animals. Such muteins, may comprise mutations, such as single or multiple further amino acid substitutions, deletions and insertions.

One embodiment of the invention relates to muteins wherein the amino acid
20 residue affected by the mutation, e.g., a substitution, deletion, or insertion, corresponds to a residue selected from the group of conserved amino acid residues between Leu302 (302L) and Phe1140 (1140F) of the cytoplasmic dynein heavy chain1 amino acid sequence, e.g., SEQ ID NO:2 (*Mus musculus*) specified in Table 19.

25 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 302L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 303K.

A preferred mutein of the invention is one wherein the conserved amino acid
30 affected by said mutation is the amino acid 305G.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 306K.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 307R.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 308F.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 309H.

5 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 310A.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 311T.

10 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 312V.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 314F.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 315D.

15 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 317D.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 319G.

20 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 320L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 321K.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 322Q.

25 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 324L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 327V.

30 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 329D.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 330Y.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 331N.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 333L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 334M.

5 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 335K.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 337F.

10 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 338P.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 342L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 344S.

15 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 345A.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 346T.

20 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 350K.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 354A.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 358I.

25 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 359F.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 361H.

30 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 362L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 363R.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 364K.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 366R.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 368T.

5 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 369K.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 370Y.

10 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 371P.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 373Q.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 374R.

15 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 376L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 378L.

20 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 380E.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 381A.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 382I.

25 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 383S.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 384R.

30 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 385D.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 386L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 389Q.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 390L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 391L.

5 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 392K.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 393V.

10 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 394L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 399L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 400M.

15 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 406E.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 407F.

20 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 411M.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 414C.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 418F.

25 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 421W.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 422D.

30 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 423D.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 424E.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 425Y.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 427K.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 431L.

5 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 432L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 433R.

10 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 434D.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 435I.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 437K.

15 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 439K.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 440R.

20 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 445K.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 448W.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 454H.

25 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 457L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 460R.

30 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 467F.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 468R.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 470Q.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 471H.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 472E.

5 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 473Q.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 475R.

10 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 477V.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 478I.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 480R.

15 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 481V.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 482L.

20 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 483R.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 484P.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 519E.

25 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 521V.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 524A.

30 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 525Y.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 526E.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 529K.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 531V.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 532D.

5 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 534L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 535D.

10 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 543A.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 544W.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 545E.

15 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 547A.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 549K.

20 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 550R.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 551Y.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 555I.

25 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 558V.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 559E.

30 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 560T.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 562I.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 563T.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 566L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 569Q.

5 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 570L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 575N.

10 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 577N.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 578E.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 579M.

15 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 580F.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 582I.

20 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 583F.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 584S.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 585R.

25 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 587N.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 588A.

30 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 589L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 590F.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 592R.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 593P.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 595I.

5 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 596R.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 597G.

10 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 598A.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 599I.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 601E.

15 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 602Y.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 603Q.

20 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 604T.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 606L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 607I.

25 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 609R.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 610V.

30 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 611K.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 613D.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 614I.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 617L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 621F.

5 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 639L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 640P.

10 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 641P.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 646W.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 655Q.

15 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 656L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 659Y.

20 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 661K.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 662R.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 663V.

25 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 664E.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 665D.

30 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 666V.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 667L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 668G.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 669K.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 671W.

5 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 672E.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 674H.

10 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 677G.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 680L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 681K.

15 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 683D.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 684G.

20 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 685D.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 687F.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 690F.

25 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 691L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 697F.

30 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 700W.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 704V.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 705N.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 715I.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 717T.

5 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 731L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 733L.

10 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 736N.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 744L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 746K.

15 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 747E.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 748V.

20 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 752K.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 755G.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 756F.

25 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 757R.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 758V.

30 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 759P.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 760L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 762I.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 763V.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 764N.

5 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 766A.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 767H.

10 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 768Q.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 769A.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 770N.

15 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 771Q.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 774P.

20 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 776A.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 778S.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 779L.

25 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 780I.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 781E.

30 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 784R.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 785T.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 802L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 804A.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 808K.

5 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 816E.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 817G.

10 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 820L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 822W.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 824S.

15 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 825Y.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 826K.

20 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 828D.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 830Y.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 834L.

25 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 836E.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 838V.

30 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 842Q.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 843E.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 848L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 849L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 862L.

5 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 865C.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 867Y.

10 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 871T.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 876L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 880Q.

15 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 883V.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 884D.

20 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 886L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 888L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 891Y.

25 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 892S.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 893N.

30 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 894L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 897W.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 898V.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 899N.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 901L.

5 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 902D.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 906E.

10 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 909L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 912R.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 920W.

15 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 921T.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 951P.

20 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 955N.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 957V.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 963T.

25 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 965Q.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 968Y.

30 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 971P.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 975E.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 977R.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 987W.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1001R.

5 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1003Q.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1017Y.

10 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1019N.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1021L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1025P.

15 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1027G

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1031L.

20 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1032E.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1035Y.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1048Y.

25 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1052W.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1053L.

30 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1055Y.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1056Q.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1058L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1059W.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1062Q.

5 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1063A.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1070L.

10 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1071G.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1077W.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1081L.

15 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1084I.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1088R.

20 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1091F.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1092D.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1096T.

25 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1102P.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1107Y.

30 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1109K.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1111Q.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1113K.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1117K.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1118Y.

5 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1119D.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1121W.

10 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1122H.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1123K.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1124E.

15 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1126L.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1128K.

20 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1129F.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1130G.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1134G.

25 A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1137W.

A preferred mutein of the invention is one wherein the conserved amino acid affected by said mutation is the amino acid 1140F.

30 It will be understood that human muteins of the cytoplasmic dynein heavy chain1 having mutations as described herein, e.g., carrying a substitution, deletion, or insertion at a position within the human amino acid sequence corresponding to any of the above individualized conserved amino acids of the mouse amino acid sequence, are likewise within the scope of the invention. The corresponding human amino acids

will, as they are conserved between, e.g. mouse and human, be identical while their relative position within the amino acid sequence may vary. The skilled person will be readily able to identify the corresponding human amino acids, e.g., within SEQ ID NO:18, or from Figures 9 or 10.

5

In addition to the mutant proteins described by SEQ ID NO:4, and SEQ ID NO:6, the skilled artisan will further appreciate that changes can be introduced by mutation into the nucleotide sequence encoding a dynein heavy chain polypeptide (e.g., the sequences of SEQ ID NO:3 and SEQ ID NO:5), thereby leading to changes in the amino acid sequence of the encoded dynein heavy chain proteins without altering properties of the mutant dynein heavy chain proteins. For example, nucleotide substitutions leading to amino acid substitutions at "non-essential" amino acid residues can be made in the sequence of SEQ ID NO:3 and SEQ ID NO:5. A "non-essential" amino acid residue is a residue that can be altered from the wild-type sequence of a dynein heavy chain polypeptide without altering the biological activity, whereas an "essential" amino acid residue is required for biological activity. For example, amino acid residues that are conserved among the cytoplasmic dynein heavy chain1 polypeptide or polypeptide fragments of the present invention are predicted to be particularly unamenable to alteration.

20

Preferably, such alterations replace an amino acid with one of similar size and polarity (e.g., conservative substitution). In one embodiment, the polypeptide has at least 75 %, preferably at least 80 %, more preferably at least 90 %, even more preferably 95% and most preferably at least 99 % sequence identity with the wild type cytoplasmic dynein heavy chain1 sequence. In a particularly preferred embodiment, the polypeptide is identical with the wild type sequence except for a replacement of the Tyr residue at position 1055 of the amino acid sequence, as shown in SEQ ID NO: 4. In another particularly preferred embodiment, the polypeptide is identical to the wild type sequence except for a replacement of the Tyr residue at position 1057 of the amino acid sequence, as shown in SEQ ID NO: 6 or at the corresponding position in other cytoplasmic dynein heavy chain1 sequences. Preferred modifications of the amino acid sequence, in addition to the replacement at, e.g., position 1055 of the amino acid sequence shown in SEQ ID NO: 4, and at, e.g., position 1057 of the amino acid sequence shown in SEQ ID NO: 6, or at a corresponding position in other dynein

25
30

heavy chains are at any of the positions which are conserved among the vertebrate dynein heavy chains as described in individualized manner in connection with the preferred muteins above.

5 Preferred modifications of the amino acid sequence, in addition to the replacement at position 1055 of the amino acid sequence shown in SEQ ID NO: 4, and at position 1057 of the amino acid sequence shown in SEQ ID NO: 6, or at a corresponding position in other dynein heavy chains are at positions which are not conserved among the vertebrate dynein heavy chains.

10

Amino acids in the cytoplasmic dynein heavy chain 1 proteins of the present invention that are essential for function can be identified by methods known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (Cunningham and Wells, Science 244:1081-1085, 1989). The latter procedure introduces single alanine
15 mutations at every residue in the molecule. The resulting mutant molecules are then tested for biological activity such as receptor binding or in vitro proliferative activity. Sites that are critical for ligand-receptor binding can also be determined by structural analysis such as crystallization, nuclear magnetic resonance or photoaffinity labeling (Smith et al., J. Mol. Biol. 224:899-904, 1992; de Vos et al., Science 255:306-312,
20 1992).

An "isolated" or "purified" polypeptide or protein or biologically-active portion thereof is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the polypeptide or protein is derived, or
25 substantially free from chemical precursors or other chemicals when chemically synthesized. The language "substantially free of cellular material" includes preparations of dynein heavy chain protein in which the protein is separated from cellular components of the cells from which it the protein is isolated or in which it is recombinantly produced.

30

Further as used herein, a "mature" form of a polypeptide or protein may arise from a step of post-translational modification other than a proteolytic cleavage event. Such additional processes include, by way of non-limiting example, glycosylation, myristoylation or phosphorylation. In general, a mature polypeptide or protein may

result from the operation of only one of these processes, or a combination of any of them.

To determine the percent homology of two amino acid sequences or of two
5 nucleic acids, the sequences are aligned for optimal comparison purposes (*e.g.*, gaps can be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second comparison amino acid or nucleic acid sequence). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is
10 occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are homologous at that position (*e.g.*, as used herein amino acid or nucleic acid "homology" is equivalent to amino acid or nucleic acid "identity"). The nucleic acid sequence homology may be determined as the degree of identity between two sequences. The homology may be determined
15 using computer programs known in the art, such as GAP software provided in the GCG program package. See, Needleman and Wunsch (1970) J Mol Biol 48, 443-453. Using GCG GAP software with the following settings for nucleic acid sequence comparison: GAP creation penalty of 5.0 and GAP extension penalty of 0.3, the coding region of the analogous nucleic acid sequences referred to above exhibits a
20 degree of identity preferably of at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99%, with the CDS (encoding) part of the DNA sequence shown in SEQ ID NOS:1, 3, 5, and 17.

The term "sequence identity" refers to the degree to which two polynucleotide
25 or polypeptide sequences are identical on a residue-by-residue basis over a particular region of comparison. The term "percentage of sequence identity" is calculated by comparing two optimally aligned sequences over that region of comparison, determining the number of positions at which the identical nucleic acid base (*e.g.*, A, T, C, G, U, or I, in the case of nucleic acids) occurs in both sequences to yield the
30 number of matched positions, dividing the number of matched positions by the total number of positions in the region of comparison (*e.g.*, the window size), and multiplying the result by 100 to yield the percentage of sequence identity. The term "substantial identity" as used herein denotes a characteristic of a polynucleotide sequence, wherein the polynucleotide comprises a sequence that has at least 80

percent sequence identity, preferably at least 85 percent identity and often 90 to 95 percent sequence identity, more usually at least 99 percent sequence identity as compared to a reference sequence over a comparison region.

5 The phrases "percent identity" or "% identity" refer to the percentage of sequence similarity found in a comparison of two or more amino acid or nucleic acid sequences. Percent identity can be determined electronically, *e.g.*, by using the MEGALIGN program (DNASTAR, Inc., Madison WI, USA). The MEGALIGN program can create alignments between two or more sequences according to different
10 methods, *e.g.*, the clustal method (see, for example, Higgins and Sharp (1988) Gene 73:237-244. The clustal algorithm groups sequences into clusters by examining the distances between all pairs. The clusters are aligned pairwise and then in groups. The percentage similarity between two amino acid sequences, *e.g.*, sequence A and sequence B, is calculated by dividing the length of sequence A, minus the number of
15 gap residues in sequence A, minus the number of gap residues in sequence B, into the sum of the residue matches between sequence A and sequence B, times one hundred. Gaps of low homology or of no homology between the two amino acid sequences are not included in determining percentage similarity. Percent identity between nucleic acid sequences can also be counted or calculated by other methods known in the art,
20 *e.g.*, the method described in Hein (1990) Methods Enzymol 183, 626-645. Identity between sequences can also be determined by other methods known in the art, *e.g.*, by varying hybridization conditions.

25 The comparison of two or more amino acid or nucleic acid sequences to determine sequence identity can be performed between ortholog sequences, preferably between mouse and human, more preferably between mouse, rat, and human sequences. When a position of an amino acid or nucleotide in one ortholog sequence is occupied by the same amino acid or nucleotide in at least a second ortholog sequence, this amino acid or nucleotide is "evolutionary conserved" for the purpose of
30 this invention. The term "evolutionary conserved" also comprises amino acid substitutions, where an amino acid is replaced by another (*i.e.*, different) amino acid that represents a conservative substitution as defined below.

When, e.g., residue 1055 of SEQ ID NO:2, or residue 1057 of SEQ ID NO:18 or any of the residues corresponding to the conserved residues described in individualized manner in connection with the preferred muteins of the invention above is replaced by an amino acid with different size and/or polarity (excluding the wild type residue at this position), this is termed a non-conservative amino acid substitution. Non-conservative substitutions are defined as exchanges of an amino acid by another amino acid listed in a different group of the five standard amino acid groups shown below:

1. small aliphatic, nonpolar or slightly polar residues: Ala, Ser, Thr, (Pro), (Gly);
2. negatively charged residues and their amides: Asn, Asp, Glu, Gln;
3. positively charged residues: His, Arg, Lys;
4. large aliphatic, nonpolar residues: Met, Leu, Ile, Val, (Cys);
5. large aromatic residues: Phe, Tyr, Trp.

Conservative substitutions are defined as exchanges of an amino acid by another amino acid listed within the same group of the five standard amino acid groups shown above. Three residues are parenthesized because of their special role in protein architecture. Gly is the only residue without a sidechain and therefore imparts flexibility to the chain. Pro has an unusual geometry which tightly constrains the chain. Cys can participate in disulfide bonds.

In a preferred embodiment, the cytoplasmic dynein heavy chain1 expressed in the animal model of the present invention carries a mutation, which affects the conserved amino acids of the muteins described in individualized manner in connection with the preferred muteins of the invention above.

In the most preferred embodiment, the cytoplasmic dynein heavy chain1 expressed in the animal model of the present invention has the amino acid sequence shown in SEQ ID NO:4.

In another most preferred embodiment, the cytoplasmic dynein heavy chain1 expressed in the animal model of the present invention has an amino acid sequence selected from the sequences shown in SEQ ID NO:6 and SEQ ID NO:18.

The invention also provides novel chimeric or fusion proteins as used herein, a novel "chimeric protein" or "fusion protein" comprises a novel cytoplasmic dynein heavy chain1 polypeptide linked to a non-cytoplasmic dynein heavy chain1 polypeptide (e.g., a polypeptide that does not comprise cytoplasmic dynein heavy chain1 or a fragment thereof).

In one embodiment, the fusion protein is a GST-cytoplasmic dynein heavy chain1 fusion protein in which the cytoplasmic dynein heavy chain1 sequences are fused to the C-terminus of the GST (glutathione S-transferase) sequences. Such fusion proteins can facilitate the purification of recombinant cytoplasmic dynein heavy chain1 polypeptides.

In yet another embodiment, the fusion protein is a cytoplasmic dynein heavy chain1-immunoglobulin fusion protein in which the cytoplasmic dynein heavy chain1 sequences are fused to sequences derived from a member of the immunoglobulin protein family, especially Fc region polypeptides. Also contemplated are fusions of cytoplasmic dynein heavy chain1 sequences (mutant or wild type or functional fragments) fused to amino acid sequences that are commonly used to facilitate purification or labeling, e.g. polyhistidine tails (especially hexahistidine segments), FLAG tags, streptavidin.

The amino acid sequences of the present invention may be made by using peptide synthesis techniques well known in the art, such as solid phase peptide synthesis (see, for example, Fields *et al.* "Principles and Practice of Solid Phase Synthesis" in *Synthetic Peptides, A Users Guide*, Grant GA (ed.), (W.H. Freeman Co. New York NY, USA, 1992) at Chapter 3, pp. 77-183; Barlos K and Gatos D "Convergent Peptide Synthesis" in *FMOC Solid Phase Peptide Synthesis*, Chan WC and White PD (eds.), (Oxford University Press, New York NY, USA, 2000) at Chapter 9, pp. 215-228) or by recombinant DNA manipulations and recombinant expression. Techniques for making substitution mutations at predetermined sites in DNA having known sequence are well known and include, for example, M13 mutagenesis. Manipulation of DNA sequences to produce variant proteins which

manifest as substitution, insertion or deletion variants are conveniently described, for example, in Sambrook *et al.* (1989), *supra*.

Antibodies

5 Also included in the invention are antibodies to fragments of cytoplasmic dynein heavy chain1 polypeptides and muteins as described in individualized manner in connection with the preferred muteins of the invention above (including amino terminal fragments), as well as antibodies to fusion proteins containing cytoplasmic dynein heavy chain1 polypeptides or fragments of cytoplasmic dynein heavy chain1
10 polypeptides or muteins as described in individualized manner in connection with the preferred muteins of the invention above. The term "antibody" as used herein refers to immunoglobulin molecules and immunologically active portions of immunoglobulin (Ig) molecules, *e.g.*, molecules that contain an antigen binding site that specifically binds (immunoreacts with) an antigen. Such antibodies include, *e.g.*,
15 polyclonal, monoclonal, chimeric, single chain, F_{ab} , F_{ab}' and $F_{(ab)2}$ fragments, and an F_{ab} expression library. In general, an antibody molecule obtained from humans relates to any of the classes IgG, IgM, IgA, IgE and IgD, which differ from one another by the nature of the heavy chain present in the molecule. Certain classes have subclasses as well, such as IgG₁, IgG₂, and others. Furthermore, in humans, the light chain may
20 be a kappa chain or a lambda chain. Reference herein to antibodies includes a reference to all such classes, subclasses and types of human antibody species.

A cytoplasmic dynein heavy chain1 polypeptide 1 of the invention may be intended to serve as an antigen, or a portion or fragment thereof, and additionally can
25 be used as an immunogen to generate antibodies that immunospecifically bind the antigen, using standard techniques for polyclonal and monoclonal antibody preparation. Antigenic peptide fragments of the antigen for use as immunogens includes, *e.g.*, at least 7 amino acid residues of the amino acid sequence of the mutated region such as an amino acid sequence shown in SEQ ID NO:4 or SEQ ID NO:6, and
30 encompasses an epitope thereof such that an antibody raised against the peptide forms a specific immune complex with the full length protein or with any fragment that contains the epitope. Preferably, the antigenic peptide comprises at least 10 amino acid residues, or at least 15 amino acid residues, or at least 20 amino acid residues, or

at least 30 amino acid residues. Preferred epitopes encompassed by the antigenic peptide are regions of the protein that are located on its surface; commonly these are hydrophilic regions.

5 In certain embodiments of the invention, at least one epitope encompassed by the antigenic peptide is a region of cytoplasmic dynein heavy chain1 polypeptide that is located on the surface of the protein, *e.g.*, a hydrophilic region. A hydrophobicity analysis of a cytoplasmic dynein heavy chain1 polypeptide will indicate which regions of a cytoplasmic dynein heavy chain1 protein are particularly hydrophilic and,
10 therefore, are likely to encode surface residues useful for targeting antibody production. As a means for targeting antibody production, hydropathy plots showing regions of hydrophilicity and hydrophobicity may be generated by any method well known in the art, including, for example, the Kyte Doolittle or the Hopp Woods methods, either with or without Fourier transformation. (See, for example, Hopp and
15 Woods (1981) *Proc Nat Acad Sci USA* 78, 3824-3828; Kyte and Doolittle (1982) *J Mol Biol* 157, 105-142.) Antibodies that are specific for one or more domains within an antigenic protein, or derivatives, fragments, analogs or homologs thereof, are also provided herein.

20 A protein of the invention, or a derivative, fragment, analog, homolog or ortholog thereof, may be utilized as an immunogen in the generation of antibodies that immunospecifically bind these protein components.

Various procedures known within the art may be used for the production of
25 polyclonal or monoclonal antibodies directed against a protein of the invention, or against derivatives, fragments, analogs homologs or orthologs thereof. (See, for example, Harlow and Lane *Antibodies: A Laboratory Manual*, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, USA, 1988).) Some of these antibodies are discussed below.

30

Polyclonal Antibodies

For the production of polyclonal antibodies, various suitable host animals (*e.g.*, rabbit, goat, mouse or other mammal) may be immunized by one or more injections with the protein of the invention, a synthetic variant thereof, or a derivative of the

foregoing. An appropriate immunogenic preparation can contain, for example, the naturally occurring immunogenic protein, a chemically synthesized polypeptide representing the immunogenic protein, or a recombinantly expressed immunogenic protein. Furthermore, the protein may be conjugated to a second protein known to be immunogenic in the mammal being immunized. Examples of such immunogenic proteins include but are not limited to keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin and soybean trypsin inhibitor.

The preparation can further include an adjuvant. Various adjuvants used to increase the immunological response include, but are not limited to, Freund's (complete and incomplete), mineral gels (*e.g.*, aluminum hydroxide), surface active substances (*e.g.*, lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, dinitrophenol, etc.), adjuvants usable in humans such as Bacille Calmette-Guerin and *Corynebacterium parvum*, or similar immunostimulatory agents. Additional examples of adjuvants which can be employed include MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate).

The polyclonal antibody molecules directed against the immunogenic protein can be isolated from the mammal (*e.g.*, from the blood) and further purified by well known techniques, such as affinity chromatography using protein A or protein G, which provide primarily the IgG fraction of immune serum. Subsequently, or alternatively, the specific antigen which is the target of the immunoglobulin sought, or an epitope thereof, may be immobilized on a column to purify the immune specific antibody by immunoaffinity chromatography. Purification of immunoglobulins is discussed, for example, by Wilkinson (Wilkinson (2000) *The Scientist*, 14, 25-28).

Monoclonal Antibodies

The term "monoclonal antibody" (MAb) or "monoclonal antibody composition", as used herein, refers to a population of antibody molecules that contain only one molecular species of antibody molecule consisting of a unique light chain gene product and a unique heavy chain gene product. In particular, the complementarity determining regions (CDRs) of the monoclonal antibody are identical in all the molecules of the population. MAbs thus contain an antigen binding

site capable of immunoreacting with a particular epitope of the antigen, the antigen binding site being characterized by its unique binding affinity for this epitope. Similarly, the epitope may be characterized by its binding affinity for antigen binding sites of one or more particular MAbs having binding sites directed towards that epitope.

Monoclonal antibodies can be prepared using hybridoma methods, such as those described by Kohler and Milstein (1975) Nature 256, 495. In a hybridoma method, a mouse, hamster, or other appropriate host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes can be immunized *in vitro*.

The immunizing agent will typically include the protein antigen, a fragment thereof or a fusion protein thereof. Generally, either peripheral blood lymphocytes are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. The lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (Goding, *Monoclonal Antibodies: Principles and Practice* (Academic Press / Elsevier Science Sidcup, Kent, UK, 1986) at pp. 59-103). Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine and human origin. Usually, rat or mouse myeloma cell lines are employed. The hybridoma cells can be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine ("HAT medium"), which substances prevent the growth of HGPRT-deficient cells.

Preferred immortalized cell lines are those that fuse efficiently, support stable high level expression of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. More preferred immortalized cell lines are murine myeloma lines, which can be obtained, for instance, from the Salk Institute

Cell Distribution Center, San Diego, California and the American Type Culture Collection, Manassas, Virginia. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies (Kozbor (1984) J Immunol, 133, 3001; Brodeur *et al.*, *Monoclonal Antibody*
5 *Production Techniques and Applications* (Marcel Dekker, Inc., New York NY, USA, 1987) at pp. 51-63).

The culture medium in which the hybridoma cells are cultured can then be assayed for the presence of monoclonal antibodies directed against the antigen.
10 Preferably, the binding specificity of monoclonal antibodies produced by the hybridoma cells is determined by immunoprecipitation or by an *in vitro* binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA). Such techniques and assays are known in the art. The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of
15 Munson and Pollard (1980) Anal. Biochem., 107:220. Preferably, antibodies having a high degree of specificity and a high binding affinity for the target antigen are isolated.

After the desired hybridoma cells are identified, the clones can be subcloned
20 by limiting dilution procedures and grown by standard methods. Suitable culture media for this purpose include, for example, Dulbecco's Modified Eagle's Medium and RPMI-1640 medium. Alternatively, the hybridoma cells can be grown *in vivo* as ascites in a mammal.

25 The monoclonal antibodies secreted by the subclones can be isolated or purified from the culture medium or ascites fluid by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.

30 The monoclonal antibodies can also be made by recombinant DNA methods, such as those described in U.S. Patent No. 4,816,567. DNA encoding the monoclonal antibodies of the invention can be readily isolated and sequenced using conventional procedures (*e.g.*, by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). The

hybridoma cells of the invention serve as a preferred source of such DNA. Once isolated, the DNA can be placed into expression vectors, which are then transfected into host cells such as simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. The DNA also can be modified, for example, by substituting the coding sequence for human heavy and light chain constant domains in place of the homologous murine sequences (U.S. Patent No. 4,816,567; Morrison (1994) Nature 368, 812-13) or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide. Such a non-immunoglobulin polypeptide can be substituted for the constant domains of an antibody of the invention, or can be substituted for the variable domains of one antigen-combining site of an antibody of the invention to create a chimeric bivalent antibody.

15 Humanized Antibodies

The antibodies directed against the protein antigens of the invention can further comprise humanized antibodies or human antibodies. These antibodies are suitable for administration to humans without engendering an immune response by the human against the administered immunoglobulin. Humanized forms of antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab')₂ or other antigen-binding subsequences of antibodies) that are principally comprised of the sequence of a human immunoglobulin and contain minimal sequence derived from a non-human immunoglobulin. Humanization can be performed following the method of Winter and co-workers (Jones *et al.* (1986) Nature 321, 522-525; Riechmann *et al.* (1988) Nature 332, 323-327; Verhoeven *et al.* (1988) Science 239, 1534-1536), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. (See also U.S. Patent No. 5,225,539.) In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies can also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the framework regions are those of a

human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin (Jones *et al.* (1986) *Nature* 321, 522-525; Riechmann *et al.* (1988) *Nature* 332, 323-327; and Presta (1992) *Curr Op Struct Biol* 2, 593-596).

Human Antibodies

Fully human antibodies relate to antibody molecules in which essentially the entire sequences of both the light chain and the heavy chain, including the CDRs, arise from human genes. Such antibodies are termed "human antibodies", or "fully human antibodies" herein. Human monoclonal antibodies can be prepared by the trioma technique; the human B-cell hybridoma technique (see Kozbor *et al.* (1983) *Immunol Today* 4, 72) and the EBV hybridoma technique to produce human monoclonal antibodies (see Cole *et al.* in: *Monoclonal Antibodies and Cancer Therapy* (Alan R. Liss, Inc., New York NY, USA, 1985) at pp. 77-96). Human monoclonal antibodies may be utilized in the practice of the present invention and may be produced by using human hybridomas (see Cote *et al.* (1983) *Proc Natl Acad Sci USA* 80, 2026-2030) or by transforming human B-cells with Epstein Barr Virus *in vitro* (see Cole *et al.* in: *Monoclonal Antibodies and Cancer Therapy* (Alan R. Liss, Inc., New York NY, USA, 1985) at pp. 77-96).

In addition, human antibodies can also be produced using additional techniques, including phage display libraries (Hoogenboom and Winter (1992) *J Mol Biol* 227, 381-388; Marks *et al.* (1991) *J Mol Biol* 222, 581-597). Similarly, human antibodies can be made by introducing human immunoglobulin loci into transgenic animals, *e.g.*, mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, for example, in U.S. Patents No. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in Marks *et al.* (1992) *Bio/Technology* 10, 779-783; Lonberg *et al.* (1994) *Nature* 368, 856-859; Morrison (1994) *Nature* 368, 812-13; Fishwild *et al.* (1996) *Nature Biotechnology* 14, 845-51; Neuberger (1996) *Nature*

Biotechnology 14, 826; and Lonberg and Huszar (1995) Intern Rev Immunol 13, 65-93.

Human antibodies may additionally be produced using transgenic nonhuman
5 animals which are modified so as to produce fully human antibodies rather than the
animal's endogenous antibodies in response to challenge by an antigen (see PCT
publication WO94/02602). The endogenous genes encoding the heavy and light
immunoglobulin chains in the nonhuman host have been incapacitated, and active loci
encoding human heavy and light chain immunoglobulins are inserted into the host's
10 genome. The human genes are incorporated, for example, using yeast artificial
chromosomes containing the requisite human DNA segments. An animal which
provides all the desired modifications is then obtained as progeny by crossbreeding
intermediate transgenic animals containing fewer than the full complement of the
modifications. The preferred embodiment of such a nonhuman animal is a mouse, and
15 is termed the XenomouseTM as disclosed in PCT publications WO-A-96/33735 and
WO-A-96/34096. This animal produces B cells which secrete fully human
immunoglobulins. The antibodies can be obtained directly from the animal after
immunization with an immunogen of interest, as, for example, a preparation of a
polyclonal antibody, or alternatively from immortalized B cells derived from the
20 animal, such as hybridomas producing monoclonal antibodies. Additionally, the
genes encoding the immunoglobulins with human variable regions can be recovered
and expressed to obtain the antibodies directly, or can be further modified to obtain
analogs of antibodies such as, for example, single chain Fv molecules.

25 An example of a method of producing a nonhuman host, exemplified as a
mouse, lacking expression of an endogenous immunoglobulin heavy chain is
disclosed in U.S. Patent No. 5,939,598. Such a host can be obtained by a method
including deleting the J segment genes from at least one endogenous heavy chain
locus in an embryonic stem cell to prevent rearrangement of the locus and to prevent
30 formation of a transcript of a rearranged immunoglobulin heavy chain locus, the
deletion being effected by a targeting vector containing a gene encoding a selectable
marker; and producing from the embryonic stem cell a transgenic mouse whose
somatic and germ cells contain the gene encoding the selectable marker.

A method for producing an antibody of interest, such as a human antibody, is disclosed in U.S. Patent No. 5,916,771. The method includes introducing an expression vector that contains a nucleotide sequence encoding a heavy chain into one mammalian host cell in culture, introducing an expression vector containing a nucleotide sequence encoding a light chain into another mammalian host cell, and fusing the two cells to form a hybrid cell. The hybrid cell expresses an antibody containing the heavy chain and the light chain.

In a further improvement on this procedure, a method for identifying a clinically relevant epitope on an immunogen, and a correlative method for selecting an antibody that binds immunospecifically to the relevant epitope with high affinity, are disclosed in PCT publication WO-A-99/53049.

F_{ab} Fragments and Single Chain Antibodies

According to the invention, techniques can be adapted for the production of single-chain antibodies specific to an antigenic protein of the invention (see for example U.S. Patent No. 4,946,778). In addition, methods can be adapted for the construction of F_{ab} expression libraries (see for example Huse *et al.* (1989) Science 246, 1275-1281) to allow rapid and effective identification of monoclonal F_{ab} fragments with the desired specificity for a protein or derivatives, fragments, analogs or homologs thereof. Antibody fragments that contain the idiotype to a protein antigen may be produced by techniques known in the art including, but not limited to:

- (i) an F_{(ab)²} fragment produced by pepsin digestion of an antibody molecule;
- (ii) an F_{ab} fragment generated by reducing the disulfide bridges of an F_{(ab)²} fragment;
- (iii) an F_{ab} fragment generated by the treatment of the antibody molecule with papain and a reducing agent; and
- (iv) F_v fragments.

Bispecific Antibodies

Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens. In the

present case, one of the binding specificities is for an antigenic protein of the invention. The second binding target is any other antigen, and advantageously is a cell-surface protein or receptor or receptor subunit.

5 Methods for making bispecific antibodies are known in the art. Traditionally, the recombinant production of bispecific antibodies is based on the co-expression of two immunoglobulin heavy-chain/light-chain pairs, where the two heavy chains have different specificities (Milstein and Cuello (1983) *Nature* 305, 537-539). Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas
10 (quadromas) produce a potential mixture of ten different antibody molecules, of which only one has the correct bispecific structure. The purification of the correct molecule is usually accomplished by affinity chromatography steps. Similar procedures are disclosed in WO-A-93/08829 and in Traunecker *et al.* (1991) *EMBO J* 10, 3655-3659.

15 Antibody variable domains with the desired binding specificities (antibody-antigen combining sites) can be fused to immunoglobulin constant domain sequences. The fusion preferably is with an immunoglobulin heavy-chain constant domain, comprising at least part of the hinge, CH2, and CH3 regions. It is preferred to have
20 the first heavy chain constant region (CH1) containing the site necessary for light-chain binding present in at least one of the fusions. DNAs encoding the immunoglobulin heavy-chain fusions and, if desired, the immunoglobulin light chain are inserted into separate expression vectors and are co-transfected into a suitable host organism. For further details of generating bispecific antibodies see, for example,
25 Suresh *et al.* (1986) *Methods in Enzymology* 121, 210.

 In accordance with another approach described in WO-A-96/27011, the interface between a pair of antibody molecules can be engineered to maximize the percentage of heterodimers which are recovered from recombinant cell culture. The
30 preferred interface comprises at least a part of the CH3 region of an antibody constant domain. In this method, one or more small amino acid side chains from the interface of the first antibody molecule are replaced with larger side chains (*e.g.* tyrosine or tryptophan). Compensatory "cavities" of identical or similar size to the large side chain(s) are created on the interface of the second antibody molecule by replacing

large amino acid side chains with smaller ones (e.g. alanine or threonine). This provides a mechanism for increasing the yield of the heterodimer over other unwanted end-products such as homodimers.

5 Bispecific antibodies can be prepared as full length antibodies or antibody fragments (e.g. $F(ab')_2$ bispecific antibodies). Techniques for generating bispecific antibodies from antibody fragments have been described in the literature. For example, bispecific antibodies can be prepared using chemical linkage. Brennan *et al.* ((1985) Science 229, 81) describe a procedure wherein intact antibodies are
10 proteolytically cleaved to generate $F(ab')_2$ fragments. These fragments are reduced in the presence of the dithiol complexing agent sodium arsenite to stabilize vicinal dithiols and prevent intermolecular disulfide formation. The Fab' fragments generated are then converted to thionitrobenzoate (TNB) derivatives. One of the Fab'-TNB derivatives is then reconverted to the Fab'-thiol by reduction with mercaptoethylamine
15 and is mixed with an equimolar amount of the other Fab'-TNB derivative to form the bispecific antibody. The bispecific antibodies produced can be used as agents for the selective immobilization of enzymes.

 Additionally, Fab' fragments can be recovered directly from *E. coli* and
20 chemically coupled to form bispecific antibodies. Shalaby *et al.* ((1992) J Exp Med 175, 217-225) describe the production of a fully humanized bispecific antibody $F(ab')_2$ molecule. Each Fab' fragment was secreted separately from *E. coli* and subjected to directed chemical coupling *in vitro* to form the bispecific antibody. The bispecific antibody thus formed was able to bind to cells overexpressing the ErbB2 receptor and
25 normal human T cells, as well as trigger the lytic activity of human cytotoxic lymphocytes against human breast tumor targets.

 Various techniques for making and isolating bispecific antibody fragments directly from recombinant cell culture have also been described. For example,
30 bispecific antibodies have been produced using leucine zippers. Kostelny *et al.* (1992) J Immunol 148, 1547-1553. The leucine zipper peptides from the Fos and Jun proteins were linked to the Fab' portions of two different antibodies by gene fusion. The antibody homodimers were reduced at the hinge region to form monomers and then re-oxidized to form the antibody heterodimers. This method can also be utilized

for the production of antibody homodimers. The "diabody" technology described by Hollinger *et al.* ((1993) Proc Natl Acad Sci USA 90, 6444-6448) has provided an alternative mechanism for making bispecific antibody fragments. The fragments comprise a heavy-chain variable domain (V_H) connected to a light-chain variable domain (V_L) by a linker which is too short to allow pairing between the two domains on the same chain. Accordingly, the V_H and V_L domains of one fragment are forced to pair with the complementary V_L and V_H domains of another fragment, thereby forming two antigen-binding sites. Another strategy for making bispecific antibody fragments by the use of single-chain Fv (sFv) dimers has also been reported (see Gruber *et al.* (1994) J Immunol 152, 5368-74.

Antibodies with more than two valencies are contemplated. For example, trispecific antibodies can be prepared (Tutt *et al.* (1991) J Immunol 147, 60-69).

Exemplary bispecific antibodies can bind to two different epitopes, at least one of which originates in the protein antigen of the invention. Alternatively, an anti-antigenic arm of an immunoglobulin molecule can be combined with an arm which binds to a triggering molecule on a leukocyte such as a T-cell receptor molecule (*e.g.* CD2, CD3, CD28, or B7), or Fc receptors for IgG (Fc R), such as Fc RI (CD64), Fc RII (CD32) and Fc RIII (CD16) so as to focus cellular defense mechanisms to the cell expressing the particular antigen. Bispecific antibodies can also be used to direct cytotoxic agents to cells which express a particular antigen. These antibodies possess an antigen-binding arm and an arm which binds a cytotoxic agent or a radionuclide chelator, such as EOTUBE, DPTA, DOTA, or TETA. Another bispecific antibody of interest binds the protein antigen described herein and further binds tissue factor (TF).

Heteroconjugate Antibodies

Heteroconjugate antibodies are also within the scope of the present invention. Heteroconjugate antibodies are composed of two covalently joined antibodies. Such antibodies have, for example, been proposed to target immune system cells to unwanted cells (U.S. Patent No. 4,676,980), and for treatment of HIV infection (WO-A-91/00360; WO-A-92/20373; EP-A3-0308936). It is contemplated that the antibodies can be prepared *in vitro* using known methods in synthetic protein

chemistry, including those involving crosslinking agents. For example, immunotoxins can be constructed using a disulfide exchange reaction or by forming a thioether bond. Examples of suitable reagents for this purpose include iminothiolate and methyl-4-mercaptobutyrimidate and those disclosed, for example, in U.S. Patent No. 4,676,980.

5

Effector Function Engineering

It can be desirable to modify the antibody of the invention with respect to effector function, so as to enhance, *e.g.*, the effectiveness of the antibody. For example, cysteine residue(s) can be introduced into the Fc region, thereby allowing
10 interchain disulfide bond formation in this region. The homodimeric antibody thus generated can have improved internalization capability and/or increased complement-mediated cell killing and antibody-dependent cellular cytotoxicity (ADCC) (see Caron *et al.* (1992) *J Exp Med* 176; 1191-1195 and Shopes (1992) *J Immunol* 148, 2918-2922). Homodimeric antibodies with enhanced anti-tumor activity can also be
15 prepared using heterobifunctional cross-linkers as described in Wolff *et al.* (1993) *Cancer Res* 53, 2560-2565. Alternatively, an antibody can be engineered that has dual Fc regions and can thereby have enhanced complement lysis and ADCC capabilities (see Stevenson *et al.* (1989) *Anti-Cancer Drug Design* 3, 219-230).

20 Immunoconjugates

The invention also pertains to immunoconjugates comprising an antibody conjugated to a cytotoxic agent such as a chemotherapeutic agent, toxin (*e.g.*, an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments thereof), or a radioactive isotope (*e.g.*, a radioconjugate).

25

Enzymatically active toxins and fragments thereof that can be used include diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from *Pseudomonas aeruginosa*), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, *Phytolaca americana* proteins
30 (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the tricothecenes. A variety of radionuclides are available for the production of radioconjugated antibodies. Examples include ^{212}Bi , ^{131}I , ^{131}In , ^{90}Y , and ^{186}Re .

Conjugates of the antibody and cytotoxic agent are made using a variety of bifunctional protein-coupling agents such as N-succinimidyl-3-(2-pyridyldithiol) propionate (SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaredehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as tolyene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). For example, a ricin immunotoxin can be prepared as described in Vitetta *et al.* (1987) Science 238, 1098-1104. Carbon-14-labeled 1-isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of radionucleotide to the antibody (see WO-A-94/11026).

15

In another embodiment, the antibody can be conjugated to a "receptor" (such as streptavidin) for utilization in tumor pretargeting wherein the antibody-receptor conjugate is administered to the patient, followed by removal of unbound conjugate from the circulation using a clearing agent and then administration of a "ligand" (*e.g.*, avidin) that is in turn conjugated to a cytotoxic agent.

20

Vectors and Cells Expressing cytoplasmic dynein heavy chain1

Another aspect of the invention pertains to vectors, preferably expression vectors, containing a nucleic acid encoding a cytoplasmic dynein heavy chain1 protein or a mutein as described in individualized manner in connection with the preferred muteins of the invention above, or derivatives, fragments, analogs or homologs thereof. As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", which refers to a circular double stranded circular DNA molecule into which additional DNA segments can be ligated. Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (*e.g.* bacterial vectors having a bacterial origin of replication and

25

30

episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively-linked.

5 Such vectors are referred to herein as "expression vectors".

A host cell of the invention, such as a prokaryotic or eukaryotic host cell in culture, can be used to produce (e.g., express) cytoplasmic dynein heavy chain1 protein or mutein as described in individualized manner in connection with the preferred muteins of the invention above. Accordingly, the invention further provides

10 methods for producing cytoplasmic dynein heavy chain1 protein or mutein using the host cells of the invention. In one embodiment, the method comprises culturing the host cell of invention (into which a recombinant expression vector encoding cytoplasmic dynein heavy chain1 protein has been introduced) in a suitable medium

15 such that cytoplasmic dynein heavy chain1 protein or mutein is produced. In another embodiment, the method further comprises isolating cytoplasmic dynein heavy chain1 protein or mutein from the medium or the host cell.

The host cells of the invention can also be used to produce non-human

20 transgenic animals. For example, in one embodiment, a host cell of the invention is a fertilized oocyte or an embryonic stem cell into which cytoplasmic dynein heavy chain1 protein- or cytoplasmic dynein heavy chain1 mutein-coding sequences have been introduced. Such host cells can then be used to create non-human transgenic animals in which exogenous cytoplasmic dynein heavy chain1 sequences have been

25 introduced into their genome or homologous recombinant animals in which endogenous cytoplasmic dynein heavy chain1 sequences have been altered. Such animals are useful for studying the function and/or activity of cytoplasmic dynein heavy chain1 protein and for identifying and/or evaluating modulators of cytoplasmic dynein heavy chain1 protein activity. As used herein, a "transgenic animal" is a

30 non-human animal, preferably a mammal, more preferably a rodent such as a rat or mouse, which contains one or more cells bearing genetic information (a transgene), received, directly or indirectly, by deliberate genetic manipulation at the subcellular level, such as by microinjection or transfection with recombinant DNA, or infection with a recombinant virus. Other examples of transgenic animals include non-human

primates; ungulates such as cows, horses, goats, sheep; dogs, cats, and also chickens, amphibians, etc. Standard methods are known in the art that may be used in conjunction with the polynucleotides and of the invention and methods described herein to produce a transgenic animal expressing a modified cytoplasmic dynein heavy chain1 of the invention.

As used herein, a "transgene" is a foreign gene that has been artificially introduced into the genome of of an non human organism. A transgene present in germ cells is inherited by offspring. If such offspring in fact possesses the transgene, they too are transgenic animal.s

A transgene present only in somatic cells is nor passed on to the gametes.

As used herein, the term "transgenic" describes an organism whose genome incorporates and expresses genes from another species.

Animal Models

The present invention provides a non-human animal model which expresses a cytoplasmic dynein heavy chain1 protein modified as described herein, e.g. for the muteins described in individualized manner in connection with the preferred muteins above, as compared to the amino acid sequence of the wild type protein. The cytoplasmic dynein heavy chain1 expressed may have similarity in sequence and secondary structure to a vertebrate dynein heavy chain, including, but not limited to mammalian dynein heavy chain proteins, preferably of bovine, rat, and preferably mouse origin. The animal is preferably from a genus selected from the group consisting of *Mus* (e.g., mice), *Rattus* (e.g., rats), *Oryctologus* (e.g., rabbits) and *Mesocricetus* (e.g., hamsters). In a particularly preferred embodiment the animal is a mouse.

Animals carrying a mutated cytoplasmic dynein heavy chain1 allele expressing the modified cytoplasmic dynein heavy chain1 proteins of the invention, e.g. a mutein as described in individualized manner in connection with the preferred muteins above, exhibit a variety of phenotypical features including: myoclonic cramps (which are especially pronounced in the hindlimbs), movement hyperactivity, reduced muscle endurance, excitatory neuronal damage ("dark neurons") in the hippocampus (gyrus

dentatus, CA4, CA3) as well as in the upper layer of the cortex and in the Purkinje cell layer of the cerebellum.

5 Compared with heterozygous animals, homozygous individuals exhibit an elevated incidence of perinatal lethality (100% in homozygous animals, *versus* approximately 20% amongst heterozygous animals), accelerated neuron degeneration in the anterior horns of the spinal cord, and accelerated neurodegeneration in the dorsal root ganglia. Neurodegeneration in heterozygous animals is apparent at a much later stage, *i.e.* late adulthood.

10

The term "phenotype" according to the invention refers to a collection of morphological, physiological, behavioral and biochemical traits possessed by a cell or organism that results from the interaction of the genotype and the environment. Thus, the animal model of the present invention displays readily observable abnormalities.

15 In a preferred embodiment the animal of the invention shows at least 2, preferably at least 4, more preferably 6 and most preferably all of the above listed phenotypical features.

In the present invention, mice were generated carrying a point mutation in the

20 thirteenth exon (exon 13) of the mouse cytoplasmic dynein heavy chain1 gene, which is illustrated in SEQ ID NO:1, thereby replacing the tyrosine residue at position 1055 in the N-terminal domain of the protein. This modification results in the above mentioned phenotypical features. Amino acid position 1055 according to the present invention refers to the non-mature cytoplasmic dynein heavy chain1 protein, as

25 numbered in SEQ ID NO:4. However, it will be appreciated by the person skilled in art that also the mature protein is encompassed by the present invention and may be expressed in the animal model of the present invention. A mature protein may result from a cleavage of several amino acids, and therefore may alter the numbering of the amino acids in the mature protein relative to the numbering of an unprocessed protein.

30 The tyrosine residue corresponding to the Tyr located at position 1055 in the amino acid sequence of SEQ ID NO:2 is conserved among the cytoplasmic dynein heavy chain proteins of different species as can be seen in the alignment in Table 9.

Table 9. Clustal W comparison of wild-type Dynein Heavy Chains

[illegible]

Thus, the non-human animal model of the present invention carries, e.g., a nucleic acid sequence encoding cytoplasmic dynein heavy chain1, whereby the codon for the amino acid at position 1055 of the amino acid sequence shown in SEQ ID NO:2 or the codon corresponding to said position in other dynein heavy chain proteins (especially cytoplasmic dynein heavy chain1 proteins), like position 1057 of the amino acid sequence shown in SEQ ID NO:18, which encodes a Tyr in the wild type, is mutated to encode a different amino acid. In a preferred embodiment, the animal model of the present invention expresses the amino acid sequence shown in SEQ ID NO:4.

In a preferred embodiment the animal model of the invention carries a modified cytoplasmic dynein heavy chain1 nucleic acid sequence derived from a vertebrate, preferably from a mammal, in particular from mouse, for example, a cytoplasmic dynein heavy chain1 nucleic acid sequence encoding a cytoplasmic dynein heavy chain1 mutein as described in individualized manner in connection with the preferred muteins of the invention above. In a particularly preferred embodiment the nucleic acid sequence is derived from the nucleic acid sequence of SEQ ID NO:1, 3, 5, or 17.

The animal model of the invention preferably expresses a modified cytoplasmic dynein heavy chain1 protein of the invention (e.g. as shown in SEQ ID

NO:4, or SEQ ID NO:6 or a mutein as described in individualized manner in connection with the preferred muteins above) in all of its cells, and particularly in the brain and spinal cord. However, animals which express the modified cytoplasmic dynein heavy chain1 protein in some, but not all cells, which are termed cellular
5 mosaic animals, are also contemplated.

The present invention further provides for inbred successive lines of animals carrying the mutant cytoplasmic dynein heavy chain1 nucleic acid of the present invention that offer the advantage of providing a virtually homogenous genetic
10 background. A genetically homogenous line of animals provides a functionally reproducible model system for disorders or symptoms associated with movement hyperactivity, hyperexcitability disorders (e.g. myoclonic cramping, epilepsy), excitotoxicity disorders and neurodegeneration; over-activity or undesirable activity of endogenous cytoplasmic dynein heavy chain1; over-expression, over-production or
15 undesirable production of endogenous cytoplasmic dynein heavy chain1; excessive or undesirable condition shown to be modulated by endogenous cytoplasmic dynein heavy chain1.

The animal model of the present invention may use any of the cytoplasmic
20 dynein heavy chain1 muteins described herein, e.g., those described in an individualized manner in connection with the preferred muteins of the invention above, and is not limited to the modification of the residue at position 1055 of the amino acid sequence shown in SEQ ID NO:4 or at a corresponding position in other dynein heavy chain orthologs (e.g. position 1057 of the amino acid sequence shown in
25 SEQ ID NO:6) so long as the mutein used imparts the desired mutant dynein phenotype to the animal of the present invention. Suitable muteins include those with modifications in the amino acid sequence of the mouse or human cytoplasmic dynein heavy chain1 proteins so long as they impart a phenotype as described herein in connection with the animals of the invention. Such muteins may comprise mutations,
30 such as single or multiple further amino acid substitutions, deletions and insertions, particularly mutations that affect the conserved amino acids of mouse or human cytoplasmic dynein heavy chain1, as described, e.g., in an individualized manner in connection with the preferred muteins of the invention above. Amino acid insertional derivatives of the present invention include amino and/or carboxyl terminal fusions as

well as intra-sequence insertions of single or multiple amino acids. Insertional amino acid sequence variants are those in which one or more amino acid residues are introduced into a predetermined site in the protein although random insertion is also possible with suitable screening of the resulting product. Deletional variants are characterized by the removal of one or more amino acids from the sequence. Substitutional amino acid variants are those in which at least one residue in the sequence has been removed and a different residue inserted in its place. Preferably, the cytoplasmic dynein heavy chain1 expressed in the animal model of the invention has a degree of identity preferably of at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or most preferably 99%, with the wild type cytoplasmic dynein heavy chain1 sequence from vertebrate, preferably from mammals, most preferably from bovine, and from rat and even most preferably from mouse (SEQ ID NO:2), excluding the wild type mouse cytoplasmic dynein heavy chain1 sequence itself. In another preferred embodiment, the cytoplasmic dynein heavy chain1 expressed in the animal model of the invention is human cytoplasmic dynein heavy chain1 (SEQ ID NO:18) or has a degree of identity preferably of at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or most preferably 99%, with the human cytoplasmic dynein heavy chain1 sequence in SEQ ID NO:18 (e.g. SEQ ID NO:6). The human wild type cytoplasmic dynein heavy chain1 sequence is a further embodiment of the invention.

20

In a particularly preferred embodiment the animal model expresses a polypeptide as shown in SEQ ID NO:4. Further preferred embodiments include the animal model of the invention, that expresses a polypeptide selected from those shown in SEQ ID NO:6 and SEQ ID NO:18. Preferred modifications of the cytoplasmic dynein heavy chain1 amino acid sequence in the animal models of the present invention, in addition to the modification at, e.g, position 1055 of the amino acid sequence shown in SEQ ID NO:4, (or in addition to the modification in the equivalent position 1057 of the amino acid sequence shown in SEQ ID NO:6) are at positions which are conserved among the vertebrate dynein heavy chain proteins (especially those conserved among vertebrate cytoplasmic dynein heavy chain1 proteins), as described in individualized manner in connection with the preferred muteins above.

25
30

Another preferred modification of the cytoplasmic dynein heavy chain1 amino acid sequence in the animal models of the present invention, in addition to the

modification at position 1055 of the amino acid sequence shown in SEQ ID NO:4, (or in addition to the modification in the equivalent position 1057 of the amino acid sequence shown in SEQ ID NO:6) are at positions which are not conserved among the vertebrate dynein heavy chain proteins (especially those not conserved among vertebrate cytoplasmic dynein heavy chain1 proteins), as described above.

It will be appreciated that the animal model of the invention may carry a mutated cytoplasmic dynein heavy chain1 nucleic acid according to the present invention derived from the same species or from a different species. Preferably, the mutated cytoplasmic dynein heavy chain1 nucleic acid of the present invention is homozygous in the animals of the present invention. Preferably, transcription of the mutated cytoplasmic dynein heavy chain1 gene of the present invention is under the control of the promoter sequence controlling transcription of the endogenous wild type cytoplasmic dynein heavy chain1 sequence of the animal, although a different promoter may be used.

The animals of the invention can be produced by using any technique known to the person skilled in the art; including but not limited to micro-injection, electroporation, cell gun, cell fusion, micro-injection into embryos of teratocarcinoma stem cells or functionally equivalent embryonic stem cells. The animals of the present invention may be produced by the application of procedures which result in an animal with a genome that incorporates and/or integrates exogenous genetic material in such a manner as to modify or disrupt the function of the normal cytoplasmic dynein heavy chain1 gene or protein. The preferred procedure for generating animal models of this invention as described in Example 1.

Alternatively, the procedure may involve obtaining genetic material, or a portion thereof, which encodes a cytoplasmic dynein heavy chain1. The isolated native sequence is then genetically manipulated by the insertion of a mutation appropriate to replace the residue at position 1055 of the amino acid sequence shown in SEQ ID NO:2. The manipulated construct may then be inserted into embryonic stem cells, *e.g.* by electroporation. The cells subjected to said procedure are screened to find positive cells, *e.g.* cells which have integrated into their genome the desired construct encoding an altered cytoplasmic dynein heavy chain1. The positive cells

may be isolated, cloned (or expanded) and injected into blastocysts obtained from a host animal of the same species or a different species. For example, positive cells are injected into blastocysts from mice, the blastocysts are then transferred into a female host animal and allowed to grow to term, following which the offspring of the female
5 are tested to determine which animals are transgenic, *e.g.* which animals have an inserted exogenous mutated DNA sequence. One method involves the introduction of the recombinant gene at the fertilized oocyte stage ensuring that the gene sequence will be present in all of the germ cells and somatic cells of the "founder" animal. The term "founder animal" as used herein means the animal into which the recombinant
10 gene was introduced at the one cell embryo stage.

The animals of the invention can also be used as a source of primary cells from a variety of tissues, for cell culture experiment, including but not restricted to, the production of immortalized cell lines by any methods known in the art, such as
15 retroviral transformation. Cells from the animals may advantageously exhibit desirable properties of both normal and transformed cultured cells, *e.g.* they will be normal or nearly normal morphologically and physiologically, but can be cultured for long, and perhaps indefinite periods of time. The present invention provides such primary cells and cell lines derived therefrom, obtained from the animals of the
20 present invention. These primary cells or cell lines derived thereof may be used for the construction of an animal model of the present invention.

In other embodiments cell lines may be prepared by the insertion of a nucleic acid construct comprising the nucleic acid sequence of the invention or a fragment
25 thereof comprising the codon imparting the above-described phenotype to the animal model of the invention (*vide infra*). Suitable cells for the insertion include primary cells harvested from an animal as well as cells which are members of an immortalized cell line. Recombinant nucleic acid constructs of the invention, described below, may be introduced into the cells by any method known in the art, including but not limited to,
30 to, transfection, retroviral infection, micro-injection, electroporation, transduction or DEAE-dextran. Cells which express the recombinant construct may be identified by, for example, using a second recombinant nucleic acid construct comprising a reporter gene which is used to produce selective expression. Cells that express the nucleic

acid sequence of the invention or a fragment thereof may be identified indirectly by the detection of reporter gene expression.

Pharmaceutical Compositions

5 The invention also includes pharmaceutical compositions containing mutein nucleic acids or proteins of the invention, e.g. those muteins as described in individualized manner in connection with the preferred muteins of the invention above, as well as pharmaceutical compositions containing antibodies to them. The compositions are preferably suitable for internal use and include an effective amount
10 of a pharmacologically active compound of the invention, alone or in combination, with one or more pharmaceutically acceptable carriers. The compounds are especially useful in that they have very low, if any toxicity.

 The mutated nucleic acid sequences and muteins of this invention, and
15 antibodies thereto, may be used in pharmaceutical compositions, when combined with a pharmaceutically acceptable carrier. As used herein, "pharmaceutically acceptable carrier" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. Suitable carriers are described
20 in the most recent edition of *Remington's Pharmaceutical Sciences* (e.g. currently the 18th edition), Alfonso R. Gennaro, ed. (Mack Publishing Co., Easton PA, USA, 1990), a standard reference text in the field, which is incorporated herein by reference. Preferred examples of such carriers or diluents include, but are not limited to, water, saline, finger's solutions, dextrose solution, and 5% human serum albumin.
25 Liposomes and non-aqueous vehicles such as fixed oils may also be used. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.

30

 A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g. intravenous, intradermal, subcutaneous, oral (e.g. inhalation), transdermal (e.g. topical), transmucosal, and rectal administration. Solutions or

suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; 5 antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid (EDTA); buffers such as acetates, citrates or phosphates, and agents for the adjustment of tonicity such as sodium chloride or dextrose. The pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, 10 disposable syringes or multiple dose vials made of glass or plastic.

Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For 15 intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, NJ, U.S.A.) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringeability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the 20 contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the 25 case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition. Prolonged 30 absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

For instance, for oral administration in the form of a tablet or capsule (e.g. a gelatin capsule), the active drug component can be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like. Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents and coloring agents can also be incorporated into the mixture. Suitable binders include starch, magnesium aluminum silicate, starch paste, gelatin, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, polyethylene glycol, waxes and the like. Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, silica, talcum, stearic acid, its magnesium or calcium salt and/or polyethyleneglycol and the like. Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum, starches, agar, alginic acid or its sodium salt, or effervescent mixtures, and the like. Examples of diluents include, without limitation, lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycine.

Injectable compositions are preferably aqueous isotonic solutions or suspensions, and suppositories are advantageously prepared from fatty emulsions or suspensions. The compositions may be sterilized and/or contain adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers. In addition, they may also contain other therapeutically valuable substances. The compositions are prepared according to conventional mixing, granulating or coating methods, respectively, and contain about 0.1 to 75%, preferably about 1 to 50%, of the active ingredient.

The compounds of the invention can also be administered in such oral dosage forms as timed release and sustained release tablets or capsules, pills, powders, granules, elixers, tinctures, suspensions, syrups and emulsions.

Liquid, particularly injectable compositions can, for example, be prepared by dissolving, dispersing, *etc.* The active compound is dissolved in or mixed with a pharmaceutically pure solvent such as, for example, water, saline, aqueous dextrose, glycerol, ethanol, and the like, to thereby form the injectable solution or suspension.

Additionally, solid forms suitable for dissolving in liquid prior to injection can be formulated. Injectable compositions are preferably aqueous isotonic solutions or suspensions. The compositions may be sterilized and/or contain adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for
5 regulating the osmotic pressure and/or buffers. In addition, they may also contain other therapeutically valuable substances.

The compounds of the present invention can be administered in intravenous (both bolus and infusion), intraperitoneal, subcutaneous or intramuscular form, all
10 using forms well known to those of ordinary skill in the pharmaceutical arts. Injectables can be prepared in conventional forms, either as liquid solutions or suspensions.

Parental injectable administration is generally used for subcutaneous,
15 intramuscular or intravenous injections and infusions. Additionally, one approach for parenteral administration employs the implantation of a slow-release or sustained-released systems, which assures that a constant level of dosage is maintained, according to U.S. Pat. No. 3,710,795, incorporated herein by reference.

Furthermore, preferred compounds for the present invention can be
20 administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in that art. To be administered in the form of a transdermal delivery system, the dosage administration will, of course, be continuous rather than
25 intermittent throughout the dosage regimen. Other preferred topical preparations include creams, ointments, lotions, aerosol sprays and gels, wherein the concentration of active ingredient would range from 0.1% to 15%, w/w or w/v.

For solid compositions, excipients include pharmaceutical grades of mannitol,
30 lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate, and the like may be used. The active compound defined above, may be also formulated as suppositories using for example, polyalkylene glycols, for example, propylene glycol, as the carrier. In some

embodiments, suppositories are advantageously prepared from fatty emulsions or suspensions.

The compounds of the present invention can also be administered in the form
5 of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, containing cholesterol, stearylamine or phosphatidylcholines. In some embodiments, a film of lipid components is hydrated with an aqueous solution of drug to a form lipid layer encapsulating the drug, as described in U.S. Pat. No. 5,262,564.

10

Compounds of the present invention may also be delivered by the use of monoclonal antibodies as individual carriers to which the compound molecules are coupled. The compounds of the present invention may also be coupled with soluble polymers as targetable drug carriers. Such polymers can include
15 polyvinylpyrrolidone, pyran copolymer, polyhydroxypropyl-methacrylamide-phenol, polyhydroxyethylaspanamidephenol, or polyethyleneoxidepolylysine substituted with palmitoyl residues. Furthermore, the compounds of the present invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyepsilon caprolactone, polyhydroxy butyric
20 acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross-linked or amphipathic block copolymers of hydrogels.

If desired, the pharmaceutical composition to be administered may also contain minor amounts of non-toxic auxiliary substances such as wetting or emulsifying
25 agents, pH buffering agents, and other substances such as for example, sodium acetate, triethanolamine oleate, *etc.*

The dosage regimen utilizing the compounds is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of
30 the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound or salt thereof employed. An ordinarily skilled physician or veterinarian can readily determine and prescribe the effective amount of the drug required to prevent, counter or arrest the progress of the condition.

Oral dosages of the present invention, when used for the indicated effects, will range between about 0.05 to 1000 mg/day orally. The compositions are preferably provided in the form of scored tablets containing 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100.0, 250.0, 500.0 and 1000.0 mg of active ingredient. Effective plasma levels of the compounds of the present invention range from 0.002 mg to 50 mg per kg of body weight per day.

Compounds of the present invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three or four times daily.

Any of the above pharmaceutical compositions may contain 0.1-99%, preferably 1-70% of the cytoplasmic dynein heavy chain1 polypeptide.

15

If desired, the pharmaceutical compositions can be provided with an adjuvant. Adjuvants are discussed above. In some embodiments, adjuvants can be used to increase the immunological response, depending on the host species, include Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and *Corynebacterium parvum*. Generally, animals are injected with antigen using several injections in a series, preferably including at least three booster injections.

25

Assays and Diagnostics

The animals of the present invention present a phenotype whose characteristics are representative of many symptoms associated with disorders associated with dynein heavy chain deficiency (especially cytoplasmic dynein heavy chain1 deficiency), therefore making the animal model of the present invention a particularly suitable model for the study of these diseases including movement hyperactivity, hyperexcitability disorders (e.g. myoclonic cramping, epilepsy), excitotoxicity disorders and neurodegeneration; over-activity or undesirable activity of endogenous

30

cytoplasmic dynein heavy chain1; over-expression, over-production or undesirable production of endogenous cytoplasmic dynein heavy chain1; excessive or undesirable condition shown to be modulated by endogenous cytoplasmic dynein heavy chain1. In particular the animal model of the invention presents a phenotype
5 characterized by cramping, movement hyperactivity; excitatory neuronal damage in the CA3 and CA4 sector of the hippocampus, as well as in the upper layer of the cortex and in the Purkinje cell layer of the cerebellum and neurodegeneration. These are all phenotypical characteristics of human diseases related to hyperexcitability and neurodegeneration, such as epilepsy, Alzheimer's disease, Huntington's disease, and
10 Parkinson's disease. Therefore, the animals of the invention can be used to study diseases or symptoms associated with movement hyperactivity and impairment, hyperexcitability disorders (e.g. myoclonic cramping, epilepsy), excitotoxicity disorders, cognitive disorders and neurodegeneration in general.

15 The animals of the present invention can also be used to identify early diagnostic markers for diseases associated with cytoplasmic dynein heavy chain1 deficiency. Surrogate markers, including but not limited to ribonucleic acids or proteins, can be identified by performing procedures of proteomics or gene expression analysis known in the art. For example procedures of proteomics analysis include, but
20 are not restricted to, ELISA, 2D-gel, protein microarrays or mass spectrophotometric analysis of any organ or tissue samples, such as blood samples, or derivatives thereof, preferably plasma, at different age or stage of cytoplasmic dynein heavy chain1 activity deficiency associated disease development, or symptom thereof. As a further example, gene expression analysis procedures include, but are not restricted to,
25 differential display, cDNA microarrays, analysis of quality and quantity of ribonucleic acids species from any organ or tissue samples, such as blood samples, or derivatives thereof, at different age or stage of development of cytoplasmic dynein heavy chain1 activity deficiency associated disease, or symptom thereof.

30 The animal model of the present invention can be used to monitor the activity of agents useful in the prevention or treatment of the above-mentioned diseases and disorders. The agent to be tested can be administered to an animal of the present invention and various phenotypic parameters can be measured or monitored. In a further embodiment the animals of the invention may be used to test therapeutics

against any disorders or symptoms that have been shown to be associated with cytoplasmic dynein heavy chain1 deficiency or overexpression.

The animals of the present invention can also be used as test model systems for materials, including but not restricted to chemicals and peptides, particularly medical drugs, suspected of promoting or aggravating the above-described diseases associated with cytoplasmic dynein heavy chain1 deficiency. For example, the material can be tested by exposing the animal of the present invention to different time, doses and/or combinations of such materials and by monitoring the effects on the phenotype of the animal of the present invention, including but not restricted to movement activity; latency to fall in a hanging wire assay, motor coordination test assays, such as rotarod, stationary beam and coat hanger motor performance, excitatory neuronal damage in the hippocampus (CA3, CA4 and gyrus dentatus) and in the pyramidal area of the cortex, histopathological and biochemical parameters of motor neuron degeneration and spinal muscular atrophy, as well as tracer experiments to determine the functionality of the retrograd axonal transport.

Furthermore, the animals of the present invention may be used for the dissection of the molecular mechanisms of the cytoplasmic dynein heavy chain1 pathway, that is for the identification of downstream genes or proteins thereof regulated by cytoplasmic dynein heavy chain1 activity and deregulated in cytoplasmic dynein heavy chain1 activity deficiency associated disorders. For example, this can be done by performing differential proteomics analysis, using techniques including but not restricted to 2D gel analysis, protein chip microarrays or mass spectrophotometry, on tissues of the animal of the present invention which express cytoplasmic dynein heavy chain1 and which respond to cytoplasmic dynein heavy chain1 stimuli.

The animal model of the present invention can be used to identify and clone so-called modifier genes which are able to modify, aggravate, reduce or inhibit the phenotype associated with a cytoplasmic dynein heavy chain1 activity deficiency. Particularly, for this purpose, the animal model of the present invention can be mated to mice of different strains carrying a different genetic background, which gives the possibility to map the genes modifying the phenotype. For example, the animal model

of the present invention, when produced in an C3HeB/FeJ inbred strain background can be bred to C57B1/6Jico inbred mice. The hybrid animals of this progeny, are then further bred, either in back-cross strategy with C57B1/6Jico inbred mice again, or in an intercross strategy between each other. The modifier gene can be then mapped and
5 cloned by using microsattelites or a single nucleotide polymorphism (SNP) strategy on the mice resulting from the backcross or intercross breeding that have been grouped with respect to their phenotype intensity.

An exemplary method for detecting the presence or absence of cytoplasmic
10 dynein heavy chain1 in a biological sample, e.g. a mutein of the present invention, e.g., those described in individualized manner in connection with the preferred muteins of the invention above, involves obtaining a biological sample from a test subject and contacting the biological sample with a compound or an agent capable of detecting cytoplasmic dynein heavy chain1 protein, mutein, or nucleic acid (e.g.
15 mRNA, genomic DNA) that encodes cytoplasmic dynein heavy chain1 protein or mutein such that the presence of cytoplasmic dynein heavy chain1 is detected in the biological sample. An agent for detecting cytoplasmic dynein heavy chain1 mRNA or genomic DNA is a labeled nucleic acid probe capable of hybridizing to cytoplasmic dynein heavy chain1 mRNA or genomic DNA.

20

The diagnostic methods described herein can furthermore be utilized to identify subjects having or at risk of developing a disease or disorder associated with aberrant cytoplasmic dynein heavy chain1 expression or activity. For example, the assays described herein, such as the preceding diagnostic assays or the following
25 assays, can be utilized to identify a subject having or at risk of developing a disorder associated with cytoplasmic dynein heavy chain1 protein, nucleic acid expression or activity. Alternatively, the prognostic assays can be utilized to identify a subject having or at risk for developing a disease or disorder. Thus, the invention provides a method for identifying a disease or disorder associated with aberrant cytoplasmic
30 dynein heavy chain1 expression or activity in which a test sample is obtained from a subject and cytoplasmic dynein heavy chain1 protein or nucleic acid (e.g. mRNA, genomic DNA) is detected, wherein the presence of cytoplasmic dynein heavy chain1 protein or nucleic acid is diagnostic for a subject having or at risk of developing a disease or disorder associated with aberrant cytoplasmic dynein heavy chain1

expression or activity. As used herein, a "test sample" refers to a biological sample obtained from a subject of interest. For example, a test sample can be a biological fluid (e.g., blood, plasma, serum), cell sample, or tissue.

5 Furthermore, the prognostic assays described herein can be used to determine whether a subject can be administered an agent (e.g. an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate) to treat a disease or disorder associated with aberrant cytoplasmic dynein heavy chain1 expression or activity. For example, such methods can be used to
10 determine whether a subject can be effectively treated with an agent for a disorder.

Agents, or modulators that have a stimulatory or inhibitory effect on cytoplasmic dynein heavy chain1 activity (e.g. cytoplasmic dynein heavy chain1 gene expression), as identified by a screening assay described herein can be administered to
15 individuals to treat (prophylactically or therapeutically) cytoplasmic dynein heavy chain1-mediated disorders. Differences in metabolism of therapeutics can lead to severe toxicity or therapeutic failure by altering the relation between dose and blood concentration of the pharmacologically active drug. Thus, the pharmacogenomics of the individual permits the selection of effective agents (e.g. drugs) for prophylactic or
20 therapeutic treatments based on a consideration of the individual's genotype. Such pharmacogenomics can further be used to determine appropriate dosages and therapeutic regimens. Accordingly, the activity of cytoplasmic dynein heavy chain1 protein, expression of cytoplasmic dynein heavy chain1 nucleic acid, or mutation content of cytoplasmic dynein heavy chain1 genes in an individual can be determined
25 to thereby select one or more appropriate agents for therapeutic or prophylactic treatment of the individual.

The present invention also provides a diagnostic method for cytoplasmic dynein heavy chain1 activity deficiency. Patients' peptide material, particularly that in or from blood, serum or plasma, is subjected to analysis for one or more of the
30 amino acid sequences of the present invention. The peptide material may be analyzed directly or after extraction, isolation and/or purification by standard methods.

In one embodiment of the invention, the diagnostic method comprises the identification of the modified cytoplasmic dynein heavy chain1, e.g., modified as

described in individualized manner in connection with the preferred muteins of the invention above, whereby the modification is, e.g., associated with the replacement of an amino acid at a position corresponding to position 1055 in the amino acid sequence shown in SEQ ID NO:2. In another embodiment of the invention, the diagnostic method comprises the identification of the modified cytoplasmic dynein heavy chain1, e.g., the mutein as described in individualized manner in connection with the preferred muteins of the invention above, whereby the modification is, e.g., associated with the replacement of an amino acid at a position corresponding to position 1057 in the amino acid sequence shown in SEQ ID NO:18. In yet another embodiment of the invention, the diagnostic method comprises the identification of the modified cytoplasmic dynein heavy chain1, e.g., modified as described in individualized manner in connection with the preferred muteins of the invention above, wherein the modification is, e.g., associated with the replacement of an amino acid at a position that is conserved between the vertebrate cytoplasmic dynein heavy chain1 proteins. Such diagnostic methods include those employing detection of the modified cytoplasmic dynein heavy chain1 by its failure to activate a biological pathway. The diagnostic methods of the invention also include those employing detection of the modified cytoplasmic dynein heavy chain1 by its activity in competing with and blocking the action of native dynein heavy chain. Methods of identifying the modified cytoplasmic dynein heavy chain1 include any methods known in the art which are able to identify altered conformational properties of the amino acid sequence of the present invention compared to those of the wild type cytoplasmic dynein heavy chain1. These include, without limitation, the specific recognition of the modified protein by other proteins, particularly antibodies; individual or combined patterns of amino acid sequence digestion by known proteases or chemicals. In an additional, similar embodiment, the method exploits the failure of another protein to recognize the modified protein, examples being antibodies directed to an epitope of wild type cytoplasmic dynein heavy chain1 that incorporates residue 1055 of SEQ ID NO:2, or SEQ ID NO:18, and cytoplasmic dynein heavy chain1 receptors in which this portion of the molecular surface of wild type cytoplasmic dynein heavy chain1 is recognized or involved in cytoplasmic dynein heavy chain1 activation.

In a further embodiment of the present invention, the principle of the diagnostic method is the detection of a nucleic acid sequence encoding the modified

cytoplasmic dynein heavy chain1 of the invention. This includes, but is not restricted to any methods known in the art using nucleic acid hybridizing properties, such as Northern blot, Southern blot, nucleic acid (genomic DNA, cDNA, mRNA, synthetic oligonucleotides) standard methods employing microarrays, and patterns of nucleic acid digestion by known restriction enzymes.

Subunits of the Dynactin/Dynein Complex

As explained above, the present invention is not only concerned with the identification of neurodegenerative disease relevant mutations in the dynein heavy chain 1 gene, but is also based on the recognition that other components (hereinafter also referred to as "subunits") of the dynactin/dynein complex may likewise be subject to mutations that are involved in, or affect, the pathogenesis of such diseases. When reference is made in the present specification to subunits of the dynactin/dynein complex, these subunits include in particular the cytoplasmic dynein heavy chain 1, cytoplasmic dynein intermediate chain 1, cytoplasmic dynein intermediate chain 2, cytoplasmic dynein light intermediate chain 1, cytoplasmic dynein light intermediate chain 2; cytoplasmic dynein 10 kDa light chain, cytoplasmic dynein light chain Tctex 1, cytoplasmic dynein light chain 2B, DCTN 1, DCTN 2, DCTN 3, DCTN 4, DCTN 5, DCTN 6, ARP1, ARP11, HAP1, and CLIP-170, preferably encoded by the genomic nucleic acid sequences identified in Table 25, or defined by the amino acid sequences identified in Tables 26, 27, and 29-35.

Table 25. Subunits of the Dynein Complex and their genomic sequences assigned as NCBI contig Accession Numbers (Gen Bank Acc. No., except where otherwise indicated) (NCBI contigs are derived from genomic sequence data assembled by NCBI staff)

Name of the Subunit	Gen Bank Accession Number	SEQ ID NO.:
Cytoplasmic dynein heavy chain 1	Mm NW_000055	28

Cytoplasmic dynein heavy chain 1	Hs	AL118558	29
Cytoplasmic dynein intermediate chain 1	Mm	NW_000272	30
Cytoplasmic dynein intermediate chain 1	Hs	NT_023947	31
Cytoplasmic dynein intermediate chain 2	Mm	NW_000176	32
Cytoplasmic dynein intermediate chain 2	Hs	NT_005332.11	33
Cytoplasmic dynein light intermediate chain 1	Mm	AC115796.2	34
Cytoplasmic dynein light intermediate chain 1	Hs	NT_034532.2	35
Cytoplasmic dynein light intermediate chain 2	Mm	AC118211.3	36
Cytoplasmic dynein light intermediate chain 2	Hs	NT_010478.11	37
Cytoplasmic dynein 10kDa light chain	Mm	NW_000236	38
Cytoplasmic dynein 10kDa light chain	Hs	NT_009775	39
Cytoplasmic dynein light chain Tctex 1	Mm	NW_000269	40
Cytoplasmic dynein light chain Tctex 1	Hs	NT_007422	41
Cytoplasmic dynein light chain 2B	Hs	NT_024797	42
DCTN 1	Mm	NT_003134	43
DCTN 1	Hs	NT_022184	44
DCTN 2	Mm	MGI107733*	159

DCTN 2	Hs	NT_009509	45
DCTN 3	Mm	NW_000206	46
DCTN 3	Hs	NT_023974	47
DCTN 4	Mm	NW_000134	48
DCTN 4	Hs	NT_034779	49
DCTN 5	Mm	NT_036652	50
DCTN 6	Mm	NW_000340	51
DCTN 6	Hs	NT_007995	52
ARP1	Mm	NW_000148	53
ARP1	Hs	AL121928	54
ARP11	Mm	NW_000053	55
ARP11	Hs	AC005586	56
HAP1	Mm	NT_033680	57
HAP1	Hs	NT_010840	58
CLIP-170	Mm	NW_000236	59
CLIP-170	Hs	NT_009438	60

* Mouse Genome Informatics Tool of the Jackson Laboratory Accession No.

Table 26. Cytoplasmic dynein intermediate chain1 amino acid sequence (SEQ ID NO.: 61)

5

Gen Bank Accession No.: NP_034193.1(mouse)

MSDKSDLKAELEKKQRLAQIREKKRKEEERKKKEADMQQKEPVQDDSDLDRKRRETEALLQSIGIS
 PEPPLVPTPMSPPSSKSVSTPSDAGSQDSGLGPLTRTLQWDTDPSVLQLQSDSELGRRHLKLGVSQVTKQ
 10 VDFLPREVVSYSKETQTPLATHQSEDEDEEMVEPKIGHDSELENQEKQETKEAPPRELTEEEKQOI
 LHSEEFLLIFFDRTIRVIERALAEDSDIFFDYSGRELEEKDGDVQAGANLSFNRQFYDEHWSKHRVVTM
 DWSLQYPELMVASYSNNEDAPHEPDGVALVWNMFKKTTPEYVFHCQSSVMSVCFARFHPNLVVGGTYS
 GQIVLWDNRSHRRTPVQRTPLSAAATHPVYCVNVVGTHNARNLITVSTDGKMCSWSLDMLSTPQESME
 LVYNKSKPVAVTGMAFPTGDVNNFVVGSEEGTVYTACRHGSKAGIGEVFEGHQGPVTGINCHMAVGPID
 15 FSHLFVTSSFDWTVKLWTTKHNKPVYSSDNADYVYDVMWSPVHPALFACVDGMGRDLWNLNSDTEVP
 TASVAIEGASALNRVRWAQGGKEVAVGDSEGRWIYDVGELAVPHNDEWTRFARTLVEIRANRADSEEE
 GAVELAA

Table 27. Cytoplasmic dynein intermediate chain1 amino acid sequence (SEQ ID NO.: 62)

20

Gen Bank Accession No.: NP_004402.1(human)

MSDKSDLKAELEKQRLAQIREKKRKEEERKKKEADMQQKKEPVQDDSDLDKRRRETEALLQSIGIS
 PEPPLVQPLHFLTWDTCYFHYLVPTPMSPPSSKSVSTPSEAGSQDSDLGPLTRTLQWDTDPSVLQLQSD
 SELGRRHLKLGVSQVDFLPREVVSYSKETQTPLATHQSEDEEDEEMVESKVGQDSELENQDKKQE
 5 VKEAPPRELTEEEKQQLHSEEFLLFFDRTIRVIERALAEDSDIFFDYSGRELEEKDGDVQAGANLSFN
 RQFYDEHWSKHRVTCMDWSLQYPELMVASYNNEADAPHEPDGVALVWNMKFKKTTPEYVFHCQSSVMS
 VCFARFHPNLVGGTYSGQIVLWDNRSHRTPVQRTPLSAAATHPVYCVNVVGTQNAHNLTIVSTDGK
 MCSWSLDMSTPQESMELVYNKSKPVAVTGMAFPDGDVNNFVVGSEEGTVYTACRHGSKAGIGEVFEGH
 QGPVTGINCHMAVGPIDFSHLFTSSFDWTVKLWTTKHNKPLYSFEDNADYVDVMWSPVHPALFACVD
 10 GMGRDLWNLNNDTEVPTASVAIEGASALNRVRWAQAGKEVAVGDSEGRIVYDVGELAVPHNDEWTRF
 ARTLVEIRANRADSEEGTVELSA

Table 29. Cytoplasmic dynein intermediate chain1 amino acid sequence (SEQ ID NO.: 63)

15

Gen Bank Accession No.: NP_062107.1(rat)

MSDKSDLKAELEKQRLAQIREKKRKEEERKKKEADMQQKKEPVQDDSDLDKRRRETEALLQSIGIS
 PEPPLVQPLHFLTWDTCYFHYLVPTPMSPPSSKSVSTPSEAGSQDDLGLTRTLQWDTDPSVLQLQSDSE
 20 LGRRNLNKLGVSKVTQVDFLPREVVSYSKETQTPLATHQSEDEEDEEMVEPKVGHDSLENQDKKQETK
 EAPPRELTEEEKQQLHSEEFLLFFDRTIRVIERALAEDSDIFFDYSGRELEEKDGDVQAGANLSFNQ
 FYDEHWSKHRVTCMDWSLQYPELMVASYSNNEADAPHEPDGVALVWNMKFKKTTPEYVFHCQSSVMSVC
 FARFHPNLVGGTYSGQIVLWDNRSHRTPVQRTPLSAAATHPVYCVNVVGTQNAHNLTIVSTDGKMC
 SWSLDMSTPQESMELVYNKSKPVAVTGMAFPDGDVNNFVVGSEEGTVYTACRHGSKAGIGEVFEGHQG
 25 PVTGINCHMAVGPIDFSHLFTSSFDWTVKLWTTKHNKPLYSFEDNADYVDVMWSPVHPALFACVDGM
 GRDLWNLNNSDTEVPTASVAIEGAYALNRVRWAQGGKEVAVGDSEGRIVIYDVGELAVPHNDEWTRFAR
 TLVEIRANRADSEEGAVELAA

Table 30. Cytoplasmic dynein intermediate chain 2 amino acid sequence (SEQ ID NO.: 64)

30

Gen Bank Accession No.: NP_034194.1(mouse)

MSDKSDLKAELEKQRLAQIREKKRKEEERKKKETDQKKEAAVSVQEEEDLEKKRREAEALLQSMGL
 35 TTDSPIVPPMSPSSKSVSTPSEAGSQDSDGAVGSRGPIKLGMAKITQVDFPPREIVTYTKETQTPV
 TAQPKDEDEEEDDVATPKPPVEPEEEKTLKKDEENDSKAPPHELTEEEKQQLHSEEFLLFFDHSTRIV
 ERALSEQINIFFDYSGRDLEDKEGEIQAGAKLSLNQFFDERWSKHRVVSCLDWSSQYPELLVASYNNE
 EEAPHEPDGVALVWNMKYKKTTPYVFHCQSAVMSATFAKFHPNLVGGTYSGQIVLWDNRNKRTPVQ
 RTPLSAAATHPVYCVNVVGTQNAHNLTIVSTDGKICSWSLDMLSHPDQSMELVHKQSKAVAVTSMSPF
 40 VGDVNNFVVGSEEGSVYTACRHGSKAGISEMFEGHQGPITGIHCHAAVAVDFSHLFTSSFDWTVKLW

TTKNNKPLYSFEDNSDYVDVMWSPTHPALFACVDGMGRDLWNLNNDTEVPTASISVEGNPALNRVRW
THSGREIAVGDSSEGQIVIIYDVGEQIAVPRNDEWARFGRTLAEINANRADEEEEAATRIPA

Table 31. Cytoplasmic dynein intermediate chain 2 amino acid sequence (SEQ ID NO.: 65)

Gen Bank Accession No.: NP_001369.1(human)

MSDKSELKAELERKKQRLAQIREKKRKEEERKKKETDQKKEAVAPVQEEEDLEKKRREAEALLQSMGL
TPESPIVFSEYWVPPMSPSSKSVSTPSEAGSQDSGDGAVGSRTLHWDTDPSVLQLHSDSDLGRGPIKL
GMAKITQVDFPPREIVTYTKETQTPVMAQPKEDDEEDDDVAPKPIEPEEEKTLKKDEENDSKAPPHE
LTEEEKQQILHSEEFLSFFDHSTRIVERALSEQINIFFDYSGRDLEDKEGEIQAGAKLSLNRQFFDERW
SKHRVVSCLDWSSQYPELLVASYNNEEDAPHEPDGVALVWNMXYKTTPEYVFHCQSAVMSATFAKFHP
NLVVGTTYSGQIVLWDNRSNKRTPVQRTPLSAAAHTHPVYCVNVVGTQNAHNLISISTDGKICSWSLDM
LSHPQDSMELVHKQSKAVAVTSMSFPVGDVNNFVVGSEEGSVYTACRHGSKAGISEMFEGHQGPITGIH
CHAAVGAVDFSHLFVTSSFDWTVKLWTTKNNKPLYSFEDNADYVDVMWSPTHPALFACVDGMGRDLW
NLNNDTEVPTASISVEGNPALNRVRWTHSGREIAVGDSSEGQIVIIYDVGEQIAVPRNDEWARFGRTLAEI
NANRADEEEEAATRIPA

Table 32. Cytoplasmic dynein intermediate chain 2 amino acid sequence (SEQ ID NO.: 66)

Gen Bank Accession No.: NP_446332.1(rat)

MSDKSELKAELERKKQRLAQIREKKRKEEERKKKETDQKKEAAVSVQEEEDLEKKRREAEALLQSMGL
TTDSPIVFSEHWVPPMSPSSKSVSTPSEAGSQDSGDGAVGSRTLHWDTDPSALQLHSDSDLGRGPIKL
GMAKITQVDFPPREIVTYTKETQTPVTAQPKEDDEEEDDVAAPKPPVEPEEEKILKKDEENDSKAPPHE
LTEEEKQQILHSEEFLSFFDHSTRIVERALSEQINIFFDYSGRDLEDKEGEIQAGAKLSLNRQFFDERW
SKHRVVSCLDWSSQYPELLVASYNNEEAPHEPDGVALVWNMXYKTTPEYVFHCQSAVMSATFAKFHP
NLVVGTTYSGQIVLWDNRSNKRTPVQRTPLSAAAHTHPVYCVNVVGTQNAHNLISISTDGKICSWSLDM
LSHPQDSMELVHKQSKAVAVTSMSFPVGDVNNFVVGSEEGSVYTACRHGSKAGISEMFEGHQGPITGIH
CHAAVGAVDFSHLFVTSSFDWTVKLWSTKNNKPLYSFEDNSDYVDVIGSPTHPALFACVDGMGRDLW
NLNNDTEVPTASISVEGNPALNRVRWTHSGREIAVGDSSEGQIVIIYDVGEQIAVPRNDEWARFGRTLAEI
NASRADAEEEAATRIPA

35

Table 33. DCTN1; Dynactin subunit p150 amino acid sequence (SEQ ID NO.: 67)

Gen Bank Accession No.: NP_031861.1 p150 (mouse)

MAQSRHRMSSRTPSGSRMSTEASARPLRVGSRVEVIGKGRGTVAIVGATLFATGKWWGVILDEAKGKN
 DGTVQGRKYFTCDEGHGIFVRQSQIQVFEDGADTTSPETPDSSASKVLKREGADAAAKTSKLRGLKPKK
 APTARKTTTTRRPKPTRPASTGVAGPSSSLGPSGSASAGELSSSEPSTPAQTPLAAPIIPTPALTSFGAA
 PPLPSPSKEEEGLRAQVRDLEEKLETLLRLKRSEDKAKLKELEKHKIQLEQVQEWKSKMQEQQADLQRRRL
 5 KEARKEAKEALEAKERYMEEMADTADAIEMATLDKEMAEERAESLQQEVEALKERVDELTTDLEILKAE
 IEEKGSDGAASSYQLKQLEEQNARLKDALVRMRDLSSEKQEHVKLQKLMEKKNQEELEVVRRQRRERLQE
 ELSQAESTIDELKEQVDAALGAEEMVEMLTDRNLNLEEKVRELRETVDLEAMNEMNDXLQENARETEL
 ELREQLDMAGARVREAQKRVEAAQETVADYQQTICKYRQLTAHLQDVNRELTNQQEASVERQQQPPPET
 FDFKIKFAETKAHAKAIEMELRQMEVAQANRHMSLLTAFMPDSFLRPGGDHDCVLLVLLMPRLICKAEL
 10 IRKQAEQKFDLSENCSESRPGLRGAAGEQLSFAAGLVYSLSLQATLHRYEHALSQCSVDVYKKGVS LYP
 EMSAHERSLDFLIELLHKDQLDET VNVEPLNKGIKYYQHLYRIHLAEQPEDSTMQLADHIKFTQSALDC
 MGVEVGRRLRAFLQGGQEATDIALLLRDLETSCSDTRQFCKKIRRRMPGTDAPGIPAALAFGSQVSDTLL
 DCRKHLTWVAVLQEVAAAAQLIAPLAENEGLPVAALEELAFKASEQIYGSPSSSPYECLRQSC TILI
 STMNKLATAMQEGEYDAERPPSKPPVELRAAALRAEITDAEGLGLKLEDRETVIKELKSLKIKGEEL
 15 SEANVRXSLLEKKLDSAAKDADERIEKVQTRLDETQTLRKKEKDFEETMDALQADIDQLEAEKAE LKQ
 RLNSQSKRTIEGLRGPPPSGIATLVSGIAGEEPQRRGAPGAPGALPGPGLVKDSPLLLQQISAMRLHI
 SQLQHENSILRGAQMKA SLAALPPLHVAKLSLPPHEGPGGNLVAGALYRKTSQLEKLNQLSTH THVVD
 ITRSSPAAKSPSAQLMEQVAQLKSLSDTIEKLKDEV LKETVTQRP GATVPTDFATFPSSAFRAKEEQQ
 DDTVYMGKVTFS CAAGLGQRHRLVLTQEQLHQLHSRLIS

20

Table 34. DCTN1; Dynactin subunit p150 amino acid sequence (SEQ ID NO.: 68)

Gen Bank Accession No.: AAD55811.1(human)

25 MAQSKRHVYSRTPSGSRMSAEASARPLRVGSRVEVIGKGRGTVAIVGATLFATGKWWGVILDEAKGKN
 DGTVQGRKYFTCDEGHGIFVRQSQIQVFEDGADTTSPETPDSSASKVLKREGD TTTAKTSKLRGLKPKK
 APTARKTTTTRRPKPTRPASTGVAGASSSLGPSGSASAGELSSSEPSTPAQTPLAAPIIPTPVLTSPGAV
 PPLPSPSKEEEGLRAQVRDLEEKLETLLRLKRAEDKAKLKELEKHKIQLEQVQEWKSKMQEQQADLQRRRL
 KEARKEAKEALEAKERYMEEMADTADAIEMATLDKEMAEERAESLQQEVEALKERVDELTTDLEILKAE
 30 IEEKGSDGAASSYQLKQLEEQNARLKDALVRMRDLSSEKQEHVKLQKLMEKKNQEELEVVRRQRRERLQE
 ELSQAESTIDELKEQVDAALGAEEMVEMLTDRNLNLEEKVRELRETVDLEAMNEMNDELQENARETEL
 ELREQLDMAGARVREAQKRVEAAQETVADYQQTICKYRQLTAHLQDVNRELTNQQEASVERQQQPPPET
 FDFKIKFAETKAHAKAIEMELRQMEVAQANRHMSLLTAFMPDSFLRPGGDHDCVLLVLLMPRLICKAEL
 IRKQAEQKFELSENCSESRPGLRGAAGEQLSFAAGLVYSLSLQATLHRYEHALSQCSVDVYKKGVS LYP
 35 EMSAHERSLDFLIELLHKDQLDET VNVEPLTKAIKYYQHLYSIHLAEQPEDCTMQLADHIKFTQSALDC
 MSVEVGRRLRAFLQGGQEATDIALLLRDLETSCSDIRQFCKKIRRRMPGTDAPGIPAALAFGPQVSDTLL
 DCRKHLTWVAVLQEVAAAAQLIAPLAENEGLLVAALEELAFKASEQIYGT PSSSPYECLRQSCNILI
 STMNKLATAMQEGEYDAERPPSKPPVELRAAALRAEITDAEGLGLKLEDRETVIKELKSLKIKGEEL
 SEANVRLSLEKKLDSAAKDADERIEKVQTRLEETQALLRKKEKEFEETMDALQADIDQLEAEKAE LKQ
 40 RLNSQSKRTIEGLRGPPPSGIATLVSGIAGEEQRGAIPGQAPGSVPGPGLVKDSPLLLQQISAMRLHI
 SQLQHENSILKGAQMKA SLASLPPLVAKLSHEGPGSEL PAGALYRKTSQLETLNQLSTH THVVDITR

TSPAAKSPSAQLMEQVAQLKSLSDTVEKLKDEVLKETVSRPGATVPTDFATFPSSAFLRAKEEQDDT
VYMGKVTFSCAAGFGQRHRLVLTQEQLHQLHSRLIS

Table 35. DCTN1; Dynactin subunit p150 amino acid sequence (SEQ ID NO.: 69)

5

Gen Bank Accession No.: NP_077044.1 (rat)

MAQSKRHMYNRTPSGRMSTEASARPLRVGSRVEIGKGRGTVAIVGATLFATGKWVGVLDEAKGKN
DGTVQGRKYFTCDEGHGIFVRQSQIQVFEDGADTTSPETPDSSASKILKREGADAAAKTSKLRGLKPKK
10 APTARKTTTTRPKPTRPASTGVAGPSSSLGPSGSASAGELSSSEPSTPAQTPLAAPIIPTPALTSFGAA
PPLPSPSKEEEGLRDQVRDLEEKLETLRLKRSDEKAKLKELEKHKIQLEQVQEWKSKMQEQQADLQRR
KEAKEAKEALEAKERYMEEMADTADAIEMATLDKEMAEERAESLQEQVEALKERVDELTTDLEILKAEI
EEKSGDGAASSYQLKQLEEQNARLKDALVRMRDLSSSEKQEHVKLQKLMKKNQELEVVRRQRRERLQEE
LSQAESTIDELKEQVDAALGAEMVEMLTDRNLNLEEKVRELRETVGDLEAMNEMNDELQENARETELE
15 LREQDMAGARVREAQKRVEAAQETVADYQQTIKKYRQLTAHLQDVNRELTNQQEASVERQQQPPPETF
DFKIKFAETKAHAKAIEMELRQMEVAQANRHMSLLTAFMPDSFLRPGGDHDCVLVLLLMPRLICKAELI
RKQAQEKFDLSENCSESRPGLRGAAGEQLSFAAGLVYSLSLQATLHRYEHALSQCSVDVYKKGVSGLYPE
MSAHERSLDFLIELLHKDQLDET VNVEPLTKAIKYYQHLYSIHLAEQPEESTMQLADHIKFTQSALDCM
SVEVGRRLRAFLQGGQEATDIALLLRDLETSCSDIRQFCKKIRRRMPGTDAPGIPAAALFGSQVSDTLDD
20 CRKHLTWVAVLQEVAAAAAQLIAPLAENEGLPVAALEELAFKASEQIYGSPSSSPYECLRQSCSILIS
TMNKLATAMQEGEYDAERPPSKPPPVEPWPAALRAEITDAEGLGLKLEDRETVIKELKKSILKIKGEELS
EANVRLSILLEKKLDSAAKDADERIEKVQTRLEETQTLLRKKKEFEETMDALQADIDQLEAEKTELKQR
LNSQSKRTIEGLRPPPSGIATLVSGIAGEEQQRGGTPGQAPGALPGPGPVKDSPLLLQQISAMRLHIS
QLQHENSILRGAQMKASLAALPPLHVAKFSLPPHEGPGGNLLSGALYRKTSQLEKLNQLSTYTHVVDI
25 TRSSPACKSPSAQLMEQVAQLKSLSDTIEKLKDEVLKETVTQRPATVPTDFATFPSSAFLRAKEEQDD
DTVYMGKVTFSCAAGLQGRHRLVLTQEQLHQLHGRLLIS

Methods of Screening for Disease-Relevant Mutations in Proteins, which are a

30 **Subunit of the Dynactin/Dynein Complex**

The invention *inter alia* relates to the identification of a protein or a nucleic acid marker indicative of an increased risk of a mammalian subject, particularly a human subject, of developing a neurodegenerative disease or of an association of a neurodegenerative disease in a mammalian subject, particularly a human subject, with
35 a mutation which leads to a neurodegenerative disease.

Preferably the above-mentioned neurodegenerative diseases are Alzheimer's Disease, Parkinson's Disease, or Huntington's Disease. In a preferred embodiment the neurodegenerative disease is a motoneuron degenerative disease. In an even more preferred embodiment, the motoneuron degenerative disease is Amyotrophic Lateral Sclerosis, Spinal Muscular Atrophy, Bulbo-Spinal Muscular Atrophy, Progressive Bulbar Palsy, Progressive Muscular Atrophy, and Primary Lateral Sclerosis.

In a preferred embodiment, the mutation selectively affects cell types associated with or suspected to be involved in neurodegenerative diseases. In a more preferred embodiment, these cell types are motoneurons. In an even more preferred embodiment, the motoneurons are α -motoneurons. In another preferred embodiment, the mutation affects cellular processes, e.g., neuronal axonal transport, cellular transport, proliferation, differentiation, or apoptosis. In another preferred embodiment, the mutation leads to a deficiency or malfunction, e.g. an alteration in the functional interaction or a disruption of the dynactin/dynein complex in neurons, preferably in motoneurons.

On a molecular basis, said mutation results in a deletion of an amino acid or an insertion of an additional amino acid not normally present in the amino acid sequence of the protein encoded by said allele or in a substitution by another amino acid of an amino acid encoded by said allele. In a preferred embodiment, said deletion, substitution, or insertion is encoded by both alleles of the gene coding for said protein and/or occurs in an evolutionary conserved region of said protein. In another preferred embodiment, the substitution of an amino acid which is identical between the corresponding mouse and human, preferably between the corresponding mouse, rat, and human protein encoded by said allele, by another amino acid, preferably by a non-conservative amino acid and/or the substitution of the amino acid occurs by a naturally occurring amino acid.

In another embodiment of the invention, the amino acid affected by the mutation is encoded by a codon within the open reading frame of a nucleic acid sequence, preferably by an exon, as set forth in the following tables.

Table 36. Mouse cytoplasmic dynein intermediate chain1 (GenBank Acc. No.: NM 010063) (SEQ ID NO.: 70)

Exon1 (nucleotide)

5 ATGTCCTGACAAGAGCGACCTAAAGGCCGAGCTGGAGCGCAAAAAGCAGCGCTTAGCACAGATAAGAGAG
GAGAAGAAACGGAAGGAAGAGGAGAGGAAGAAGAAAGAG

Table 37. Mouse cytoplasmic dynein intermediate chain1 (GenBank Acc. No.: NM 010063) (SEQ ID NO.: 71)

10

Exon2 (nucleotide)

GCAGATATGCAGCAAAAGAAAGAGCCCGTTCAAGATGACTCCGATCTGGATCGCAAACGACGGGAGACA
GAAGCTTTGCTTCAGAGCATTGGCATATCACCGGAGCCCCCTCTAG

15 **Table 38. Mouse cytoplasmic dynein intermediate chain1 (GenBank Acc. No.: NM 010063) (SEQ ID NO.: 72)**

Exon3 (nucleotide)

20 TCCCAACCCCTATGTCTCCCTCTCGAAATCAGTGAGCACTCCAGTGATGCTGGAAGCCAAGACTCGG
GCGATCTGGGGCCATTAACAAG

Table 39. Mouse cytoplasmic dynein intermediate chain1 (GenBank Acc. No.: NM 010063) (SEQ ID NO.: 73)

25 Exon4 (nucleotide)

GACCCTGCAGTGGGACACAGACCCCTCAGTGCTCCAGCTGCAGTCAGACTCAGAACTTGG

Table 40. Mouse cytoplasmic dynein intermediate chain1 (GenBank Acc. No.: NM 010063) (SEQ ID NO.: 74)

30

Exon1 to 4 (nucleotide)

ATGTCCTGACAAGAGCGACCTAAAGGCCGAGCTGGAGCGCAAAAAGCAGCGCTTAGCACAGATWAGAGAG
GAGAAGAAACGGAAGGAAGAGGAGAGGAAGAAGAAAGAGGCAGATATGCAGCARAAGAAAGAGCCCGTT
CAAGATGACTCCGATCTGGATCGCAAACGACGGGAGACAGAAGCTTTGCTTCAGAGCATTGGCATATCA
35 CCGGAGCCCCCTCTAGTCCCAACCCCTATGTCTCCCTCTTCGAAATCAGTGAGCACTCCAGTGATGCT
GGAAGCCAAGACTCGGGCGATCTGGGGCCATTAACAAGGACCCCTGCAGTGGGACACAGACCCCTCAGTG
CTCCAGCTGCAGTCAGACTCAGAACTTGG

Table 41. Mouse cytoplasmic dynein intermediate chain1 (GenBank Acc. No.: NM 010063) (SEQ ID NO.:75)

Exon5 (nucleotide)

5 GAGACGACTGCACAAGCTGGGCGTGTCAAAGGTGACCCAGGTGGATTTCCTGCCTAGGGAAGTAGTATC
CTACTCCAAGGAGACACAGACTCCTCTTGCAACACATCAGTCTGAAG

Table 42. Mouse cytoplasmic dynein intermediate chain1 (GenBank Acc. No.: NM 010063) (SEQ ID NO.: 76)

10

Exon7 (nucleotide)

CCCCCCAAGAGAGTTGACGGAGGAAGAAAACAGCAGATCCTGCACTCAGAAGAATTCCTCATCTTCT
TTGACCGGACAATCCGAGTAATTGAAAGAGCTCTTGCAAGGACTCGGACATCTTTTTTGACTACAGCG
GTCGAGAGCTGGAGGAGAAAGATGG

15

Table 43. Mouse cytoplasmic dynein intermediate chain1 (GenBank Acc. No.: NM 010063) (SEQ ID NO.: 77)

Exon8 (nucleotide)

20 GGATGTGCAGGCTGGAGCCAACCTGTCTTTCAACCGTCAGTTCTACGATGAACATTGGTCTAAGCATCG
GGTGGTCACATGTATGGACTGGTCTCTCCAG G

Table 44. Mouse cytoplasmic dynein intermediate chain1 (GenBank Acc. No.: NM 010063) (SEQ ID NO.: 78)

25

Exon9 (nucleotide)

TACCCTGAGCTGATGGTTGCTTCTTATAGCAACAACGAAGATGCTCCCCACGAGCCAGATGGAGTGGCC
TTGGTTTGGAACATGAAGTTCAAGAAAACCACACCAGAATATGTCTTCCACTGTCAG

Table 45. Mouse cytoplasmic dynein intermediate chain1 (GenBank Acc. No.: NM 010063) (SEQ ID NO.: 79)

Exon7 to 9 (nucleotide)

35 CCCCCAAGAGAGTTGACGGAGGAAGAAAACAGCAGATCCTGCACTCAGAAGAATTCCTCATCTTCT
TTGACCGGACAATCCGAGTAATTGAAAGAGCTCTTGCAAGGACTCGGACATCTTTTTTGACTACAGCG
GTCGAGAGCTGGAGGAGAAAGATGGGGATGTGCAGGCTGGAGCCAACCTGTCTTTCAACCGTCAGTTCT
ACGATGAACATTGGTCTAAGCATCGGGTGGTCACATGTATGGACTGGTCTCTCCAGGTACCCTGAGCTG
ATGGTTGCTTCTTATAGCAACAACGAAGATGCTCCCCACGAGCCAGATGGAGTGGCCTTGGTTTGGAAAC
ATGAAGTTCAAGAAAACCACACCAGAATATGTCTTCCACTGTCAG

Table 46. Human cytoplasmic dynein intermediate chain1 (GenBank NM_004411) (SEQ ID NO.: 80)

5 Exon1 (nucleotide)

TCCAAGGAAACCAACATGTCTGACAAAAGTGACTTAAAAGCTGAGCTAGAGCGCAAAAAGCAGCGCTTA
GCACAGATAAGAGAAGAGAAGAAACGGAAGGAAGAGGAGAGGAAAAAGAAAGAG

10 **Table 47. Human cytoplasmic dynein intermediate chain1 (GenBank NM_004411) (SEQ ID NO.: 81)**

Exon2 (nucleotide)

GCTGATATGCAGCAGAAGAAAGAACCCGTTCAAGGACGACTCTGATCTGGATCGCAAACGACGAGAGACA
GAGGCTTTGCTGCAAAGCATTGGTATCTCACCGGAGCCGCTCTAG

15

Table 48. Human cytoplasmic dynein intermediate chain1 (GenBank NM_004411) (SEQ ID NO.: 82)

Exon3 (nucleotide)

20 TGCAGCCGCTGCATTTTTTAACATGGGATACCTGTTATTTTCATTATTTAGTCCCAACCCCTATGTCTC
CCTCCTCGAAATCAGTGAGCACTCCAGTGAAGCTGGAAGCCAAGACTCAGGCGATCTGGGGCCATTAA
CAAG

25 **Table 49. Human cytoplasmic dynein intermediate chain1 (GenBank NM_004411) (SEQ ID NO.: 83)**

Exon4 (nucleotide)

GACCCTGCAGTGGGACACAGACCCCTCAGTGCTCCAGCTGCAGTCAGACTCAGAACTTGG

30 **Table 50. Human cytoplasmic dynein intermediate chain1 (GenBank NM_004411) (SEQ ID NO.: 84)**

Exon 1 to4 (nucleotide)

35 TCCAAGGAAACCAACATGTCTGACAAAAGTGACTTAAAAGCTGAGCTAGAGCGCAAAAAGCAGCGCTTA
GCACAGATAAGAGAAGAGAAGAAACGGAAGGAAGAGGAGAGGAAAAAGAAAGAGGCTGATATGCAGCAG
AAGAAAGAACCCGTTCAAGGACGACTCTGATCTGGATCGCAAACGACGAGAGACAGAGGCTTTGCTGCAA
AGCATTGGTATCTCACCGGAGCCGCTCTAGTGAGCCGCTGCATTTTTTAACATGGGATACCTGTTAT
TTTCATTATTTAGTCCCAACCCCTATGTCTCCCTCCTCGAAATCAGTGAGCACTCCAGTGAAGCTGGA

AGCCAAGACTCAGGCGATCTGGGGCCATTAACAAGGACCCTGCAGTGGGACACAGACCCTCAGTGCTC
CAGCTGCAGTCAGACTCAGAACTTGG

5 **Table 51. Human cytoplasmic dynein intermediate chain1 (GenBank
NM_004411) (SEQ ID NO.: 85)**

Exon5 (nucleotide)

AAGAAGACTGCATAAACTGGGCGTGTCAAAGGTCACCCAAGTGGATTTCCTGCCAAGGGAAGTAGTGTC
CTACTCAAAGGAGACCCAGACTCCTCTTGCCACGCATCAGTCTGAAG

10

**Table 52. Human cytoplasmic dynein intermediate chain1 (GenBank
NM_004411) (SEQ ID NO.: 86)**

15 Exon7 (nucleotide)

CCCCCTCCAAGAGAGTTGACAGAGGAAGAAAAACAGCAGATCCTTCATTCAGAGGAATTTCTCATCTTTT
TTGACCGGACAATACGGGTAATTGAAAGAGCCCTGGCTGAAGATCCGACATCTTTTTTGACTACAGCG
GCCGAGAGTTAGAGGAAAAGATGG

20 **Table 53. Human cytoplasmic dynein intermediate chain1 (GenBank
NM_004411) (SEQ ID NO.: 87)**

Exon8 (nucleotide)

GGATGTTCAGGCTGGAGCCAATCTTTCTTTCAATCGTCAGTTCTATGATGAACATTGGTCCAAGCATCG
25 AGTGGTCACTTGTATGGACTGGTCCCTCCAG

**Table 54. Human cytoplasmic dynein intermediate chain1 (GenBank
NM_004411) (SEQ ID NO.: 88)**

30 Exon9 (nucleotide)

TACCCTGAGCTGATGGTGGCTTCTTACAACAACATGAAGATGCTCCCATGAACCAGATGGAGTGGCC
TTGGTTTGGAAATGAAGTTTAAGAAAACCACACCAGAATACGTCTTCCACTGTCAG

35 **Table 55. Human cytoplasmic dynein intermediate chain1 (GenBank
NM_004411) (SEQ ID NO.: 89)**

Exon7 to 9 (nucleotide)

CCCCCTCCAAGAGAGTTGACAGAGGAAGAAAAACAGCAGATCCTTCATTCAGAGGAATTTCTCATCTTTT
TTGACCGGACAATACGGGTAATTGAAAGAGCCCTGGCTGAAGATCCGACATCTTTTTTGACTACAGCG

GCCGAGAGTTAGAGGAAAAAGATGGGGATGTTTCAGGCTGGAGCCAATCTTTCTTTCAATCGTCAGTTCT
ATGATGAACATTGGTCCAAGCATCGAGTGGTCACTTGTATGGACTGGTCCCTCCAGTACCCTGAGCTGA
TGGTGGCTTCTTACAACAACAATGAAGATGCTCCCATGAACCAGATGGAGTGGCCTTGGTTTGAACA
TGAAGTTTAAGAAAACCACACCAGAATACGTCTTCCACTGTCAG

5

Table 56. Mouse cytoplasmic dynein intermediate chain2 (GenBank Acc. No. NM 010064) (SEQ ID NO.: 90)

Exon2 (nucleotide)

10 GTCACAACCATGTCGGACAAAAGTGATTTAAAAGCTGAGTTGGAACGTAAGAAGCAACGGTTGGCCCAA
ATCAGAGAAGAAAAGAAGAGGAAAGAAGAGGAAAGGAAAAAAAAGGAA

Table 57. Mouse cytoplasmic dynein intermediate chain2 (GenBank Acc. No. NM 010064) (SEQ ID NO.: 91)

15

Exon3 (nucleotide)

ACTGATCAGAAGAAGGAAGCTGCTGTTTCTGTACAAGAAGAGTCTGATCTTGAAAAAAAAGAAGAGAA
GCTGAGGCATTGCTTCAAAGCATGGGACTAACTACGGACTCCCCATTG

20 **Table 58. Mouse cytoplasmic dynein intermediate chain2 (GenBank Acc. No. NM 010064) (SEQ ID NO.: 92)**

Exon4 (nucleotide)

TCCCTCCTCCTATGTCTCCATCTCCAAGTCGGTGAGCACGCCAAGTGAAGCTGGAAGCCAGGATTCTG
25 GAGATGGCGCCGTGGGATCTAG

Table 59. Mouse cytoplasmic dynein intermediate chain2 (GenBank Acc. No. NM 010064) (SEQ ID NO.: 93)

30 Exon5 (nucleotide)

ACGAGGACCTATTAAACTTGAATGGCCAAAATTACTCAAGTTGACTTCCCCCTCGAGAAATCGTCAC
ATACACAAAGGAACTCAGACCCCGGTACAGCTCAACCCAAAGAAG

35 **Table 60. Mouse cytoplasmic dynein intermediate chain2 (GenBank Acc. No. NM 010064) (SEQ ID NO.: 94)**

Exon2 to 5 (nucleotide)

GTCACAACCATGTCGGACAAAAGTGATTTAAAAGCTGAGTTGGAACGTAAGAAGCAACGGTTGGCCCAA
ATCAGAGAAGAAAAGAAGAGGAAAGAAGAGGAAAGGAAAAAAAAGGAACTGATCAGAAGAAGGAGCT

GCTGTTTCTGTACAAGAAGAGTCTGATCTTGAAAAAAGAAGAGAAGCTGAGGCATTGCTTCAAAGC
ATGGGACTAACTACGGACTCCCCTATTGTCCCTCCTCCTATGTCTCCATCCTCCAAGTCGGTGAGCAG
CCAAGTGAAGCTGGAAGCCAGGATTCTGGAGATGGCGCCGTGGGATCTAGACGAGGACCTATTAACTT
GGAATGGCCAAAATTACTCAAGTTGACTTTCCCCCTCGAGAAATCGTCACATACACAAAGGAACTCAG
5 ACCCCGGTTACAGCTCAACCCAAAGAAG

Table 61. Mouse cytoplasmic dynein intermediate chain2 (GenBank Acc. No. NM 010064) (SEQ ID NO.: 95)

10 Exon7 (nucleotide)
CTCCACCTCATGAAGTAACTGAAGAAGAAAAGCAACAGATTTTACACTCAGAAGAATTTTAAGTTTCT
TTGACCATTCTACGAGAATTGTAGAAAGAGCCCTTTCTGAGCAGATTAACATCTTCTTTGACTACAGTG
GGAGAGACTTGGAAAGACAAAGAAGG

15 **Table 62. Mouse cytoplasmic dynein intermediate chain2 (GenBank Acc. No. NM 010064) (SEQ ID NO.: 96)**

Exon8 (nucleotide)
GGAGATTCAAGCAGGTGCTAAGCTGTCATTAAATCGACAGTTCTTTGATGAGCGTTGGTCAAAGCATCG
20 AGTTGTTAGTTGTTTGGATTGGTCATCCCAG

Table 63. Mouse cytoplasmic dynein intermediate chain2 (GenBank Acc. No. NM 010064) (SEQ ID NO.: 97)

25 Exon9 (nucleotide)
TATCCAGAATTACTTGTGGCTTCCTATAATAACAATGAAGAGGCTCCTCATGAGCCTGATGGTGTGGCC
CTCGTGTGGAATATGAAGTACAAAAAACTACCCAGAGTATGTGTTCCACTGCCAG

30 **Table 64. Mouse cytoplasmic dynein intermediate chain2 (GenBank Acc. No. NM 010064) (SEQ ID NO.: 98)**

Exon7 to 9 (nucleotide)
CTCCACCTCATGAAGTAACTGAAGAAGAAAAGCAACAGATTTTACACTCAGAAGAATTTTAAGTTTCT
TTGACCATTCTACGAGAATTGTAGAAAGAGCCCTTTCTGAGCAGATTAACATCTTCTTTGACTACAGTG
35 GGAGAGACTTGGAAAGACAAAGAAGGGGAGATTCAAGCAGGTGCTAAGCTGTCATTAAATCGACAGTTCT
TTGATGAGCGTTGGTCAAAGCATCGAGTTGTTAGTTGTTTGGATTGGTCATCCCAGTATCCAGAATTAC
TTGTGGCTTCCTATAATAACAATGAAGAGGCTCCTCATGAGCCTGATGGTGTGGCCCTCGTGTGGAATA
TGAAGTACAAAAAACTACCCAGAGTATGTGTTCCACTGCCAG

Table 65. Human cytoplasmic dynein intermediate chain2, transcript 2
(GenBank Acc. No. NM 001378) (SEQ ID NO.: 99)

Exon1 (nucleotide)

5 ATGTCAGACAAAAGTGAATTAAAGGCTGAGTTGGAACGTAAGAAGCAGCGACTGGCCCCAAATCAGAGAG
GAAAAGAAGAGAAAAGAAGAAGAAAGGAAAAAAGAAACAG

Table 66. Human cytoplasmic dynein intermediate chain2, transcript 2
(GenBank Acc. No. NM 001378) (SEQ ID NO.: 100)

10

Exon2 (nucleotide)

ACCAGAAGAAGGAAGCTGTTGCTCCTGTGCAAGAAGAATCAGATCTTGAAAAAAGGAGAGAAGCTG
AAGCATTGCTTCAAAGCATGGGGCTAACTCCAGAATCCCCATTG

15 **Table 67. Human cytoplasmic dynein intermediate chain2 (GenBank Acc. No.**
NM 001378) (SEQ ID NO.: 101)

Exon3 (nucleotide)

TCCCTCCTCCTATGTCTCCATCCTCCAAATCTGTGAGCACTCCAAGTGAAGCTGGAAGCCAAGACTCTG
20 GAGATGGCGCCGTGGGATCTAG

Table 68. Human cytoplasmic dynein intermediate chain2 (GenBank Acc. No.
NM 001378) (SEQ ID NO.: 102)

25 Exon4 (nucleotide)

ACGAGGACCTATTAACTTGAATGGCTAAAATCACGCAAGTCGACTTTCCTCCTCGAGAAATTGTCAC
GTATACAAAGGAACTCAGACTCCAGTTATGGCTCAACCCAAAGAAG

30 **Table 69. Human cytoplasmic dynein intermediate chain2 (GenBank Acc. No.**
NM 001378) (SEQ ID NO.: 103)

Exon1 to 4 (nucleotide)

ATGTCAGACAAAAGTGAATTAAAGGCTGAGTTGGAACGTAAGAAGCAGCGACTGGCCCCAAATCAGAGAG
GAAAAGAAGAGAAAAGAAGAAGAAAGGAAAAAAGAAACAGACCAGAAGAAGGAAGCTGTTGCTCCT
35 GTGCAAGAAGAATCAGATCTTGAAAAAAGGAGAGAAGCTGAAGCATTGCTTCAAAGCATGGGGCTA
ACTCCAGAATCCCCATTGTCCCTCCTCCTATGTCTCCATCCTCCAAATCTGTGAGCACTCCAAGTGAA
GCTGGAAGCCAAGACTCTGGAGATGGCGCCGTGGGATCTAGACGAGGACCTATTAACTTGAATGGCT
AAAATCACGCAAGTCGACTTTCCTCCTCGAGAAATTGTCACGTATACAAAGGAACTCAGACTCCAGTT
ATGGCTCAACCCAAAGAAG

Table 70. Human cytoplasmic dynein intermediate chain2 (GenBank Acc. No. NM 001378) (SEQ ID NO.: 104)

5 Exon6 (nucleotide)
CTCCCCCTCATGAGCTGACTGAAGAAGAAAAGCAACAAATCCTGCACTCTGAGGAATTTTAAAGTTTCT
TTGACCATTCTACAAGAATTGTAGAAAGAGCTCTTTCTGAGCAGATTAACATCTTCTTTGACTATAGTG
GGAGAGATTTGGAAGACAAAGAAGG

10 **Table 71. Human cytoplasmic dynein intermediate chain2 (GenBank Acc. No. NM 001378) (SEQ ID NO.: 105)**

Exon7 (nucleotide)
AGAGATTCAAGCAGGTGCTAACTGTCATTAAATCGACAATTTTTTGACGAACGTTGGTCAAAGCATCG
15 GGTGGTTAGTTGTTTGGATTGGTCATCTCAG

Table 72. Human cytoplasmic dynein intermediate chain2 (GenBank Acc. No. NM 001378) (SEQ ID NO.: 106)

20 Exon8 (nucleotide)
TATCCGGAGTTACTCGTGGCTTCTATAACAACAATGAAGATGCCCTCATGAGCCTGATGGTGTGGCC
CTTGATGGAATATGAAATACAAAAAACTACCCAGAGTATGTGTTTCACTGCCAG

25 **Table 73. Human cytoplasmic dynein intermediate chain2 (GenBank Acc. No. NM 001378) (SEQ ID NO.: 107)**

Exon6 to 8 (nucleotide)
CTCCCCCTCATGAGCTGACTGAAGAAGAAAAGCAACAAATCCTGCACTCTGAGGAATTTTAAAGTTTCT
TTGACCATTCTACAAGAATTGTAGAAAGAGCTCTTTCTGAGCAGATTAACATCTTCTTTGACTATAGTG
30 GGAGAGATTTGGAAGACAAAGAAGGAGAGATTCAAGCAGGTGCTAACTGTCATTAAATCGACAATTTT
TTGACGAACGTTGGTCAAAGCATCGGGTGGTTAGTTGTTTGGATTGGTCATCTCAGTATCCGGAGTTAC
TCGTGGCTTCTATAACAACAATGAAGATGCCCTCATGAGCCTGATGGTGTGGCCCTTGATGGAATA
TGAAATACAAAAAACTACCCAGAGTATGTGTTTCACTGCCAG

35

Table 74. Mouse Dctn1 (P150) protein (SEQ ID NO.: 108)

Exon1 (nucleotide)

-134-

ATGGCCCAGAGCAGGAGGCACATGTCCAGTCGGACGCCGAGTGGCAGCAGGATGAGTACGGAGGCAAGC
GCCCCGCCCCCTGCGGGTTGGCTCCCGCGTGGAGGTGATTGGGAAGGGCCACCGAGGCACTGTGGCCTAT
GTTGGAGCCACACTCTTTGCCACTGGCAAATGGGTGGGCGTGATTCTGGATGAAGCAAAAGGCAAAAAT
GATGGCACTGTCCAGGGAAGGAAGTATTTACATGTGATGAAGGCCACGGCATCTTTGTACGCCAGTCC
5 CAG

Table 75. Mouse Dctn1 (P150) protein (SEQ ID NO.: 109)

Exon2 (nucleotide)
10 ATCCAAGTATTTGAAGATGGAGCAGATACTACTTCCCCAGAGACTCCTGATTCTTCTGCTTCAAAGGTC
CTCAAGAGAG

Table 76. Mouse Dctn1 (P150) protein (SEQ ID NO.: 110)

15 Exon3 (nucleotide)
AGGGAGCCGATGCAGCTGCAAAGACCAGCAAAC TG

Table 77. Mouse Dctn1 (P150) protein (SEQ ID NO.: 111)

20 Exon4 (nucleotide)
ACCACAAC TCGACGGCCCAAG

Table 78. Mouse Dctn1 (P150) protein (SEQ ID NO.: 112)

25 Exon1 to 4 (nucleotide)
ATGGCCCAGAGCAGGAGGCACATGTCCAGTCGGACGCCGAGTGGCAGCAGGATGAGTACGGAGGCAAGC
GCCCCGCCCCCTGCGGGTTGGCTCCCGCGTGGAGGTGATTGGGAAGGGCCACCGAGGCACTGTGGCCTAT
GTTGGAGCCACACTCTTTGCCACTGGCAAATGGGTGGGCGTGATTCTGGATGAAGCAAAAGGCAAAAAT
GATGGCACTGTCCAGGGAAGGAAGTATTTACATGTGATGAAGGCCACGGCATCTTTGTACGCCAGTCC
30 CAGATCCAAGTATTTGAAGATGGAGCAGATACTACTTCCCCAGAGACTCCTGATTCTTCTGCTTCAAAG
GTCCTCAAGAGAGAGGGAGCCGATGCAGCTGCAAAGACCAGCAAAC TCGGGGACTGAAGCCTAAGAAG
GCACCGACAGCCCGAAAGACCACAAC TCGACGGCCCAAG

Table 80. Mouse Dctn1 (P150) protein (SEQ ID NO.: 114)

35 Exon5 (nucleotide)
CCTACTCGCCCAGCCAGCACTGGGGTGGCTGGGCCCAGTAGCTCCCTTGGCCCCCTGGGCTCAGCGTCA
GCCGGGGAAC TAAGCAGCAGTGAGCCCAGCACCCAGCTCAGACTCCGCTGGCAGACCCATCATCCCC
ACACCGGCCCTCACCTCTCTGGAGCAGACCCCCACTTCCATCTCCCTCTAAG
40

Table 81. Mouse Dctn1 (P150) protein (SEQ ID NO.: 115)

Exon6 (nucleotide)

GAAGAGGAAGGGCTGAGGGCTCAGGTACGGGACCTGGAGGAGAAGCTGGAGACCTGCGCCTAAACGC
5 TCAGAAGACAAAGCAAAGCTGAAAGAGCTGGAGAAGCACAAAGATCCAGCTGGAGCAGGTGCAGGAATGG
AAGAGCAAATGCAGGAGCAGCAGGCAGACCTGCAGCGGCGCCTCAAGGAGGCTCGGAAG

Table 82. Mouse Dctn1 (P150) protein (SEQ ID NO.: 116)

10 Exon7 (nucleotide)

GAAGCCAAGGAGGCGCTAGAGGCAAAGGAACGCTACATGGAGGAGATGGCCGACACAGCCGACGCTATC
GAGATGGCCACTCTGGACAAGGAGATGGCTGAAGAGCGCGCTGAGTCTCTGCAGCAAGAGGTGGAGGCA
CTGAAGGAACGGGTAGACGAGCTCACCACAGACCTGGAGATTCTCAAGGCTGAAATCGAAGAGAAAG

15 **Table 83. Mouse Dctn1 (P150) protein (SEQ ID NO.: 117)**

Exon8 (nucleotide)

GCTCTGATGGGGCCGCATCAAGCTACCAGCTCAAGCAGCTGGAGGAGCAGAATGCCCGCCTGAAGGATG
CCCTGGTGAG

20

Table 84. Mouse Dctn1 (P150) protein (SEQ ID NO.: 118)

Exon9 (nucleotide)

GATGCGAGACCTCTCTTCTCAGAGAAGCAGGAGCACGTGAAGCTGCAGAACTCATGGAAGAAAAA
25 CCAGGAGCTGGAGGTCGTGCGGCAGCAGCGCAGCGTCTTCAGGAGGAGCTGAGCCAGGCTGAGAGCAC
CATCGATGAGCTCAAAGAGCAG

Table 85. Mouse Dctn1 (P150) protein (SEQ ID NO.: 119)

30 Exon10 (nucleotide)

GTGGACGCCGCTCTGGGAGCCGAGGAGATGGTGGAGATGCTGACCGACCGGAACCTGAATCTAGAGGAG
AAAGTGCGGGAGTTACGGGAGACTGTGGGGGACTTG

Table 86. Mouse Dctn1 (P150) protein (SEQ ID NO.: 120)

35

Exon11 (nucleotide)

GAAGCCATGAACGAGATGAACGATGAGCTGCAGGAGAACGCACGGGAGACGGAGCTGGAACCTCCGAGAG
CAGCTGGACATGGCGGGCGCCGAGTGAGGGAAGCGCAGAAGCGAGTGGAAAGCCGCCAGGAGACAGTC
GCCGACTACCAGCAGACCATCAAGAAGTACCGCCAGTTGACTGCCACCTACAG

Table 87. Mouse Dctn1 (P150) protein (SEQ ID NO.: 121)

Exon12 (nucleotide)

5 GATGTCAATCGGGAGCTGACAAACCAGCAGGAAGCGTCTGTAGAGAGGCAGCAGCAGCCGCCAGAG
ACTTTTGATTTCAAATCAAGTTTGCTGAGACCAAGGCTCATGCCAAG

Table 88. Mouse Dctn1 (P150) protein (SEQ ID NO.: 122)

10 Exon13(nucleotide)

GCCATTGAGATGGAGTTGAGACAGATGGAAGTTGCCAGGCCAACCGGCACATGTCCCTGCTGACAGCC
TTTATGCCTGACAGCTTCCTTCGGCCAGGTGGAGACCAGACTGTGTCCTGGTGCTGCTGCTCATGCCC
CGACTCATTGCAAG

Table 89. Mouse Dctn1 (P150) protein (SEQ ID NO.: 123)

Exon14 (nucleotide)

GCAGAGCTCATCCGAAGCAGGCCAGGAGAAGTTTGACCTGAGCGAGAACTGTTGCGAGCGGCCCGGG
CTGCGGGGAGCTGCCGGGGAGCAGCTGAGCTTTGCTGCTGGACTGGTGTACTCGCTGAGTCTGCTGCAG
20 GCCACGCTGCACCGCTATGAGCA

Table 90. Mouse Dctn1 (P150) protein (SEQ ID NO.: 124)

Exon15 (nucleotide)

25 TGCCCTCTCTCAGTGCACTGTGGACGTGTATAAGAAGGTCGGCAGCCTGTACCCCGAGATGAGCGCCCA
CGAGCGCTCCTTAGATTTCTCATTGAGCTGCTGCACAAGGATCAGCTGGATGAGACTGTCAACGTGGA
GCCCCTACCAAGGCCATCAAGTATTACCAG

Table 91. Mouse Dctn1 (P150) protein (SEQ ID NO.: 125)

30

Exon16 (nucleotide)

TGCCCTCTCTCAGTGCACTGTGGACGTGTATAAGAAGGTCGGCAGCCTGTACCCCGAGATGAGCGCCCA
CGAGCGCTCCTTAGATTTCTCATTGAGCTGCTGCACAAGGATCAGCTGGATGAGACTGTCAACGTGGA
GCCCCTACCAAGGCCATCAAGTATTACCAG

35

Table 92. Mouse Dctn1 (P150) protein (SEQ ID NO.: 126)

Exon17 (nucleotide)

TGCCCTCTCTCAGTGCAGTGTGGACGTGTATAAGAAGGTCGGCAGCCTGTACCCCGAGATGAGCGCCCA
CGAGCGCTCCTTAGATTTCCTCATTTAGCTGCTGCACAAGGATCAGCTGGATGAGACTGTCAACCTGGA
GCCCCTCACCAAGGCCATCAAGTATTACCAG

5 **Table 93. Mouse Dctn1 (P150) protein (SEQ ID NO.: 127)**

Exon18 (nucleotide)

GGTGGGCAGGAGGCAACAGATATTGCCCTTCTTCTCCGAGACCTGGAAACATCATGTAGTGACACCCGT
CAGTTCTGCAAGAAGATCCGAAGGCGGATGCCGGGACGGATGCTCCTGGGATCCCAGCAGCGCTGGCC
10 TTTGGCTCACAG

Table 94. Mouse Dctn1 (P150) protein (SEQ ID NO.: 128)

Exon19 (nucleotide)

15 GTATCCGACACACTCCTGGACTGCAGGAAGCACTTGACGTGGGTGGTAGCTGTTCTGCAGGAGGTGGCA
GCTGCAGCCGCCAGCTTATTGCCCCCTTGGCAGAGAACGAGGGGCTGCCTGTGGCTGCACTGGAGGAG
CTGGCCTTCAAAGCAAGCGAGCAG

Table 95. Mouse Dctn1 (P150) protein (SEQ ID NO.: 129)

20

Exon20 (nucleotide)

ATCTACGGGAGCCCCCTCCAGCAGCCCCCTATGAGTGTCTACGCCAGTCATGCACCATCCTCATCAGCAG
ATGAACAAGCTGGCCACAGCCATGCAAGAAGGCGAGTATGACGCAGAGCGACCCCCGAGCAAG

25 **Table 96. Mouse Dctn1 (P150) protein (SEQ ID NO.: 130)**

Exon3 to 20 (nucleotide)

AGGGAGCCGATGCAGCTGCAAAGACCAGCAAAGTGCGGGGACTGAAGCCTAAGAAGGCACCGACAGCCC
GAAAGACCACAACTCGACGGCCCAAGCCTACTCGCCAGCCAGCACTGGGGTGGCTGGGCCCAGTAGCT
30 CCCTTGCCCCCTCTGGCTCAGCGTCAGCCGGGGAAGTAAGCAGCAGTGAGCCAGCACCCCAGCTCAGA
CTCCGCTGGCAGCACCCATCATCCCCACACCGGCCCTCACCTCTCCTGGAGCAGCACCCCCACTTCCAT
CTCCCTCTAAGGAAGAGGAAGGGCTGAGGGCTCAGGTACGGGACCTGGAGGAGAAGCTGGAGACCCCTGC
GCCTAAAACGCTCAGAAGACAAAGCTGAAAGAGCTGGAGAAGCACAAGATCCAGCTGGAGCAGG
TGCAGGAATGGAAGAGCAAAATGCAGGAGCAGCAGGCAGACCTGCAGCGGCGCCTCAAGGAGGCTCGGA
35 AGGAAGCCAAGGAGGCGCTAGAGGCAAGGAACGCTACATGGAGGAGATGGCCGACACAGCCGACGCTA
TCGAGATGGCCACTCTGGACAAGGAGATGGCTGAAGAGCGCGCTGAGTCTCTGCAGCAAGAGGTGGAGG
CACTGAAGGAACGGGTAGACGAGCTCACCACAGACCTGGAGATTCTCAAGGCTGAAATCGAAGAGAAAG
GCTCTGATGGGGCCGCATCAAGCTACCAGCTCAAGCAGCTGGAGGAGCAGAAATGCCCCCTGAAGGATG
CCCTGGTGAGGATGCGAGACCTCTCTCTCTCAGAGAAGCAGGAGCAGTGAAGCTGCAGAACTCATGG
40 AAAAGAAAAACAGGAGCTGGAGGTCGTGCGGCAGCAGCGGAGCGTCTTCAGGAGGAGCTGAGCCAGG

CTGAGAGCACCATCGATGAGCTCAAAGAGCAGGTGGACGCCGCTCTGGGAGCCGAGGAGATGGTGGAGA
TGCTGACCGACCGGAACCTGAATCTAGAGGAGAAAGTGCGGGAGTTACGGGAGACTGTGGGGGACTTGG
AAGCCATGAACGAGATGAACGATGAGCTGCAGGAGAACGCACGGGAGACGGAGCTGGAATCCGAGAGC
AGCTGGACATGGCGGGCGCCCGAGTGAGGGAAGCGCAGAAGCGAGTGGAAGCCGCCAGGAGACAGTCG
5 CCGACTACCAGCAGACCATCAAGAAGTACCGCCAGTTGACTGCCACCTACAGGATGTCAATCGGGAGC
TGACAAACCAGCAGGAAGCGTCTGTAGAGAGGCAGCAGCAGCCGCCAGAGACTTTTGATTTCAAAA
TCAAGTTTGCTGAGACCAAGGCTCATGCCAAGGCCATTGAGATGGAGTTGAGACAGATGGAAGTTGCCC
AGGCCAACCGGCACATGTCCCTGCTGACAGCCTTTATGCCTGACAGCTTCCTTCGGCCAGGTGGAGACC
ACGACTGTGTCTGGTGTCTGCTCATGCCCCGACTCATTTGCAAGGCAGAGCTCATCCGGAAGCAGG
10 CCCAGGAGAAGTTTGACCTGAGCGAGAAGTGTTCGGAGCGGCCCGGGCTGCGGGGAGCTGCCGGGGAGC
AGCTGAGCTTTGCTGTGGACTGGTGTACTCGCTGAGTCTGCTGCAGGCCACGCTGCACCGCTATGAGC
ATGCCCTCTCTCAGTGCAGTGTGGACGTGTATAAGAAGTTCGGCAGCCTGTACCCCGAGATGAGCGCCC
ACGAGCGCTCCTTAGATTTCCTCATTGAGCTGCTGCACAAGGATCAGCTGGATGAGACTGTCAACGTGG
AGCCCCTCAMCAAGGSCATCAAGTATTACCAGCATCTGTACAGSATCCACCTCGCTGAACAACCCGAGG
15 ACTCCACCATGCAGCTGGCTGACCACATCAAGTTCACCCAGAGTGCCCTGGACTGCATGGGCGTGGAGG
TGGGGCGGCTGCGTGCCTTCTTGCAAGGTGGGCAGGAGCAACAGATATTGCCCTTCTTCTCCGAGACC
TGGAACATCATGTAGTGACACCCGTCAGTTCTGCAAGAAGATCCGAAGGCGGATGCCGGGGACGGATG
CTCCTGGGATCCCAGCAGCGCTGGCCTTTGGCTCACAGGTATCCGACACACTCCTGGACTGCAGGAAGC
ACTTGACGTGGGTGGTAGCTGTTCTGCAGGAGGTGGCAGCTGCAGCCGCCAGCTTATTGCCCCCTTGG
20 CAGAGAACGAGGGGCTGCCTGTGGCTGCACTGGAGGAGCTGGCCTTCAAAGCAAGCGAGCAGATCTACG
GGAGCCCCCTCCAGCAGCCCCATGAGTGTCTACGCCAGTCATGCACCATCCTCATCAGCAGCATGAACA
AGCTGGCCACAGCCATGCAAGAAGGCGAGTATGACGCAGAGCGACCCCGAGCAAG

Table 97. Mouse Dctn1 (P150) protein (SEQ ID NO.: 131)

25

Exon22 (nucleotide)

GGAGAGGAGCTGAGTGAGGCCAACGTGCGGCTCAGCCTCCTGGAGAAGAAGTTGGACAGCGCTGCCAAG
GATGCAGACGAGCGAATCGAGAAAGTTCAGACACGGCTGGACGAGACTCAGACCCCTGCTGCGGAAGAAG
GAGAA

30

Table 98. Mouse Dctn1 (P150) protein (SEQ ID NO.: 132)

Exon23 (nucleotide)

AGACTTTGAGGAGACAATGGACGCACTCCAGGCTGACATCGACCAGCTGGAGGCAGAGAAGGCAGAGCT
35 CAAGCAGCGCTGAACAGCCAGTCCAAGCGCACAATCGAGGGGCTCCGGGGCCCCCTCCGTCAAGCAT
CGCTACCCTGGTCTCTGGCATCGCTGGTG

Table 99. Mouse Dctn1 (P150) protein (SEQ ID NO.: 133)

40 Exon 22 to 23 (nucleotide)

GGAGAGGAGCTGAGTGAGGCCAACGTGCGGCTCAGCCTCCTGGAGAAGAAGTTGGACAGCGCTGCCAAG
GATGCAGACGAGCGAATCGAGAAAGTTCAGACACGGCTGGACGAGACTCAGACCCTGCTGCGGAAGAAG
GAGAAAGACTTTGAGGAGACAATGGACGCACTCCAGGCTGACATCGACCAGCTGGAGGCAGAGAAGGCA
GAGCTCAAGCAGCGCCTGAACAGCCAGTCCAAGCGCACAAATCGAGGGGCTCCGGGGCCCCCTCCGTCA
5 GGCATCGCTACCCTGGTCTCTGGCATCGCTGGTG

Table 100. Human DCTN 1 (P150) protein (SEQ ID NO.: 134)

Exon 2 (nucleotide)

10 ACGCCCAGCGGCAGCAGGATGAGTGCGGAGGCAAGCGCCCGCCTCTGCGGGTGGGCTCCCGTGTAGAG
GTGATTGGAAAAGGCCACCGAGGCACTGTGGCCTATGTTGGAGCCACACTGTTTGCCACTGGCAAATGG
GTAGGCGTGATTCTGGATGAAGCAAAGGGCAAAAATGATGGAAGTGTTCAGGCAGGAAGTACTTCACT
TGTGATGAAGGGCATGGCATCTTTGTGCGCCAGTCCCAG

15 **Table 101. Human DCTN 1 (P150) protein (SEQ ID NO.: 135)**

Exon3 (nucleotide)

ATCCAGGTATTTGAAGATGGAGCAGATACTACTTCCCAGAGACACCTGATTCTTCTGCTTCAAAAGTC
CTCAAAAGAG
20

Table 102. Human DCTN 1 (P150) protein (SEQ ID NO.: 136)

Exon4 (nucleotide)

25 AGGGAACTGATACAACTGCAAAGACTAGCAAAGT

Table 103. Human DCTN 1 (P150) protein (SEQ ID NO.: 137)

Exon5 (nucleotide)

30 ACCACAACTCGGCGACCCAAG

Table 104. Human DCTN 1 (P150) protein (SEQ ID NO.: 138)

Exon2 to 5 (nucleotide)

35 ACGCCCAGCGGCAGCAGGATGAGTGCGGAGGCAAGCGCCCGCCTCTGCGGGTGGGCTCCCGTGTAGAG
GTGATTGGAAAAGGCCACCGAGGCACTGTGGCCTATGTTGGAGCCACACTGTTTGCCACTGGCAAATGG
GTAGGCGTGATTCTGGATGAAGCAAAGGGCAAAAATGATGGAAGTGTTCAGGCAGGAAGTACTTCACT
TGTGATGAAGGGCATGGCATCTTTGTGCGCCAGTCCCAGATCCAGGTATTTGAAGATGGAGCAGATACT
ACTTCCCAGAGACACCTGATTCTTCTGCTTCAAAAGTCCTCAAAAGAGAGGGAAGTATACAACTGCA

AAGACTAGCAAACCTGCGGGGACTGAAGCCTAAGAAGGCACCGACAGCCCGAAAGACCACAACCTCGGCGA
CCCAAG

Table 105. Human DCTN 1 (P150) protein (SEQ ID NO.: 139)

5

Exon6 (nucleotide)

CCCACGCGCCAGCCAGTACTGGGGTGGCTGGGGCCAGTAGCTCCCTGGGCCCTCTGGCTCAGCGTCA
GCAGGTGAGCTGAGCAGCAGTGAGCCCAGCACCCCGGCTCAGACTCCGCTGGCAGCACCCATCATCCCC
ACGCCGGTCCTCACCTCTCCTGGAGCAGTCCCCCGCTTCCTTCCCCATCCAAG

10

Table 106. Human DCTN 1 (P150) protein (SEQ ID NO.: 140)

Exon7 (nucleotide)

GAGGAGGAGGGACTAAGGGCTCAGGTGCGGGACCTGGAGGAGAACTAGAGACCCTGAGACTGAAACGG
15 GCAGAAGACAAAGCAAAGCTAAAAGAGCTGGAGAAACACAAAATCCAGCTGGAGCAGGTGCAGGAATGG
AAGAGCAAAATGCAGGAGCAGCAGGCCGACCTGCAGCGGCGCCTCAAGGAGGCGAGAAAG

Table 107. Human DCTN 1 (P150) protein (SEQ ID NO.: 141)

20 Exon8 (nucleotide)

GAAGCCAAGGAGGCGCTGGAGGCAAAGGAACGCTATATGGAGGAGATGGCTGATACTGCTGATGCCATT
GAGATGGCCACTTTGGACAAGGAGATGGCTGAAGAGCGGGCTGAGTCCCTGCAGCAGGAGGTGGAGGCA
CTGAAGGAGCGGGTGGACGAGCTCACTACTGACTTAGAGATCCTCAAGGCTGAGATTGAAGAGAAGG

25

Table 108. Human DCTN 1 (P150) protein (SEQ ID NO.: 142)

Exon9 (nucleotide)

GCTCAGATGGCGCTGCATCCAGTTATCAGCTCAAGCAGCTTGAGGAGCAGAATGCCCGCCTGAAGGATG
CCCTGGTGAG

30

Table 109. Human DCTN 1 (P150) protein (SEQ ID NO.: 143)

Exon10 (nucleotide)

GATGCGGGATCTTTCTTCCTCAGAGAAGCAGGAGCATGTGAAGCTCCAGAAGCTCATGGAAAAGAAGAA
35 CCAAGAGCTGGAAGTTGTGAGGCAACAGCGGGAGCGTCTGCAGGAGGAGCTAAGCCAGGCAGAGAGCAC
CATTGATGAGCTCAAGGAGCAG

Table 110. Human DCTN 1 (P150) protein (SEQ ID NO.: 144)

Exon11 (nucleotide)

GTGGATGCTGCTCTGGGTGCTGAGGAGATGGTGGAGATGCTGACAGATCGGAACCTGAATCTGGAAGAG
AAAGTGCGCGAGTTGAGGGAGACTGTGGGAGACTTG

5 **Table 112. Human DCTN 1 (P150) protein (SEQ ID NO.: 145)**

Exon12 (nucleotide)

GAAGCGATGAATGAGATGAACGATGAGCTGCAGGAGAATGCACGTGAGACAGAACTGGAGCTGCGGGAG
CAGCTGGACATGGCAGGCGCGGGGTTCGTGAGGCCCAGAAGCGTGTGGAGGCAGCCCAGGAGACGGTT
10 GCAGACTACCAGCAGACCATCAAGAAGTACCGCCAGCTGACCGCCCATCTACAG

Table 113. Human DCTN 1 (P150) protein (SEQ ID NO.: 146)

Exon13(nucleotide)

15 GATGTGAATCGGGAAGTACAAACCAGCAGGAAGCATCTGTGGAGAGGCAACAGCAGCCACCTCCAGAG
ACCTTTGACTTCAAAATCAAGTTTGCTGAGACTAAGGCCCATGCCAAG

Table 114. Human DCTN 1 (P150) protein (SEQ ID NO.: 147)

20 Exon14 (nucleotide)

GCAATTGAGATGGAATTGAGGCAGATGGAGGTGGCCCAGGCCAATCGACACATGTCCTTGCTGACAGCC
TTCATGCCTGACAGCTTCCTTCGGCCAGGTGGGGACCATGACTGCGTTCTGGTGCTGTTGCTCATGCCT
CGTCTCATTGCAAG

25 **Table 115. Human DCTN 1 (P150) protein** (SEQ ID NO.: 148)

Exon15 (nucleotide)

GCAGAGCTGATCCGGAAGCAGGCCAGGAGAAGTTTGAACCTAAGTGAGAACTGTTTCAGAGCGGCCTGGG
CTGCGAGGAGCTGCTGGGGAGCAACTCAGCTTTGCTGCTGGACTGGTGTACTCGCTGAGCCTGCTGCAG
30 GCCACGCTACACCGCTATGAGCA

Table 116. Human DCTN 1 (P150) protein (SEQ ID NO.: 149)

Exon16 (nucleotide)

35 TGCCCTCTCTCAGTGCAGTGTGGATGTGTATAAGAAAGTGGGCAGCCTGTACCCTGAGATGAGTGCCCA
TGAGCGCTCCTTGGATTTCCTCATTGAAGTCTGCTGCACAAGGATCAGCTGGATGAGACTGTCAATGTGGA
GCCTCTCACCAAGGCCATCAAGTACTATCAG

Table 117. Human DCTN 1 (P150) protein (SEQ ID NO.: 150)

Exon17 (nucleotide)

CATCTGTACAGCATCCACCTTGCCGAACAGCCTGAGGACTGTACTATGCAGCTGGCTGACCACATTAAG

5 **Table 118. Human DCTN 1 (P150) protein (SEQ ID NO.: 151)**

Exon18 (nucleotide)

TTCACGCAGAGTGCTCTGGACTGCATGAGTGTGGAGGTAGGACGGCTGCGTGCCTTCTTGCAAG

10 **Table 119. Human DCTN 1 (P150) protein (SEQ ID NO.: 152)**

Exon19 (nucleotide)

GGTGGGCAGGAGGCTACAGATATTGCCCTCCTGCTCCGGGATCTGGAACTTCATGCAGTGACATCCGC
CAGTTCTGCAAGAAGATCCGAAGGCGAATGCCAGGGACAGATGCTCCTGGGATCCCAGCTGCACTGGCC
15 TTTGGACCAACAG**Table 120. Human DCTN 1 (P150) protein (SEQ ID NO.: 153)**

Exon20 (nucleotide)

20 GTATCTGACACGCTCCTAGACTGCAGGAACACTTGACGTGGGTCTGGCTGTGCTGCAGGAGGTGGCA
GCTGCTGCTGCCAGCTCATTGCCCCACTGGCAGAGAATGAGGGGCTACTTGTGGCTGCTCTGGAGGAA
CTGGCTTTCAAAGCAAGCGAGCAG**Table 121. Human DCTN 1 (P150) protein (SEQ ID NO.:154)**

25

Exon21 (nucleotide)

ATCTATGGGACCCCTCCAGCAGCCCTATGAGTGTCTGCGCCAGTCATGCAACATCCTCATCAGTACC
ATGAACAAGCTGGCCACAGCCATGCAGGAGGGGGAGTATGATGCAGAGCGGCCCCCAGCAAG30 **Table 122. Human DCTN 1 (P150) protein (SEQ ID NO.: 155)**

Exon4 to 21 (nucleotide)

AGGGAAGTGTACAACTGCAAAGACTAGCAAAGTGCAGGGGACTGAAGCCTAAGAAGGCACCGACAGCCC
GAAAGACCACAAGTTCGGCGACCCAAAGCCACGCGCCAGCCAGTACTGGGGTGGCTGGGGCCAGTAGCT
35 CCTGGGCCCTCTGGCTCAGCGTCAGCAGGTGAGCTGAGCAGCAGTGAAGCCAGCAGCCCGGCTCAGA
CTCCGCTGGCAGCAGCCATCATCCCCACGCGGTCTCACCTCTCCTGGAGCAGTCCCCCGCTTCCTT
CCCCATCCAAGGAGGAGGAGGGGACTAAGGGCTCAGGTGCGGGACCTGGAGGAGAACTAGAGACCTGA
GACTGAAACGGGCAGAGACAAAGCAAAGCTAAAAGAGCTGGAGAAACACAAAATCCAGCTGGAGCAGG
TGCAGGAATGGAAGAGCAAAATGCAGGAGCAGCAGGCCGACCTGCAGCGGCGCTCAAGGAGGCGAGAA
40 AGGAAGCCAAGGAGGCGCTGGAGGCAAAGGAACGCTATATGGAGGAGATGGCTGATACTGCTGATGCCA

TTGAGATGGCCACTTTGGACAAGGAGATGGCTGAAGAGCGGGCTGAGTCCCTGCAGCAGGAGGTGGAGG
CACTGAAGGAGCGGGTGGACGAGCTCACTACTGACTTAGAGATCCTCAAGGCTGAGATTGAAGAGAAGG
GCTCAGATGGCGCTGCATCCAGTTATCAGCTCAAGCAGCTTGAGGAGCAGAATGCCCCCTGAAGGATG
CCCTGGTGAGGATGCGGGATCTTTCTTCTCAGAGAAGCAGGAGCATGTGAAGCTCCAGAAGCTCATGG
5 AAAAGAAGAACCAAGAGCTGGAAGTTGTGAGGCAACAGCGGGAGCGTCTGCAGGAGGAGCTAAGCCAGG
CAGAGAGCACCATTGATGAGCTCAAGGAGCAGGTGGATGCTGCTCTGGGTGCTGAGGAGATGGTGGAGA
TGCTGACAGATCGGAACCTGAATCTGGAAGAGAAAGTGCGCGAGTTGAGGGAGACTGTGGGAGACTTGG
AAGCGATGAATGAGATGAACGATGAGCTGCAGGAGAATGCACGTGAGACAGAACTGGAGCTGCGGGAGC
AGCTGGACATGGCAGGCGCGGGTTTCGTGAGGCCAGAAAGCGTGTGGAGGCAGCCCAGGAGACGGTTG
10 CAGACTACCAGCAGACCATCAAGAAGTACCGCCAGCTGACCGCCCATCTACAGGATGTGAATCGGGAAC
TGACAAACCAGCAGGAAGCATCTGTGGAGAGGCAACAGCAGCCACCTCCAGAGACCTTTGACTTCAAAA
TCAAGTTTGCTGAGACTAAGGCCCATGCCAAGGCAATTGAGATGGAATTGAGGCAGATGGAGGTGGCCC
AGGCCAATCGACACATGTCCCTGCTGACAGCCTTCATGCCTGACAGCTTCCTTCGGCCAGGTGGGGACC
ATGACTGCGTTCTGGTGCTGTTGCTCATGCCTCGTCTCATTTGCAAGGCAGAGCTGATCCGGAAGCAGG
15 CCCAGGAGAAGTTTGAACAAAGTGAGAACTGTTTCAAGCGGCCTGGGCTGCGAGGAGCTGCTGGGGAGC
AACTCAGCTTTGCTGCTGGACTGGTGTACTCGCTGAGCCTGCTGCAGGCCACGCTACACCGCTATGAGC
ATGCCCTCTCTCAGTGCAGTGTGGATGTGTATAAGAAAGTGGGCAGCCTGTACCTGAGATGAGTGCCC
ATGAGCGCTCCTTGATTTCCTCATTGAACTGCTGCACAAGGATCAGCTGGATGAGACTGTCAATGTGG
AGCCTCTCACCAAGGCCATCAAGTACTATCAGCATCTGTACAGCATCCACCTTGCCGAACAGCCTGAGG
20 ACTGTACTATGCAGCTGGCTGACCACATTAAGTTCACGCAGAGTGCTCTGGACTGCATGAGTGTGGAGG
TAGGACGGCTGCGTGCCTTCTTGACGGGTGGGCAGGAGGCTACAGATATTGCCCTCCTGCTCCGGGATC
TGGAACCTTCATGCAGTGACATCCGCCAGTTCTGCAAGAAGATCCGAAGGCGAATGCCAGGGACAGATG
CTCCTGGGATCCCAGCTGCACTGGCCTTTGGACCACAGGTATCTGACACGCTCCTAGACTGCAGGAAAC
ACTTGACGTGGGTGCTGGCTGTGCTGCAGGAGGTGGCAGCTGCTGCTGCCCAGCTCATTGCCCCACTGG
25 CAGAGAATGAGGGGCTACTTGTGGCTGCTCTGGAGGAACTGGCTTTCAAAGCAAGCGAGCAGATCTATG
GGACCCCTCCAGCAGCCCTATGAGTGTCTGCGCCAGTCATGCAACATCCTCATCAGTACCATGAACA
AGCTGGCCACAGCCATGCAGGAGGGGGAGTATGATGCAGAGCGGCCCCCAGCAAG

Table 123. Human DCTN 1 (P150) protein (SEQ ID NO.: 156)

30

Exon23 (nucleotide)

GGAGAGGAGCTAAGTGAGGCCAATGTGCGGCTGAGCCTCCTGGAGAAGAAGTTGGACAGTGCTGCCAAG
GATGCAGATGAGCGCATCGAGAAAGTCCAGACTCGGCTGGAGGAGACCCAGGCAGTGTGCGAAAGAAG
GAGAA

35

Table 124. Human DCTN 1 (P150) protein (SEQ ID NO.: 157)

Exon24 (nucleotide)

AGAGTTTGAGGAGACAATGGATGCACTCCAGGCTGACATCGACCAGCTGGAGGCAGAGAAGGCAGAACT
40 AAAGCAGCGTCTGAACAGCCAGTCCAACGCACGATTGAGGGACTCCGGGGCCCTCCTCCTTCAGGCAT
TGCTACTCTGGTCTCTGGCATTGCTGGTG

Table 125. Human DCTN 1 (P150) protein (SEQ ID NO.: 158)

Exon 23 to 24 (nucleotide)

5 GGAGAGGAGCTAAGTGAGGCCAATGTGCGGCTGAGCCTCCTGGAGAAGAAGTTGGACAGTGCTGCCAAG
 GATGCAGATGAGCGCATCGAGAAAGTCCAGACTCGGCTGGAGGAGACCCAGGCACTGCTGCGAAAGAAG
 GAGAAAGAGTTTGAGGAGACAATGGATGCACTCCAGGCTGACATCGACCAGCTGGAGGCAGAGAAGGCA
 GAACTAAAGCAGCGTCTGAACAGCCAGTCCAAACGCACGATTGAGGGACTCCGGGGCCCTCCTCCTTCA
 GGCATTGCTACTCTGGTCTCTGGCATTGCTGGTG

10

In another embodiment, the amino acid affected by the mutation is located in a domain of said protein, which is capable of binding to another subunit of the dyactin/dynein complex. Specifically, said domain comprises amino acids 147-157, amino acids 243-314, amino acids 140-157, or amino acids 1-123 of SEQ ID NO.: 61, in case the protein is mouse cytoplasmic dynein intermediate chain 1, or, in case the protein is human cytoplasmic dynein intermediate chain 1 amino acids 1-140, amino acids 157-174, amino acids 164-174, or amino acids 260-331 of SEQ ID NO.: 62. In case the protein is mouse cytoplasmic dynein intermediate chain 2, said domain comprises amino acids 1-123, amino acids 122-139, amino acids 129-130, or amino acids 226-297 of SEQ ID NO.: 64, or, in case the protein is human cytoplasmic dynein intermediate chain 2 amino acids 1-149, amino acids 148-165, amino acids 155-165, or amino acids 252-323 of SEQ ID NO.: 65. In case the protein is mouse DCTN 1 (SEQ ID NO.: 67), said domain comprises amino acids 39-150, amino acids 1006-1021, or amino acids 133-899 of SEQ ID NO.: 67, or, in case the protein is human DCTN 1 amino acids 39-150, amino acids 133-899, or amino acids 1006-1021 of SEQ ID NO.: 68.

In another preferred embodiment, the amino acid affected by the mutation is any one as described in individualized manner in connection with the preferred mutants of the invention above, e.g., those specified in Tables 19, 20, 21, 22 or 24.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is amino acid 39G.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is amino acid 40H.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is amino acid 41R.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is amino acid 42G.

5 In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is amino acid 43T.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is amino acid 44V.

10 In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 45A.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 46Y.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 47V.

15 In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 48G.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 49A.

20 In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 50T.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 51L.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 52F.

25 In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 53A.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 54T.

30 In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 55G.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 56K.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 57W.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 58V.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 59G.

5 In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 60V

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 61I.

In case the protein is human DCTN 1, another preferred embodiment is one
10 wherein the amino acid affected by said mutation is the amino acid 62L.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 63D.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 64E.

15 In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 65A.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 66K.

In case the protein is human DCTN 1, another preferred embodiment is one
20 wherein the amino acid affected by said mutation is the amino acid 67G.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 68K.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 69N.

25 In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 70D.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 71G.

In case the protein is human DCTN 1, another preferred embodiment is one
30 wherein the amino acid affected by said mutation is the amino acid 72T.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 73V.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 74Q.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 75G.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 76R.

5 In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 77K.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 78Y.

10 In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 79F.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 80T.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 81C.

15 In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 82D.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 83E.

20 In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 84G.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 85H.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 86G.

25 In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 87I.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 88F.

30 In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 89V.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 90R.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 91Q.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 92S.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 93Q.

5 In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 94I.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 95Q.

10 In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 96V.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 97F.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 98E.

15 In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 99D.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 100G.

20 In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 101A.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 102D.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 103T.

25 In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 104T.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 105S.

30 In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 106P.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 107E.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 108T.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 109P.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 110D.

5 In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 111S.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 112S.

10 In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 113A.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 114S.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 115K.

15 In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 117L.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 118K.

20 In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 119R.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 120E.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 121G.

25 In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 123D.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 126A.

30 In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 127K.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 128T.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 129S.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 130K.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 131L.

5 In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 132R.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 133G.

10 In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 134L.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 135K.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 136P.

15 In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 137K.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 138K.

20 In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 139A.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 140P.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 141T.

25 In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 142A.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 143R.

30 In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 144K.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 145T.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 146T.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 147T.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 148R.

5 In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 149R.

In case the protein is human DCTN 1, another preferred embodiment is one wherein the amino acid affected by said mutation is the amino acid 150P.

10 The method of identifying a protein or nucleic acid marker indicative of an increased risk of a mammalian subject of developing a neurodegenerative disease, or the method of identifying a protein or nucleic acid marker indicative of an association of a neurodegenerative disease in a mammalian subject with a mutation in an allele of a gene coding for a protein, which is a subunit of the dynactin/dynein complex
15 comprise the step of analyzing a test sample derived from said subject for the presence of a difference compared to a similar test sample if derived from a subject of the same species that is unaffected by, or known not to be at risk of, developing said disease, wherein said difference is indicative of the presence of a mutation in an allele of the gene coding for a protein, which is a subunit of the dynactin/dynein complex.

20

In the above methods, the test sample derived from a mammalian subject, particularly a human subject, may be directly obtained from said subject. It may, however, also be a sample that has been obtained previously. Also included test samples according to the invention are, for example, cDNA preparations that have
25 been prepared from mRNA obtained from a tissue sample from a human subject at an earlier stage. It may also be cloned or PCR-amplified DNA that originates from DNA contained in such tissue sample obtained at an earlier stage.

According to the claimed method, the test sample will be analyzed for a difference to a similar test sample derived from a human subject unaffected by or
30 known not to be at risk of developing a neurological disease. While the method may include actually deriving or directly obtaining a test sample from such a mammalian subject, particularly a human subject, for comparative purposes, the necessary information regarding the relevant structural features and properties of such similar test sample to be used for comparison will often already be available. Thus, it will

often be sufficient for the purposes of the above methods of the invention to perform an analysis for a difference to a similar test sample as it would be observed if said similar test sample were in fact obtained from a subject of the same species, which subject is unaffected by or known not to be at risk of developing the above medical
5 condition.

The test sample may be a nucleic acid sample, e.g., mRNA (or cDNA derived therefrom), or genomic DNA.

10 It may also be a protein sample. In a preferred embodiment the nucleic acid sample or the protein sample comprises one or more of the nucleic acids coding for proteins or the proteins itself, which are subunits of the dynactin/dynein complex, preferably the cytoplasmic dynein heavy chain 1, e.g. according to SEQ ID NOS.: 28 or 29, the cytoplasmic dynein intermediate chain 1, e.g. according to SEQ ID NOS.:
15 30 or 31, the cytoplasmic dynein intermediate chain 2, e.g. according to SEQ ID NOS.: 32 or 33, the cytoplasmic dynein light intermediate chain 1, e.g. according to SEQ ID NOS.: 34 or 35, the cytoplasmic dynein light intermediate chain 2, e.g. according to SEQ ID NOS.: 36 or 37; the cytoplasmic dynein 10 kDa light chain, e.g. according to SEQ ID NOS.: 38 or 39, the cytoplasmic dynein light chain Tctex 1, e.g.
20 according to SEQ ID NOS.: 40 or 41, the cytoplasmic dynein light chain 2B, e.g. according to SEQ ID NO.: 42, DCTN 1, e.g. according to SEQ ID NOS.: 43 or 44, DCTN 2, e.g. according to SEQ ID NO.: 45, DCTN 3, e.g. according to SEQ ID NOS.: 46 or 47), DCTN 4, e.g. according to SEQ ID NOS.: 48 or 49, DCTN 5, e.g. according to SEQ ID NO.: 50, DCTN 6, e.g. according to SEQ ID NOS.: 51 or 52),
25 ARP1, e.g. according to SEQ ID NOS. 53 or 54, ARP11, e.g. according to SEQ ID NOS. 55 or 56), HAP1, e.g. according to SEQ ID NO. 57 or 58, and CLIP-170, e.g. according to SEQ ID NOS.: 59 or 60), more preferably the cytoplasmic dynein heavy chain 1, cytoplasmic dynein intermediate chain 1, cytoplasmic dynein intermediate chain 2, and/or DCTN 1, e.g., according to the above-mentioned corresponding SEQ
30 ID NOS.

The difference analyzed may furthermore be one relating to the expression level of said nucleic acid or protein. Alternatively, it may be analyzed whether there is a difference in terms of the nucleotide or the amino acid sequence level.

The step of analysis for differences between the test samples may comprises the partial or complete determination of the sequence of the nucleic acid, or a PCR-amplified portion of the nucleic acid, of the test sample, and optionally also of the nucleic acid or at PCR-amplified portion of the nucleic acid of the similar test sample
5 (or the similar test samples).

Accordingly, another embodiment of the invention relates to oligonucleotides suitable for identifying a mutation in an allele coding for a protein, which is a subunit
10 of the dynactin/dynein complex. In a preferred embodiment, the nucleic acid sequence of the oligonucleotide corresponds to one within said allele, which contains a mutation as defined above. In another preferred embodiment the oligonucleotide is suitable for hybridizing to the nucleic acid of said allele or a portion of its nucleic acid under stringent conditions. In another preferred embodiment, the oligonucleotide is suitable
15 as primer for amplifying the nucleic acid of said allele or a portion of its nucleic acid.

Suitable methods for the determination of partial or complete nucleic acid sequences, and thus, detection of the above-mentioned differences, are well known to the skilled artisan. They include, for example, Southern blotting, TGGE (temperature
20 gradient gel electrophoresis), DGGE (denaturing gradient gel electrophoresis), SSCP (single chain conformation polymorphism) detection, and the like. High throughput sequence analysis methods such as those described by Kristensen et al. (Kristensen et al., BioTechniques 30 (2001), 318-332), which is incorporated herein by reference in its entirety, are likewise suitable, and hence, contemplated in connection with the
25 present invention.

One embodiment of the present invention relates to the determination whether the above-mentioned differences are present in one or both alleles of the gene coding for the protein, which is a subunit of the dynactin/dynein complex, i.e., whether the
30 mammalian subject (or certain cell samples derived therefrom) is (are) homozygous or heterozygous with respect to said mutation. In a preferred embodiment, the portion of the allele to be tested is PCR-amplified and digested with a suitable restriction enzyme and the resulting restriction pattern obtained from the amplified portion is compared to the restriction pattern obtained from the corresponding amplified portion of the

similar sample or the similar samples (see Example (8)). In another preferred embodiment, the above-mentioned determination whether differences are present in one or both alleles of the gene coding for said protein is TGCE, as explained below.

5 Another preferred embodiment of the invention relates to the separation of PCR-amplified portions of the allele via electrophoresis through a gradient of increasing temperature via TGCE (see Example 20). Differences in the amplified portion of the allele compared to amplified portions of the alleles contained in the similar test sample(s) are indicated by a difference in migration during
10 electrophoresis.

As mentioned above, the invention *inter alia* relates to high throughput screening methods. Preferably, the oligonucleotides according to the invention, used in these high throughput methods, are fixed on a solid support to form an array. The
15 solid support can comprise microplates, standard blotting membranes, or glass chips. In a preferred embodiment, the solid support is a glass chip with a modified surface capable of covalently binding to said oligonucleotides. Nucleic acid samples, preferably genomic DNA, are tagged, e.g. with a fluorescent marker, and allowed to interact with said oligonucleotides bound to the solid support. Hybridization will occur
20 at complementary sequences between nucleic acid sample and oligonucleotide, which is indicative for the presence of a mutation in said nucleic acid sample. Hybridization is then determined by scanning with a laser beam and analyzing the signal on a computer.

25 Suitable methods for the determination of partial or complete amino acid sequences are likewise well known, and include, for example, detection of particular epitopes within a protein sample via specific antibodies in dot blot, slot blot, or Western blot assays, or via ELISAs or RIAs, or partial amino acid sequence determination on a sequencer via Edman degradation. Also, high-throughput methods
30 may again be employed.

A further aspect of the present invention is represented by a method for identifying a predisposition of a mammalian subject, particularly a human subject, for developing a neurodegenerative disease, said method comprising the step of

determining whether a test sample derived from said subject indicates the presence of a mutation in an allele of the gene coding for a protein, which is a subunit of the dynactin/dynein complex, indicative of an increased risk of said human subject of developing said neurodegenerative disease.

5

Also contemplated in connection with the present invention is a method for determining whether a neurodegenerative disease in a mammalian subject, particularly a human subject, which is associated with a mutation in an allele of a gene coding for a protein, which is a subunit of the dynactin/dynein complex, said method comprising
10 the step of determining whether a test sample derived from said subject indicates the presence of a mutation in an allele of the gene coding for said protein.

As in the case of the methods described above, the test sample may also be a sample that has been obtained previously. Furthermore, suitable test samples
15 according to the invention are, for example, cDNA preparations that have been prepared from mRNA obtained from a tissue sample from a mammalian subject, particularly a human subject, at an earlier stage. It may also again be cloned or PCR-amplified DNA that originates from DNA contained in such tissue sample obtained at an earlier stage.

20

Again, the previously mentioned methods of determining partial or complete nucleic acid or amino acid sequences may be employed for the step of determining whether the test sample (which may be a nucleic acid or protein test sample as previously defined) indicates the presence of said mutation.

25

According to the above methods of identifying a predisposition in a mammalian subject, particularly a human subject, of developing a neurodegenerative disease, or determining a potential association between such a neurodegenerative disease and certain mutations, the test sample is analyzed for the presence of a
30 mutation in an allele of a gene of a protein, which is a subunit of the dynactin/dynein complex, which mutation is indicative of an increased risk of developing such a neurodegenerative disease.

On the molecular level, said methods would comprise analyzing said sample for the presence of a mutation, which would indicate an altered expression or function of said protein. It will be appreciated that such mutations are *inter alia* those referred to herein in connection with the proteins and nucleic acids according to the invention, and that mutations of this kind may be readily identified, for example, by *in vitro* assays. Such *in vitro* assays to determine whether the mutation in an allele of a gene coding for said protein affects the function of the complex may comprise the quantitative and/or qualitative determination of the binding of the subunits to each other within the complex. Qualitative methods may comprise SDS-PAGE and subsequent Western blotting of homogenates of, e.g. the spinal cord, using antibodies specific for the dynactin/dynein subunits. Disruption of the dynactin/dynein complex by a mutation in said proteins can be determined by, e.g. a difference in migration of the subunits compared to proteins derived from homogenates of similar tissue comprising the corresponding proteins without mutation (LaMonte *et al.*, see above.).

In another embodiment of the invention, disruption, or at least functional alteration of the dynactin/dynein complex due to mutations in its subunits, may be analyzed by affinity chromatography as described in Karki *et al.* (J Biol Chem 270, 28806-28811, 1995) or co-precipitation experiments as described in Paschal *et al.* (J Biol Chem 268, 15318-23, 1993). Quantitative methods to determine quantitative binding of the subunits within the complex to each other are, e.g. those using surface plasmon resonance (SPR), such as, for example, the Biacore technology (Biacore AB, Uppsala, Sweden) (see also Example 18). Further suitable *in vitro* assays comprise the step of determining whether a mutation in one or more subunits of the dynactin/dynein complex affects dynein motility. Such tests comprise, e.g. immunohistology with appropriate antibodies. To determine an effect of the mutation on axonal transport, antibodies directed against tubulin or synaptotagmin may be suitable (Martin *et al.*, 1999, Mol Biol Cell 10, 3717-3728).

In another embodiment of the invention, dynein motility may be determined by analysis of single-lipid-droplet motility as described by Welte *et al.* (Cell 92: 547-557, 1998) or a microtubule gliding assay (see Example 16). In another embodiment, the *in vitro* assays may comprise tests to determine whether the mutation in an allele of a gene coding for said protein affects the expression of the protein. In this regard, quantitative analysis of the mRNA expression levels may be applicable. These

methods may comprise, for example, Northern blotting or quantitative Polymerase Chain Reaction, which are well known to those skilled in the art.

In a further embodiment of the present invention, the above-mentioned mutations may be readily identified, for example, by an animal model (see Example 1).

The above-mentioned mutations may also be identified by any of the aforementioned methods of screening for disease-relevant alleles of said proteins.

10

The invention further comprises a kit for identifying a predisposition of a mammalian subject, particularly a human subject, for developing a neurodegenerative disease, or for identifying an association of a neurodegenerative disease of said subject with a mutation in an allele coding for a protein, which is a subunit of the dynactin/dynein complex. The kit according to the invention comprises one or more of the above-mentioned oligonucleotides suitable for identifying a mutation in an allele of a gene coding for a protein which is a subunit of the dynactin/dynein complex. In one preferred embodiment, the kit comprises oligonucleotide(s), the nucleotide sequence of which correspond(s) to a nucleotide sequence within said allele, which contains a mutation. In another preferred embodiment, the oligonucleotide(s) is(are) suitable for hybridizing to the nucleic acid of said allele or a portion of its nucleic acid under stringent conditions. In another preferred embodiment, the oligonucleotide(s) is(are) suitable as primer(s) for amplifying the nucleic acid of said allele or a portion of its nucleic acid. In another preferred embodiment, the kit further comprises instructions to use the oligonucleotide or the oligonucleotides for identifying said predisposition in said subject or said association of the neurodegenerative disease of said subject with said mutation.

The invention further comprises a solid support, wherein at least two oligonucleotides are individually fixed to separate areas of the solid support to form an array. Preferably the oligonucleotides fixed on the solid support are suitable for identifying a mutation in an allele of a gene coding for a protein, which is a subunit of the dynactin/dynein complex. Preferably, the oligonucleotides fixed on the solid support have a nucleotide sequence, which corresponds to a nucleotide sequence within said allele, which contains a mutation and, are suitable for hybridizing to the

nucleic acid of said allele or a portion of its nucleic acid under stringent conditions. The solid support can be a microplate or standard blotting membranes, such as nylon or nitrocellulose membranes. In a preferred embodiment, the solid support is a glass chip, preferably a glass chip with a modified surface. The surface of the glass chip is modified as to bind nucleic acids, preferably oligonucleotides, more preferably oligonucleotides with a nucleotide sequence, which corresponds to a nucleotide sequence within said allele, which contains a mutation.

A further embodiment of the present invention comprises the use of the previously mentioned oligonucleotides, or the previously mentioned kit, or the above-mentioned solid support, in a method for identifying a predisposition of a mammalian subject, particularly a human subject, for developing a neurodegenerative disease or in a method for determining whether a neurodegenerative disease in a mammalian subject, particularly a human subject, is associated with a mutation in an allele of a gene coding for a protein, which is a subunit of the dynactin/dynein complex as mentioned previously.

The invention will be further described in the following examples, which do not limit the scope of the invention described in the claims. The following examples are offered for illustrative purposes only, and are not intended to limit the scope of the present invention in any way.

EXAMPLE 1: Production of Animals of the Invention and Breeding Strategies

To produce mouse mutants, a C3HeB/FeJ male mouse (The Jackson Laboratory, Bar Harbor ME, USA) was injected intraperitoneally three times in weekly intervals between 8–10 weeks of age with ethyl-nitroso-urea (ENU) (Serva Electrophoresis GmbH, Heidelberg, Germany) at 90mg/kg body weight.

Generation of F1 Progeny:

50 days after the last injection the injected male mouse was mated to wild type C3HeB/FeJ female partners. The F1 progeny (up to 100 offspring) were then analyzed for phenotypes of dominant traits.

Generation of F2 Progeny-genetic confirmation of dominant phenotype:

Affected F1 individuals were mated to wild type C3HeB/FeJ mice and the resulting F2 progeny was screened for the identical pathological phenotype as identified in F1 generation.

Generation of F3 Progeny:

For maintenance purposes affected F2 individuals were mated to wild type C3HeB/FeJ mice. Affected F2 individuals were intercrossed to produce homozygous F3 individuals, which undergo perinatal lethality; therefore fetal tissues of these animals were analyzed. Heterozygous F3 individuals were used for the histochemical, neurological and physiological characterization of the *Cral* phenotype.

EXAMPLE 2: First Identification of Phenotype

The *Cral* mouse mutant was identified by the observation of hind limb cramping during manual tail suspension in the heterozygous condition (Figure 1). Adult mice were manually suspended by their tails for one minute. During this period it was observed whether the mice display cramping of their hind limbs. In all tests, the observation of hind limb cramping was invariably correlated to the heterozygous *Cral*/+ genotype.

A broad range of standard physiological values were tested, but were within wild type (control) ranges.

EXAMPLE 3: Analysis of Muscle Endurance and Motor Coordination

A semi-quantitative evaluation of the phenotype was accomplished by the application of the hanging wire assay (for results see Figure 3), as a tool for measuring muscle endurance. Muscle endurance of adult heterozygous *Cral* individuals (*Cral*/+) was measured in comparison to wildtype individuals by placing individual mice on a wire grid, mildly shaking the grid to cause the mouse to grip the wires with their paws, and then inverting the grid. The grid was held stationary in the inverted position and the time elapsed until the mouse fell was recorded as the latency to fall.

Both sexes of Cral mice exhibit a significantly reduced latency to fall off the grid in comparison to wild type mice.

A reduction in motor coordination was subsequently suggested by a reduced performance in the coat hanger and stationary beam assays. In a coat hanger assay a single heterozygous Cral animal was placed in the middle of the horizontal part of a metal coat hanger. The movements of the animal were observed for 45 seconds and assessed in comparison to movements of a wildtype mice in a separate assay. The following classification was used to describe the performance of the animal: "normal", the mouse climbs up the wire (horizontal and vertical movements); "abnormal", the mouse displays only horizontal movements or it does not display any movements (freeze) or it falls from the metal coat hanger.

In the stationary beam assay, a heterozygous mouse was placed in the middle of a stationary beam, which was divided into fourteen 5 cm zones. The animal was observed for 45 seconds. The following classification was used to describe the performance of the animal: "normal", the mouse moves between at least 3 zones; "abnormal", the mouse moves within less than 3 zones, or the mouse is falls from the stationary beam.

EXAMPLE 4: Determination of Movement Activity

To determine movement activity during an 24 hour interval, individual heterozygous Cral or wild type mice were monitored with a photobeam activity system (San Diego Instruments, San Diego, CA, USA), according to the manufacturer's instructions. A single animal was transferred into a type 3 mouse cage, with a photobeam frame assembled. Beam breaks caused by a moving mouse were counted automatically using a software package "SDI PAS Photobeam System V2" following the instructions of the manufacturer's handbook. Data were collected over a period of 24 hours after the animals had been acclimatized to the cages for 48 hours.

Figure 2 indicates that heterozygous Cral mice exhibit increased ambulatory activity in the early dark phase of an alternating 12 hour light/dark cycle.

EXAMPLE 5: Necropsy and Organ Histology of Mutant Animals

For sampling of organs, adult animals were perfusion fixed with 4% paraformaldehyde. Muscle samples were collected from anaesthetised mice and cryopreserved in liquid nitrogen cooled isopentane at -50°C . Embryos were immersion fixed in paraformaldehyde. Tissues were sampled and processed to paraffin wax. Sections were cut at 5 microns and stained according to subsequent usage.

1. Heterozygotes

The following histopathological aberrations were observed in adult $\text{Cral}^{+/-}$ (as compared to wild type mice)

in I). Brain:

Slight enlargement of the lateral and 3rd ventricles.

Neuronal eosinophilic inclusions in the arcuate and the preoptic nuclei of the hypothalamus.

Excitatory neuronal damage ("dark neurons") in hippocampus (gyrus dentatus, CA4, CA3), some areas of the upper cortex and the Purkinje cell layer of the cerebellum (see Figure 4A: hippocampus):

This type of neuronal damage is reversible: it can be evoked by challenging the individuals by tail suspension for two minutes immediately before sacrifice by cervical dislocation, and can be demonstrated as follows. Brains were removed immediately, immersion fixed in paraformaldehyde and processed for paraffin embedding using standard histopathological techniques. Coronal sections of 5 μm were mounted on glass slides and stained with hematoxylin and eosin by standard histological protocols. The phenomenon of dark neurons after acute neuronal cell stress is well recognized since some years in the neuropathological literature and resembles a fixation effect by aldehyde fixation. This cellular pathomorphology is not accompanied by astro- or microglial activation, it occurs under normal neuronal cell count, and it is only detectable after aldehyde fixation, but not by cryosectioning.

in II). Muscle:

Decreasing numbers of α -motor neurons and altered composition of musculus vastus fibre types. Muscle samples were processed according to standard protocols

and were cut at 5 μ m. Staining of NeuN protein was performed by immunohistochemical analysis with an anti NeuN antibody Mab377 (Chemicon Int. Inc., Temecula, CA, USA), detecting decreasing numbers of α -motor neurons. Periodic acid-Schiff (PAS) staining was performed according to standard protocols, detecting an altered composition of musculus vastus fiber tybes (see Fig. 4B).

2. Homozygotes

The following preliminary histopathological observations were made in organs of E17.5

Cral/Cral fetus as compared to wild type individuals: Neurodegeneration in the anterior horns of the spinal cord:

Mature motor neurons were sparse in the anterior horn region of homozygotes when compared to heterozygote or wildtype littermates. From a histomorphological aspect approximately 50 % of motor neuros were missing, the remaining neurons were smaller of size and did not have a normal mature aspect.

Detection of apoptotic cell death within the anterior horns of the spinal cord:

Apoptosis detection was performed as follows: deparaffinized and rehydrated paraffin sections were treated with proteinase K (20 μ g/ml) for 15 minutes at room temperature. Apoptotic cells were detected in situ by the TUNEL (terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling) assay using the Roche *in situ* cell death detection kit POD (Roche Diagnostics GmbH, Mannheim, Germany), according to the manufacturer's instructions, and using diaminobenzidine as a staining dye. The percentage of TUNEL positive cells was clearly increased in the anterior horn region of the homozygous embryos when compared to heterozygote and wildtype littermates, where only few positive neuronal cells were detected.

EXAMPLE 6: Mapping and Cloning of the Mutation in Mutant Animals of the Invention

1. Generation of F3- and F4-Hybrids

F3-hybrids were generated by mating affected F2-individuals to C57BL/6J wildtype mice. F3 hybrids were designated as DO1. DO1 individuals were screened for the Cral phenotype directly after weaning. For mapping and positional cloning of the mutated gene affected F3-hybrids were either intercrossed to generate F4

intercross individuals, designated as DIC individuals, or outcrossed to C57BL/6J wildtype mice to generate F4-individuals, designated as DO2 individuals.

2. DNA Isolation from Rodent Tails and Macromapping

5 Mouse genomic DNA was purified from 1 cm long pieces of tails of DIC or DO2 mice by using the "DNeasy 96 Tissue Kit" (Qiagen, Hilden, Germany) according to the manufacturer's protocol.

10 For chromosomal mapping of the mutant locus in the Cral mouse line standard outcross/backcross and outcross/intercross strategies in strain C57Bl/6Jico (Ifacredo, France) were used in combination with microsatellite markers specific for the C3HeB/FeJ and C57Bl/6Jico strains equally distributed over all 19 mouse chromosomes.

15 Oligonucleotides were obtained from MWG-Biotech AG (Ebersberg, Germany). PCR reactions were performed with fluorescent-labeled primers, whose sequences were taken from Schalkwyk et al., 1999, <http://www-genome.wi.mit.edu/> (site maintained by the Whitehead Institute for Genome Research, Cambridge MA, USA). The PCR reactions were performed in a MJ tetrad thermocycler PTC 225
20 device (MJ Research, Inc., Waltham MA, USA) in 25µl reaction volumes, using BioTherm-DNA-polymerase (Genecraft, Germany). A four minute denaturation step was then followed by 28 amplification cycles, each comprising 30 seconds denaturation and 30 seconds annealing at the respective temperatures given in Schalkwyk et al., see above, and 30 seconds extension at 72°C. Samples were
25 amplified with different dyes and products were separated on an ABI 3700 DNA sequencing device (PE Applied Biosystems, Foster City, USA) using internal length standards in every lane. Analysis was performed with Genescan version 3.0 and Genotyper version 2.1 software from ABI. We macromapped the locus of the mutation by identifying a chromosomal region having an increased allele frequency of
30 markers representing the C3H founder strain.

Our analysis of DO2 and DIC mice indicated that the Cral mutation cosegregates with the marker D12Mit141 on chromosome 12.

3. Fine Mapping

A detailed haplotype analysis of affected and non-affected Cra1 mice using identified single nucleotide polymorphisms (SNPs) located in the critical region demonstrated, that the mutation was located between SNP markers in the Ppp2r5c
5 gene (encoding the protein phosphatase 2, regulatory subunit B (B56), gamma isoform) and the Traf3 gene (encoding the Tnf receptor-associated factor 3).

4. PCR Amplification of Cytoplasmic Dynein Heavy Chain1 Gene

10 Oligonucleotides were obtained from MWG-Biotech AG (Ebersberg, Germany). The PCR reactions were performed in a MJ tetrad thermocycler PTC 225 device (MJ Research, Inc., Waltham MA, USA) in 25µl reaction volumes using BioTherm-DNA-polymerase (Genecraft, Germany). A four minute denaturation step was then followed by 28 amplification cycles comprising each 30 seconds
15 denaturation and 30 seconds annealing at the respective temperatures given in Schalkwyk *et al.* (1999), and 30 seconds extension at 72°C. A total of 77 exon sequences of the murine Dnchc1 gene were identified by sequence alignment of the full-length mouse Dnchc1 cDNA sequence (GenBank Acc. No. AY004877) and mouse BAC clone RPCI-23-134O19 (GenBank Acc. No. AL596265) using
20 Sequencher™ Version 4.0.5 (Gene Codes Corp., Ann Arbor MI, USA). Exon specific primers located in the flanking intronic sequences were designed using Primer3, maintained by the Whitehead Institute for Biomedical Research.

All 77 exons of the Dnchc1 gene were amplified using a DNA pool of 4
25 affected pups (Cra1/Cra1) as well as C3H and C57 control DNA as PCR templates.

5. DNA Sequence Analysis

PCR amplicons were purified by using the QIAquick PCR Purification Kit (Qiagen, Hilden, Germany) according to the manufacturers protocol. PCR products
30 were sequenced using forward/reverse PCR primers and "Big Dye" thermal cycle

sequencing Kit (ABI PRISM, Applied Biosystems, Foster City CA, USA). The reaction products were analyzed on an ABI 3700 DNA sequencing device.

The sequences were edited manually and contig assembly for mutation detection was performed using Sequencher version 4.0.5 (Gene Codes Corp., Ann Arbor MI, USA). The sequence analysis detected an A to G (codon TAC to TGC) transition in exon 13 of the mouse gene, at a location corresponding to nucleotide position 3328 (position +3164 of the coding sequence) in the Dnchc1 mRNA sequence (GenBank Acc. No. AY004877, SEQ ID NO:1). The PCR amplicons with 364 bp in size, and including exon 13, were generated by PCR amplification with oligonucleotide Dnchc 1-25 (5'-TCCAAGACTTTGAAGTGAGGTTC; located in intron 12, SEQ ID NO:15) and with oligonucleotide Dnchc1-26 (5'-CAGGGCCAAACACCAATACT; located in intron 13, SEQ ID NO 16). The PCR amplicons generated contain either the wild type sequence (SEQ ID NO:13) or the mutated sequence (SEQ ID NO:14), as listed in Tables 10 and 11, respectively.

Table 10. Wild type Dnchc1 364 bp PCR Amplicon (SEQ ID NO:13)

wild type:

```

20   TCCAAGACTTTGAAGTGAGGTTCCTAATGGTGTGAAGACATGGA
    CTGTTGACATGGTGGGTTCTAGCATATTAATAGTCTACAGCACTG
    CAGACTAGAATTGAGCTGTGTTTCCTTTGCAGGTTTGGCTTCAGT
    ACCAGTGTTTGTGGGATATGCAGGCAGAAAACATTTACAACAGGC
    TAGGGGAAGATCTCAACAAGTGGCAAGCTCTCCTGGTCCAGATAA
25   GGAAAGCCAGAGGAACCTTTGACAATGCGGAAACCAAGAAAGAGT
    TTGGTCCGGTGGTGATAGATTACGGCAAGGTGAGCTTGGCTTGTT
    GTCAAAGGCACCAGGCAGCCGTAAGATCAGTATTGGTGTTTGGC
    CCTG

```

30

Table 11. Mutant Dnchc1 364 bp PCR Amplicon (SEQ ID NO:14)

mutant:

```

35   TCCAAGACTTTGAAGTGAGGTTCCTAATGGTGTGAAGACATGGA
    CTGTTGACATGGTGGGTTCTAGCATATTAATAGTCTACAGCACTG
    CAGACTAGAATTGAGCTGTGTTTCCTTTGCAGGTTTGGCTTCAGT
    GCCAGTGTTTGTGGGATATGCAGGCAGAAAACATTTACAACAGGC
    TAGGGGAAGATCTCAACAAGTGGCAAGCTCTCCTGGTCCAGATAA
    GGAAAGCCAGAGGAACCTTTGACAATGCGGAAACCAAGAAAGAGT
    TTGGTCCGGTGGTGATAGATTACGGCAAGGTGAGCTTGGCTTGTT
40   GTCAAAGGCACCAGGCAGCCGTAAGATCAGTATTGGTGTTTGGC
    CCTG

```

The A to G transition (see nucleotide exchange underlined in SEQ ID NO:14) results in an Tyr (Y) to Cys (C) amino acid exchange at aa position 1055 in SEQ ID NO:2. The mutation was confirmed by sequence analysis of 13 adult *Cra1*^{+/+} mice and 5 *Cra1*^{-/-} pups, respectively. The complete nucleic acid sequence of the mutant transcript (SEQ ID NO:3) and the complete amino acid sequence of the mutant protein (SEQ ID NO:4) are shown above.

EXAMPLE 7: Method for Production of Mutant Animals of the Invention by Gene Targeting Technology

10 The construction of a recombinant targeting vector to insert a point mutation in exon 13 of the mouse *Dnchc1* gene may be performed according to well known techniques: for example by the Lambda-KO-*Sfi* system of Nehls and Wattler, WO-A2-01/75127.

1. Vector construction

15 In a first step, a 1,5kbp genomic DNA fragment was PCR amplified, representing the left arm of homology of the targeting vector to be constructed. After subsequent subcloning of the PCR fragment into a plasmid vector, for example *pCR 2.1-TOPO* (K4500-01, Invitrogen Corp., Carlsbad, California, USA), according to the manufacturer's instructions, plasmid DNA, bearing the correct *Dnchc1* insert is subject to site-directed mutagenesis, using a *QuickChange Site-Directed Mutagenesis Kit* (200518, Stratagene, La Jolla CA, USA), as outlined in the manufacturer's instructions. The plasmid vector (parental DNA template) and two oligonucleotide primers, each primer complementary to opposite strands of the vector insert and containing the desired point mutation (exon 13, position 3169 of *Dnchc1*cDNA), were denatured and subject to PCR amplification with a proof-reading DNA polymerase (*Pfu* Turbo), provided in the kit. Using the non-strand displacing action of *Pfu* Turbo DNA polymerase, mutagenic primers were incorporated and extended, resulting in nicked circular DNA strands. In a restriction digest with *DpnI*, only the methylated parental parental DNA template was susceptible to *DpnI* digestion. After transformation in XL1-Blue supercompetent cells, provided with the kit, nicks in the mutated (point mutation) plasmid DNA were repaired. Mutation positive colonies were selected and plasmid DNA was isolated, according to the manufacturer's instructions (Stratagene, La Jolla CA, USA).

20

25

30

Plasmid DNA, bearing the point mutation in exon 13, as described in the present invention, was subject to PCR amplification with primers, bearing *Sfi*C and *Sfi*A sequence overhangs, respectively, as described in the published patent application WO-A2-01/75127. The PCR fragment, representing the left arm of homology was further processed as described in the aforementioned patent application. The vector described in WO-A2-01/75127, includes a linear lambda vector (lambda-KO-*Sfi*) that comprises a stuffer fragment, an *E. coli* origin of replication, an antibiotic resistance gene for bacteria selection, two negative selection markers suitable for use in mammalian cells, and LoxP sequences for cre-recombinase mediated conversion of linear lambda phages into high copy plasmids. In a final lambda targeting vector, the stuffer fragment was replaced by *Sfi* A,B,C,D ligation of the left arm of homology (bearing the Dnchc1 point mutation in exon 13), an ES cell selection cassette, and a right arm of homology, as described in the aforementioned patent application. In-vitro packaging of the ligation products, plating of a phage library, plasmid conversion, and DNA isolation of the homologous recombination plasmid vector is performed according to standard procedures known to persons skilled in the art.

2. ES Cell Transformation and Production of Mice

Targeting vectors containing the point mutation were used for mouse ES cell transformation and to producing chimeric mice by blastocyst injection and transfer using standard methodology, well known in the art. The chimeras were bred to wild type mice to determine germline transmission. Heterozygotes and subsequently homozygotes were generated according to well-known techniques.

25

EXAMPLE 8: Method for the Detection of Nucleic Acid of the Present Invention: Mutation Detection using a Polymorphic *Rsa*I Restriction Site

The nucleotide transition A to G in the nucleic acid sequence of the Dnchc1 gene results in the disappearance of a restriction site for the restriction enzyme *Rsa*I. As a result, the restriction pattern of the nucleic acid sequence of Dnchc1 will differ between the wild type and the mutant sequence. Diagnostic analysis was applied on amplified fragments from nucleic acids extracted from mutant and wild type mice as

30

already described in the example. PCR and restriction steps were performed as follows.

The PCR reactions were carried out on 10ng genomic DNAs using primers
5 Dnchc1-25
(5'-TCCAAGACTTTGAAGTGAGGTTC, located in intron 12, SEQ ID
NO:15) and Dnchc1-26 (5'-CAGGGCCAAACACCAATACT, located in intron 13,
SEQ ID NO:16), generating PCR products of either SEQ ID NO:13 (including the
wild type exon 13 sequence) or SEQ ID NO:14 (including the mutant exon 13
10 sequence). The products have a size of 364 bp.

PCR reactions were performed in 25 µl using *Taq*-DNA polymerase (SIGMA,
Deisenhofen, Germany) according to the manufacturer's protocol. A further 4 minute
denaturation step was followed by 28 cycles of denaturation at 94°C for 30 seconds;
15 annealing at 55°C for 30 seconds; and 90 seconds extension at 72°C or the enzymatic
digestion, 7 µl of PCR reaction, 10 µl H₂O, 2 µl NEB buffer 1 and 1 unit *Rsa*I (New
England BioLabs, Inc., Beverly MA, USA) were incubated at 37°C for 2 hours.
Restriction fragments were size separated by electrophoresis on 2% agarose gels
(SeaKem ME agarose, Biozym Diagnostik GmbH, Hess. Oldenburg, Germany) with
20 0.5 µg ethidium bromide ml⁻¹ agarose. Gels were photographed after 2 hours
electrophoresis at 3 V m⁻¹. The presence of the point mutation deletes the *Rsa*I site
present in the PCR product of the wild type. This results in the appearance of a non-
restricted fragment of 364 bp in the *Cral*^{-/-} mutant samples in contrast to two
restriction fragments of 136 bp and 228 bp in the wild type. This procedure even
25 allows the discrimination of heterozygous and homozygous *Cral* mutants.

EXAMPLE 9: Identification of the Full-Length cDNA Sequence of Human DNCH1

No full-length cDNA sequences of the human DNCH1 gene have been
30 published. Here, we disclose a full-length cDNA sequence of the human DNCH1
gene, which has the highest homology to the coding sequence of the orthologous
mouse gene, Dnchc1 (mRNA sequence published as Genbank Accession No.
AY004877).

Although incomplete human DNCH1 mRNA sequences, and several EST sequences containing partial sequences of human DNCH1, have been published, construction of the correct, full-length sequence for human DNCH1 cDNA has not previously been achieved, perhaps as a consequence of the large size of the transcript, approximately 14.5 kb. Sequencing of several full-length cDNA clones generated from RNA of various human tissues obtained from independent sources confirms the sequence disclosed herein as SEQ ID NO:17. Particular attention is required to prevent RNA degradation, especially in those tissues known to exhibit high RNase activity (e.g. brain tissues); the use of fresh tissue being especially important.

EXAMPLE 10: Comparison of the Full-Length cDNA Sequences of Human DNCH1 and Mouse Dnchc 1

An exon structure comparison, as schematically depicted in Fig. 7, indicates an almost perfect identity in exon number and exon lengths between the mouse cytoplasmic dynein heavy chain1 (Dnchc 1) and the human cytoplasmic dynein heavy chain1 (DNCH 1) cDNAs. Exonic sequences were aligned with Sequencher software (version 4.0.5, GeneCodes Corp., Ann Arbor MI, USA).

Figure 8 exhibits a comparative listing of all mouse (MmDnchc1) and human (Hs DNCH1) cytoplasmic dynein heavy chain1 gene exons. The size of each exon is indicated in length by basepairs (bp). The human gene consists of 78 exons, and the mouse gene consists of 77 exons. The difference is caused by an additional RNA splice event in human, separating exon 67 (61 bp) and exon 68 (124 bp). The total lengths of the cDNAs are 13.941 bp in human DNCH 1, and 13.935 bp in mouse Dnchc 1.

EXAMPLE 11: Characteristics of Human and Mouse Cytoplasmic Dynein Heavy Chain1 Protein

The human ortholog of the mouse cytoplasmic dynein heavy chain1 protein, human cytoplasmic dynein heavy chain1 protein, has a length of 4646 amino acid residues (in comparison to 4644 for the corresponding mouse protein). Figure 9 represents an amino acid alignment of human DNCH 1 and mouse Dnchc 1, with

black boxes indicating amino acid identity, and grey boxes indicating amino acid similarity. The amino acid identity is 97%, indicating that these are true orthologs.

EXAMPLE 12: Detection of Transcriptionally Deregulated Genes Expressed in the Brain

A series of genes selected for their putative biological relevance to cytoplasmic dynein heavy chain1 function were analysed for altered RNA expression levels in the brain of homozygous Cra1 mice, in comparison to expression levels in brain of wild type mice.

Significantly altered expression levels were found for those genes listed in Figure 6. Transcriptional deregulation was determined by quantitative PCR-Light Cycler technology (Roche Diagnostics GmbH, Mannheim, Germany), according to the manufacturer's instructions.

EXAMPLE 13: Exons 12 and 13

Exon 13 is critical for activity of the cytoplasmic dynein heavy chain1, as demonstrated by the altered activity of the mouse protein bearing the amino acid substitution at position 1055, encoded by exon 13, the causative point mutation being located close to the 5' end of exon 13. The nucleotide sequence of exon 13 of the mouse wild type Dnchc 1 is provided as SEQ ID NO:19.

Table 12. Nucleotide sequence of mouse exon 13 (SEQ ID NO:19)

```
GTTTGGCTTCAGTACCAGTGTGTTGTGGGATATGCAGGCAGAAAAC
ATTTACAACAGGCTAGGGGAAGATCTCAACAAGTGGCAAGCTCTC
CTGGTCCAGATAAGGAAAGCCAGAGGAACCTTTGACAATGCGGAA
ACCAAGAAAGAGTTTGGTCCGGTGGTGATAGATTACGGCAAG
```

As the causative point mutation is close to the 5' end of exon 13, it is probable that the amino acid sequence encoded by exon 12 also has a significant influence on the activity of the protein.

SEQ ID NO:20 indicates the nucleotide sequence of exons 12 plus 13 of the mouse wild type Dnchc 1.

Table 13. Nucleotide sequence of mouse exon12 and 13 (SEQ ID NO:20)

GTGGGAGTGCATTACGAGTTGACAGAGGAAGAGAAGTTCTATCGG
AATGCACTGACAAGGATGCCCCACGGCCCTGTCGCCCTGGAAGAG
5 TCCTACTCTGCGGTCATGGGCATAGTGAAGTTGAGCAGTAT
GTTAAGGTTTGGCTTCAGTACCAGTGTTTGTGGGATATGCAGGCA
GAAAACATTTACAACAGGCTAGGGGAAGATCTCAACAAGTGGCAA
GCTCTCCTGGTCCAGATAAGGAAAGCCAGAGGAACCTTTGACAAT
GCGGAAACCAAGAAAGAGTTTGGTCCGGTGGTGATAGATTACGGC
10 AAG

The amino acid sequences encoded by exons 12 plus 13 are located within a region known to be important for heavy chain dimerization (Tynan *et al.* (2000) J Biol Chem 275, 32769-32774). Therefore these amino acid sequences, and the peptide
15 sequences encoded by the corresponding exons in other mammalian systems, may be used as targets for inactivation of the protein by small molecules, antibodies, antibody fragments, aptamers and other molecules designed to bind thereto.

20 **Table 14. Amino acid sequence encoded in-frame by nucleotide sequences of mouse exon 13 (SEQ ID NO:21)**

VWLQYQCLWDMQAENIYNRLGEDLNKWQALLVQIRKARGTFDNAE
TKKEFGPVVIDYGK
25

Table 15. Amino acid sequence encoded in-frame by nucleotide sequences of mouse exon 12 and 13 (SEQ ID NO:22)

30 VGVHYELTEEEKFYRNALTRMPDGPVALEESYSAVMGIVTEVEQY
VKVWLQYQCLWDMQAENIYNRLGEDLNKWQALLVQIRKARGTFDN
AETKKEFGPVVIDYGK

The corresponding human peptide sequences, encoded by human exon 13 (SEQ ID NO:23), or human exon 12 and 13 (SEQ ID NO:24), are preferred embodiments of the invention.

5

Table 16. Amino acid sequence encoded in-frame by nucleotide sequences of human exon 13 (SEQ ID NO:23)

VWLQYQCLWDMQAENIYNRLGEDLNKWQALLVQIRKARGTFDNAE
10 TKKEFGPVVIDYGK

Table 17. Amino acid sequence encoded in-frame by nucleotide sequences of human exon 12 and 13 (SEQ ID NO:24)

15

VGVHYELTEEEKFYRNALTRMPDGPVALEESYSAVMGIVSEVEQY
VKVWLQYQCLWDMQAENIYNRLGEDLNKWQALLVQIRKARGTFDN
AETKKEFGPVVIDYGK

Table 18. Amino acid sequence encoded in-frame by nucleotide sequences of human exon 12 and 13 (SEQ ID NO:24)

VGVHYELTEEEKFYRNALTRMPDGPVALEESYSAVMGIVSEVEQY
VKVWLQYQCLWDMQAENIYNRLGEDLNKWQALLVQIRKARGTFDN
25 AETKKEFGPVVIDYGK

EXAMPLE 14: Gene Therapy

A number of viruses, including retroviruses, adenoviruses, herpes viruses, and
30 pox viruses, have been developed as live viral vectors for gene therapy. A nucleic acid that codes for mutated cytoplasmic dynein heavy chain1 protein (e.g. SEQ ID NO:4, SEQ ID NO:6) is inserted into the genome of a parent virus to allow it to be expressed by that parent virus. This task is accomplished by first constructing a DNA donor vector for *in vivo* recombination with a parent virus.

The DNA donor vector contains:

- (i) a prokaryotic origin of replication, so that the vector may be amplified in a prokaryotic host;
- 5 (ii) a gene encoding a marker which allows selection of prokaryotic host cells that contain the vector (*e.g.* a gene encoding antibiotic resistance);
- (iii) at least one gene encoding a desired protein located adjacent to a transcriptional promoter capable of directing the expression of the gene; and
- (iv) DNA sequences homologous to the region of the parent virus genome
- 10 where the foreign gene or genes will be inserted, flanking the construct of element (iii).

The donor vector further contain additional genes which encodes one or more marker which will allow identification of recombinant viruses containing inserted

15 foreign DNA. The marker genes to be used include genes that encode antibiotic or chemical resistance (*e.g.* see Spyropoulos *et al.* (1988) J Virol 62, 1046-1054; Falkner and Moss (1988) J Virol 62, 1849-1854; Franke *et al.* (1985) Mol Cell Biol 5, 1918-1924), as well as genes such as the *E. coli lacZ* gene, that permit identification of recombinant viral plaques by calorimetric assay (Panicali *et al.* (1986) Gene 47,

20 193-199).

Homologous recombination between donor plasmid DNA and viral DNA in an infected cell are made using standard techniques. The recombination results in the formation of recombinant viruses that incorporate the nucleic acid encoding SEQ ID

25 NO:4. Appropriate host cells for *in vivo* recombination are eukaryotic cells that can be infected by the virus and transfected by the plasmid vector such as, for example, chick embryo fibroblasts, HuTK143 cells (human cells), and CV-1 and BSC-40 cells (both monkey kidney cells). Infection of cells by the virus and transfection of these cells with plasmid vectors is accomplished by techniques standard in the art.

30

Following *in vivo* recombination, recombinant viral progeny are identified by co-integration of a gene encoding a marker or indicator gene with the foreign gene or genes of interest, which, in this case, is the β -galactosidase gene. The presence of the β -galactosidase gene is selected using the chromogenic substrate 5-bromo-4-chloro-3-

indolyl- β -D-galactosidase (Panicali *et al.* (1986) Gene 47, 193). Recombinant virus appears as blue plaques in a lawn of the host cells. Expression of the polypeptide encoded by the inserted gene is further confirmed by *in situ* enzyme immunoassay performed on viral plaques and confirmed by Western blot analysis, radioimmunoprecipitation assay (RIPA), and/or enzyme immunoassay (EIA). Positive viruses are cultured and expanded and stored.

In gene therapy, B cells are collected from peripheral blood of a patient and infected at MOI of 1, 2, 4, 8, 10 and 20. Expression of the cytoplasmic dynein heavy chain1 is assayed 24 hours post-infection. Wild type virus is used as the negative control. The percent of cells transduced as a function of MOI and days after infection was determined by antibody and chromogenic substrate assays described above. B cells transduced at high efficiency are reintroduced into the patient.

EXAMPLE 15: Transgenic animal model bearing transgenic cytoplasmic dynein heavy chain1

Transgenic mice carrying a mammalian dynein heavy chain 1 transgene are generated by either using the embryonic stem cell method, or the pronucleus method, both of them well-known methods in the art; preferably using the method of Nehls and Wattler, as described in WO-A2-01/75127. For transgenic methods see also US patents US6436701, US6018097, US5942435, US5824837, US5731489, and US5523226.

EXAMPLE 16: In vitro dynein motility assay

Abnormalities in axonal transport are described in the human disease ALS (Sasaki and Iwata (1996) Neurology 47, 535-540). Such abnormalities are also observed in several mouse models with motor neuron degeneration, *e.g.* the wobbler mouse (Mitumoto *et al.* (1986) Ann Neurol 19, 36-43) and transgenic mice overexpressing the heavy chain of neurofilament protein (Collard *et al.* (1995) Nature 375, 61-64), SOD-1 (Zhang *et al.* (1997) J Cell Biol 139, 1307-1315) and dynamin (LaMonte *et al.* (2002) Neuron 34, 715-727). Studies in *Drosophila* have shown that mutations in the cytoplasmic dynein heavy chain (*cDhc64c*) lead to a disruption of axonal organelle transport in both directions and as a consequence to axonal swelling and posterior paralysis (Martin *et al.* (1999) Mol Biol Cell 10, 3717-3728).

A microtubule gliding assay is performed based on a commercial assay offered by Cytoskeleton, Inc. (Denver, CO, USA). In brief, the assay involves coating a glass slide with the protein of interest and then examining, by time-lapse or by real time microscopy, the protein's ability to translocate microtubules in the presence of ATP. Cytoplasmic dynein heavy chain 1 proteins, carrying non-conserved amino acid substitutions at residue positions as highlighted in Figures 9 and 10, and listed in Example 19, are over-expressed either in a bacterial, or in an eucaryotic expression system. A preferred method is the cDNA subcloning into expression vectors of the Gateway cloning and expression system (Invitrogen, California, USA), according to the manufacturer's instructions. Purification of recombinant dynein heavy chain 1 from host cells can be performed using standard methods well-known to those skilled in the art. For standard references, see in Sambrook et al. (eds.), MOLECULAR CLONING: A LABORATORY MANUAL (2nd Ed.), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989; and Ausubel et al. (eds.), CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, NY, 1993.

Differences in proteins ability to translocate microtubules in the presence of ATP, whereby the proteins carry particular non-conserved amino acid substitution, are indicative of functional domains of dynein heavy chain 1 in axonal transport.

20

EXAMPLE 17: Interaction of the dynein complex with the EAAT2 glutamate transporter

A direct link between the Cral mouse line and the excitotoxicity hypothesis for ALS, as described in the background of the Invention, is the excitatory neuronal damage detected in the brains of heterozygote Cral animals. Comparable defects have been found in the brains of mice lacking EAAT2, an glutamate transporter (Tanaka et al., Science vol.276, 1699-1702, june 1997).

Co-immunoprecipitation studies using antibodies raised against the cytoplasmic dynein heavy chain 1, the 74 kDa intermediate chain, the dynactin p150 component and against the EAAT2 transporter in various combinations are performed using brain homogenates of wild type mice, Cral homozygotes, and Cral heterozygotes. Anti dynein heavy chain 1 antibodies are raised against epitopes, which carry non-conserved amino acid substitutions of those amino acid residues highlighted

in Figures 9 and 10, and listed in Example 19. Protein expression vectors and antibodies are generated as described, in example, in Ausubel et al., Current protocols in Molecular Biology, Massachusetts general Hospital, Harvard Medical School, 1996 by John Wiley and Sons, Inc.). Antibodies raised against the 74 kDa intermediate chain, the dynactin p150 component and against the EAAT2 transporter are commercially available (anti-EAAT2 antibody from Accurate Chemical and Scientific Corp; anti-74 kDa intermediate chain antibody from Chemicon Int. Corp.; anti-dynactin p150 antibody from BD Transduction Laboratories). Co-Immunoprecipitation studies are well known in the art and are performed as described, for example, in Ausubel et al., Current protocols in Molecular Biology, Massachusetts general Hospital, Harvard Medical School, 1996 by John Wiley and Sons, Inc.).

The results of the assay are indicative for dynein heavy chain 1 function in EAAT2 glutamate transporter/dynein motor complex interaction. Functional amino acid residues are identified.

EXAMPLE 18: Quantitative Binding Study

To investigate a possible influence of an cytoplasmic dynein heavy chain 1 mutation on the whole dynein complex, which might result in an impaired transport process, quantitative binding studies are performed. Surface plasmon resonance (SPR) spectroscopy, such as, in example, in the Biacore technology (Biacore AB, Uppsala, Sweden) is an appropriate tool. By this method the interaction of two molecules binding each other is described by two rate parameters, the association rate parameter $k(a)$ and the dissociation rate parameter $k(d)$. Under standardized conditions these kinetic parameters can be determined by analysis of their interaction in an affinity-based biosensor system. The association rate describes the collision frequency and the attraction between two molecules. The dissociation rate describes the stability of the complex.

30

Using the SPR technique, the affinity of mutated dynein heavy chain domains, carrying non-conserved amino acid substitutions of the residues highlighted in Figures 9 and 10, and listed in Example 19, to other components of the dynein complex are analysed.

In similar studies the influence of mutations on protein – protein affinities have been studied (Hobba et al., J Biol Chem 273(31):19691-19698) 1998; Starling et al., J Exp Med 185(8):1487-1492, 1997).

5

EXAMPLE 19: Characterization of dynactin/dynein complex proteins from different species – amino acid conservation

Inter-species comparison of mouse and human dynein heavy chain 1, dynein intermediate chain 1, dynein intermediate chain 2, and DCTN 1 amino acids was performed. The degree of identity and the degree of similarity are summarized in the following table:

10

Protein of the dynactin/dynein complex	Degree of Identity	Degree of Similarity
Dynein heavy chain1	97%	98%
Dynein intermediate chain 1	88%	89%
Dynein intermediate chain 2	94%	95%
DCTN 1	97%	98%

The high degree of amino acid identity and similarity is indicative for highly conserved residues between the species indicating functional significance of these conserved residues in the proteins compared in this Example, see Figures 9, 11, 13 and 15. The amino acid being exchanged in dynein heavy chain 1 (1055Y to C, as described in the invention herein) is conserved between the species compared, as indicated in Figure 9.

20

In an inter-species comparison of mouse, human, and rat dynein heavy chain 1, dynein intermediate chain 1, dynein intermediate chain 2, and DCTN 1 amino acids was performed, the degree of identity and the degree of similarity are summarized in the following table:

25

Protein of the dynactin/dynein complex	Degree of Identity	Degree of Similarity
---	--------------------	----------------------

Dynein heavy chain1	95%	96%
Dynein intermediate chain 1	87%	88%
Dynein intermediate chain 2	93,5%	94,5%
DCTN 1	95%	96%

The high degree of amino acid identity and similarity is indicative for highly conserved residues between the species indicating functional significance of these conserved residues in the proteins compared in this Example, see Figure 10, 12, 14, and 16. The amino acid being exchanged in dynein heavy chain 1 (1055Y to C, as described in the invention herein) is conserved between the species compared, as indicated in Figure 10.

For several subunits of the dynactin/dynein complex, several binding domains are predicted, with which the individual proteins of the dynactin/dynein complex binds to other subunits of the complex. The binding domains of several proteins, which are subunits of the dynactin/dynein complex are summarized in respect to the amino acids positions:

a) With respect to mouse Dnchc1 the following domains and binding sites are predicted, which are summarized in respect to the amino acid positions of the mouse Dnchc1 protein:

heavy chain dimerization domain (Hcd) between amino acids 300 and 1140; 74 kDa intermediate chains binding domain (Icd) between amino acids 446 and 701; 53-59 kDa light intermediate chains binding domains (Lcds) between amino acids 649 and 800 (Tynan *et al.* (2000) J Biol Chem. 275, 32769-32774).

b) With respect to cytoplasmic dynein intermediate chain 1 the following binding domains are predicted, which are summarized in respect to the amino acid positions of the mouse cytoplasmic dynein intermediate chain 1 protein:

10 kDa light chain binding domain (10kDad) between amino acids 147 and 157 (Lo *et al.*, J.Biol. Chem. 276(17):14059-14066, 2000); light chain 2B binding domain (2Bd) between amino acids 243 and 314 (Susalka *et al.*, J. Biol. Chem. 277(36):32939-32946, 2002); Tctex1 binding domain (Tctex1d) between amino acid 140 and 157 (Mok *et al.* J. Biol. Chem. 276(17):14067-14074, 2001); p150 binding

domain (p150d) between amino acid 1 and 123 (see in Susalka et al., J. Biol. Chem. 277(36):32939-32946, 2002).

c) For mouse cytoplasmic dynein intermediate chain 2 several binding
5 domains are predicted, which are summarized in respect to the amino acid positions of the mouse cytoplasmic dynein intermediate chain 2 protein:

10 kDa light chain binding domain (10kDad) between amino acids 129 and 139; light chain 2B binding domain (2Bd) between amino acids 226 and 297; Tctex1 binding domain (Tctex1d) between amino acid 122 and 139; p150 binding domain
10 (p150d) between amino acid 1 and 123 (see in Susalka et al., J. Biol. Chem. 277(36):32939-32946, 2002).

d) For mouse p150 (DCTN 1) several binding domains are predicted, which are summarized in respect to the amino acid positions of the mouse p150
15 protein:

microtubule binding domain (Microtd) between amino acids 39 and 150 (Waterman-Storer et al, P.N.A.S. 92:1634-1638, 1995); ARP1 binding domain (ARP1d) between amino acids 1006 and 1021 (see in Waterman-Storer et al, P.N.A.S. 92:1634-1638, 1995); cytoplasmic dynein intermediate chain binding domain (Dicd)
20 between amino acid 133 and 899 (Karki and Holzbaur, J. Biol. Chem. 270:28806-28811, 1995).

In an inter-species comparison of the amino acids of the corresponding mouse and human proteins, the degree of conserved (i.e. identical and similar) amino acids in
25 these domains and binding sites is summarized in the following tables:

Cytoplasmic dynein heavy chain 1	
Binding site to	Degree of conservation
Hcd	99,5%
Icd	99%
Lcds	99,5%

Cytoplasmic dynein intermediate chain 1

-180-

Binding site to	Degree of conservation
10kDad	100%
2Bd	98,6%
Tctex1d	100%
P150d	86,2%

Cytoplasmic dynein intermediate chain 2	
Binding site to	Degree of conservation
10kDad	90%
2Bd	98,6%
Tctex1d	94%
P150d	74%

P150 (DCTN 1)	
Binding site to	Degree of conservation
Microd	98%
ARP1d	100%
Dicd	98,5%

- In an inter-species comparison of the amino acids of the corresponding mouse, rat, and human proteins, the degree of conserved (i.e. identical and similar) amino acids in these domains and binding sites is summarized in the following tables:

Cytoplasmic dynein heavy chain 1	
Binding site to	Degree of conservation
Hcd	99%
Icd	99%
Lcds	99%

Cytoplasmic dynein intermediate chain 1	
Binding site to	Degree of conservation
10kDad	100%
2Bd	98,6%

-181-

Tctex1d	100%
P150d	85,3%

Cytoplasmic dynein intermediate chain 2*	
Binding site to	Degree of conservation
10kDad	90%
2Bd	98,6%
Tctex1d	94%
P150d	74%

*(mouse and rat amino acid sequences are 100% identical for cytoplasmic dynein intermediate chain 2)

P150 (DCTN 1)	
Binding site to	Degree of conservation
Microd	98%
ARP1d	100%
Dicd	98,7%

- 5 In an inter-species comparison of cytoplasmic dynein heavy chain 1 amino acid sequences of the species mouse, human, rat, *Drosophila*, and *C. elegans*, the degree of conserved (i.e., identical and similar) amino acids in these domains and binding sites is the following:

Cytoplasmic dynein heavy chain 1	
Binding site to	Degree of conservation
Hcd	64%
Icd	70%
Lcds	61%

10

Conserved amino acid residues within the defined binding domains of the individual proteins are listed in Table 19, 20, 21, and 22.

15

Evolutionary pressure has conserved these residues at their particular locations in the molecule. It is predicted that any non-conservative amino acid substitution will modify the protein's normal biological function in a manner analogous to that observed in the present invention. Hence, identification of such an abnormal
5 cytoplasmic dynein intermediate chain 1 protein sequence in a biological sample, or of the a DNA encoding such an abnormal cytoplasmic dynein intermediate chain 1 protein, will be indicative of an increased probability of developing the phenotype of the present invention.

10 **EXAMPLE 20: Mutation Detection at Human Patient Samples by Heteroduplex Analysis using Temperature Gradient Capillary Electrophoresis (TGCE) – Mutation Detection in Exon 13 of Human Cytoplasmic Dynein Heavy Chain 1 (DNCH1)**

15 Assay Description: Human genomic DNA is isolated and is subject to PCR amplification according to standard methods in the art, in example, as described in Example 6. For detection of mutations with unknown positions in PCR amplified DNA fragments, double-stranded (ds) DNA is electrophoresed through a temporal gradient of increasing temperature (Temperature Gradient Capillary Electrophoresis
20 (TGCE); RevealSystem, SCE9610, by SpectruMedix LLC, State College, PA, USA). Because retardation of dsDNA during electrophoresis is greatest at the temperature of partial denaturation, DNA fragments of the same size can be separated according to their thermodynamic stabilities. Base mismatches within dsDNA molecules (heteroduplices) lead to a significant destabilization resulting in significant differences
25 in melting temperatures (T_m) between heteoduplices and perfectly paired dsDNA (homoduplices). Such differences in T_m allow the separation of heteroduplices from homoduplices in a temperature gradient electrophoresis and serve as the basis for mutation detection by TGCE.

30 Detection of point mutations in exon 13: For detection of homo- or heterozygous mutations, an equimolar mixture of chromosomal DNA from 5 to 10 healthy individuals is prepared. An equimolar amount of this template DNA (healthy individuals) is added to each sample DNA (patient), and the target region is amplified

-183-

using a standard PCR reaction with gene specific primers. For analysis of human DNCH1 exon 13, a 290 bp DNA fragment containing all exon 13 DNA sequence, was generated with the following intronic primers:

5	<u>primer</u>	<u>sequence</u>	<u>location in intron no.</u>
	hDnchc1-21 (SEQ ID NO: 26)	5'-TGTGAACATAAGAGGTGCCAGT	12
	hDnchc1-22 (SEQ ID NO: 27)	5'-CTACCCGTGACACCTTTCAA	13

10 Following the manufacturers instructions, hybrids of wildtype and mutant sequences are formed in a denaturation/renaturation step, transforming base pair exchanges into heteroduplices with lower thermal stability. A typical temperature profile for denaturation/renaturation is:

- 15
- heat sample to 95°C and hold for 3 min
 - decrease from 95°C to 80°C at 3°C/min
 - decrease from 80°C to 55°C at 1°C/min
 - hold 20 min at 55°C
 - decrease from 55°C to 45°C at 1°C/min
- 20
- decrease from 45°C to 25°C at 2°C/min

Depending on the DNA concentration obtained in the PCR reaction the sample is diluted in a range of 1:10 to 1:50 and subjected to TGCE. Washing, dilution and running buffers are supplied by the manufacturer. Typical operation parameters for

25 TGCE are:

- Prerun: 25 min
 - Injection voltage: 3-8 kV
 - Injection time: 3-10 sec.
- 30
- Running voltage: 10 kV
 - Electrophoresis time: 60 min

The applied temperature gradient during electrophoresis depends on the base composition (G+C content) of the analyzed fragment and ranges from 55°C to 70°C. For the 290 bp exon 13 fragment of hDNCH1 a temperature gradient from 55°C to 65°C with a ramp time of 21 min was applied.

5

Upon completion the obtained electrophoresis pattern is analyzed for additional bands resulting from decreased mobility of heteroduplices during TGCE, using the manufacturers software program Revelation 2.10. Candidate fragments are further analyzed by DNA sequencing, using the method described in Example 6,

10 Section DNA Sequence Analysis.

Table 19. Conserved amino acid residues in binding domains Hcd, Icd, and Lcd of Dnchc1 of mouse (*M. musculus*), rat (*R. norvegicus*), human (*H. sapiens*), *Drosophila melanogaster*, and *Caenorhabditis elegans*:

- conserved residues numbered as mouse Dnchc1 amino acid positions.

302L	303K	305G	306K	307R	308F	309H	310A	311T	312V	314F	315D	317D	319G
320L	321K	322Q	324L	327V	329D	330Y	331N	333L	334M	335K	337F	338P	342L
344S	345A	346T	350K	354A	358I	359F	361H	362L	363R	364K	366R	368T	369K
370Y	371P	373Q	374R	376L	378L	380E	381A	382I	383S	384R	385D	386L	389Q
390L	391L	392K	393V	394L	399L	400M	406E	407F	411M	414C	418F	421W	422D
423D	424E	425Y	427K	431L	432L	433R	434D	435I	437K	439K	440R	445K	448W
454H	457L	460R	467F	468R	470Q	471H	472E	473Q	475R	477V	478I	480R	481V
482L	483R	484P	519E	521V	524A	525Y	526E	529K	531V	532D	534L	535D	543A
544W	545E	547A	549K	550R	551Y	555I	558V	559E	560T	562I	563T	566L	569Q
570L	575N	577N	578E	579M	580F	582I	583F	584S	585R	587N	588A	589L	590F
592R	593P	595I	596R	597G	598A	599I	601E	602Y	603Q	604T	606L	607I	609R
610V	611K	613D	614I	617L	621F	639L	640P	641P	646W	655Q	656L	659Y	661K
662R	663V	664E	665D	666V	667L	668G	669K	671W	672E	674H	677G	680L	681K
683D	684G	685D	687F	690F	691L	697F	700W	704V	705N	715I	717T	731L	733L
736N	744L	764K	747E	748V	752K	755G	756F	757R	758V	759P	760L	762I	763V
764N	766A	767H	768Q	769A	770N	771Q	774P	776A	778S	779L	780I	781E	784R
785T	802L	804A	808K	816E	817G	820L	822W	824S	825Y	826K	828D	830Y	834L
836E	838V	842Q	843E	848L	849L	862L	865C	867Y	871T	876L	880Q	883V	884D
886L	888L	891Y	892S	893N	894L	897W	898V	899N	901L	902D	906E	909L	912R
920W	921T	951P	955N	957V	963T	965Q	968Y	971P	975E	977R	987W	1001R	1003Q
1017Y	1019N	1021L	1025P	1027G	1031L	1032E	1035Y	1048Y	1052W	1053L	1055Y	1056Q	1058L
1059W	1062Q	1063A	1070L	1071G	1077W	1081L	1084I	1088R	1091F	1092D	1096T	1102P	1107Y
1109K	1111Q	1113K	1117K	1118Y	1119D	1121W	1122H	1123K	1124E	1126L	1128K	1129F	1130G
1134G	1137W	1140F											

5

Explanation of amino acid single letter code:

A=Ala C=Cys D=Asp E=Glu F=Phe G=Gly H=His I=Ile N=Asn
P=Pro Q=Gln R=Arg S=Ser T=Thr V=Val K=Lys L=Leu M=Met
W=Trp Y=Tyr

Binding Domains

P150d = binding domain for p150 protein
Tctex1d = binding domain for Tctex1 protein
10kDad = binding domain for 10kDa light chain
2Bd = binding domain for 2B light chain protein

Table 20. Conserved amino acid residues in binding domains p150d, Tctex1d, 10kDad, and 2Bd of cytoplasmic dynein intermediate chain1 of mouse (*Mus musculus*), rat (*Rattus norvegicus*), and human (*Homo sapiens*)

conserved residues numbered as human cytoplasmic dynein heavy chain 1 amino acid positions

A. Conserved amino acid residues in binding domain p150d

1M	2S	3D	4K	5S	6D	7L	8K	9A	10E	11L	12E	13R	14K
15K	16Q	17R	18L	19A	20Q	21I	22R	23E	24E	25K	26K	27R	28K
29E	30E	31E	32R	33K	34K	35K	36E	37A	38D	39M	40Q	41Q	42K
43K	44E	45P	46V	48D	49D	50S	51D	52L	53D	54R	55K	56R	57R
58E	59T	60E	61A	62L	63L	64Q	65S	66I	67G	68I	69S	70P	71E
72P	73P	74L	75V	93P	94T	95P	96M	97S	98P	99S	100S	101K	102S
103V	104S	105T	106P	107S	109A	110G	111S	112Q	113D	116D	117L	118G	119P
120L	121T	122R	123T	124L	125Q	126W	127D	128T	129D	130P	131S	132V	133L
134Q	135L	136Q	137S	138D	139S	140E							

5

B. Conserved amino acid residues in binding domain Tctex1d

157F	158L	159P	160R	161E	162V	163V	164S	165Y	166S	167K	168E	169T	170Q
171T	172P	173L	174A										

C. Conserved amino acid residues in binding domain 10kDad

164S	165Y	166S	167K	168E	169T	170Q	171T	172P	173L	174A

10

D. Conserved amino acid residues in binding domain 2Bd

260L	261E	262E	263K	264D	265G	266D	267V	268Q	269A	270G	271A	272N	273L
274S	275F	276N	277R	278Q	279F	280Y	281D	282E	283H	284W	285S	286K	287H
288R	289V	290V	291T	292C	293M	294D	295W	296S	297L	298Q	299Y	300P	301E
302L	303M	304V	305A	306S	307Y	309N	310N	311E	312D	313A	314P	315H	316E
317P	318D	319G	320V	321A	322L	323V	324W	325N	326M	327K	328F	329K	330K
331T													

Explanation of amino acid single letter code:

A=Ala C=Cys D=Asp E=Glu F=Phe G=Gly H=His I=Ile N=Asn
P=Pro Q=Gln R=Arg S=Ser T=Thr V=Val K=Lys L=Leu M=Met
W=Trp Y=Tyr

Binding Domains

P150d = binding domain for p150 protein
Tctex1d = binding domain for Tctex1 protein
10kDad = binding domain for 10kDa light chain
2Bd = binding domain for 2B light chain protein

Table 21. Conserved amino acid residues in binding domains p150d, Tctex1d, 10kDad, and 2Bd of cytoplasmic dynein intermediate chain 2 of mouse (*Mus musculus*), rat (*Rattus norvegicus*), and human (*Homo sapiens*)

conserved residues numbered as human cytoplasmic dynein heavy chain 2 amino acid positions

A. Conserved amino acid residues in binding domain p150d

1M	2S	3D	4K	5S	7L	8K	9A	10E	11L	12E	13R	14K	15K
16Q	17R	18L	19A	20Q	21I	22R	23E	24E	25K	26K	27R	28K	29E
30E	31E	32R	33K	34K	35K	36E	37T	38D	39Q	40K	41K	42E	43A
47V	48Q	49E	50E	51S	52D	53L	54E	55K	56K	57R	58R	59E	60A
61E	62A	63L	64L	65Q	66S	67M	68G	69L	70T	73S	74P	75I	76V
77P	84P	85P	86M	87S	88P	89S	90S	91K	92S	93V	94S	95T	96P
97S	98E	99A	100G	101S	102Q	103D	104S	105G	106D	107G	108A	109V	110G
111S	112R	133R	134G	135P	136I	137K	138L	139G	140M	141A	142K	143I	144T
145Q	146V	147D	148F	149P									

B. Conserved amino acid residues in binding domain Tctex1

148F	149P	150P	151R	152E	153I	154V	155T	156Y	157T	158K	159E	160T	161Q
162T	163P	164V	165M										

10

C. Conserved amino acid residues in binding domain 10kDad

155T	156Y	157T	158K	159E	160T	161Q	162T	163P	164V	165M
------	------	------	------	------	------	------	------	------	------	------

D. Conserved amino acid residues in binding domain 2Bd

252L	253E	254D	255K	256E	257G	258E	259I	260Q	261A	262G	263A	264K	265L
266S	267L	268N	269R	270Q	271F	272F	273D	274E	275R	276W	277S	278K	279H
280R	281V	282V	283S	284C	285I	286D	287W	288S	289S	290Q	291Y	291P	293E
294L	295L	296V	297A	298S	299Y	300N	301N	302N	303E	305A	306P	307h	308E
309P	310D	311G	312V	313A	314L	315V	316W	317N	318M	319K	320Y	321K	322K
323T													

Explanation of amino acid single letter code:

A=Ala C=Cys D=Asp E=Glu F=Phe G=Gly H=His I=Ile N=Asn
P=Pro Q=Gln R=Arg S=Ser T=Thr V=Val K=Lys L=Leu M=Met
W=Trp Y=Tyr

Binding Domains

P150d = binding domain for p150 protein
Tctex1d = binding domain for Tctex1 protein
10kDad = binding domain for 10kDa light chain
2Bd = binding domain for 2B light chain protein

Table 22. Conserved amino acid residues in binding domains Microd, Arp1d, and Dcd of p150 of mouse (*M. musculus*), rat (*rattus norvegicus*) and human (*Homo sapiens*).

conserved residues numbered as human p150 amino acid positions

A. Conserved amino acid residues in binding domain Microd

39G	40H	41R	42G	43T	44V	45A	46Y	47V	48G	49A	50T	51L	52F
53A	54T	55G	56K	57W	58V	59G	60V	61I	62L	63D	64E	65A	66K
67G	68K	69N	70D	71G	72T	73V	74Q	75G	76R	77K	78Y	79F	80T
81C	82D	83E	84G	85H	86G	87I	88F	89V	90R	91Q	92S	93Q	94I
95Q	95Q	96V	97F	98E	99D	100G	101A	102D	103T	104T	105S	106P	107E
107E	108T	109P	110D	111S	112S	113A	114S	115K	117L	118K	119R	120E	121G
123D	126A	127K	128T	129S	130K	131L	132R	133G	134L	135K	136P	137K	138K
139A	140P	141T	142A	143R	144K	145T	146T	147T	148R	149R	150P		

5

B. Conserved amino acid residues in binding domain ARP1

1006R	1007K	1008K	1009E	1010K	1012F	1013E	1014E	1015T	1016M	1017D	1018A	1019L
1020Q	1021A											

C. Conserved amino acid residues in binding domain Dcd.

133G	134L	135K	136P	137K	138K	139A	140P	141T	142A	143R	144K	145T	146T
147T	148R	149R	150P	151K	152P	153T	154R	155P	156A	157S	158T	159G	160V
161A	162G	164S	165S	166S	167L	168G	169P	170S	171G	172S	173a	174S	175A
176G	177E	178L	179S	180S	181S	182E	183P	184S	185T	186P	187A	188Q	189T
190P	191L	192A	193A	194P	195I	196I	197P	198T	199P	201L	202T	203S	204P
205G	206A	208P	209P	210L	211P	212S	213P	214S	215K	216E	217E	218E	219G
220L	221R	223Q	224V	225R	226D	227L	228E	229E	230K	231L	232E	233T	234L
235R	236L	237K	238R	240E	241DE	242K	243A	244K	245L	246K	247E	248L	249E
250K	251H	252K	253I	254Q	255L	256E	257Q	258V	259Q	260E	261W	262K	263S
264K	265M	266Q	267E	268Q	269Q	270A	271D	272L	273Q	274R	275R	276L	277K
278E	279A	281K	282E	283A	284K	285E	286A	287L	288E	289A	290K	291E	292R
293Y	294M	295E	296E	297M	298A	299D	300T	301A	302D	303A	304I	305E	306M
307A	308T	309L	310D	311K	312E	313M	314A	315E	316E	317R	318A	319E	320S
321L	322Q	323Q	324E	325V	326E	327A	328L	329K	330E	331R	332V	333D	334E
335L	336T	337T	338D	339L	340E	341I	342L	343K	344A	345E	346I	347E	348E
349K	350G	351S	352D	353G	354A	355A	356S	357S	358Y	359Q	360L	361K	362Q
363L	364E	365E	366Q	367N	368A	369R	370L	371K	372D	373A	374L	375V	376R
377M	378R	379D	380L	381S	382S	383S	384E	385K	386Q	387E	388H	389V	390K
391L	392Q	393K	394L	395M	396E	397K	398K	399N	400Q	401E	402L	403E	404V
405V	406R	407Q	408Q	409R	410E	411R	412L	413q	414E	415E	416L	417S	418Q
419A	420E	421S	422T	423I	424D	425E	426L	427K	428E	429Q	430V	431D	432A
433A	434L	435G	436A	437E	438E	439M	440V	441E	442M	443L	444T	445D	446R
447N	448L	449N	450L	451E	452E	453K	454V	455R	456E	457L	458R	459E	460T
461V	462G	463D	464L	465E	466A	467M	468N	469E	470M	471N	472D	474L	475Q

476E	477N	478A	479R	480E	481T	482E	483L	484E	485L	486R	487E	488Q	489L
490D	491M	492A	493G	494A	495R	496V	497R	498E	499A	500Q	501K	502R	503V
504E	505A	506A	507Q	508E	509T	510V	511A	512D	513Y	514Q	515Q	516T	517I
518K	519K	520Y	521R	522Q	523L	524T	525A	526H	527L	528Q	529D	530V	531NR
532R	533E	534L	535T	536N	537Q	538Q	539E	540A	541S	542V	543E	544R	545Q
546Q	547Q	548P	549P	550P	551E	552T	553F		554D	555F	556K	557I	558K
559F	560A	561E	562T	563K	564A	565H	566A	567K	568A	569I	570E	571M	572E
573L	574R	575Q	576M	577E	578V	579A	580Q	581A	582N	583R	584H	585M	586S
587L	588L	589T	590A	591F	592M	593P	594D	595S	596F	597L	598R	599P	600G
601G	602D	603H	604D	605C	606V	607L	608V	609L	610L	611L	612M	613P	614R
615L	616I	617C	618K	619A	620E	621L	622I	623R	624K	625Q	626A	627Q	628E
629K	630F	632L	633S	634E	635N	636C	637S	638E	639R	640P	641G	642L	643R
644G	645A	646A	647G	648E	649Q	650L	651S	652F	653A	654A	655G	656L	657V
658Y	659S	660L	661S	662L	663L	664Q	665A	666T	667L	668H	669R	670Y	671E
672H	673A	674L	675S	676Q	677C	678S	679V	680D	681V	682Y	683K	684K	685V
686G	687S	688L	689Y	690P	691E	692M	693S	694A	695H	696E	697R	698S	699L
700D	701F	702L	703I	704E	705L	706L	707H	708K	709D	710Q	711L	712D	713E
714T	715V	716N	717V	718E	719P	720L	722K	724I	725K	726Y	727Y	728Q	729H
730L	731Y	733I	734H	735L	736A	737E	738Q	739P	740E	743T	744M	745Q	746L
747A	748D	749H	750I	751K	752F	753T	754Q	755S	756A	757L	758D	759C	760M
762V	763E	764V	765G	766R	767L	768R	769A	770F	771L	772Q	773G	774G	775Q
776E	777A	778T	779D	780I	781A	782L	783L	784L	785R	786D	787L	788E	789T
790S	791C	792S	793D	795R	796Q	797F	798C	799K	800K	801I	802R	803R	804R
805M	806P	807G	808T	809D	810A	811P	812G	813I	814P	815A	816A	817L	818A
819F	820G	822Q	823V	824S	825D	826T	827I	828L	829D	830C	831R	832K	833H
834L	835T	836W	837V	838V	839A	840V	841L	842Q	843E	844V	845A	846A	847A
848A	849A	850Q	851L	852I	853A	854P	855L	856A	857E	858N	859E	860G	861L
863V	864A	865A	866L	867E	868E	869L	870A	871F	872K	873A	874S	875E	876Q
877I	878Y	879G	881P	882S	883S	884S	885P	886Y	887E	888C	889L	890R	891Q
892S	893C	895I	896L	897I	898S	899T							

Explanation of amino acid single letter code:

A=Ala C=Cys D=Asp E=Glu F=Phe G=Gly H=His I=Ile N=Asn
 P=Pro Q=Gln R=Arg S=Ser T=Thr V=Val K=Lys L=Leu M=Met
 W=Trp Y=Tyr

Binding Domains

P150d = binding domain for p150 protein
 Tctex1d = binding domain for Tctex1 protein
 10kDad = binding domain for 10kDa light chain
 2Bd = binding domain for 2B light chain protein

This invention has been described in detail including the preferred embodiments thereof. However, it will be appreciated that those skilled in the art, upon consideration of this disclosure, may make modifications and improvements thereon without departing from the spirit and scope of the invention as set forth in the
5 claims. All references, patents, patent applications and Genbank references recited in this patent application is hereby incorporated by reference in their entirety.

Table 23. List of certain sequences provided in this application

SEQ ID NO:	Description
1	Coding sequence (cDNA) of wild type mouse cytoplasmic dynein heavy chain1.
2	Amino acid sequence of wild type mouse cytoplasmic dynein heavy chain1.
3	Coding sequence (cDNA) of mutant mouse cytoplasmic dynein heavy chain1.
4	Amino acid sequence of mutant mouse cytoplasmic dynein heavy chain1.
5	Coding sequence (cDNA) of mutant human cytoplasmic dynein heavy chain1.
6	Amino acid sequence of mutant human cytoplasmic dynein heavy chain1.
7	ClustalW mouse sequence cytoplasmic dynein heavy chain1.
8	ClustalW rat sequence dynein heavy chain.
9	ClustalW human sequence cytoplasmic dynein heavy chain1.
10	ClustalW <i>Drosophila</i> sequence dynein heavy chain.
11	ClustalW <i>Paramecium</i> sequence dynein heavy chain.
12	ClustalW <i>C. elegans</i> sequence dynein heavy chain.
13	Wildtype PCR amplicon of Dnchc1, exon 13.
14	Mutant PCR amplicon of Dnchc1, exon 13.
15	Primer Dnchc1-25.
16	Primer Dnchc1-26.
17	Coding sequence (cDNA) of wild type human cytoplasmic dynein heavy chain1.
18	Amino acid sequence of wild type human cytoplasmic dynein heavy chain1.
19	Nucleotide sequence of wild type mouse cytoplasmic dynein heavy chain1, exon 13.
20	Nucleotide sequence of wild type mouse cytoplasmic dynein heavy chain1, exons 12 and 13.

21	In-frame amino acid sequence derived from SEQ ID NO:19.
22	In-frame amino acid sequence derived from SEQ ID NO:20.
23	In-frame amino acid sequence derived from human Dchc1 exon13.
24	In-frame amino acid sequence derived from human Dchc1 exons 12 + 13.
25	Amino acid sequence of residues positioned within ten residues of Tyr 1055 in wild type cytoplasmic dynein heavy chain1 of mouse, rat and human.
26	Primer hDnchc1-21
27	Primer hDnchc1-22